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SUMMARY
In order to clarify the effect of blood transfusion in uraemic 
patients, 48 dialysis patients who had not received previous blood 
transfusion were randomly allocated to receive 5 or 10 units of 
third-party packed cells at two week intervals. Twelve dialysis 
patients and 12 healthy subjects who had not received previous blood 
transfusion were also studied as control groups.
The cell-mediated immunity (CMI) of the transfused patients was 
measured by skin testing with DNCB and four recall antigens before 
the first transfusion and 14 days after the last unit of blood. In 
addition, prior to the first and 14 days after each transfusion 
patients were screened for a) haematological and biochemistry 
results, b) cytotoxic antibodies, c) complement levels, d) titres of 
IgG secreting cells (PFC) in the peripheral blood both spontaneously 
and after stimulation with PWM and SAC, using a protein A plaque 
assay, and e) prostaglandin E (PGE) production in supernatants from 
both Con A-stimulated PBMC cultures and unstimulated ones. The two 
control groups were screened for these parameters on 3-4 occasions 
over a period of 3 months. The methods and results from this 
randomised controlled study are described in detail in the first 8 
chapters of this thesis. In Chapter 9, I describe results from a 
large number of patients with regard to factors determining the 
response to DNCB and its value as a means of predicting renal 
allograft survival. This retrospective analysis was done from an 
angle and evidence provided by the prospective study.
The aim of the study was, a) to assess the effect of blood 
transfusion in uraemic patients, b) to see whether patients with 
strong or weak reaction to DNCB differ in their response to 
transfusion, and try to define the optimum number of transfusions for 
each group to achieve a beneficial effect, c) to see whether blood 
transfusion-induced alterations in immune responses could be 
monitored with simple skin tests and d) to define possible factors 
determining the response to DNCB and assess the predictive value of 
the skin test regarding graft survival.
In the group of the previously non-transfused dialysis patients 
more than half were strong DNCB responders. This proportion was two 
fold higher compared to that of the overall dialysis population.
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There was a progressive decline in strong responders as patients 
received more blood, and in multi-transfused patients CMI was 
profoundly suppressed. Multivariate analysis revealed that the most 
significant factor associated with the response to DNCB was blood 
transfusion. A number of factors did not show any association, 
namely age, sex, primary renal disease, type of dialysis, parity, ABO 
and rhesus blood groups, interval between last transfusion and test, 
cytotoxic antibodies and a number of haematological and biochemical 
parameters.
HLA-DRW6 positive patients were more likely to be strong 
responders when tested prior to any blood transfusion, but the DRW6 
effect was not observed in patients sensitised after one or more 
transfusions. This suggests that HLA-DRW6 is a marker of strong CMI, 
but this strong response can be modified by transfusion.
Sequential skin testing with DNCB and recall antigens did not 
reflect changes induced by transfusion, as repeated immunisation 
resulted in stronger anamnestic responses, regardless of the amount 
of blood or whether they were transfused at all. Follow-up DNCB skin 
testing showed that blood transfusion at the time of sensitisation to 
DNCB was a crucial event for secondary responses to DNCB. Patients 
eliciting a strong primary response retained and gave even stronger 
responses on subsequent tests regardless of transfusion status at the 
time of sensitisation to DNCB. Contrary to that, weak responders who 
were sensitised after transfusion showed a further depression in 
their secondary responses, while weak responders sensitised prior to 
any transfusion were more likely to show increased secondary 
responses. As a result of this, approximately one third of the 
latter patients changed to strong responders in follow-up tests.
The predictive value of the DNCB test with regard to graft 
survival in patients treated with azathioprine and prednisolone was 
best expressed when the last test prior to transplantation was used. 
Weak DNCB responders had significantly better graft survival compared 
to strong responders over a five year follow-up. This effect on graft 
survival was independent of the blood transfusion effect and was most 
clearly seen in patients receiving 1-5 units of blood. In transplant 
recipients treated with cyclosporin the DNCB test did not have any 
predictive value.
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The risk of sensitisation to HLA antigens was negligible with 
3-4 units of blood, but increased with more transfusions, 
particularly in women. Strong DNCB responders developed cytotoxic 
antibodies earlier, but after 5 units both rate and level of panel 
reactive antibodies was comparable between weak and strong DNCB 
responders.
Transfusion of 1-10 units of blood did not induce any 
measurable changes in serum complement levels and the difference 
between weak and strong DNCB responders was not significant. Serum 
C3, C4, factor B and Cl inhibitor levels did not correlate with IgG 
production either spontaneously or after stimulation with SAC or PWM 
prior to and after transfusion.
Blood transfusion had a suppressive effect on IgG production in 
the PWM-driven system, but not after stimulation with SAC. As the 
former system is dependent on suppressor cell activity, whereas the 
latter is not, it is likely that the blood tranfusion-induced 
suppression was due to activation of a non-specific suppressor cell 
system. This activation was evident after the second transfusion and 
was equally induced in weak and strong DNCB responders, whose 
response did not change significantly with more than 5 units of 
blood. Subgroups of patients with a high or low rate of IgG 
production, both spontaneously and after stimulation with PWM or SAC 
were observed, but the DNCB skin test failed to identify these 
patients.
Blood transfusion induced a significant increase of PGE
synthesis in Con A-stimulated PBMC supernatants which was more 
pronounced after the 3rd unit of blood. The difference in PGE 
concentration between weak and strong DNCB responders prior to and 
after each of 1-10 transfusions was not significant. A further 5 
units of blood did not have any significant effect on PGE release in 
comparison with the initial five transfusions. PGE concentrations 
did not correlate with IgG production in the peripheral blood either 
spontaneously or after stimulation with PWM or SAC. This finding 
suggests that the blood transfusion-induced suppression of PWM-IgG 
production was not mediated by PGE. However, patients who were 
successfully transplanted showed a significant increase in PGE
release after the last elective pre-transplant transfusion, as
13
opposed to a small number of patients with irreversible rejection in 
whom such an increase was not observed. These findings suggest that 
multiple mechanisms might be responsible for the blood transfusion 
effect on graft survival, one of which might be mediated by PGE.
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INTRODUCTION
I THE CELLULAR BASIS OF IMMUNITY
Overview
Immunity is concerned not only with resistance to infectious 
agents but also to other foreign agents including toxins, living 
cells and host cancer cells. The word itself derived from the Latin 
'Immunitas' which originally meant 'freedom from public service' and 
later came to mean freedom from disease. The most striking thing 
about immunity is the specific nature of its enhancement after the 
recognition and response to what is regarded as foreign. It soon 
appeared, however, that such specific immune responses might confer 
unpleasant and harmful effects on subsequent exposure to the 
provoking antigen. Von Pirquet in 1906 pointed out that what 
develops after exposure to antigen is an altered reactivity 
recognised as immunity or hypersensitivity. This changed reactivity 
he called allergy (1). Von Pirquet's concept was fundamental because 
behind all human responses he established a common process of 
specific sensitisation regardless of clinical outcome. To accomplish 
this, mammalian organisms possess a self-regulating system, involving 
organs, cells, proteins and numerous low-molecular weight signals.
Immune responses may be classified into two categories, namely, 
specific and non-specific. Specific immune responses depend upon 
exposure to a foreign configuration and the subsequent recognition 
and reaction to it takes place in a highly discriminatory fashion. 
Non-specific responses, on the other hand, are not dependent upon 
specific recognition and merely repeat the same general response to 
the substance. Thus, specific responses are characterised by 
specificity, heterogeneity and memory which include the induction and 
interaction of a variety of cells specific for the inducing antigen, 
while the non-specific immune responses include a limited number of 
pre-existent cells which are not characterised by the property of 
memory.
When antigen enters the body two different types of adaptive 
immunological reactions may occur, namely those dependent on antibody 
(humoral responses) and those dependent on sensitised lymphocytes
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which are themselves the effectors of cell mediated immunity (CMI).
These two different types of responses are indicative of the basic
division of lymphocytes into B and T cells. This two-compartment 
concept of immunological responses is interwined in a complex manner, 
but the distinction has been retained to simplify description. B and 
T cells interact with each other and with the antigen presenting 
cells (APC) and are found throughout the body in the blood and 
lymphoid tissues (2).
The organs that comprise the lymphoid system are classified as 
primary (central) or secondary (peripheral). The primary organs are 
the bone marrow, the foetal liver and the thymus, representing the 
sites where cells derive from a common pluripotent stem cell and give 
rise to two distinct progenitors for the lymphoid and myeloid cells 
(3,4). The lymphocytes generated in the central organs differentiate 
into mature B and T cells in an antigen-independent fashion and then 
migrate to the secondary organs, namely, the spleen, lymph nodes and 
the non-encapsulated accumulations of lymphoid tissue thoughout the 
body, where the specific immune reactions take place. The myeloid
cells differentiate into phagocytes which include the granulocytes
(neutrophils, eosinophils and basophils) and the mononuclear 
phagocyte system (monocytes and macrophages).
Lymphocytes
Glick et al in 1956 showed that chickens whose bursa of 
Fabricius was removed in the neonatal period had a depressed antibody 
response to salmonella antigens, but rejected foreign grafts, 
indicating that CMI was intact (5). The converse was achieved in 
thymectomised neonatal chickens (6) and mice (7). These experiments 
provided the first evidence of the two-compartment concept of immune 
mechanisms. Similarities between experimental models and patients 
with selective ionmune deficiencies emphasised further this concept 
(8) and led eventually to the T- (thymus derived) and B- 
(Bursa-equivalent derived) cell nomenclature (9).
Tests to characterise T and B lymphocytes by their surface 
markers rather than their functional properties have been extensively 
developed over the past 10 years. The differences are expressed in 
cell surface structures which can be identified by suitably labelled
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antisera or other reagents (10-12). There are also relative physical 
and histochemical differences between T and B cells which do not 
completely distinguish them, but together with the better defined 
membrane binding sites or receptors provide a means of separating 
lymphocytes into varying degress of homogeneity (13).
B lymphocytes
B lmphocytes represent about 5-15% of the circulating lymphoid 
cells. They express a number of surface markers which are 
characteristic of both animal and human B cells but not resting T 
cells (14-16). B cells were identified as cells bearing surface 
immunoglobulin (slg) namely IgM, IgD, or both IgM and IgD as their 
surface receptors (17). Nearly all B cells have Fc receptors (FcR)
for IgG (18), and two types of surface receptors for complement (CR),
CR1 which is the receptor for C4b and C3b, and CR2 which is the 
receptor for C3d (19). The majority of B cells can also be 
characterised by the presence of class II MHC la (mouse) or HLA-DR 
(human) antigens (20), receptors for Epstein-Barr Virus (EBV) (21), 
and for mouse erythrocytes (22).
The classification of B cells based on their stage of 
differentiation has been reviewed in detail (23). The first 
recognisable human B lymphocytes, called pre-B cells, appear in the 
foetal liver during the seventh week of gestation. They contain 
small amounts of cytoplasmic but not surface IgM, and bear specific B 
cell antigens and la-like determinants, but lack FcR and CR. 
Immature B cells appear at week 8 of gestation in the liver and bone 
marrow and they possess surface IgM but few FcR or CR. These cells 
by the onset of the third trimester reach adult proportions and
develop into 'virgin' B lymphocytes bearing slg, la, FcR and CR.
Stimulation by antigen, together with some signal from T cells, 
induces proliferation and differentiation into immunoglobulin 
secreting cells (ISC) which are called plasma cells.
T lymphocytes
T lymphocytes have a variety of functions in the host defence 
system and consequently there are different subpopulations, all of 
which are characterised by specific cell surface antigens consisting
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of membrane glycoproteins. Thus, Thy-1 is expressed by all mouse T 
cells, whereas most human T cells express three surface markers, 
namely, CD2 (synonyms, Til, Leu5, E rosette receptor), CD3 (T3, Leu 
4), and CD5 (Tl, Leul) (24-26). Human T cells can also be identified 
by their ability to bind and form rosettes with sheep erythrocytes, 
called E rosetting (27). Other specific cell surface antigens are 
acquired during differentiation and allow further distinction of T 
cell subsets responsible for helper (Th), cytotoxic (Tc), and 
suppressor (Ts) functions, and also regulatory functions 
(25,26,28-30).
Mouse Th cells express the Qal, and the Lyt-1, L3T4 antigens 
which are equivalent to the CD5 (Tl, Leul) and CD4 (T4, Leu3) markers 
in the human. Th cells are essential for normal activation of B, Tc 
and Ts cells. By means of the clonally restricted CD4 receptor, they 
recognise foreign antigen in association with HLA class II antigen on 
accessory cells.
Ts and Tc cells bear the Lyt-2,3 in mouse or the CD8 (T8, Leu2) 
antigen in man. Ts cells regulate the T-dependent antibody 
production or the generation of Tc cells either by cell to cell 
contact or by production of specific and non-specific soluble 
mediators. Tc cells are the effector killers against nucleated cells 
and parasites.
Murine la and human HLA-DR antigens are expressed only on T 
cells when they are activated by antigens or mitogens. All activated 
human T cells express the interleukin 2 (IL-2) receptor (CD25, TAC). 
Human T cell subsets can also be separated functionally on the basis 
of the presence or absence of FcR for either IgG or IgM (31). In 
addition to these primary markers, one per cent of E-rosette forming 
cells (ERFC) also express receptors for C4b and C3b (32,33), and 
there are a number of other surface receptors and antigens the 
functional significance of which is unknown.
'Null* cells
A third population of human PBMC, the 'null' cells are both E 
rosette negative and slg negative (34). Null cells are subdivided on 
the basis of the presence or absence of either FcR and/or CR (35).
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IgG FcR-positive null cells functionally are the predominant antibody 
dependent cellular cytotoxic cells (ADCC) (36), and may also manifest 
natural killer (NK) activity against tumour cells (37).
Mononuclear phagocyte system
Mononuclear phagocytes represent a distinct class among PBMC, 
arising from monoblasts and promonocytes in the bone marrow. 
Promonocytes develop into monocytes, which after 24-48 hours leave 
the circulation and migrate to tissues where they become macrophages 
(38). The term 'macrophages' was given by Metchnikoff in 1892 
because they were able to ingest large particles. In 1924 Aschoff 
introduced the term reticuloendothelial system (RES) to describe the 
whole spectrum of wandering and fixed mononuclear phagocytes. Apart 
from the well established role of these cells in defence mechanisms 
through phagocytosis and killing of micro-organisms, the excitement 
about their immunological function was triggered by Fishman and Adler 
in 1963 (39). Later Unanue and Askonas, and Mitchison took the 
concept further when they showed that antigen associated with live 
macrophages was capable of producing a strong immune response 
(40,41). Since then an extensive literature with excellent reviews 
has defined the role of macrophages in the antigen presentation which 
leads to antibody production and T cell stimulation, regulation of T 
cell differentiation, and secretion of the molecules that can 
regulate lymphocyte function (42-44).
Approximatley 90% of monocytes and macrophages have Fc 
receptors for IgG (45) while CR for C4b and C3b (CR1) have been 
described on both monocytes and tissue macrophages and receptors for 
C3d (CR2) have been found only on monocytes (46). In addition, 
monocytes and macrophages also have receptors for lymphokines, such 
as ^-interferon and migration inhibition factor (26).
The diversity of functions assigned to macrophages in the 
development and expression of immune responses led to the concept 
that they, like lymphocytes, consist of a heterogeneous cell 
population. For example only some human macrophages possess 
receptors for IgE (26). Also since Rosenthal and Shevach showed that 
the interaction between Th cells and antigen presented by macrophages 
takes place in an MHC-restricted fashion (47), it has been
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established that only a small proportion of activated macrophages 
bear la and HLA-DR surface molecules (26,48). This subpopulation of 
macrophages is referred to as antigen presenting cells (APC).
Antigen presenting cells
In their classical work in guinea pigs, Rosenthal and Shevach 
examined the function of immune response (Ir) genes at the level of 
antigen presentation, using synthetic co-polymers composed of 
L-glutamic acid plus L-lysine (GL) and L-glutamic acid plus 
L-tyrosine (GT) as antigens in the activation of Th cells (47). They 
found that although T cells were capable of responding to either GT or 
GL, they did so only when the appropriate la bearing macrophage
presented the antigen. Subsequently, further studies in the mouse
and in humans established that T cells, unlike B cells, are not 
activated by direct interaction of their receptors with soluble 
antigens, and also the interaction between APC and the responding T
cells is la restricted, that is, the clones of T cells and APC must
share the same allelic form of their class II molecules (44,49).
In the past ten years knowledge of the role of APC in the 
induction of immune responses has greatly increased. Thus it has 
become clear that the capacity of APC to synthesise and express la 
antigen on their surface is not constitutive, but varies depending on 
the state of maturation, on the duration of stimulation and on the 
balance of stimulatory and inhibitory conditions. Therefore it seems 
that the la marker is not a stable surface molecule, but represents a 
specific stage of cell activation (44). For example, in murine 
tissue cultures, la positive macrophages synthesised la briefly and 
the period of la expression was within the range of 12-48 hours. 
Subsequently, these cells rapidly become la-negative and lost both 
their antigen presenting function and their capacity to stimulate in 
a mixed lymphocyte reaction (MLR) (50,51). In humans, the expression 
of la molecules by monocytes also decays in culture, and may be 
increased by ^-interferon and inhibited by endotoxin and zymosan 
(52-54). Also, prostaglandins of the E series (PGE), 
alpha-fetoprotein and glucocorticoids have been found to inhibit la 
expression (44, 55, 56).
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Another interesting point which has emerged from recent studies 
is that each tissue has a characteristic ratio of la-positive to 
la-negative macrophages, probably reflecting microenvironmental 
influences of positive and negative regulatory signals. The 
production of la-positive macrophages in various tissues has been 
reviewed recently (44).
The stimuli for la induction can either be T-independent or 
T-dependent, the latter consisting of lymphokines secreted by 
activated T cells. The major lymphokine responsible for la induction 
is ft-interferon (57), which seems to behave in a non-specific manner 
in that it is not restricted by the MHC haplotype of the responding 
cell. The increase in la-positive cells takes place under all 
conditions that result in T cell activation, particularly in 
infections with intracellular pathogens like Listeria monocytogenes 
(58), Mycobacterium tuberculosis (59), and Trypanosoma cruzi (60). 
The findings from these and other studies (61,62) show the excellent 
correlation between the number of la-positive macrophages and the 
degree of antigen-dependent T cell stimulation, which in turn, 
through an amplification loop of cellular interactions, calls for 
more la-positive macrophages promoting the presentation of antigen.
During the last few years, increasing interest has been focused 
on the intracellular events of transport and degradation of antigens 
by APC. This function has been termed antigen processing (reviewed 
in 44,49,63,64). The initial antigen processing studies were carried 
out in Unanue's laboratory using the bacterial agent Listeria 
monocytogenes. It was shown that endocytosis of the antigen by APC 
was followed by an active metabolic step involving trafficking of the 
antigen to lysosomes where proteolytic cleavage takes place. The 
processed antigen is then recycled on the surface membrane after a 
lag period that takes approximately one hour to complete (44,49,63). 
Treatment of APC with ammonium chloride or chloroquine completely 
abrogates the processing and presenting capacity of the treated cells 
indicating that during processing, the antigen must encounter an 
acidic intracellular compartment. These results have been confirmed 
in many antigen systems, and it is now accepted that bacterial 
antigens and small globular proteins need to be processed (49,63). 
However, there are antigens which do not require processing including
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in humans the large protein fibrinogen (63). This finding suggests 
that it could be the nature of the antigen that dictates the 
requirement for processing. The determinant recognised by 
fibrinogen-specific T cells has been located on a portion of the 
peptide chain which has enough conformational freedom to allow the 
segregation of the binding sites of the interacting cells. Thus, it 
seems that the requirement for antigen processing by APC might be 
dependent on the configuration of T-cell determinants. Those which 
require proteolytic cleavage might be those which need conformational 
flexibility to form the correct la and T cell contact structures 
(63).
As there are a variety of cells other than macrophages that 
express la molecules, the question is whether all these la-positive 
cells can function as APC. B cells constitutively express la on 
their surface (20,44) and can present some antigen to T cells in a 
MHC restricted fashion (65). Other la-positive cells with proven APC 
function include the Langerhans cells, the Kupffer cells in the 
liver, the dendritic cells in the spleen, the veiled cells and 
interdigitating cells in the skin and lymph nodes, and the skin 
keratinocytes. This last type of cell is normally la-negative, but 
following activation is capable of expressing la and is shown to 
produce a soluble cytokine similar to interleukin-1 (IL-1) (reviewed 
in 49).
The Langerhans cells have an important role in delayed-type 
hypersensitivity (DTH) reactions and will be discussed in detail 
later.
Lymphokines
Lymphokines have been defined as non-immunoglobulin secretory 
products of activated lymphocytes and macrophages with a wide range 
of potent physiological effects in inflammation and immunity. There 
is enough evidence now to suggest that they represent hormone-like 
intercellular agents that both positively and negatively regulate 
interactions between T and B cells and macropahges, and non-lymphoid 
tissues.
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The initial demonstration that soluble mediators could be 
liberated by activated lymphocytes was a by-product of research into 
the mechanisms of DTH. In 1928 Rich and Lewis showed that migration 
in culture of tuberculin-sensitised cells from spleen and lymph nodes 
was inhibited when tuberculin was present in the culture (66). Until 
the late 60 's it was not known how the interaction of sensitised 
lymphocytes with antigen triggered the local inflammation seen in DTH 
reactions. Only after the discovery of the first lymphocyte-derived 
product, the macropahge migration inhibition factor (MIF), by Bennett 
and Bloom and David (67,68), was it realised that DTH responses are 
mediated by soluble agents released locally by antigen-activated 
lymphocytes. In the following years, a number of additional 
lymphocyte - derived factors were described which were collectively 
termed 'lymphokines'. The first macrophage-derived soluble helper 
factor was described by Bach et al in 1970 and subsequently a variety 
of both helper and suppressor agents were described in culture 
supernatants (69) . By 1977 Waksman in a comprehensive review had 
listed 98 named lymphokines and monokines (70). As most studies on 
lymphokines utilised supernatants from antigen or mitogen-stimulated 
cultures which contained a crude mixture of molecules rather than 
biochemically pure entities, it could be safely assumed that some of 
the identified lymphokines represented different forms of the same 
molecular substances which express different activities depending on 
the nature of the assay. For example, IL-1 has been variously 
described as lymphocyte activating factor (LAF), endogenous mediator 
of fever, the co-mitogen for thymocytes, the stimulant for cartilage 
resorption, and the stimulant for muscle wasting. Only recently have 
all these mediators been attributed to a single factor ie IL-1 (71).
Although lymphokines are defined in terms of their 
immunological properties, the production of some of these factors is 
not limited to lymphoid cells, but extends to other cell types such 
as fibroblasts, kidney cells, and other cell lines, and they may 
regulate growth and division in non-lymphoid tissues (72). With 
regard to lymphokine production by lymphoid cells, it seems that both 
T and B cells are capable of producing most lymphokines and those 
from both sources appear to have similar functional properties while 
macrophages may also produce lymphokines such as interferon.
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Although non-lymphoid cells can produce some lymphokines, the 
synthesis of others is restricted to T cells, B cells, or macrophages 
(70,72).
As lymphokine production is the result of cell activation, it 
is essential to understand the nature of the activating event, since 
this is the major determinant of whether T or B cells will be the 
source of a specific lymphokine. In other words the process of 
activation of lymphokine production is similar to the activation that 
results in cell proliferation or antibody production. Thus, T-cell 
polyclonal activators, such as phytohaemagglutinin (PHA) and 
Concanavalin A (Con A) , preferentially induce T-cell lymphokine 
production, whereas stimulation with B cell polyclonal activators, 
such as pokeweed mitogen (PWM) and bacterial lipopolysaccharide 
(LPS), induce B-cell lymphokine production (72).
Lymphokines affect a variety of cells including lymphocytes, 
macrophages, neutrophils, basophils, eosinophils, thymocytes, bone 
marrow cells, platelets, fibroblasts, osteoclasts and endothelial 
cells (69). Thus their precise classification is difficult since a 
single factor may have different effects on different target cells. 
Nonetheless, attempts have been made to group lymphokines according 
to their cellular source (72), by the nature of their target cells 
(73), and by their immunological properties, ie whether they are 
specific or non-specific mediators, restricted or unrestricted by 
MHC, and whether they are helper or suppressor factors (70).
In the following section I shall discuss in detail one of the 
many lymphokines, the prostaglandins.
Prostaglandins
In 1930 two American gynaecologists, Kurzork and Lieb, made the 
original observation that uterus strips in contact with human sperm 
either contract or relax (74). These results were confirmed a few 
years later by Goldblatt (75) and by von Euler, who showed that the 
responsible substance was a lipid which he called 'prostaglandin' 
(76). After thirty years of research, during which some hundred 
kilograms of vesicular glands from young Icelandic sheep were used to
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provide the PG standard, Bergstrom and Samuelsson, and van Dorp et al 
identified the chemical structure of prostaglandins (PG) and 
elucidated their biosynthesis from arachidonic acid (77,78).
Chemistry and metabolism
All PG molecules are 20-carbon unsaturated fatty acids 
including a cyclopentane ring and are synthesised within or close to 
the cell membrane by cyclo-oxygenase activity. They are synthesised 
in nearly every tissue of the body and all types of cells can respond 
to them.
The most widely known fatty acid precursor is arachidonic acid 
which is stored in the phospholipid portion of cell membranes. 
Following the activation of endogenous phospholipases, arachidonic 
acid is released from phospholipids and through the cyclo-oxygenase 
enzymatic pathway, PGG2 and PGH2 are generated; the subscript denotes 
the number of double bonds in the molecule, ie PGG2 has two double 
bonds. PGG2 and PGH2 are called endoperoxidases, are short lived and 
are metabolised to form the six primary prostanoids, namely PGE2 , 
PGF2 a , PGD2 , PGI2 or prostacyclin, TXA2 or thromboxane, and a 
17-carbon cleavage product, hydroxyheptadecatrienoic acid (HHT). PGE 
and PGF are rapidly converted to inactive 15-keto-, and 15-keto-13, 
14-dihydrometabolites by a dehydrogenase which was first identified 
in the lung but subsequently has been found in several tissues. 
These sequential enzymatic conversions occur with such great 
efficiency that in a single passage of serum-borne PG through the 
lungs, virtually all PGE is quickly removed from the circulation. 
This accounts for the short biological half-life of PGs, which, 
because of this, have been considered as 'local hormones' having 
essentially no systemic action (reviewed in 79-82).
The generation of PGG2 from arachidonic acid can be blocked 
irreversibly by aspirin and reversibly by non-steroidal 
anti-inflammatory drugs (NSAIDs), such as indomethacin, which blocks 
the action of cyclo-oxygenase. This important finding was made by 
Vane et al in 1971 and since then numerous publications have 
confirmed the anti-inflammatory action of NSAIDs resulting from 
inhibition of PG synthesis (reviewed in 83) .
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PGE can be converted to PGA and PGB through isomerases which 
are normally present in serum (81). The metabolism of PGF2 a has been 
studied in man with tritium-labelled material and it was found that 
90% of the administered substance can be recovered in the urine 
within about five hours. Of the 14 or so urine excretion products 
known to man, all are dinor or tetranor analogues which are generated 
by further metabolism through side chain oxidation of the 15-keto, 
13,14 dihydro metabolite compounds (82).
Isolation and measurement
Because some intermediate PG metabolies do not remain 
chemically intact in aqueous solvents, there are restrictions on 
which compounds can be isolated and measured. The relatively stable 
end-products of PG synthetase adequately reflect the synthesis of 
their respective biologicaly active parent compounds, such as PGE2 , 
PGF2a, PGI2, or TXA2 (81).
Sample material is best stored at -15°C to -20°C following 
extraction from aqueous solvents. The extraction step from aqueous 
media is facilitated by the lipid solubility of PGs and favoured by 
acidification of the aqueous media, ie with citric acid. For samples 
with significant contamination by neutral lipids, initial extraction 
with petroleum ether is carried out, and following this, separation 
of the classes of PG compounds serves to lessen the requirement for 
highly specific anti-PG-antiserum (81).
The most frequent method used for chemical separation has been 
column chromatography, utilising silicic paper (81,84). For 
analytical purposes, thin layer chromatography (TLC), high 
performance liquid chromatography (HPLC), gas-liquid chromatography 
with mass spectroscopy (GLC-MS), radioimmunoassay (RIA), coupled 
enzyme analysis, receptor binding, spectrofluorometric and isotope 
dilution assays have all been employed to measure PG compounds with 
varying success regarding accuracy and reproducibility (reviewed in 
81, 84). However, quantitative determination of PGs has to date
relied mainly on two bioassays, namely GLC-MS and RIA. The 
adaptability of RIA to most laboratories and the high degree of
27
sensitivity and reproducibility due to available specific anti-PG 
antisera made RIA the favoured method for measuring PG levels. This 
procedure is described in detail in Chapter 7.
Cellular sources of PG production
Most leukocytes can produce PGs, including macrophages, T 
lymphocytes, granulocytes - in particular neutrophils and to a much 
lesser degree eosinophils, platelets and possibly B lymphocytes (85, 
86). However, leukocytes in various locations of the body produce 
different quantities of PGs and the significance of PG synthesis by 
each cell type is not clear. Thus, PGE production by granulocytes is 
usually much lower than that of macrophages and does not persist for 
periods longer than 6-8 hours in vitro (85). It is conceivable that 
PGE release from neutrophils may be primarily responsible for the 
rapid pro - inflammatory effects, such as vasodilatation and 
potentiation of vasopermeability, oedema formation and pain, which 
occur during acute inflammation. By contrast, PGE release from 
macrophages may be involved predominantly in the longer lasting 
immunoregulatory circuits which, as will be discussed in the next 
section, may represent the anti- inflammatory effects of PGs (83, 85).
In comparison to other immune cells, the monocyte/macrophage 
cells are the major source of PGs, particularly PGE2 in human 
peripheral blood (81,83,85,86). The macrophage membrane is rich in 
precursor fatty acids and phospholipase Al and A2 which can be 
activated by several physical and chemical stimuli. To date zymosan, 
antibody-coated red blood cells, phorbol myristrate acetate, Con A, 
PHA, LPS, colchicine, silica, carrageenan, dextran sulphate, Fc 
fragments of IgG, immune complexes, endotoxin and colony stimulating 
factor have been shown to trigger macrophage PG synthesis (81,85,86). 
The available evidence clearly indicates that PGs are not stored 
within cells, but following stimulation are freshly synthesised and 
instantly released into the extracellular space (80,81,85,86). In 
that sense PG release and PG synthesis are interchangeable terms.
Measurements of PG synthesis have shown that PGE2 and TXA2 are 
the major products in guinea pigs, mouse and man (81). Isotopic 
labelling with tritiated arachidonic acid showed that the label is 
rapidly incorporated into the macrophage cell membrane, is equally
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rapidly converted in the cell and is then recovered as tritiated 
PGE2 , 6-ketoPGF^a , PGF2 a and Txl^. Less than one per cent of the 
label can be identified as intracellular PG, confirming that 
virtually all the cyclo-oxygenase products are rapidly secreted (81).
Although there is a basal level of PG synthesis by 
monocyte/macrophage cells, production increases markedly upon 
stimulation. Phagocytosis of latex particles does not induce PG 
synthesis above basal levels but bacteria coated with IgG or 
complement or both are more efficient stimuli (85) . These findings 
suggest that the phagocytic process itself is not responsible for 
initiation of PG production, but some alteration on the membrane 
surface or cell damage is required to potentiate PGE release. 
Similarly, PGE synthesis by lymphocytes is minimal unless the cells 
are stimulated by antigens or mitogens to undergo blastogenesis (87).
Human peripheral blood lymphocytes and rat thymocytes have 
specific membrane receptors for one or more PG types, but restricted 
distribution of these receptors helps to maintain local specificity 
of PG actions (88,89). Goodwin et al found specific reversible 
binding for ^H-PGE^ and PGE2 (but not for ^H-PGA, F^a or F2 a) which 
could not be inhibited by the addition of 10- to 1000-fold greater 
amounts of unlabelled PGA, F ^a or F2 a (88).
Binding of PGs to membrane receptors has long been associated 
with activation of adenylate cyclase and elevation of intracellular 
cyclic 3,5-adenosine monophosphate (cAMP) (86,90). As the increase 
in cAMP levels have been implicated in the regulation of leukocyte 
activation (91), in vitro experiments using PGE have been widely used 
to establish the link between the functional properties of PGE and 
cAMP. However, in addition to cell surface receptors for PGE, there 
exist active mechanisms for the uptake of PGE into many animal 
tissues both in vivo and in vitro. This uptake can be inhibited by 
metabolic poisons, inhibitors of biotransport such as probenecid and 
anti-inflammatory drugs (92). Thus, it does not necessarily follow 
that all effects of PGs on immune function are accompanied by changes 
in cAMP levels. In fact with such evidence of functional 
heterogeneity in the lymphocytes which are involved in the expression 
of immunity, it would hardly be surprising for these cells to exhibit 
functional differences in terms of control mechanisms for their
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secretory actions. Adenylate cyclase activation can act as a 
bidirectional control system with both activation and suppression of 
lymphocyte secretory processes (93), and this can explain some of the 
functional differences seen in lymphocytes.
Regulation of immune responses bv PGs
In the early 1970s, PGs were linked with inflammation in 
studies which showed that the mechanical irritation of rabbit eyes 
released a substance called 'irin' into the anterior chamber of the 
eye. This substance was later identified as a mixture of PGE2 and 
PGF2 a (94). However, the role of PGs in the development of 
inflammatory responses was not generally accepted because they did 
not reproduce two important cardinal signs of inflammation, namely, 
increased vascular permeability and pain. The answer to this came a 
little later when it was shown that PGs enhanced the oedema and pain 
producing effects of other mediators of inflammation such as 
histamine, bradykinin and C5 (83). On the other hand, Vane and his 
colleagues had already established the anti-inflammatory role of 
NSAIDs by their inhibition of PG synthetase. Thus in the mid 1970's 
there was abundant evidence showing that PGs were potent mediators of 
inflammation. In particular, PGs of the E series were found to 
produce vasodilatation in most systems, to cause fever when injected 
into the central nervous system of experimental animals and to 
potentiate the inflammatory effects of certain other mediators. Also 
they were found to be increased in inflammatory exudates, and their 
biosynthesis was strongly inhibited by NSAIDs (95).
In spite of the evidence that PGs have pro-inf lammatory 
properties, many reports suggested that PGs may act as 
anti-inflammatory agents as well. PGs of the E series were found to 
be potent activators in leucocytes of membrane adenylate cyclase 
leading to an increase in intracellular cAMP (86,90). Bourne et al 
measured the release of histamine as an indicator of basophil 
function and showed that J^-adrenergic catecholamines, PGEs and 
histamine itself stimulated the accumulation of cAMP by activating 
adenylate cyclase and reducing histamine release (90). At the same 
time a large number of reports supported the concept that an increase 
in cAMP in leukocytes served as an intracellular signal for
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inhibition (reviewed in 91) . Functions such as stimulation of 
lymphocytes, cytotoxicity, antibody and lymphokine production, 
release of lysosomal enzymes, killing activity against Candida and 
enzyme induction could consistently be suppressed by raising 
intracellular cAMP levels (83,85). These findings led to the 
suggestion that cAMP may be a potent intracellular modulator of 
leukocyte activities and that agents such as PGE which increase 
intracellular cAMP may thereby regulate the character and intensity 
of inflammatory and immune responses (90). This may seem 
contradictory to the observations supporting the pro-inflammatory 
role of PGs. However, it seems that PGs have opposing effects on 
inflammation under different circumstances or at different times 
during an inflammatory response. The rapidly occuring 
pro-inflammatory effects may not primarily affect lymphocytes but 
rather other cell types that are active in inflammed tissue. It has 
been suggested that the puzzling role of PGE as a pro- and 
anti-inflammatory mediator may be temporally related to acute and 
chronic states of inflammation respectively and in both, PGE may act 
as a homeostatic agent to secure a well balanced immune system 
(83,85).
In 1971 Smith et al showed that PGE^ and PGE2 , when added to 
human PHA-stimulated PBMC could suppress DNA synthesis (96). 
Thereafter, many investigators using PGs in various experimental 
systems demonstrated their inhibitory role on the immune system. The 
list of these inhibitory actions include:-
1) suppression of in vitro humoral immune responses to 
SRBC
2) inhibition of mitogen stimulation
3) inhibition of antibody-dependent
cytotoxicity
4) inhibition of cellular cytotoxicity
5) inhibition of MLR
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6) inhibition of lymphokine and monokine 
secretion
7) inhibition of antibody secretion (97).
In addition to this list, glomerulonephritis in NZB/W hybrid 
mice, a model for human SLE, was effectively suppressed in animals 
treated with PGE^ resulting in prolonged survival of the mice (98). 
In another report, allografted kidneys in rats treated with a stable 
analogue of PGE-inhibited splenic T cells resulted in increased 
survival of graft recipients and improved graft function which was 
coincident with the suppression of splenic T cell cytolytic activity 
(99).
In view of the inhibitory actions of PGE it was not surprising 
that addition of inhibitors of PG synthesis often produced a marked 
increase in lymphocyte proliferation. Studies using specific PG 
synthetase inhibitors in different models have resulted in 
enhancement in a variety of ways including the in vivo primary 
responses to SRBC, DNA synthesis in response to T cell mitogens, DNA 
synthesis in mixed lymphocyte responses, in vivo secondary antibody 
responses and an enhanced DTH reaction (86,92,97). However, it 
should be noted at this point that the use of indomethacin to block 
in vitro and in vivo PGE synthesis has certain limitations. Firstly, 
it has sometimes been used in too high a concentration (more than 
5ug/ml) which is toxic to lymphocytes (92). Secondly, PGE synthetase 
inhibitors also have other actions such as inhibition of 
cAMP-dependent-protein kinase and phosphodiesterase. Finally, 
indomethacin, aspirin and the other similar agents inhibit the entire 
cycloxygenase pathway including the synthesis of thromboxane and 
prostacyclin, the immunological relevance of which is less well 
defined (85,92). Thus, any effect ascribed to PGE synthesis through 
indirect experiments with PGE synthetase inhibitors should be 
confirmed by abrogation of these effects when exogenous PGE is added 
in amounts found in control cultures.
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T lymphocytes are probably heterogeneous with regard to their 
sensitivity to PGE. Stobo et al showed that PGE-induced suppression 
of blastogenic response was 60% in a T cell population of high 
density, while populations of intermediate density cells were 
inhibited by only 20%, and populations of low density cells even 
showed an enhanced blastogenic response (100). This last finding 
suggests that PGE should not be regarded as a simple, overall 
inhibitory agent as this inhibition represents a net result of 
different T cell subsets, the sensitivity of which to PGE largely 
depends upon cell cycle events. Suppressive effects of PGE were 
usually noticed during the early phase of lymphocyte activation and 
addition of PGE after 12-16 hours of culture no longer caused 
significant suppression of DNA synthesis (85,86,92). The available 
evidence indicates that the lymphocyte response to PGE may be 
determined by the lymphocyte subclass tested, the time of addition of 
PGE, and the amount and type of mitogen employed. Mitogens 
stimulating T cells such as Con A or PHA appear to be more easily 
suppressed by PGE than mitogens like PWM which stimulate B cells 
(92).
With regard to PG-induced regulation of B cell activation it 
appears that there are species differences. In both the rat and 
mouse, antibody responses to SRBC measured by plaque forming cells 
(PFC) are inhibited by PGE, whereas in rabbits and humans the effect 
of PGE on IgG and IgM synthesis appears to be stimulatory (101).
Despite the well established immunosuppressive effect of PGE 
under in vitro conditions, there are few diseases which have been 
influenced by the effects of PGE in vivo. PGs are known to be 
released by tumour cells and this may be responsible for 
tumour-induced suppression of the host immune response as suggested 
by Plescia et al (102). The best example of this principle in 
disease states is Hodgkin's lymphoma which is characterised by 
profound defects in CMI. Macrophages from patients with Hodgkin's 
lymphoma produce PGE at 4 times the normal rate and the reduced 
response of lymphocytes to mitogens can be entirely reversed in vitro 
by indomethacin or removal of glass adherent cells from lymphocyte 
cultures (92). Other diseases which have been associated with either 
excessive PGE production or altered PGE sensitivity include
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rheumatoid arthritis, sarcoidosis, chronic fungal infections, 
tuberculosis, multiple sclerosis, juvenile periodonitis, Kaposi's 
sarcoma, extensive burns, graft-versus-host disease, allergic 
encephalomyelitis and diseases associated with autoimmunity and old 
age (85,92.94).
The highly specific cell interactions during an immune response 
are governed by gene-coded surface structures (la antigens), IL-1, 
IL-2 and the activities of a spectrum of lymphocyte subsets with 
identifiable surface characteristics. The question arises whether an 
immune system which is responding specifically also requires 
additional modulation by non-specific factors such as PGE. 
Convincing experimental evidence that PGE is an essential modulator 
of normal macrophage-lymphocyte interactions is still lacking. PGE 
seems to act as only one of many regulatory factors because the 
inhibition of its production, while leading to enhanced lymphocyte 
responses does not result in a major change in immune reactivity. 
Thus PGE may be a modulator of an auxiliary or even reserve 
regulatory system. The higher release of PGE from activated 
macrophages led Morley and his colleagues to suggest that 
macropahge-derived PGE could provide a negative feedback signal that 
inhibits lymphokine production from stimulated lymphocytes (103). 
The basic point of this hypothesis is that upon antigenic 
stimulation, macrophages release IL-2 which stimulates T cells to 
release lymphokines, including IL-2. One of the lymphokines in turn 
activates macrophages to produce PGE which causes inhibition of 
lymphocyte function (83,85,86). The aim of such a feedback 
regu l a t i o n  could be to maintain a bal a n c e  betw e e n  
lymphokine-activated macrophages and PGE-inhibited lymphocytes and to 
adjust the intensity of immune response in a homeostatic manner to 
the amount and type of antigen introduced into the system. An 
interesting feature of the PGE-mediated suppression is its rapid 
induction within 3 to 5 days and its cessation after 2 to 3 weeks 
with either a restoration to the previous state or a switch to 
another, more permanent suppressor mechanism (85). The latter 
finding led Webb and his co-workers to suggest that PGE may induce 
suppressor activities in T cells. They have characterised two 
PGE-induced-suppressor factors produced by mouse T cells which they
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termed prostaglandin-induced T cell derived suppressor (PITS) (104). 
PITS has a wide spectrum of suppressive actions, including PHA- and 
LPS-induced blastogenesis, one-way and two-way MLR, and both T-cell 
dependent and T-cell independent antibody responses (105,106).
It now seems likely that PGE-induced immunosuppression occurs 
through at least two mechansisms, one based on macrophages and PGE 
and the other on PGE-induced T suppressor cells and the synthesis or 
the release of protein intermediates, the PITS factors which in turn 
modulate the immune response. In any case, the relative contribution 
of these mechanisms toward overall regulation of the immune response 
in vivo remain to be determined.
The complement system
In 1884 Grohmann showed that plasma could kill bacteria in a 
reaction which did not require leukocytes, and in 1889 Buchner showed 
that cell free serum possessed the ability to destroy typhoid 
bacilli. This bactericidal activity which at that time was termed 
alexin and later complement, was found to be sensitive to heat and 
did not increase during immunisation. In contrast a second 
bactericidal factor, now known to be antibody was noted to be 
heat-stable, increased by immunisation and to react specifically with 
the immunising organism (107).
The entire complement system, as currently understood, consists 
of 20 proteins which collectively are a major fraction of the pi and 
$2 globulins. These proteins are synthesised in the liver, but 
several are also produced at extrahepatic sites, such as in 
monocytes, macrophages, fibroblasts and epithelial cells of the 
gastrointestinal and genito-urinary systems (108). Two pathways are 
known to activate the complement cascade, the classical and the 
alternative pathways. The classical pathway is triggered by 
interaction of the first component of complement (Cl) with antibodies 
of the IgG and IgM classes in complex with antigen. The proteins of 
this pathway are numbered C1-C9, though the correct sequence of 
activation of the components (Cl,4,2,3,5,6,7,8,9) does not follow 
exactly the original discovery and numbering of the components. The 
alternative pathway is triggered by endotoxins, zymosan, cobra venom 
factor and IgA without requirement for IgG or IgM and components Cl,
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C4, and C2. The alternative pathway components are termed factors 
and each is represented by a letter eg factor B, factor D, properdin 
(P). The alternative pathway enables complement assisted 
phagocytosis and inflammation to proceed before the influx of 
antibody.
Activation of the complement system results in a cascade with 
interactions of these proteins, leading to the generation of products 
that have important biological activities and constitute important 
humoral mediators in inflammation and immunity. Thus, a) C3a and C5a 
induce increased vascular permeability due to their action on smooth 
muscle and the release of histamine by mast cells, b) C3b facilitates 
the localisation and degradation of immune complexes in germinal 
centres and the opsonisation and phagocytosis of bacteria, c) 
neutrophils, eosinophils and monocytes are attracted by C5a to the 
area of inflammation to phagocytose the opsonised micro-organisms ie 
chemotaxis, d) the membrane attack complex C5-C9, is responsible for 
the lysis of bacteria and other cells recognised as foreign, and e) 
the production of T-dependent antibody production in mice is delayed 
by prior depletion of C3 which also appears to be important to the 
development of primary B memory cells (107).
Major histocompatibility complex
Landsteiner in his Nobel lecture in 1931 in which he emphasised 
the parallel between the problems of matching for blood transfusion 
and transplantation triggered a search for leukocyte blood groups 
that could form the basis of matching donors and recipients for 
transplantation. In the middle and late 1930s Gorer, with his 
pioneering work in mice, showed that a single locus situated in 
linkage group IX (now known as the 17th chromosome) controlled a cell 
surface antigen (antigen II) that elicited rapid allograft rejection 
and could be detected by alloantibody (109). The discovery that
genetically controlled antigens present in grafted tissue and absent
in the host could result in graft destruction was a milestone in our 
understanding of graft rejection. The antigens relevant for tissue
matching were called histocompatibility antigens and the locus
controlling antigen II in mice was coined histocompatibility 2, or 
H-2 by Snell (110). Subsequent studies using inbred strains of mice
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showed that transplants between H-2 incompatible strains were rapidly 
rejected, whereas transplants between strains differing for antigens 
not linked to H-2 were more slowly rejected. As the H-2 locus in 
mice was later shown to be polymorphic and composed of a cluster of 
antigens, the H-2 complex was designated the major histocompatibility 
complex (MHC) (reviewed in 111).
Within a short time from the discovery of the H-2 system in 
mice, studies in man were initiated. In 1954 Dausset et al described 
the presence of antibodies against human white cells in the sera of 
leucopenic and multitransfused patients, multiparous women and normal 
volunteers immunised with leukocytes (112). Soon many different 
antigenic specificities were detected by such antisera, and genetic 
analysis of families and populations established the presence of a 
series of closely linked genes in man. Furthermore, as in the mouse, 
genetic studies demonstrated a relationship between the tissue 
alloantigens defined by serological methods and those detected by 
tissue transplantation. This resulted in the identification of the 
MHC in man, the HLA system (Human Leukocyte antigen system A) which 
is a cluster of genes located on the short arm of chromosome 6 (113).
The mouse H-2 complex
The H-2 complex contains at least nine discrete genetic regions 
in 5 major groups K, I, S, G and D. The I region has been further 
subdivided in 5 subregions, namely, I-A, I-B, I-J, I-E and I-C 
(reviewed in 111, 114).
The K and D regions contain the H-2k and H-2d loci which 
determine cell membrane antigens in graft rejection, cell-mediated 
lympholysis (CML), mixed lymphocyte reaction (MLR) and 
graft-versus-host-reaction (GVHR). The S region contains the Ss 
locus and controls components of the complement system. The G region 
contains the H-2G locus and controls the resistance of F-^ hybrids to 
parental transplants of bone marrow or tumours of lymphoid origin. 
The I region or immune response region was originally identified as a 
region where specific immune response (Ir) genes are located. The 
antigens controlled by the I region stimulate MLR and control the 
immune response to synthetic polypeptides and to naturally occurring 
protein antigens (111,114,115). They also control CML, GVHR and in
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addition essential cell interactions occurring during immune 
responses such as macrophage-T cell and T cell-B cell interactions
(111.114.116). The ability to suppress the immune response to some 
antigens is also regulated by the I-A or I-B subregion (111,114,115) 
and several soluble factors that potentiate immune responses have 
been shown to bear determinants controlled by the I-A subregion
(111.114.117).
The H-2 system is one of the most thoroughly studied segments 
of a chromosome in the mammalian system. Several new techniques, 
such as DNA hybridisation, gene cloning and monoclonal antibodies 
have facilitated genetic and functional studies of the H-2 gene 
complex and permitted identification and isolation of single gene 
products and cells bearing these products.
The human HLA complex
More than one hundred HLA antigens have already been identified 
belonging to at least 3 regions, namely class I, class II and class 
III. The class I genes (HLA-A, HLA-B and HLA-C) encode cell surface 
antigens that are expressed on most nucleated cells and are 
recognised by serological techniques. The class II genes are 
arranged into at least 3 subregions, HLA-DP, HIA-DQ and HLA-DR. The 
DQ and DR products can be detected serologically whereas the DP 
products are determined by analysis of T cell reactivity and 
specifically by the measurement of thymidine uptake during blast 
transformation in the MLC test. The products of the HLA-D region are 
expressed on certain cell types, primarily B lymphocytes, monocytes, 
activated T cells, endothelial and epidermal cells (118). The class 
III region comprises the genes for the serum complement components C2 
and factor B, the 2 genes for the cytochrome P-450 21-hydroxylase and 
the 2 genes for complement component C4 (C4A and C4B).
HLA antigens are identified by numbers with the letter of the 
locus as a prefix. Antigens for which good reagents are not 
generally available have the extra prefix w (from workshop) (113). 
The various specific combinations of alleles at all loci within the 
MHC are referred to as haplotypes, and each HLA haplotype is 
transmitted as a single Mendelian codominant trait. The HLA-A, -B, 
and -C antigens are membrane glycoproteins with a molecular weight of
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44,000 daltons which are associated with a 12,000 molecular weight 
polypeptide, the >^2 microglobulin. The gene for ^2 microglobulin 
lies on a separate chromosome to that containing the MHC loci and 
although this peptide does not form part of the antigenic site of the 
HLA molecule, it is necessary for the expression of the class I 
antigens. HLA-DR determinants have also a 2 polypeptide chain 
structure (a and b chain with a molecular weight of 34,000 and 28,000 
respectively) (119).
The extreme polymorphism of the MHC and the fact that 
homologous systems exist in all mammalian species studied suggest 
that the MHC has an important biological role. Direct proof for this 
in the mouse was reported by Lilly et al who found that 
susceptibility to and mortality from Gross leukaemia virus infection 
were controlled by the H-2 system (120). Also, studies by Benacerraf 
and McDevitt established that the immune response to various 
pathogens and antigens is controlled by the Ir genes in the MHC in 
the mouse, guinea pig and rhesus monkey (115, 121, 122). These
findings suggest that the major role of the MHC might be not only its 
role of histocompatibility matching in organ transplantation, but 
also its influence on resistance to infectious diseases.
Genetic control of immune responses
Any gene that can modify immune reactivity may be classified as 
an immune response (Ir) gene. To ensure that the species maintain 
the ability to resist a variety of micro-organisms at least some of 
these genes need to be polymorphic. Biozzi et al analysed the immune 
response in inbred mice with high and low antibody responses to 
heterologous erythrocytes and identified 10 independent polymorphic 
Ir loci (123). These loci were non-antigen specific as they 
controlled the response to many antigens unrelated to the antigen 
used for selective breeding. The study of antigen-specific Ir genes 
began with the discovery by Benacerraf's team in 1963 that the 
ability to respond to selected antigens was controlled by autosomal 
genes inherited in a simple Mendelian fashion (115,124,125). Using 
random-bred guinea pigs which were immunised with dinitrophenyl 
conjugate of the synthetic polymer L-lysine (DNP-PLL), some guinea 
pigs developed both a specific DTH response and high levels of serum
39
antibody to DNP-PLL (high responder animals), whereas others failed 
to develop such a response (non-responder animals). Thus by 
presenting the immune system with a highly specific antigenic 
stimulus it was possible to detect specific Ir genes. Later, 
McDevitt et al studied the genetic control of the immune response in 
mice to the synthetic polypeptides tyrosine, glutamic acid, alanine 
and lysine (T.G-A-L) and noted that the Ir gene was linked to the 
genes of the H-2 complex. Thus they established that the MHC linked 
Ir genes map to a new region of the H-2 complex, the I region 
(122,126,127). Since these initial observations, several reports 
have confirmed that both humoral and cellular immune responses to 
many types of antigens are under MHC-linked Ir gene control which are 
the main antigen-specific Ir genes (reviewed in 111,115,128). 
Studies of the activities controlled by these genes have also shown 
that they control MLR, cell surface alloantigens (la antigens) and 
cellular interactions in several different species such as mice, 
g u i n e a  pig, rat, chicken, dog and r h e s u s  m onkey 
(44,47,111,115,128,129).
Studies associating HLA and immune responses in man were more 
difficult because of the problems regarding ethical issues of 
immunisation, standardisation of exposure to antigens and measurement 
of immune response in an outbred population. In 1972 Levine et al 
provided the first evidence for an aetiological link between Ir genes 
and a specific disease suggesting that the clinical symptoms of hay 
fever and IgE-mediated skin sensitivity to ragweed antigen were both 
controlled by HLA (130) . Thereafter a number of studies indicated 
the possible presence of Ir genes in man describing associations 
between different immune responses to microbial and non-microbial 
antigens and HLA antigens. Thus, the response to the pollen antigen 
E was associated with HLA-B7 (131), the occurrence of hepatitis B 
antigenaemia in Australian aborigines with HLA-Bw35 (132,133) and a 
high in vitro lymphocyte proliferation stimulated by streptococcal 
antigens (streptokinase and streptodornase) with HLA-B5 (134). Also 
a significant association was found between low response to tetanus 
toxoid and a Japanese HLA-D determinant HO (135) , between low 
response to vaccination with a smallpox-like virus and HLA-Cw3 (136), 
low response to influenza A virus and HLA-Bwl6 (137) and low response
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to rubella virus and HLA-A28, -B14 and Bw22 (138,139). These studies 
were carried out in the late 1970's when HLA-D typing was not 
performed routinely. Because of the presumed analogy between HLA-D 
and the murine la region, stronger associations are expected to be 
found in the near future as most associations reported are probably 
due to linkage disequilibrium for DR (140).
Humans constitute a better study population than mice in the 
search for possible associations between HLA antigens and 
susceptibility to diseases. After Lilly's report on leukaemiagenesis 
in mice (120), Amiel was the first to show an association between HLA 
and Hodgkin's lymphoma (141). Since then numerous reports have 
suggested an increased frequency of one or more HLA antigens in 
various diseases (reviewed in 142, 143). Todate a large number of 
human diseases have been found to have HLA associations and the 
majority appear to have a strong relationship with HLA-D antigens. 
However, haemochromatosis and congenital adrenal hyperplasia, which 
are both entirely non-immunological diseases have also been found to 
be associated with HLA. Thus, HLA genes not only influence the 
immune response but also play a role in other physiological functions 
such as iron metabolism and steroid hormone formation. It appears, 
therefore, that mechanisms for disease susceptibility based on genes 
controlling hormones, Fc receptors and complement components might be 
possible. Further studies on HLA-associated diseases will enable us 
to understand the relationships and classification of certain 
clinical syndromes and may even offer means for therapeutic 
interventions.
HLA and renal transplantation
Today organ transplantation is an important form of treatment 
for diseases involving an irreversible loss of organ function. In 
particular kidney transplantation, which is the commonest form of 
organ transplantation, constitutes the best treatment for end-stage 
renal failure. By the end of 1987, approximatley 75,000 renal 
transplants had been performed in Europe of which approximately
10,000 were performed in 1987 (144).
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Evidence that HLA antigens are important in allotransplantation 
is derived from tissue matching and subsequent graft survival rates. 
In 1978 an International Forum entitled 'Fifteen years of HL-A: What 
is the importance of HL-A compatibility for clinical outcome of renal 
transplantation?' was organised by J Dausset, F Kissmeyer-Nilsen, PJ 
Morris, JJ van Rood, PI Terasaki and G Opelz. The general view in 
that Forum was that matching for HLA haplotypes in living related 
transplants had a clear and significant effect on graft survival. 
Thus, graft survival at one year in HLA identical siblings was 90%, 
compared to 70% in one-haplotype matched transplants and 50% in 
sibling transplants sharing no HLA haplotype (145). These results 
reflected the experience then and later of most transplant centres 
(reviewed in 146, 147, 148). The beneficial effect of HLA matching
in living related transplants is such that nowadays most centres do 
not perform transplants between totally mismatched siblings. 
However, the fact that nearly 10% of the HLA identical transplants 
are rejected within a year despite immunosuppression implies that 
other histocompatibility antigens and non-HLA linked genes may play a 
role in graft rejection (146,148). On the other hand, more than 50% 
of totally mismatched living related grafts are still functioning 
after one year, suggesting that host factors other than HLA matching 
are crucial in graft survival.
In view of the superior graft survival with HLA identical 
sibling donors one would expect general agreement on the beneficial 
role of HLA matching in cadaver renal transplantation. However, this 
has been a controversial issue. The first reports showing that 
matching for HLA-A, B improved graft survival rates appeared soon 
after the discovery of these loci in 1968 (149,150). In a recent 
review of renal transplantation and HLA which has summarised 99 
reports from 1969 to 1984, 23 studies described a statistically
better graft survival in well-HLA-A,B matched grafts compared to 
poorly-matched grafts, while in 31 studies the difference between the 
two groups was not significant and in the remaining studies graft 
survival rates were given without p values (147). The reasons for 
the apparent discrepancy are threefold. Firstly the number of cases 
from single-centre reports is small, secondly graft outcome is 
influenced by factors other than HLA matching, such as blood
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transfusion, immunosuppression and pre-sensitisation and thirdly, the 
polymorphism of the HLA antigen system makes it virtually impossible 
to find HLA identical donor-recipient pairs in cadaver 
transplantation. However results based on large numbers of cases 
from national and regional organisations (eg Eurotransplant, UK 
Transplant Service, Collaborative Transplant Study [CTS]) show that 
the difference in graft survival at one year between 0-1 mismatched 
HLA-A,B grafts has been in the range of 10-15% (reviewed in 
146,147,148). For example, Opelz and Terasaki reported that in the 
North American Registry with more than 7,000 first cadaveric
transplants the one-year graft survival was 53% in the zero HLA-A,B 
mismatch grafts compared to 42% in the 4 HLA-A,B mismatch group
(147). In a Eurotransplant report, the long-term graft survival in 
2,522 transplants at 5 years was also better in the zero HLA-A,B 
mismatch group (51%) compared to that of the 4 mismatch grafts (32%)
(151). d'Apice in a controlled study found that matching for HLA-B
antigens gave better graft survival, while this did not apply to the 
HLA-A locus (152). The view that HLA-B antigens might be stronger 
histocompatibility antigens than HLA-A antigens was supported by 
another study the following year (153), whereas HLA-C antigens seemed 
to have no effect on graft survival (154).
Soon after the identification of the first 7 HLA-DR antigens 
(DR1-DR7) in 1977, transplant centres began to focus their attention 
on the effects of matching for these antigens, as in theory the 
expression of these surface markers like la antigens in mice trigger 
the induction of the immune response against allografts. The first 
report which showed the beneficial role of HLA-DR matching in 
cadaveric transplantation came from Oxford in 1978 (155), and
thereafter was confirmed by both single and multicentre studies 
(146,147,148,152,154,156). In 385 first cadaver grafts in Oxford the 
survival at one and 5 years of grafts with no HLA-DR mismatches was 
82% and 65% respectively, whereas those with one and 2 DR mismatches 
were 72% and 49%, and 65% and 49% respectively (148).
Mickey analysed the one year graft survival of 9,345 first 
cadaver transplants and reported an 82% survival in 98 grafts with no 
mismatches at any of the HLA-A,B and DR loci (156). Of the 5,574 
grafts analysed in the CTS report, 163 had no HLA-A,B,DR mismatches
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and their one year survival was similar at 80% which was more than 
20% better than grafts mismatched for 5 or 6 antigens (148). Also, 
the Eurotransplant study showed that in grafts with zero DR 
mismatches, additional zero A,B mismatches improved the 2 year graft 
survival to 82%, whereas zero DR mismatches with one, 2 and 3-4 A,B 
mismatches had 76%, 72% and 57% graft survival respectively (157). 
The UK Transplant Service has reported that first cadaver grafts with 
no HLA-A,B,DR mismatches had a striking 93% one year survival (148). 
It appears, therefore, from these studies that matching for HLA-A,B 
and DR has a cumulative effect, although other reports found that 
matching for HLA-A, B had an additional effect only in the DR 
incompatible grafts, but no effect in grafts with zero DR mismatches 
(146,154).
After the introduction of cyclosporin in renal transplantation, 
a Scandinavian multicentre study reported that HLA-DR matching no 
longer had any effect on graft survival and therefore was 
unnecessary, as one year graft survival rates for zero, one and 2 DR 
mismatches were 74%, 78% and 79% respectively (158). Similar results 
were obtained from Kahan et al (159), Taylor et al (160) and Ferguson 
and Sommer (161). However, other multicentre and single-centre 
studies have shown that HLA matching still has a beneficial effect on 
graft survival in patients treated with cyclosporin. The Canadian 
multicentre trial showed a clear trend towards improved graft 
survival with both HLA-A,B and DR matching from 73% to 89% when 
two-antigen identity was found in either locus (162). A similar 
trend was reported in 522 transplants by Terasaki's group who found a 
6 month graft survival of 79% and 70% in donor-recipient pairs with 
the best and worst HLA-B and DR matches respectively (163). Perhaps 
the strongest evidence that HLA-A,B and DR matching continue to be 
important in renal transplantation comes from Opelz in his CTS report
(164) and in a single-centre report from Oxford (148). In the former
study the actuarial one year graft survival was 76% in 2,198
transplants treated with cyclosporin compared to 64% of 6,392
transplants treated with azathioprine and prednisolone. This 
difference was highly significant. The difference in outcome between 
the best and worst HLA-A and B matched grafts was 10% in both 
cyclosporin and azathioprine treated patients. Similarly, grafts
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well matched at the DR locus had 10% better survival compared to 
those poorly matched in both groups treated with cyclosporin and 
prednisolone/azathioprine. Furthermore, matching for HLA-A,B and DR 
had an additive effect on improving graft survival in both groups, 
and the best survival of 86% was obtained in 161 first cadaver 
transplants treated with cyclosporin where there were no mismatches 
at the HLA-B and DR loci. This result was significantly better than 
the 67% graft survival of 181 cyclosporin treated recipients with 4 
HLA-B and DR mismatched grafts. The results from Oxford were based 
on 135 cyclosporin treated first cadaver grafts and they showed an 
84% graft survival at one and 5 years for the zero DR mismatched 
grafts compared to 75% and 59% for those with one DR mismatch and 61% 
and 57% for those with 2 DR mismatches respectively.
Despite the controversies which surround HLA matching in the 
cyclosporin era, most centres continue to use tissue typing as a 
means of improving graft survival. As HLA-A and B alleles are highly 
polymorphic, most attention has been focused on DR matching followed 
by HLA-B and then HLA-A locus matching.
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II DELAYED TYPE HYPERSENSITIVITY
The activation of T cell dependent immune responses results in 
a state of specific immunity called cell-mediated immunity (CMI). 
CMI reactions are found a) during infection by certain 
micro-organisms, b) as a component of immune reactions against 
tumours and transplanted tissues, c) in some autoimmune diseases, and 
d) in delayed type hypersensitivity (DTH) reactions.
DTH (type IV hypersensitivity) is a T cell dependent phenomenon 
manifested as an inflammatory reaction at the site of antigen 
deposition, usually the skin, which takes more than 12 hours to 
develop and with the exception of the granulomatous type of DTH, 
reaches its peak within 24-72 hours of antigen challenge. It is, 
therefore, distinguished from allergy or immediate hypersensitivity 
(Type I) , antibody-dependent hypersensitivity (Type II) , and immune 
complex mediated hypersensitivity (Type III) (165). There are 4 
types of DTH, namely, the Jones-Mote reaction, the tuberculin-type 
reaction, contact sensitivity and the granulomatous DTH. The 
Jones-Mote reaction is characterised by numerous basophils in the 
cellular infiltrate, its maximal reaction time is at 24 hours and it 
is transferable by immune serum, as well as by cells (166). 
Tuberculin-like and contact sensitivity both peak at 48-72 hours 
after antigen challenge and are characterised by intense induration 
containing mainly mononuclear cells. The site of induration in the 
tuberculin-like reaction is the dermis, whereas in contact DTH it is 
the epidermis (165). The reaction on both occasions is transferable 
by purified T cells, but not B cells or immune serum from immunised 
to non-sensitised animals (165, 167). In granulomatous DTH the
lesion develops over a period of weeks and is the result of a 
cellular reaction around discrete loci of antigen in high 
concentration.
DTH is an in vivo phenomenon which provides information on all 
the factors involved in CMI. This includes the individual capacity 
to respond to an antigen with the induction of activation of the 
relevant T cell subsets, the capacity of these cells together with 
APC and recruited cells to react with the specific antigen, and the 
capacity of the tissues to respond to the
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inflammatory agents generated from these reactions. Several in vitro 
tests which have been devised to correlate with DTH provide useful 
information which, however, cannot replace DTH as an in vivo source 
of evidence concerning the function of interacting cells in CMI.
History
The first description of DTH possibly dates back to 1798, when 
Jenner observed a papular erythematous lesion which peaked in 24-72 
hours after vaccination. In 1890 Koch reported the tuberculin-like 
reaction and the following year Epstein discussed its diagnostic
value in tuberculosis (168, 169). These initial observations were
not recognised as DTH reactions, and it was at the beginning of the 
20th century that the concept of hypersensitivity was established as 
an immunological response which can lead to tissue damage. Portier 
and Richet in 1902 observed the immediate type hypersensitivity (170) 
which von Pirquet later called allergy (1) . At that time the
tuberculin reaction was interpreted as a local anaphylactic reaction 
similar to that described by Arthus in 1903 following the daily 
subcutaneous injections of horse serum in rabbits.
The tuberculin reaction was separated from anaphylactic 
reactions by Zinsser who showed that DTH to tuberculin could not be 
passively transferred in guinea pigs by highly specific immune sera, 
as opposed to the Arthus reaction which was transferable in this way 
(171, 172). The first histological confirmation of the two different 
forms of reaction came from Dienes who described the tuberculin
reaction as being characterised by the slow development of an 
infiltrate with mononuclear cells, whereas in the anaphylactic 
reaction there was a rapid development of oedema followed by an 
intense polymorphonuclear infiltration (173,174).
The first contact sensitivity reaction was produced by 
Jadassohn in 1896 using mercury (175) and several years later Nestler 
and Cash sensitised themselves to Primula obconica and to East Indian 
Satinwood respectively (176). The systematic study of the contact 
sensitivity reaction was carried out by Landsteiner and his school 
(177). They worked with chloro and nitro-substitution products of 
benzene such as 2,4-dinitrochlorobenzene (DNCB) and
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picryl chloride (2,4,6 trinitrochlorobenzene) and suggested that 
simple chemicals like these could become antigenic substances upon 
conjugation with proteins in the skin of sensitised animals.
Landsteiner concluded that DNCB is a typical compound of contact 
dermatitis in humans and he observed that such sensitivity could not 
be transferred passively with serum in the same way as anaphylaxis. 
The passive transfer by Landsteiner and Chase in 1942 of contact 
sensitivity in guinea pigs to picryl chloride by peritoneal exudate 
cells was a milestone in our understanding of the DTH reaction (178). 
In 1945 Chase succeeded in passively transfering the tuberculin 
reaction using the same cell type (179). Also, Chase in 1941 on the 
basis of previous evidence of different degrees of contact 
sensitivity within groups of guinea pigs, proved by breeding
experiments that the susceptibility to skin sensitisation with DNCB 
was influenced by heredity (180).
By means of these experiments Landsteiner and Chase established 
that specific cellular immunity was mediated by sensitised 
lymphocytes and not by serum antibody, this at a time when T cells 
were not known to be the specific mediators of these reactions. 
These investigators found that when they used syngeneic guinea pigs 
to transfer DTH reactions, all the recipients developed strong and 
long lasting responses. By contrast, when an outbred population of
guinea pigs was used, the DTH reactions did not develop in all
recipients and were not as strong and long lasting as those in the 
inbred population (178). The explanation of these results was not 
clear at that stage and they were interpreted as rejection-type 
phenomena. The framework for understanding these findings came later 
with the description of the MHC-restriction phenomenon by Shevach and 
Rosenthal (47) which has been discussed in the previous section of 
this thesis. Thus, the successful transfer of DTH in the outbred 
population probably occurred because recipients and donors were MHC 
compatible, whereas in the unsuccessful transfer, the donor-recipient 
pairs most likely were incompatible.
Medawar and his school studied the relation between DTH and 
allograft rejection. They showed that a tolerated skin graft could 
be rejected when the host was injected with lymphoid cells from a 
syngeneic animal which had been previously injected with donor skin.
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This event seemed to have similarities with the passive transfer of 
DTH. Later, they produced a tuberculin-like reaction by injecting 
cells from regional lymph nodes of an allograft recipient back to the 
skin of the donor (181). The finding that a homografted animal 
expressed a DTH response which was transferable by lymphoid cells to 
its donor strengthened the relation between skin allograft rejection 
and DTH then, and until the present day (182, 183).
In 1961 Miller provided the first clear evidence that DTH 
reactions form a distinct group of immune responses dependent on 
thymus function by showing that skin graft rejection could be 
prevented in neonatally thymectomised animals (7,184). Soon after 
the subdivision of immune responses into cellular and humoral (5-16), 
Huber et al (185) and Vadas et al (186) showed that the T cells 
responsible for DTH carry the same surface markers as T helper cells, 
and therefore are different from T cytotoxic and T suppressor cells 
which were also known by then to mediate effector cell functions 
(187-191). The lysis of allogeneic cells by sensitised T cytotoxic 
cells was documented in tissue cultures (187-189) and the role of T 
suppressor cells was demonstrated by Asherson and Zembala who 
produced suppression of contact sensitivity to trinitrochlorobenzene 
(picryl chloride) in mice by intravenous injection of trinitrobenzene 
sulfonic acid and subsequently transferred this suppression to 
non-sensitised recipients (190,191). This sequence of events had 
been described in guinea pigs as the Sulzberger-Chase phenomenon and 
represented one of the earlier examples of tolerance to contact 
sensitivity (192,194). Guinea pigs fed or injected with picryl 
chloride were no longer able to develop contact sensitivity upon 
exposure to the chemical on the skin, presumably due to suppressor T 
cell activity induced by the systematic exposure to the antigen.
The activation of macrophages in the process of DTH was 
observed in 1928 in the original studies by Rich and Lewis (66) . 
After the discovery of MIF in 1966 it was realised that soluble 
agents released locally by antigen-sensitised lymphocytes could not 
only inhibit the migration of non-sensitised lymphocytes from 
capillary tubes (66-68) but also resulted, when injected 
intradermally, in skin reactions with DTH characteristics (195).
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From this historical review it is interesting to note that the 
study of DTH started in relation to defence mechanisms in 
tuberculosis, was then followed by critical experiments on contact 
sensitivity with fascinating results and later attracted the interest 
of transplant researchers. The role of DTH has now been defined both 
in the defence mechanisms of intracellular micro-organisms and in 
local tissue damage resulting from cell-mediated immunity which 
involves interactions between sensitised lymphocytes, activated 
macrophages and lymphokines.
Cellular interactions in DTH
DTH is primarily associated with two types of cells, T helper 
cells and macrophages which are the APC (167). As DTH is an in vivo 
phenomenon, the requirement for APC in the induction of DTH is not 
apparent. However, it was shown that doses of antigen that are not 
immunogenic by themselves become highly immunogenic when associated 
with macrophage rich cell populations (40-44, 196).
The mode of antigen presentation to T helper cells in 
association with class II MHC antigens on the surface of interacting 
cells has been discussed in the previous chapter (44,47-65). The 
role of MHC in DTH was shown in the early experiments of Landsteiner 
and Chase from the successful transfer of DTH reactions using inbred 
guinea pigs (178), although its significance was not understood then. 
The explanation came later from the work of Zinkernagel and Doherty 
(197-199) and Vadas and Miller (196,200,201). The former 
investigators found that T cytotoxic cells will recognise and lyse 
virus infected cells only in the context of the same MHC antigen to 
which sensitisation took place. This finding, together with the 
observation of Vadas and Miller that identity at the H-2 complex was 
essential to successfully transfer DTH in mice, suggested that the 
MHC could form part of the antigen specificity in CMI reactions.
Following this information, two theories developed to explain 
antigen recognition by immune cells depending on whether the T cell 
antigen receptor recognises both MHC and antigen together or whether 
the receptor sees antigen and another surface marker sees the MHC. 
These theories are referred to as 'associated recognition' and 'dual 
recognition' respectively (reviewed in 202). With the very recent
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characterisation of the T cell antigen receptor, it is now known that 
both antigen and MHC molecule are recognised together by the receptor 
(202,203). T helper cells recognise antigen on the surface of APCs 
in association with class II molecules and T cytotoxic cells in 
association with class I molecules. T suppressor cells appear to 
recognise both free antigen and the MHC but it is not clear whether 
they use the same type of antigen as other T cell subsets (203-205).
The influence of Ir genes on DTH has been reviewed in the 
previous chapter (111,114-117,121-129). The evidence which showed 
that DTH reactions are under the control of the Ir genes was provided 
by experiments using inbred strains of non-responder and responder
animals which differed only at the I region of the MHC. These
animals were tested for their immune responses to synthetic 
polypeptides either by quantitating an anti-hapten response using the 
antigens as carriers or by direct measurement of DTH to the antigens. 
As DTH reactions are T cell dependent phenomena, the Ir gene control
is expresssed at T cell level.
The Langerhans cell
Paul Langerhans described these cells in 1868 as an 
intraepidermal sensory receptor for extracutaneous signals to the 
nervous system (206). Having been considered as such for more than a 
century, evidence obtained in the early 1970's rekindled interest in 
the Langerhans cells (LC) . The possible role of LC as an 
immunologically active cell was first suggested by the observation 
that they were morphologically indistinguishable from the histiocytic 
cell in histiocytosis X (207) and by the finding of mononuclear cells 
in apposition to LC in DTH lesions induced by DNCB in guinea pigs 
(208). This information was followed by a search for surface markers 
which have fully characterised the LC. We now know that LCs are bone 
marrow-derived, non-phagocystic APC, representing 2-4% of the total 
epidermal cell population (209, 210). They express la (DR), CDl (T6) 
and CD4 (T4) antigens, carry Fc receptors for IgG, receptors for C3 
and produce IL-1 (reviewed in 211, 212). Their distinctive,
racket-like cytoplasmic organelles, the so-called Birbeck granules 
are the only reliable morphological marker and are CDl (T6) positive 
(212). The function of the Birbeck granules is still unknown. Katz
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provided evidence that LCs are not a stable resident population of 
the epidermis, but rather derive from precursor circulating cells 
that migrate into the skin (210) at a daily repopulation rate of 
about 45 million LCs for the entire skin (212). The largest number 
of LCs occur within the epidermis in close proximity to the 
superficial vascular plexus, the postcapillary venules of which are 
the sites of inflammatory cell immigration, histamine-induced 
vascular permeability and immune complex deposition under different 
pathological conditions. Skin lymphatics start with open ends within 
the papillary dermis and drain lymph to regional lymph nodes. Lymph 
nodes, with LCs and the rest of the dendritic APCs, namely the 
intermediate cells, the interdigitating cells and the veiled cells 
constitute the skin immune system which plays an important role in 
immunisation and tolerance mechanisms.
Stingl et al showed that LCs in guinea pigs not only share 
common surface markers with macrophages but also behave similarly at 
a functional level in their capacity to present antigen to T 
lymphocytes in an MHC-restricted fashion (209). Epidermal cell 
suspensions are also potent stimulators of allogeneic T cell 
proliferative responses (213) and can induce generation of T cell 
cytotoxicity against alloantigens and hapten-modified syngeneic cells 
in mice (214). Small numbers of dendritic cells taken from draining 
lymph nodes of mice one day after sensitisation with picryl chloride 
were sufficient to induce primary stimulation of lymphocytes in vitro 
and to transfer DTH reactions in vivo (215). Similar results were 
obtained in humans utilising human LCs in autologous and allogeneic 
MLC (216,217). The response of allogeneic lymphocytes to human LCs 
depended on the degree of HLA-DR mismatch and the stimulation was 
blocked by both monoclonal and alloanti-DR sera (217).
There is therefore, abundant evidence of the importance of LCs 
in the induction of contact hypersensitivity and allogeneic 
cytotoxicity and their role in graft rejection, tumour immunology and 
defence mechanisms to viral and other intracellular pathogens.
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The list of antigens that can initiate DTH reactions is large 
and they have been reviewed recently (218). They include:
1) Intracellular bacteria:
Mycobacterium tuberculosis 
Salmonella typhosa 
Brucella abortus 
Listeria monocytogenes
2) Fungi:
Candida albicans 
Cryptococcus neoformans 
Histoplasma capsulatum
3) All viruses and chlamydia
4) Insect bites
5) Serum proteins and other simple protein antigens
6) Simple chemical compounds:
Oxalone
Beryllium fluoride 
Potassium dichromate 
Mercuric chloride 
Benzene compounds
The DNCB skin test
Since Landsteiner and Jacobs in 1935 reviewed contact 
sensitivity with simple chemical compounds, sensitisation and 
challenge skin tests with DNCB have been extensively used as one 
parameter of CMI (219, 220). DNCB was selected then because it was 
shown to be a suitable compound and it has been used as such until 
now, because a) it is a simple in vivo test, b) a primary response is 
obtained as previous exposure to DNCB is rare (221) and c) 85-95% of 
normal people can be sensitised to this antigen (222-225).
Following the demonstration in 1930 by Bloch and 
Steiner-Wourlish that guinea pigs could be sensitised to an extract 
of the leaves of the plant Primula obconica, which belongs to the
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genus of Rhus (226), Landsteiner and Jacobs, while studying plant 
extracts from this genus, found that the common factor which caused 
conduct sensitivity in guinea pigs was a chloro or nitro-substituted 
benzene. Out of 20 compounds which they tested, 10 produced DTH and 
of these 10 they favoured DNCB and picryl chloride as the most 
suitable test agents.
The sensitising properties of DNCB are related to its ability 
to act as a hapten forming covalent bonds with the g-amino groups of 
lysine residues of epidermal proteins (227) . Using radioactive 
techniques it was shown that less than 5% of the applied DNCB binds 
to epidermis and about 85% of the dinitrobenzene groups were bound to 
lysine residues (228).
The technique of DNCB sensitisation has varied considerably and 
inevitably there has been a subjective element in the interpretation 
and quantitation of the test. The most widely used method has 
consisted of measurement of redness and induration of the skin in 
response to DNCB. Other methods such as employing engineering 
calipers for measurement of the induration or radioisotopic 
measurement of the intensity of the cellular infiltration may be more 
accurate and objective but are too complex for routine use (167,218).
The pathology of contact sensitivity lesions has been 
extensively studied in guinea pigs rabbits, mice, rats and humans and 
the findings have been similar in all species, resembling those of 
the tuberculin-like reaction (218,229-235). In the latter reaction 
the findings were confined to the dermis and in contact sensitivity 
to the epidermis.
On application of DNCB to the skin in the guinea pig, a diffuse 
mononuclear infiltrate is formed in the upper dermis at 4-6 hours, 
the peak reaction is reached at 12-15 hours and the same intensity is 
then maintained for 18-48 hours (232). Intracellular oedema is 
evident after 6 hours and although Flax and Ganlfield did not 
describe microscopic vesicle formation (232), Fisher and Cooke noted 
vacualation of epidermal cells 9 hours after skin testing (235). The 
majority of infiltrating cells are T lymphocytes, and macrophages 
form 20-30% of the mononuclear cells with a relative paucity of 
polymorphonuclear leucocytes at all stages of the reaction. In the 
tuberculin-like DTH, macrophages form 59% of the mononuclear cells
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but there are many polymorphonuclear cells at an early stage of the 
reaction (218). Over several days, with the constant growth of new 
cells from the basal layer of epidermis, the antigen containing cells 
are pushed outwards and ultimately lost by desquamation.
In humans the pattern of cell infiltration is similar to that 
in guinea pigs except that the cell infiltrate is not as diffuse in 
the upper part of the dermis but is perivascular in position. Turk 
et al using the acid phosphatase technique to distinguish macrophages 
from lymphocytes found that the former constituted 20% and the latter 
80% of perivascular cell infiltrates 24 hours after skin testing 
(218) . These histological changes started to appear in skin biopsies 
performed 48 hours after the test when a minimum of 30ug DNCB was 
used for primary sensitisation with 3ug being used for challenge 
tests (234). The nature of changes during the primary sensitisation 
and challenge reactions were identical (234).
Removal of the skin where the DNCB was applied 16 hours after 
its application did not prevent the subsequent development of 
sensitivity, yet the draining lymph nodes if removed at 48-72 hours, 
were not capable of transfering sensitisation to histocompatible 
guinea pigs. Successful transfer, however, occurred using lymph 
nodes removed after the fourth day, and this capacity appeared to 
correlate with the presence of large pyroninophilic cells in the 
nodes (230). These cells which were then called 'immunoblasts' 
(236), are now known as T lymphocytes (212,237,238). Using 
immunohistochemical double staining techniques in frozen sections of 
human skin after PPD injections, it was found using T cell specific 
monoclonal antibodies that the majority of infiltrating cells were T 
lymphocytes. Most of them had the helper/inducer phenotype and few 
the suppressor/cytotoxic phenotype (237). Apposition of both T cell 
subsets to HLA-DR expressing cells occurred in the dermis as well as 
in the epidermis suggesting that interactions occur in the skin 
between T cells and APCs. Antigen presenting Langerhans cells 
increased rapidly in numbers a few hours after antigen sensitisation 
(208, 238) and it appeared that the majority of them were leaving the 
epidermis presumably emigrating to regional lymph nodes, spleen and 
thymus (212,238). B cells and plasma cells were not found in the DTH 
lesions (238).
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With the above knowledge in mind (212,239), one could envisage 
the movement of the cellular components in human DTH reactions to 
DNCB as follows. Upon skin sensitisation, DNCB binds to a 'carrier', 
which is an epidermal protein, and thus the hapten-carrier complex 
acts as an immunogen and initiates the induction of a specific immune 
response. Specialised non-phagocytic, HLA-DR positive cells, the 
Langerhans cells (LC), function as APCs continually leaving the 
epidermis through afferent lymphatics. The exact localisation of 
primary sensitisation is still debatable and it remains unclear 
whether it is the hapten, the sensitised T cell already within the 
skin, or the LC-hapten complex that is carried to the regional lymph 
node. Recently it was shown that hapten-carrying dendritic cells can 
sensitise unprimed syngeneic mice (215). Nevertheless, LCs on their 
way to the lymph node change morphology and are referred to as 
'veiled' cells, which again, on reaching the paracortical area (T 
cell area) of the lymph node, change morphology to form the 
interdigitating cells. These cells present the antigen to 
paracortical T cells which in turn become activated and are induced 
to proliferate and differentiate. Effector T precursor cells 
proliferate and some of them differentiate into memory cells, 
whereas, others become effector cells. Suppressor cell precursors 
are simultaneously induced to proliferate and they stop the further 
production of effector cells.
During sensitisation, release of lymphokines plays an important 
role in DTH reactions. Thus, antigen-binding T cell factors are 
released into the circulation and sensitise skin mast cells which 
release serotonin. Through receptors on post-capillary venules 
serotonin induces vasodilatation which facilitates the entry of 
antigen-specific T cells into the site of sensitisation. It is only 
then that the DTH reaction develops in a MHC restricted fashion, 
characterised by the development of the mononuclear cell infiltrate, 
in which non-specific tissue monocytes co-operate with specific 
recirculating T cells to clear the hapten-carrier complex, the 
antigen.
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In Vitro Assays of CMI
Several in vivo functions can take place in cell or tissue 
cultures with reproducible efficiency and precision. It is beyond 
the scope of this thesis to describe in detail and review the 
literature on in vitro assays correlating with CMI. Thus, in this 
section I shall mention briefly some common in vitro tests used as 
correlates of CMI and particularly DTH.
Measurement of T lymphocyte surface markers: The most simple, direct
and commonly used in vitro assay of CMI is the determination of T 
cell surface markers. This can be done either by utilising the 
ability of T cells to non-specifically bind SRBC to their surface CD2 
receptors to form E rosettes (ERFC) (27) or using monoclonal 
antibodies which further detect T cell subsets responsible for 
helper, suppressor/cytotoxic and other regulatory functions (24-30). 
Low or absent ERFC have been found in different immunodeficiency 
states such as various malignancies and viral diseases (240), chronic 
active hepatitis (241), sarcoidosis (242) and autoimmune diseases 
(243-245), suggesting that T cells are either selectively removed 
from the circulation or are unable to form E rosettes.
Characterisation of FcR on T cell subsets is another 
interesting research topic, as T cells defined by the presence of the 
IgG FcR (Tg cells) mediate suppressor function in in vitro systems of 
Ig production and allogeneic MLR, whereas T cells bearing FcR for IgM 
(Tjj cells) mediate helper function (31).
Lymphocyte transformation test (LTT): The majority of lymphocytes
are resting cells which upon antigenic stimulation become activated 
with synthesis of both DNA and RNA. This burst of metabolic activity 
can be measured in vitro by the incorporation of tritiated thymidine 
into the cell during DNA synthesis and it is believed that 
transformation reflects in vivo events (246-248).
The LTT is basically the same regardless of the antigenic 
stimulus used in the in vitro system. Mononuclear cell populations 
are cultured in vitro in the presence or absence of various agents. 
Depending on the stimulus, variable proportions of lymphocytes will 
undergo blast transformation and after a predetermined interval the
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responses of stimulated cells are compared to those of unstimulated 
cells by measuring the radioactivity of the activated cells in an 
automatic scintillation counter (246).
Cell activation in in vitro systems can be produced by 
mitogens, antigens or lymphoid cells (autologous or allogeneic). The 
most commonly used mitogens in man are the plant lectins PWM, Con A 
and PHA and they are considered as polyclonal activators in the sense 
that they non-specifically trigger multiple cell clones. Thus, 
unlike antigens, mitogen-induced lymphocyte transformation is not 
dependent upon prior sensitisation to the particular stimulant (247). 
Con A and PHA have been considered the classical 'pure' T cell 
polyclonal activators, although stimulation of B cells through T cell 
factors has been shown to be possible (247,248). PWM is the standard 
T cell dependent polyclonal activator of B cells, whereas protein A 
of staphylococcus aureus, Cowan I (SAC) and Epstein-Barr virus (EBV) 
are not dependent on T cell presence to induce B cell proliferation 
and differentiation (247-250). Thus in vitro measurement of Ig 
production in T-dependent or T-independent systems are useful means 
of studying cellular interactions.
Antigen-induced blast transformation appears to be dependent on 
previous in vivo exposure to the particular antigen. Commonly used 
antigens include PPD, keyhole limpet haemocyanin (KLH), Candida 
species, tetanus toxoid and DNCB (251-255). These antigens appear to 
stimulate mainly T cells in fractionated T and B cell populations 
(254,255), but in the presence of T cells or antigen-stimulated T 
cell supernatants it was shown that B cell stimulation is also 
possible (254,255). Furthermore, it was observed that PPD and KLH 
may act as polyclonal B cell activators of non-sensitised lymphocytes 
(247). A good correlation was found between in vivo DTH to 
tuberculin and in vitro PPD-induced blast transformation (252). DNCB 
when coupled to autologous or allogeneic PBMC induced lymphocyte 
transformation specifically in leukocyte cultures from men sensitised 
to DNCB (253). Sequential studies showed that specifically reactive 
lymphocytes were first detected at 10 days after the in vivo primary 
sensitisation to DNCB and reached a peak at about 14-21 days (253).
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Mixed lymphocyte reaction (MLR): The in vitro LTT using as
stimulators allogeneic or autologous lymphocytes constitutes the MLR, 
which has been considered as the in vitro model of transplantation, 
and represents T cell blast transformation triggered by allogeneic or 
autologous non-T cells (146, 256). In the allogeneic MLR,
transformation depends on the degree of histoincompatibility between 
responder T cells and stimulator non-T cells, whereas in the 
autologous MLR, T cells are activated only by histoincompatible 
antigens on non-T cells (256).
Both in guinea pigs and humans, lymphocyte transformation in 
MLC correlated with the presence of DTH in the donor in vivo 
(257-261), and the intensity of blast transformation to tuberculin in 
humans showed a good correlation with the size of tuberculin-like DTH 
in the donor (252,258-260) and not with antibody levels (261).
Because the test takes up to 7 days to perform, it has been 
used prospectively only in transplants from related donors as several 
studies showed a good correlation between MLR reactivity and graft 
survival in one haplotype identical sibling transplants (reviewed in 
146) . In cadaver transplantation retrospective studies reported 
conflicting results (146). Today MLR is particularly useful in 
selecting the best donor-recipient pair between two potential one 
haplotype identical donors on the grounds of lower MLR reactivity 
(146).
Also the test has been used to study mechanisms of altered 
immunoregulation in patients with SLE where it was found that in the 
autologous MLR non-T cells were defective stimulators (262,263).
Assays of inhibition of cell migration by antigens: In 1932 Rich and
Lewis showed that tuberculin inhibited the migration of cells taken 
from animals with DTH to tuberculin and described cytotoxic changes 
in these cells (66). The explanation of this phenomenon came later 
with the discovery of the first lymphokine, the migration inhibition 
factor (MIF) which inhibited the migration of macrophages from 
sensitised donors in the presence of the sensitising antigen (67,68). 
In 1962 George and Vaughan first described a test utilising capillary 
tubes to demonstrate inhibition of migration of peritoneal exudate 
cells from guinea pigs sensitised to PPD in the presence of PPD
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(264). Since then various modifications of this test have provided 
the means to establish that this in vitro phenomenon is related both 
in animals and humans to in vivo DTH to PPD (66-68, 264-267),
histoplasmin (266), diphtheria toxoid and ovalbumin (265), Candida 
albicans (268), brucella abortus (269) and DNCB (270).
In clinical practice the migration inhibition test (MIT) has 
been used to detect cellular hypersensitivity in Hashimoto's 
thyroidits (271, 272) ulcerative colitis (272), glomerulonephritis 
(272), Sjogren's syndrome (272), and hay fever (273).
Cytotoxicity assays: In vitro cytotoxicity of effector lymphoid
cells against different targets reflects several in vivo CMI 
mechanisms. Tissue damage is important in the pathogenesis of 
allograft rejection, tumour immunity, DTH and autoimmune disease 
(34-37, 274). This tissue damage can be measured in vitro using any 
of 3 primary methods, namely the entry of dye into damaged cells, 
loss of the ability to adhere and the release of bound radioisotopes 
from damaged cells (275). The last method using chromium-51 has 
proved the most sensitive and reproducible.
Natural cytotoxicity or NK activity does not depend on previous 
exposure to target cell or in vitro stimulation, and appears to occur 
primarily through the FcR without need for opsonisation of the target 
cell with complement or antibody (37,274,276,277). Defects in NK 
activity have been described in bladder carcinoma (278), in breast 
carcinoma (279) and in severe combined immunodeficiency disease 
(280).
Antibody-dependent cytotoxicity (ADCC) involves the coating of 
target cells by specific anti-target cell antibody and destruction by 
effector cells through the FcR (36,281-283). ADCC has been expressed 
for a variety of lymphoid and non-lymphoid cells (282), but the major 
ADCC effector cell appears to be the K cell (36,283). The role of 
ADCC in vivo in autoimmunity and in tumour and allograft rejection 
remains uncertain (182,183).
Cell-mediated cytotoxicity (CMC) has been classified as direct 
and indirect. The former refers to in vivo sensitisation of effector 
cells by allogeneic cells and the classical study model has been the 
GVHR (284) . The indirect CMC has been studied in MLR where it
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appears to be generated as cell-mediated lympholysis (CML) following 
blast transformation by allogeneic stimulation (282,285). In both 
CMC and CML the effector cells appear to be T cells (284,285) and
they have been implicated in the mechanisms of graft rejection
(reviewed in 182, 183).
DTH skin testing in clinical practice
DTH skin testing using recall antigens or DNCB have been useful 
means of detecting immunodeficiency states and helping to give an 
accurate prognosis for many conditions in clinical practice. The 
list of conditions in which anergy or impairment of DTH reactions 
occur in disease states is long and includes congenital and acquired 
immunodeficiency disorders (286), sarcoidosis (286-288), lymphomas
and leukaemias (286, 289-291), multiple myeloma (291), various
malignancies (292,293), alcoholic cirrhosis (294) and hepatitis B 
carriage (295). A large number of infections have been associated
with anergy (reviewed in 296) and they include measles, rubella, 
mumps, varicella, infectious mononucleosis, yellow fever, 
tuberculosis, lepromatous leprosy, syphilis, brucellosis, scarlet 
fever, streptococcal infections, histoplasmosis, blastomycosis, 
coccidioidomycosis, toxoplasmosis, schistosomiasis (296) and 
influenza (297) .
Meakins et al produced a number of papers showing a strong 
correlation between sepsis and mortality following surgery and DTH to 
recall antigens (298-301). These findings were confirmed by Bradley 
et al (302).
Also advanced age (286,303,304), debilitating diseases (305), 
malnutrition (286,306,307) and immunosuppressive agents such as 
steroids, x-rays and ultraviolet radiation (286,308,309) have been 
found to depress DTH.
In the following chapter I shall discuss in detail the immune 
responses in uraemic patients.
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Ill IMMUNE RESPONSES IN URAEMIA
Immunologic alterations in uraemia have been the subject of 
study for many years. Among the many immune defects which have been 
attributed to uraemia lymphocytopenia has been recognised since the 
1930s (310). Although uraemia has been termed 'nature's
immunosuppressive device' (311) and the profound suppression of CMI 
has been reviewed by several authors (311-317), there are still 
conflicting findings in the literature with regard to the effect of 
uraemia on CMI and humoral immune responses. These immunologic 
alterations are not fully understood and there is uncertainty about 
the relationship between the susceptibility to infection which occurs 
in uraemia and the various immunologic defects both in humans 
(316,318) and experimental animals (319). This is due to the fact 
that most of the studies have not concurrently investigated both 
immune and host defence mechanisms in relation to infection 
susceptibility.
Granulocyte function
In 1956 Balch and Evans showed that uraemic rabbits which were 
inoculated intradermally with bacteria exhibited smaller inflammatory 
lesions compared to normal animals (320). This was the first 
indirect evidence of impaired granulocyte locomotion in uraemia. 
This finding was confirmed using microcrystalline monosodium urate
intradermally in normal and uraemic humans (321). However, reports
on in vitro measurement of granulocyte locomotion as studied by 
granulocyte adherence and chemotaxis gave conflicting results.
Granulocyte adherence in patients with renal failure was found 
to be impaired (322) or normal (323,324). In addition during 
haemodialysis it was reported to be enhanced in the first 15 minutes
but returning to normal within 60 minutes (325), or impaired 2 hours
after the start of haemodialysis, returning to predialysis values by 
the end of the procedure (324). The discrepancy in the findings with 
regard to timing of haemodialysis could be explained by the profound 
granulocytopenia observed at the early stages of haemodialysis 
(326,327), but the question of whether or not granulocyte adherence 
is abnormal in chronic renal failure is still unresolved.
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Studies on chemotaxis have produced more consistent results. 
Most investigators have reported depression of both cellular and 
serum chemotactic activity in both ESRF and haemodialysis patients 
(323,328-332) and in acute renal failure in rabbits (333). Baum et 
al found depressed chemotaxis in 40% of 15 undialysed uraemic 
patients, whereas the remainder and also 28 haemodialysis patients 
had normal results (334). In the former patients, chemotaxis 
returned to normal between 3 weeks and 3 months after starting 
haemodialysis. By contrast, other investigators demonstrated that 
defective chemotaxis in ESRF and in haemodialysis patients was 
associated with increased serum chemotactic inhibitory activity 
(328,331,332) which was mediated by a serum inhibitor of Cg fragment 
(332). This defect, once acquired, could not be reversed by 
haemodialysis and neither could it be correlated with infection or 
mortality (332).
Opsonisation of S. aureus and Candida albicans has been 
reported to be normal in chronic renal failure (323,329,335) and the 
metabolic functions of neutrophils, such as oxidative metabolism, O2  
consumption and quantitative protein iodination were also found to be 
normal (323,335). Following transplantation, an unexplained defect 
in Candida opsonisation was observed, but neutrophil metabolic 
function was normal (335). Opsonins are either heat-labile and these 
are thought to be mainly complement components or heat-stable which 
are thought to be antibodies. Serum haemolytic complement activity, 
C g  and C^, were found to be normal in non-dialysed uraemic and 
haemodialysis patients (331, 334,335). Others reported normal C ^  
and C^ esterase inactivator and normal or high C^ but low C g  and C g  
proactivator levels in both uraemic and haemodialysis patients when 
compared to controls (314, 336,337). It seems that although there 
might be a quantitative reduction in some complement components in 
renal failure, this does not result in a defective opsonic capacity 
(323,329). Also it is unlikely that the defective opsonic capacity 
could be associated with the depressed chemotaxis which seems rather 
to be due to the generation of complement inhibitory activity and not 
the low complement levels (328,331,332,334).
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Variable results have been reported from the numerous studies 
of phagocytosis by granulocytes from non-dialysed patients with ESRF 
and those treated by haemodialysis (316,317,323,324,329,335, 
337-340). The majority of these studies reported normal granulocyte 
phagocytosis by both these groups of patients in the presence of 
normal or autologous uraemic serum (317,323,324,335). However, a 
number of studies showed impaired phagocytosis (317,337-339), 
depending upon the particular micro-organism or particle studied 
(317). Two investigators reported reversal of the phagocytic defect 
by haemodialysis (338, 339), and de Gast et al showed that decreased 
carbonyl iron phagocytosis was found only in blood from the venous 
side of the dialyser, but not from the arterial side (341). This 
last finding confirms a previous report suggesting that mechanical 
trauma during extracorporeal circulation through haemodialysers may 
cause neutrophil damage and dysfunction (342).
Intracellular killing of Escherichia coli was found to be 
impaired (340) in patients treated by haemodialysis, whereas killing 
of Staph, aureus was also depressed in haemodialysis patients (340), 
but normal in those with chronic renal failure (323).
With regard to the clearing of organisms and antigens from the 
circulation by the reticulo-endothelial system (RES), it was found 
that severely uraemic rabbits failed to clear bovine serum albumin 
following primary sensitisation but clearance was very effective when 
rabbits were sensitised before uraemia was established (343). In 
another experimental study of acute renal failure, plasma clearance 
of coagulase-negative staphylococci was equally effective in normal, 
sham operated and nephrectomised rabbits (320). In haemodialysis 
patients the clearance of radiolabelled human serum albumin has been 
found to occur at a normal rate (344). However, a defect in monocyte 
Fc-receptor-mediated uptake was described in some patients with 
glomerulonephritis and chronic renal failure from non-immune causes 
(345). Reticuloendothelial and mesangial dysfunction was also 
observed in murine models of immune complex glomerulonephritis (346).
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Humoral immune responses
Studies of the effect of uraemia on humoral immunity have 
produced conflicting findings. Lymphopenia was an early observation 
(310) and was confirmed by many authors in patients with acute (347) 
and chronic renal failure (348-350) and in haemodialysis patients 
(335,348,351,352). These studies described an absolute decrease in 
both T and particularly B cells while the latter was partially 
corrected by haemodialysis (349,350). However, despite this well 
established lymphopenia the evidence for impaired humoral immune 
responses in uraemia is far from convincing.
Serum IgG, IgA and IgM levels were reported to be decreased 
(314) or normal (335,340) and the antibody response of the uraemic 
host to different specific antigens has been variable. In 1956 
Dammin et al described normal IgM synthesis in response to 
immunisation with blood group specific substances (353) and two years 
later Stoloff et al showed that the anamnestic response to diphtheria 
toxoid (which is an IgG response) was also normal (354). These 
initial observations were confirmed later when antibody titres 
against E. coli and Staph, aureus (312), and Brucella immunisation 
(355) were all similar to those in normal subjects. In contrast, 
Wilson et al described poor anti-0 (IgM) and anti-H (IgG) responses 
to typhoid vaccination in uraemic patients (356) and subnormal 
responses were also observed after immunisation against influenza 
(357), KLH (348) and bovine serum albumin in uraemic rabbits (343). 
It is interesting that in the latter study Gowaland et al was able to 
show that an abnormal antibody response to bovine serum albumin 
occurred only when rabbits were immunised with the antigen while 
uraemic. Those animals which were immunised prior to the operation 
gave normal antibody responses when subsequently challenged with the 
antigen while uraemic. This would partly explain the discrepancies 
in the findings by different investigators. It is also likely that 
factors other than uraemia such as patient selection, drugs, 
haemodialysis, blood transfusion and malnutrition might play a role 
in the conflicting results. This was emphasised by a carefully 
designed study in rats in which animals with moderate to severe
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uraemia were found to have comparable antibody responses to sheep red 
blood cells, E. coli, 0X174 bacteriophage and KLH to that found in 
sham-operated and control animals (358).
From these studies it is apparent that uraemic patients are 
usually capable of normal antibody production against a variety of 
antigenic challenges, but a proportion of patients are non-responders 
to these antigens. Studies on hepatitis B vaccination from our own 
and other centres showed that the proportion of the non-responders 
could be as high as 50% (359,360) and so far it is not established 
whether the defect is due to B cell dysfunction or to a deficiency in 
the help required from T cells or both.
Cell-mediated immunity
Contrary to the small number of studies on B cell function and 
antibody production in uraemia, numerous reports have been published 
on CMI. The abnormalities relating to depressed CMI which involve 
primarily T cell subsets, their interactions with antigen presenting 
cells (APC) and B cells, the lymphokines they produce and the 
effector cells they activate have been more clearly characterised in 
the uraemic state.
In 1955 Hume et al reported better than expected renal graft 
survival in nine uraemic humans (361). This observation was 
confirmed by subsequent studies which showed that uraemia prolonged 
survival of skin grafts in humans (353), rabbits (362) and rats 
(363), renal grafts in dogs (364) and cardiac grafts in rats (365). 
The evidence for immunosuppression induced by uraemia was further 
strengthened when skin from uraemic animal donors was promptly 
rejected by normal recipients suggesting that uraemic tissues are not 
altered per se (362).
The series of studies which followed these reports was directed 
towards investigation of the mechanisms involved in the depression of 
CMI in uraemia. Suppressed DTH responses (which will be discussed in 
the next section) did not appear to correlate with the lymphopenia
(366) which has been described in uraemia (335,430,347-352,356). The 
pathogenesis of this lymphopenia is not clear. Impaired production 
of lymphocytes is unlikely as a rapid decrease in absolute number 
occurred within 1-3 days of induction of renal failure in guinea pigs
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(367) . Structural alterations of the RES such as thymic atrophy 
associated with thymosin deficiency, poor development of secondary 
follicles of lymph nodes (317,348,356), hypersplenism (368), 
shortened half-life of lymphocytes (369), presence of antileukocyte 
antibodies and vitamin B6 coenzyme deficiency (317) have all been 
described as features of the uraemic syndrome and might contribute to 
both lymphopenia and functional abnormalities of lymphocytes.
Recent studies utilising monoclonal antibodies showed decreased 
per cent and absolute numbers of peripheral blood total T cells as 
measured by 0KT3 and 0KT11 (351,352,370). The decreased
representation of 0KT3 positive cells was mainly due to a decrease in 
the percentage (351,352) and absolute numbers of 0KT4 cell subsets 
(inducer/helper T-cells) (351,352,370), whereas 0KT8 subsets 
(suppressor/cytotoxic T-cells) were found to be either slightly 
increased (351), decreased (352) or normal (370) resulting in 
decreased (351,370) or normal OKT4/OKT8 ratios (352). One of these 
studies showed that functional assays of suppressor activity did not 
correlate with the numerical assays suggesting a discordance between 
marker and functional assays of suppressor cells (370). NK cells as 
measured by the monoclonal Leu-7 were decreased and NK activity, 
which is exhibited by cytolysis without prior sensitisation, was 
impaired in haemodialysis patients (351).
One of the first questions investigators dealt with was whether 
endogenous immunosuppression in uraemia was due to a cellular defect 
or to suppression by uraemic serum or plasma. Lymphocytes from 
uraemic patients have been reported to show impaired ability to 
stimulate an inflammatory response in the skin of normal recipients 
compared to cells from normal subjects (371). This lymphocyte 
transfer test is the in vivo equivalent of the in vitro two-way MLR. 
In both one-way and two-way MLR, uraemic lymphocytes have been shown 
to possess defective stimulatory activity in humans (352,372-374) and 
animals (375,376). One report, however, found that lymphocytes from 
haemodialysis patients had a normal ability to respond to and 
stimulate allogeneic lymphocytes in a one-way MLR (377). The authors 
of this study suggested that differences in cell culture techniques 
might explain some of the contradictory results. Further evidence of 
impaired reactivity of uraemic cells comes from reports suggesting
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that the graft versus-host reaction is suppressed in uraemic rats 
(375,378,379) and is mediated by a population of adherent suppressor 
cells (375,378).
In vitro blast transformation of lymphocytes from uraemic 
patients after stimulation with PHA has been found to be either 
depressed (335,340,349,352,373), normal (348,374,377), or even 
increased (369). Variable results utilising the lymphocyte 
transformation test (LTT) in uraemia were also reported using other 
polyclonal activators. Stimulation with PWM was impaired (352) or 
normal (377) and with PPD was either suppressed (380) or increased 
(366). Blastogenesis induced by Con-A (340,349,352), LPS (373), KLH 
and streptokinase-streptodornase (348) was reported to be decreased. 
From these studies it is apparent that conflicting LTT results were 
obtained using both T-cell (PHA, Con-A) and B-cell (PWM, LPS) 
polyclonal activators. Furthermore discrepancies were not limited to 
studies with uraemic humans, but extended to animal models. In 
uraemic rats, Alevy et al reported depressed blast transformation in 
response to PHA, Con-A and LPS (381,382), whereas Miller and Stewart 
found normal responses to stimulation with Con-A (383). Various 
reasons have been put forward to explain these discrepancies such as 
differences in blood samples (341), separation of cells, contamination 
of or duration of cell culture (348,377), viability of cells, 
counting efficiency and expression of results (369), concentration of 
activating substances (383) and suspension of the culture in 
autologous uraemic serum, normal human serum or fetal calf serum 
(369,374,377).
From this controversial data it is not possible to say whether 
the impairment in lymphocyte function is due to a primary defect in 
cellular function or whether the defect is in the host milieu. Most 
of the studies described an inhibitory effect of uraemic serum on 
blastogenesis of uraemic lymphocytes (335,372,374,377,383,384). When 
lymphocytes were washed and resuspended in normal serum the 
suppression was abolished (372,374,384). Numerous studies attempted 
to characterise the metabolites responsible for the inhibitory effect 
of uraemic sera on lymphocyte transformation. The list of the 
postulated mechanisms include increased levels of middle molecules 
such as methylguanidine and guanidinosuccinic acid, cAMP,
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corticosteroids, antileukocyte antibodies and lymphocytotoxic 
antibodies, and decreased levels of thymosin and vitamin B6 coenzyme 
(317). With regard to whether haemodialysis has any effect on the 
already compromised CMI, the evidence is inconclusive. Several 
studies did not find any difference in CMI parameters such as DTH, 
LTT, MIF and antibody production between non-dialysed and dialysed 
patients or before and after haemodialysis (348,369,372,374). In 
contrast, Newberry and Sanford reported improvement in CMI due to a 
dialysable suppressive factor (384), whereas Ludwig et al described 
further reduction in PWM-, Con A-, and PWM-induced blastogenesis 
during the early phase of dialysis followed by a marked increase in 
the response after 4 hours of haemodialysis (385). It has been 
claimed that CAPD restored CMI responses more than does haemodialysis 
due to better clearance of middle molecules (386-388), but this has 
not been confirmed by others (373,389,390).
Gouillou et al using the Con-A enhancement technique, which is a 
test that measured Con-A-induced antigen non-specific suppression, 
reported that diminished CMI responses in haemodialysis patients were 
partly associated with retention of or increased T-suppressor cell 
activity (391). This finding was in agreement with results obtained 
in uraemic rats using MLR and GVH assays (375,378,379). Subsequent 
studies, in humans however, which investigated Con A-induced 
suppression found lower or normal suppressor cell activity in 
haemodialysis patients compared to healthy controls (370,392-394) 
suggesting that T-suppressor cells were not involved in the 
immunodeficiency of uraemia. Other factors such as blood transfusion 
significantly increased the function of suppressor T cells although 
their number did not change (394).
Other in vitro correlates of CMI which have been reported to be 
suppressed in uraemia are antibody-dependent cell cytotoxicity and 
cell-mediated cytotoxicity (395) and production of lymphokines 
including MIF (270, 348,355), interferon (396) and interleukin-2
(352).
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Delayed hypersensitivity
DTH has been traditionally thought to reflect in vivo CMI 
responses which involve primarily two cell types, T helper cells and 
APC, as discussed in the previous chapter.
Numerous studies have decribed impaired DTH to skin test 
preparations in both non-dialysed (348,356,366,397) and dialysed 
uraemic patients (334,340,348,356,366,387,398-411) and in uraemic 
animals (412). The substances that have been utilised in skin 
testing to assess CMI in these reports have included either common 
recall antigens such as PPD, histoplasmin, Candida, monilia, mumps, 
trichophyton, coccidioidin, streptokinase-streptodornase and proteus 
(334,340,348,356,366,387,397,398,403-405,409,410) or de novo antigens 
such as DNCB (398-403,406-408,411), KLH (348) and oxazolone (412). 
There is general agreement that suppression of DTH is a manifestation 
of the uraemic syndrome. The proportion of non-responder patients, 
however, Varied widely from 28-87% using recall antigens (356,404) 
but was less variable (49-84%) using the DNCB skin test (398,406). 
In control groups the proportion of non-responders to skin tests with 
recall antigens and DNCB has been reported to be less than 2% and 
5-15% respectively (222-225, 399,409). These variable percentages 
are due to differences in protocols of sensitisation and the timing 
of sensitisation or other factors that might interfere with 
expression of CMI by skin testing. For example, Valderrabano et al 
noticed an increase in non-responders from 46% to 63% within 3 years 
of introducing a policy of deliberate blood transfusion in their unit 
(410).
The interest in monitoring CMI in uraemic patients using simple 
skin tests was promoted by Rolley's initial observation that 
non-responders to both recall antigens and DNCB had better renal 
graft survival (398). This finding was supported by a series of 
publications from our unit (399-402) and elsewhere (403,408-410) 
while other reports were unable to confirm an association between the 
response to DNCB and transplant outcome (406,411).
Another area where skin tests found clinical application in 
uraemic patients, was the association between DTH responses and the 
susceptibility to both infections and cancer. A number of reports 
from Canada described a positive correlation between cutaneous anergy
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to recall antigens prior to transplantation and development of 
post-transplant infections and cancer (404,405). These results, 
however were not confirmed by other studies (413, 414).
Despite these numerous studies it is still not clear at what 
stage uraemia affects the induction of DTH. From the evidence 
reviewed in this chapter it appears that uraemia-induced alterations 
in both morphological and functional properties of T helper cells and 
APC might be involved in the suppression, suggesting a defect in the 
afferent limb of the DTH response. On the other hand the fact that a 
variable proportion of uraemic patients have normal responses to skin 
tests suggests that uraemic lymphocytes are not intrinsically 
defective but a suppressive host milieu might alter their reactivity. 
This concept is supported by the failure of lymph node cells to 
transfer PPD sensitivity from non-uraemic guinea pigs to uraemic 
recipients, while transfer has been successful from uraemic donors to 
non-uraemic recipients (415). This suggests that sensitised 
lymphocytes which have the capacity to express DTH in a normal 
recipient are inhibited in the uraemic environment. Furthermore, 
there is evidence that factors other than uraemia such as 
malnutrition (286,306,307), infections (296,297), surgery (379), 
immunosuppressive agents (286,308,309), and blood transfusions 
(393,394,410) might interfere with the expression of CMI and DTH.
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IV THE EFFECT OF BLOOD TRANSFUSION ON GRAFT SURVIVAL
History
Blood has held a mysterious fascination for man from ancient 
times and the history of blood transfusion is full of mysticism, 
pseudo-science and fantasy, leading to bold experiments and a 
multitude of scientific investigations.
One of the earliest references to blood transfusion is in 
Metamorphoses by Ovid in Medea's effort to restore the youth of 
Jason's father. She drained his old blood by cutting his throat and 
then filled his veins with a rich elixir. There are many other 
ancient references to the use of blood (416). The refusal of 
Jehovah's witnesses to receive blood transfusion is based on passages 
from the Old Testament forbiding the eating of blood 'for the blood 
is the life; and thou shalt not eat the life with the flesh'. 
Ancient Egyptians bathed in blood to cure elephantiasis and ancient 
Norwegians drank the blood of seals and whales as therapy for 
epilepsy and scurvy. Galen recommended the drinking of blood for the 
cure of rabies and Pliny the Elder and Celsus described the custom of 
spectators rushing into the arena to drink the blood of dying 
gladiators. Later in 1492 the blood from three robust young boys was 
given to Pope Innocent VIII who was suffering from chronic renal 
failure. This attempt had a devastating outcome as both the Pope and 
the three young blood donors died shortly after the procedure.
All these early references cannot be considered blood 
transfusion as we regard it today because they involved transfer of 
blood per os or through the skin. The first person to advocate blood 
transfusion in the modern sense was Andreas Libavius in 1615 and his 
description of the blood transfusion procedure is an example of man's 
ingenuity. The idea that blood had a certain critical volume within 
the body below which life was in danger was not appreciated until 
William Harvey published his monograph De Motu Cordis in 1628 which 
is the cornerstone of the blood circulation theory. In the 17th 
century, many scientists claimed the honour of being the first to 
transfuse blood. Francis Potter in 1652 attempted blood transfusion 
between chickens and in 1660 Francesco Foli described techniques for 
blood transfusion using silver tubes connecting a vein of the
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recipient with an artery of an animal. The credit for the 
introduction of intravenous therapy goes to Sir Christopher Wren who 
in 1656 proposed the administration of drugs into the veins of dogs. 
Ten years later Richard Lower performed a direct dog-to-dog blood 
transfusion cannulating the cervical artery of the donor and the 
jugular vein of the recipient. Lower was the first to demonstrate 
that a dog could be bled almost to death and then be completely 
restored by blood transfusion, establishing the role of blood 
replacement in severe haemorrhage. Jean Denis in 1667 was the first 
to perform a blood transfusion in a human being. He transfused blood 
from a lamb into a 15 year old boy suffering from epilepsy and he was 
also the first to describe a classical haemolytic transfusion 
reaction. Denis continued his experiments, transfusing blood from 
lambs to five individuals in total, the last of whom died. This 
patient's wife charged Denis with murder, but he was exonerated and 
the widow was subsequently shown to have poisoned her husband with 
arsenic. Following this incident, the Faculty of Medicine in Paris 
and the British Parliament prohibited blood transfusion which 
therefore fell into oblivion for nearly 150 years.
James Blundell, an outstanding obstetrician at Guys Hospital, 
revived interest in blood transfusion as he felt helpless in the face 
of massive haemorrhage during delivery. His approach to transfusion 
was based on a new concept free from ancient ideas of mysticism and 
the desire to use blood as a tonic or to rid patients of evil 
spirits. He showed the shocking effects of blood loss which could be 
reversed by blood transfusion. He also showed that such transfusion 
was not harmful when the donor and recipient belonged to the same 
species. In 1818 he performed 10 transfusions in humans of which 
four were successful and he was rightly credited with being the 
father of modern blood transfusion. Attempts to circumvent the 
problem of blood clotting started in 1835 using stirring processes 
and were brought to a successful conclusion after more than a century 
with the introduction of the acid-citrate-dextrose solution (ADP) and 
the citrate-phosphate-dextrose solution (CPD). These attempts in 
conjunction with the discovery of the ABO blood groups by Landsteiner 
in 1901 provided practical solutions to some problems faced by early 
physicians. Other problems relating to the side effects of blood
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transfusion such as red cell destruction due to immunologic 
mechanisms were not understood until after 1900 and generated a great 
deal of interest among immunologists.
The Effect of Blood Transfusion in Transplantation
In transplant immunology, investigators were aiming to achieve 
graft acceptance by means of either treating allograft rejection or 
by inducing immunologic unresponsiveness in the recipient. The 
conditioning of skin graft recipients by pre-treatment with aliquots 
of blood from the donors was first demonstrated in rabbits by Medawar 
in 1946. He suggested that pretreatment with erythrocytes produced 
prolonged survival of subsequent skin grafts (417). This observation 
was confirmed by several authors in the late 1950's by experimental 
transplantation of skin grafts in mice and rabbits (418-420) and in 
man (421) . At the same time Egdahl and Hume (422) and Monroe et al 
(423) reported hyperacute rejection of renal and musculofascial 
grafts in dogs and rabbits respectively, when the animals were 
pretreated with donor blood. These early studies set the scene for a 
debate on the beneficial or harmful effects of blood transfusion 
which lasted for over 30 years. The balance between immunological 
unresponsiveness and the risk of sensitisation induced by blood 
transfusion has been an exciting and recurring issue in the field of 
renal transplantation.
Kissmeyer-Nielsen et al in 1966 showed that patients with 
preformed lymphocytotoxic antibodies exhibited hyperacute rejection 
of renal grafts (424). This evidence was backed by Terasaki et al 
who showed poorer graft survival in sensitised transplant patients 
(425), and these reports deterred transplant surgeons from 
transfusing patients who were awaiting a kidney transplant.
In 1973 Opelz et al in a retrospective multicentre study of 91 
cadaveric renal allograft recipients produced the first clinical 
evidence of the beneficial role of blood transfusion in graft 
survival. At one year graft survival was 29% in those who had 
previously received no blood compared to 47% in those receiving 1-10 
units of blood (426). This initial report produced considerable 
scepticism, but eventually clinicians started to adopt deliberate 
blood transfusion protocols. This attitude was justified from
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reports showing that as the proportion of the non-transfused 
recipients decreased, graft survival improved. For example, in 1975, 
the fraction of the non-transfused transplants in the Collaborative 
Transplant Survey (CTS) was 35% and the graft survival at one year 
was 45% whereas in 1982-83 those not transfused had dropped to 4% and 
the graft survival improved to 67% (425). So by the early 1980's 
only a few sceptics doubted the beneficial effect of blood 
transfusion on graft survival. The evidence for this effect had 
accumulated from prospective randomised animal studies and data from 
one-centre and multi-centre studies in humans.
In rats, Marquet et al reported specific inhibition of organ 
allograft rejection by donor blood (427). They observed that a 
single intravenous infusion of as little as 0.05ml fresh donor blood 
given between one week and several months prior to transplantation 
increased kidney survival from 12 to 100 days. These results were 
confirmed and extended by Fabre and Morris (428).
Halasz had described earlier the enhancing effect of donor and 
third party blood on skin graft survival in dogs (429) . These 
results were confirmed later in experiments with canine renal 
allografts (430), and were extended by Abouna et al who demonstrated 
that recipient treatment with whole blood transfusions from multiple 
donors was associated with significant prolongation of renal graft 
survival (431). In this study, accelerated rejection did not occur 
even in the presence of cytotoxic antibodies, whereas Fabre et al, 
studying three protocols of blood transfusion in a canine model, 
demonstrated that all transplants which were performed against a 
positive crossmatch failed to function (432). However, where the 
crossmatch was negative, the trend of the results was that the 
transfused dogs had better graft survival than non-transfused animals 
given the same protocol of azathioprine and prednisolone.
In the rhesus monkey, van Es et al described improved graft 
survival following one 20ml blood transfusion with further 
improvement following five 20ml whole blood transfusions (433). 
Myburgh and Smit studied the effect of multiple blood transfusions on 
renal graft survival in an outbred population of baboons and found no 
prolongation of graft survival although donor-recipient MLR was 
significantly reduced in approximately one half of the animals (434).
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In these experimental studies, blood transfusion prolonged 
graft survival in rats, dogs and rhesus monkeys, although not in the 
baboons. In all but one study in the dog (432), the animals did not 
reject grafts in a hyperacute or accelerated manner when transplanted 
with a kidney from a crossmatch positive donor. Furthermore in the 
rat model, cytotoxic antibodies reactive with a transplanted kidney 
appeared to have a strong enhancing effect on graft survival (428).
Following the initial report by Opelz et al (426), a large 
number of reports agreed on the fact that cadaveric kidney graft 
survival was increased in transfused patients compared to the 
non-transfused. Tiwari has reviewed data extracted from 70 reports 
published between 1972 and 1984, and in all but two there was an 
increase in one year graft survival in the transfused patients, this 
increase varying widely from 9% to 70% with a median value between 
10% and 20% (435) . The variation in the results was ascribed to the 
small sample size in some reports and also to the so-called centre 
effect (436). Sengar et al did not find any improvement in the 
transfused group (437), while Jeffery et al (438) reported a decrease 
in graft survival. The main criticism of the majority of these 
studies is that they were retrospective and the groups of patients 
were often not comparable. Since the transfusion effect seemed 
abundantly clear, there was reluctance on ethical grounds to embark 
on prospective, randomised studies. Bucin et al in a prospective 
study of a small group of 10 transfused and 10 non-transfused 
patients showed a striking difference namely 90% and 48% graft 
survival respectively (439). Thus by the early 1980's the finding 
that transfusion was effective in increasing graft survival was 
widely accepted. The concern about the risk of sensitisation was 
outweighed by the 15%-20% improvement in graft survival, particularly 
as graft survival in the transfused patients with cytotoxic 
antibodies was not inferior to that of the non-transfused without 
antibodies (440) . Although most agreed that pre-transplant blood 
transfusion was beneficial rather than harmful, it has never been 
clear which factors were responsible for the prolongation of graft 
survival and there was no unanimity on how to use blood transfusion 
as a means of immunomodulation of the transplant recipient. This was 
indeed the case, irrespective of whether the blood came from random
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donors (not selected on the basis of HLA typing) or from donors 
identical with the recipient for class I HLA antigens or class I and 
II antigens, the so-called donor-specific transfusion (DST).
Blood Component Mediating The Transfusion Effect
The active component of blood which is responsible for the 
preconditioning effect in transplant patients is uncertain. 
Different types of blood have been used and the results have been 
inconsistent. Red blood cells may be separated from leukocytes in a 
variety of ways and the same applies to platelets. Leukocyte-poor 
blood is that which has been separated from the white cells by 
centrifugation and removal of the buffy coat or filtering through 
nylon fibre columns. Washed red cells, providing that the buffy coat 
is removed at each wash, is an alternative means of producing 
leukocyte-poor blood. Frozen, thawed red cells, which are 
deglycerolised by agglomeration (Huggins technique) or by 
centrifugation, (Meryman technique) contain even fewer leukocytes 
because most of these cells are killed by the freezing and the thawed 
cells are then washed to free them from the cryoprotective glycerol 
and the leukocytes (441). Thus depending on the method used, the 
number of white cells contaminating the final red cell product can 
vary widely from nearly 5 billion in whole blood and in concentrated 
red cells to less than 2 billion in filtered or washed cells and to 
less than 10 million in frozen cells (441). This varying degree of 
white cell or platelet contamination of the differing blood products 
is one likely reason for some of the discrepancies reported in the 
literature regarding the variation in transfusion effect on graft 
survival. For example, Polesky et al reported superior graft 
survival using frozen cells compared to packed cells or whole blood 
(442), whereas Horimi et al described the opposite (443). A number 
of authors found no difference between the different blood products 
(444-446). Briggs et al from our own centre showed that transplant 
recipients receiving whole blood or washed cells had a graft survival 
of 77% at one year which was not significantly different from that of 
patients receiving frozen cells (71%). In contrast, non-transfused 
patients had a strikingly worse graft survival of 28% at one year 
(447). Opelz and Terasaki found no benefit from one unit of frozen
77
cells while multiple transfusions had a positive effect on graft 
survival (440). Finally Persijn et al in a prospective study 
described 80% graft survival at 200 days in 40 patients receiving one 
leukocyte-poor blood transfusion (90% of white cells removed) 
compared to 33% survival in the remaining 12 patients who received 
one to three units of leukocyte free blood (98% of white cells 
removed) (448). From these studies it would appear that leukocytes 
are the main mediators of the transfusion effect and the main 
antigenic stimulus for the sensitisation risk as well. Attempts to 
minimise sensitisation without altering unresponsiveness have 
focussed on less immunogenic blood products. Borleffs et al 
described a strong effect on graft survival in rhesus monkeys 
pretreated with random donor platelets (449), and this finding was 
confirmed by Oh and McClure (450). Both authors found a reduced rate 
of sensitisation possibly because platelets bear no class II 
antigens. However, these results have not been confirmed in dogs 
(451) and man (452) . Chapman et al in a prospective protocol in 
humans receiving platelets found no development of cytotoxic 
antibodies but the rejection rate was higher than expected and the 
survival rate of 44% was worse than in non-transfused patients (452). 
A poor graft survival of 55% at six months in 36 patients transfused 
with platelets was also seen in Opelz's multicentre data (453) and 
this did not further encourage platelet administration as a means of 
producing the transfusion effect.
In experimental studies in rats and rhesus monkeys the use of 
plasma only or immunoglobulin did not have any effect on graft 
survival (449, 454) and this was also the case when ultrasonicated 
(454) or irradiated blood was given (455). Purified erythrocytes 
produced enhancement of skin homografts in rabbits (419) but such 
animal models may not predict the outcome in man since most animal 
species express HLA antigens on their erythrocytes, while human red 
blood cells do not.
Amount of Blood
Opelz et al in their initial and subsequent studies found that 
the beneficial effect of blood transfusion increased as the number of 
transfusions increased (425, 426, 440). These results were confirmed
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by Horimi et al (443) and Ferhman et al (456). The former author, 
analysing the UCLA, data, reported an improvement in graft survival at 
one year, from 41% in the non-transfused to 52% with one unit of 
blood. The highest survival rate of 75% was found in those receiving 
14 units of blood, whereas subsequent transfusions did not appear to 
have any further effect (443). Fehrman et al found the best graft 
survival to be in patients receiving 4 to 19 units of blood or 20 
units or more, compared to those receiving zero or 1-3 units. 
Patients receiving 1-3 units did not have significantly better graft 
survival compared to those who were not transfused. Kerman et al 
belong also to the school advocating at least 5 units of 
pre-transplant blood as they described a difference in graft survival 
of 41% between 51 transplant recipients receiving more than 5 units 
and 53 patients receiving less than 5 transfusions (457). In
contrast to this school, Persjin et al, analysing the Dutch data,
described a striking 87% graft survival at one year in 30 patients 
receiving only one unit of blood compared to 32% in 74 patients who 
had not been transfused before transplantation (448) . Thus the 
message from Leiden was that one unit was enough and the effect was 
long lasting (458) . Williams et al from Oxford found that the 
transfusion effect was achieved with 1-3 units of blood (459) and the 
same conclusion was reached by Huncicker et al (446), whereas Feduska 
et al showed that the transfusion effect achieved with 1-5 units of
blood was as good as that resulting from 6-10 units or more than 10
units (460). Briggs et al from our centre also reported that the 
beneficial effect of transfusion was no greater in patients 
transfused with more than 5 units compared to those given less than 5 
units (447).
Ferrara et al in a prospective study used repeated small 
aliquots of 15ml blood from a single donor to induce HLA 
unresponsiveness in volunteer recipients (461). He showed that the 
anti-HLA cytotoxic response decreased progressively with time to a 
state of complete unresponsiveness despite continuation of 
immunisation. This idea was used by Wood et al who tried to induce 
the transfusion effect without provoking sensitisation in skin 
grafted mice which were transfused repeatedly with small aliquots of 
0.2-5ul of donor blood (462). This policy found its clinical
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application in a recent paper by Burrows et al who gave three 
aliquots of third party HLA-defined blood to cadaveric renal 
transplant recipients treated with azathioprine or CyA (463). The 
overall graft survival was 83% at one year, with CyA-treated patients 
having a 95% survival rate compared to 73% for the 
azathioprine-treated patients. However, Sirchia et al in an earlier 
prospective study found that small aliquots were not as effective as 
three standard units of blood in that they achieved 60% graft 
survival compared with 78% at five months in 16 and 18 patients 
respectively (464).
Timing of Transfusions
Controversy is limited not only to the number of transfusions 
required to achieve the maximum effect, but also with respect to the 
optimum interval between the last transfusion and transplantation and 
the efficacy as well of per-operative transfusions.
Werner-Favre et al reported that a delay of more than three 
months between the last transfusion and transplantation significantly 
decreased six month graft survival from 84% to 58% (464). This view 
was supported by Hourmant et al who found that patients transfused 
within three months prior to transplantation had better graft 
survival when compared to those transfused more than six months 
before (466). These findings were supported by a study in mice in 
which maximum graft survival was observed when grafting took place 
within 2 days of the last of three transfusions and less effect was 
evident when grafting was delayed for 60 days (467). In contrast, 
the Leiden group took the opposite view namely that the effect of a 
single transfusion is long lasting (448, 458). Opelz analysed the 
CTS data and found an advantage if the interval between transfusion 
and transplantation was 30 to 90 days as compared to shorter or 
longer intervals only in patients who had received a single 
transfusion prior to transplantation (453). This advantage was 
diminished in recipients who were given 2-5 transfusions and 
disappeared altogether with more than five transfusions.
Stiller et al claimed that per-operative transfusions improved 
cadaveric renal allograft survival from 44% to 79% both in those who 
had never been transfused and in those previously given blood (468).
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Williams et al reported improved graft survival with per-operative 
transfusions only in previously non-transfused recipients (469), 
whereas Corry et al showed that graft survival of the per-operatively 
transfused patients was intermediate between the non-transfused and 
the prior transfused patients (470). Several reports, however, 
including some from multi-centre studies with large numbers, failed 
to find any effect from per-operative transfusion (448,453,460). 
Glass et al argued against the use of per-operative transfusion as 
they found that it was without benefit in previously non-transfused 
patients and resulted in poorer graft survival in previously 
transfused recipients (471).
Storage Time of Blood
As preservatives can protect red cells but not white cells for 
several weeks, the question arises as to how fresh blood should be 
and there is very little information about this. One study showed 
that blood stored for less than three days induced a significantly 
better graft survival compared to blood stored for more than five 
days (425). Differences between centres which were attributed to the 
amount of blood transfused might have been due in part to differences 
in the storage time of blood.
Effect of HLA Matching in Transfused and Non-transfused Recipients
Early studies suggested that the beneficial effect of 
transfusion was confined only to well matched transplant recipients 
(472, 473). While Fehrman et al reported that a beneficial effect of 
transfusion was found only in patients receiving kidneys with two or 
less HLA-A and B incompatibilities (456) , Moen et al described 
increased graft survival only in patients receiving DR mismatched 
grafts (474).
However, most of the studies suggest that HLA matching and 
transfusion have a synergistic effect on graft survival (453, 457, 
459) . Kerman et al found that transfusion enhanced the benefit of 
HLA,B and DR compatibility on graft survival in recipients with less 
than 2 A,B and 0-1 DR mismatches. These patients had a one-year 
graft survival rate of 94% when pretreated with more than five 
transfusions compared to a survival of 38% in those receiving less
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than five units of blood (457). Opelz showed that whereas the effect 
of HLA-DR matching was stronger in non-transfused patients than in 
transfused ones, even well-matched non-transfused patients did not do 
as well as mismatched transfused recipients and the highest graft 
survival rate was observed in those who were both well matched and 
transfused (453). Schulak et al described a combined effect of HLA-A 
and B matching and blood transfusion (475). He found a one year 
graft survival of 87% in patients who were matched for one DR and 
more than two A and B antigens. This compared with a 42% survival in 
recipients with a one DR match but a poorer A and B match. The 
potentiating effect of HLA-A and B matching and transfusion in this 
study was observed only when blood was given prior to transplantation 
and not peroperatively.
HLA Matched Transfusions
In order to minimise the sensitisation risk, Nube et al gave 
HLA-A and B matched blood to 15 patients who had never been 
transfused before and compared their graft survival both with that of 
a historical non-transfused control group and a group who received 
multiple random third-party transfusions (476). The one year graft 
survival of 87% in those who received the HLA-matched blood was not 
significantly different from the 76% in those given random blood but 
was much better than the 76% of the non-transfused group. The 
sensitisation rate in patients receiving HLA-matched blood was 27% 
compared to 43% in those given random transfusions (476). In 
contrast to this report, Albert et al found that HLA-A and B matched 
transfusions were associated with poor graft survival (477), and 
Vanrenterghem et al also did not observe any prolongation of graft 
survival with HLA-A and B matched transfusions (478).
Blood Transfusion and Re-transplantation
Recipients of regrafts have a higher sensitisation rate (479), 
and transfusion prior to a regraft may further increase cytotoxic 
antibody levels. Persjin et al found that blood given between a 
first and second transplant had no effect on regraft survival, but 
patients who had been transfused prior to the failed first transplant 
had a 58% one year survival of a second graft compared to 38% in
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those who had not received any blood before their first transplant 
(480). In contrast, the results from the UCLA Transplant Registry 
did not demonstrate any beneficial effect of transfusion on regraft 
survival, particularly in those whose first graft had functioned for 
less than six months (480).
Third Party Transfusions in Living Related Transplants
A number of studies have been carried out with conflicting 
results. Oei et al found that third-party transfusions (TPT) had no 
effect on the graft survival of living related transplants (481), 
whereas Polesky et al reported minimal benefit (442). In another 
series of studies, Solheim et al (482), Brynger et al (483), and 
Richie et al (484) reported that graft survival improved in one 
haplotype matched grafts but not in HLA identical transplants. Opelz 
in an analysis of the CTS found one year graft survival of 70% in 67 
patients with no transfusion, 75% in 150 patients with one to three 
units of TPT and 90% in 226 patients with more than three TPT (453). 
Similarly, a beneficial effect of TPT in transplants from related 
donors was reported both by Fuller et al (445) and from the UCLA 
Registry (485). In the latter study, graft survival was better with 
TPT in transplants from parents to offspring, one haplotype-matched 
siblings and HLA-identical siblings. The optimum transfusion effect 
was achieved with one to four transfusions and more blood did not 
increase survival rate.
The findings from studies in dogs and monkeys has not clarified 
the controversy. A TPT effect in dogs was evident in DLA-mismatched, 
but not DLA-matched renal allografts (486). In rhesus monkeys, van 
Es and Balner did not find any synergistic or additive effect of DR 
matching and transfusions (433), whereas Borleffs et al did (487).
Effect of Donor Transfusion
Frisk et al reported that TPT given to donors led to a 
significant improvement in graft survival in transfused recipients 
(488). This observation was supported by Jeekel et al both in humans 
and rats (489). In the rat model, TPT given to the donor markedly 
influenced graft survival provided the recipient was transfused as 
well. The transfusion of recipient-type blood to the donor was not
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effective. In humans there was a one year graft survival of 84% in 
patients receiving their grafts from donors who were transfused in 
the period immediately preceding death compared with 53% in those 
whose donors were not transfused (489). Opelz found that the donor's 
transfusion status had no effect on graft outcome either in the 
complete series or in the subgroup of recipients who were not 
transfused (453).
Long-term Effect of Transfusion
The results from a single centre analysis in Scandinavia showed 
that transfused renal allograft recipients had a 20% better early 
graft survival rate than non-transfused patients but that this had 
disappeared by six years after transplantation (490). This confirmed 
an earlier report from the UCLA Registry which showed that the 
difference between transfused and non-transfused transplant 
recipients was established within three months of the transplant and 
beyond one year, pre-transplant transfusions had little or no effect 
on graft survival (485).
The Risk of Sensitisation After Third-party Transfusion
Does the risk of sensitisation offset the potential benefit of 
transfusion? Although sensitisation of some patients is unavoidable, 
identyfing patients at high risk and learning more about the factors 
that trigger broad antibody responses has been one of the main themes 
of research in an attempt to formulate guidelines that may decrease 
the incidence of sensitisation.
Most evidence suggests that blood transfusion on its own is a 
poor inducer of a primary immune response but could strongly amplify 
a response that has occured previously (420, 440, 443, 456, 479). 
Opelz and Terasaki reported that only 58 of 1852 patients (3%) who 
received solely packed cell transfusions had antibody reactivity 
against more than 50% of a random panel (440). Only 1.8% of 
non-transfused patients had broadly reactive antibodies, compared 
with 5.6% of patients who received 1-5 transfusions, 4.4% of patients 
given 6-10 transfusions and 13% of patients who had had more than 10 
transfusions. In another study from the same centre, fewer than 2%
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of the male patients formed antibodies after 10 transfusions against 
more than 90% of the panel compared with 14% of the females (491).
The difference in reactivity between males and females was associated
with the number of previous pregnancies. Almost one in three females 
with more than three previous pregnancies became broadly reactive 
(PRA>90% of the panel) after 10 transfusions. Thus the results from 
UCLA showed that pregnancy is a potent stimulus to the formation of 
lymphocytotoxic antibodies following transfusion which on its own 
results in a surprisingly low rate of sensitisation. In accord with 
this view were the findings from one centre studies by Werner-Favre 
et al (465), and Fehrman et al (456,479). Also a previously 
rejected graft was shown to be another strong co-stimulus with blood
transfusion in the induction of broad sensitisation. Sanfilippo et
al found that only 3% of non-transfused primary graft recipients had 
panel reactive antibodies (PRA) over 60% compared to 4.5% of the 
transfused primary transplants, 14% of the non-transfused recipients 
with one failed graft, and almost 50% of those transfused with two 
previous failed grafts (492). This group of authors felt that the 
benefit of blood transfusion out weighed the sensitisation risk as 
graft survival was better in transfused recipients with PRA compared 
to non-transfused patients without PRA (440, 443).
In contrast, Betuel et al showed that 62% of 77 prospectively 
transfused patients formed PRA and 11% of those with titres of more 
than 76% of a random panel became untransplantable (493). High 
responders producing antibodies before their fifth transfusion were 
especially at risk and had graft survival of 50% at two years 
compared to 73% for those who developed antibodies after the fifth 
unit. A similar view was taken by D'Apice and Tait who removed 
patients from the transplant list if PRA developed to more than 10% 
of the panel after the first two transfusions (494). Solheim et al 
suggested that if patients who died while waiting for a transplant 
because of broad sensitisation are designated as 'graft losses,' then 
the beneficial effect of transfusion was almost lost (495). This 
view is rather extreme as all deaths could hardly be attributed to 
sensitisation and the delay of receiving a transplant. It reflects,
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however, the disturbing prospect of a delay in transplantation which, 
in patients with 3-20% PRA was only three months, while in those with 
more than 80% PRA it was almost two years (496).
The type of sensitisation after transfusion is relevant to its 
beneficial effect. Antibodies with differing specificities may give 
rise to a positive crossmatch between recipient serum and donor 
lymphocytes. These antibodies may be directed against HLA-A and B 
antigens, B cell autoantigens, B and T cell antigens, T cell 
alloantigens and HLA-DR and Lewis antigens (497). Antibodies against 
B cells were found more frequently than antibodies against T cells 
after transfusion (479, 491). Most investigators consider that IgM-B 
cell cold antibodies are enhancing antibodies and prolong graft 
survival, whereas there is controversy about B cell warm antibodies 
(reviewed in 497, 498). There is evidence that IgM cold-reactive T 
and B cell autoantibodies are not directed against HLA-A, B, DR 
specificities and are not damaging to the graft (498). Most centres 
however, would be reluctant to transplant patients who had positive 
B-warm or T-warm crossmatches but it seems that even the presence of 
these antibodies was preferable to no transfusion, since grafts in 
these patients lasted longer (499).
Donor Specific Transfusion (DST)
In 1949 successful skin transplantation from parent to son was 
reported after unintentional conditioning by donor blood transfusion 
(500). The first clinical application of DST in renal 
transplantation was reported by Eschbach et al in 1965 (501). The 
transplant outcome in this case report was unsuccessful due to renal 
vein thrombosis. Two years later Dossetor et al reported the first 
successful renal transplant after DST (502). Batchelor et al 
extracted cytotoxic antibodies from the father of a uraemic child 
after immunisation with his wife's leukocytes. This preparation was 
then administered intravenously as enhancing antibody when the child 
received a kidney from his mother, immunosuppression consisting of 
small doses of azathioprine and prednisolone (503). Newton and 
Anderson reported four successful transplants, two of whom received 
donor blood from non-identical relatives and the other two from 
unrelated live donors (504).
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Cochrum et al (505) described a protocol for DST in 
one-haplotype matched pairs with high reactivity in MLC and it was 
subsequently widely established in clinical transplantation by 
Salvatierra et al (506). Utilising one 200ml unit of donor blood 
given in three aliquots at two week intervals, Salvatierra, reported 
95% and 93% graft survival at one and two years respectively in 86 
recipients who did not develop cytotoxic antibodies after the DST 
(506). These results were significantly better than the 56% and 53% 
graft survival at one and two years respectively in a historical 
control group of one haplotype pairs with highly reactive MLC who had 
not received DST. However, a high sensitisation rate of 30% was 
observed in the series and these patients could not therefore receive 
a kidney from that live donor. The DST effect was confirmed both in 
recipients who had not previously received third-party blood (507), 
and in those who had received such blood (508).
A major problem of DST protocols was the development of a 
positive crossmatch by recipients against their potential kidney 
donors. Efforts to minimise the risk of sensitisation included the 
use of stored blood instead of fresh (509, 510) and the giving of the 
DST as a single 200ml transfusion rather than 3 aliquots (511) . 
Glass et al found that the simultaneous administration of 
azathioprine with DST reduced the sensitisation rate from 31% to 14%, 
yet the one year graft survival remained high at 90% (512). Hillis 
et al gave Cyclosporin from one week before the first DST in 26 
transplant recipients and observed only a transient anti-B cell 
sensitisation which disappeared over 8-12 weeks (513). These methods 
seemed to reduce the immunogenicity of blood in terms of 
lymphocytotoxin production without adversely affecting graft 
survival.
The beneficial effect of DST in one haplotype matched related 
donor transplants was confirmed by Opelz in the CTS data analysis 
(453). However, comparison of patients receiving three units of DST 
with patients receiving more than three units of random third party 
blood without DST showed virtually identical graft survival (453).
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The few reports so far available regarding DST from unrelated 
live donors (504, 514, 515) do not allow conclusive comments. In a 
recent study of 41 such patients, 10 became sensitised (24%) and were 
excluded from transplantation (515). In the remaining 31 recipients 
graft survival was 90% at one year.
Mechanism of the Blood Transfusion Effect
The mechanism of the blood transfusion effect has remained 
uncertain and several attractive hypotheses have attempted to 
elucidate the phenomenon, sometimes contradicting each other. To 
date, despite lengthy debate of the pros and cons of various proposed 
mechanisms, it is impossible to completely resolve the confusion 
surrounding the transfusion effect in renal transplantation.
Selection theory: In clinical studies, a selection factor has been
described in the sense that patients with broadly reactive 
lymphocytotoxic antibodies after transfusion, labelled as 'high 
responders', are either excluded from transplantation or receive 
better matched kidneys (456, 479, 495). According to this theory, 
blood transfusions eliminate transplant candidates whose outcome is 
predestined to be poor or act to select better donor-recipient 
combinations by crossmatching. The observation by Opelz et al, 
however, that transfusion improves graft survival among multiply 
transfused transplants who do not produce anti-HLA antibodies 
provides evidence against this theory, at least in cadaveric 
transplantation where the number of highly sensitised patients after 
transfusion is too low to explain the entire transfusion effect 
(425). This selection theory could be more relevant in DST protocols 
where the sensitisation rate is higher and the improvement in graft 
survival would be compatible with selection by crossmatching (425, 
516) . Findings from experimental models argue against selection 
being the main cause of the transfusion effect (433, 486), but the 
significance of cytotoxic antibodies in precipitating hyperacute or 
accelerated rejection in animals seems to differ from that in man 
(427-431, 433).
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Prolongation of Uraemia: Guttmann found a statistically significant
correlation between the number of pre-transplant transfusions and the 
time of dialysis-dependent uraemia (517). He suggested that this 
association could further promote a selection factor leaving 
sensitised patients waiting for longer periods of time for a 
transplant, thus prolonging the duration of uraemia which is itself 
immunosuppressive. In a study in our own centre relating graft 
survival to the DNCB skin test response, we found that the duration 
of dialysis was associated with the results of this test (402).
Immunisation to CMV: Andrus et al suggested that transfusion induces
resistance to CMV infection during the post-transplant course by 
exposure to the virus in the transfused blood. Subsequent avoidance 
of the need to discontinue immunosuppression contributes to better 
graft survival (518). This argument does not apply to DST protocols 
where few donors have evidence of overt CMV or residual antibodies 
from prior infection. It is unlikely that CMV is related to the 
blood transfusion effect.
Transfusion-associated acquired immunodeficiency: Reports of
acquired immunodeficiency syndrome (AIDS) among haemophiliacs show 
that repeated administration of factor VIII with or without other 
blood products may cause severe immunodeficiency (519, 520). Curran
et al reported 18 cases of AIDS in adults who were not in a high-risk 
group but who had received blood transfusions within five years 
before diagnosis (521). It is interesting that no blood donor with 
clinical AIDS was identified although such a case has been reported 
elsewhere (522). It is not clear, therefore, whether 
transfusion-associated immunodeficiency is due to the blood product 
itself or a contaminating virus or other agent (523-525). As the 
latent period after acquisition is of several years duration, it is 
difficult to determine whether transfusion acquired immunodeficiency 
and the beneficial effect on graft survival are related phenomena. 
However, the former phenomenon has a very low incidence for it to be 
closely associated with the transfusion effect in transplantation 
which has been described in numerous studies both clinical and 
experimental.
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Iron Overload: De Sousa has postulated that the transfusion effect
could be related to accumulation of iron and products of red cell 
breakdown which have been shown to exert a non-specific suppression 
(526). In vitro ferritin suppresses T cell mitogen responses and the 
MLR (527), and serum ferritin levels were found to inversely 
correlate with the OKT4/OKT8 ratio in the blood of transfused 
dialysis patients (528). Patients with iron overload have been 
reported to be susceptible to infection (529), and to have a worse 
prognosis in certain forms of malignancy (530). Keown and Descamps 
applied the significance of these findings to clinical 
transplantation. They suggested that rapid endocytosis of transfused 
erythrocytes in vivo may impair antigen presentation and lymphocyte 
activation resulting in a non-specific erythrocyte-mediated 
unresponsiveness (531). Later the same authors attributed this 
effect to an inhibitory action of haemoglobin, ferritin and iron 
radicals on the proliferation of cytotoxic effector cells (532).
In monkey experiments, graft prolongation was also obtained if 
erythrocyte-free transfusions were given to the recipients (533). 
Also in humans, only one unit of blood, which could not cause 
iron-overload, was sufficient to produce the transfusion effect, a 
response not seen when leukocyte-free blood was used (448, 458). The 
results of these studies argue against any important role of iron in 
the blood transfusion effect.
Induction of Unresponsiveness: There is evidence that blood
transfusion induces both non-specific immunosuppression mediated by 
suppressor cells and specific unresponsiveness mediated by 
anti-idiotypic antibodies (394, 425, 458, 495, 516, 531-537).
Classical enhancement and acquired immunologic tolerance have been 
considered as possible explanations for the transfusion effect. 
However, both seem unlikely to be causative principles as by 
definition they represent donor-specific events and the beneficial 
effect has been described using a single random blood transfusion 
(537). Furthermore, if the transfusion effect is mediated by 
erythrocytes which do not express HLA antigens, then the effect 
cannot be attributed to any hypotheses involving enhancement or 
tolerance in their classical sense (531, 532, 537).
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In an attempt to reconcile these contradictory findings, van 
Rood suggested that non-specific and specific mechanisms act 
sequentially in a two-step or multi-step process (458) . He 
postulated that in an initial stage, suppressor cells are induced 
which suppress the formation of antibodies to class I HLA antigens. 
This is followed by a second stage in which anti-idiotype antibodies 
are formed, preventing activation of T cell clones which could react 
with the class I antigens of the blood donor. Also these antibodies, 
if they differ from those of the blood donor, can react too with the 
class I antigens of the kidney donor. The second stage is thus 
blood-donor-specific and may also be kidney-donor-specific even when 
the blood and kidney donors are distinct and do not have antigens in 
common. However, the inactivation of the responding T cell clones is 
optimal in DST protocols because in these the blood transfusion donor 
and kidney donor share antigens.
The central point in this hypothesis is that blood transfusion 
induces a state of unresponsiveness because T helper cells cannot be 
activated, and therefore if a kidney is transplanted during this time 
it will not be rejected. If this is the case, the effect of 
pre-transplant blood transfusion might be replaced or its importance 
diminished by drugs which are more effective in suppressing T helper 
cells such as antithymocyte globulin (ATG) or Cyclosporin (458) . 
However, pre-transplant transfusions, apart from inducing suppressor 
cell activity may induce T helper cells. This could lead to 
activation of K cells with their strong destructive capacity of 
allogeneic cells in monkeys and mice (533). Thus the balance between 
helper and suppressor activity might be switched either way depending 
on the disparity or matching for certain histocompatibility antigens 
between the host and donor.
The suppressor cell mechanism has been the most attractive 
explanation for the transfusion effect and the supporting evidence 
has resulted from research efforts utilising various suppressor cell 
models mostly in animals and to a lesser extent in humans. This has 
inherent limitations as no consensus exists with regard to the most 
appropriate model for suppressor cell studies which might be relevant
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to man. It has been difficult to establish which of the in vitro and 
in vivo experimental findings were relevant to the transfusion effect 
observed in human transplants (516).
MacLeod et al, in a series of papers, suggested that 
non-cytotoxic, Fc receptor blocking antibodies can develop in 
response to random and donor specific blood transfusion and their 
presence in pretransplant recipient sera was associated with improved 
renal allograft survival (538-541). They found that these blocking 
antibodies were IgG alloantibodies, not autoantibodies, that they 
were HLA linked and that they could be detected in the sera of women 
with successful pregnancies but not in the sera of those with 
repeated spontaneous abortions (542). Forwell et al from our centre 
confirmed that indeed the presence of blood-transfusion-induced Fc 
receptor blocking antibodies revealed a striking correlation with 
subsequent renal allograft survival (543-545). However, in contrast 
to the studies of MacLeod, the effect seemed to be mediated by immune 
complexes rather than monomeric IgG. Serum fractionation studies 
showed that although the IgG fraction produced significant Fc 
receptor blocking, this activity did not distinguish transplant 
acceptors from rejectors. By contrast, the serum fraction of 
molecular weight more than 19S was present more often in the 
transplant acceptor group (544). Of interest too, the level of 
blocking activity produced by this high molecular weight serum factor 
in vitro was found to correlate with depressed CMI as assessed in 
vivo by the DNCB skin test, the response to which has been reported 
elsewhere to correlate with graft survival (399-402).
Donnely et al measured plasma-suppressive activity using an 
electrophoretic test of normal lymphocyte function to define 
pretransplant patients with high and low activity, which they 
attributed to a qualitative but not quantitative change in 
02-macroglobulin (546). They found that plasma suppressive activity 
was greater in transfused patients compared with controls and 
correlated with renal graft survival.
From these studies it is apparent that sera from transfused 
pre-transplant patients exhibit immunosuppressive activity mediated 
by either specific anti-idiotypic antibodies or non-specific Fc 
receptor blocking antibodies or immune complexes. However the
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relationship between these types of antibody and prolongation of 
graft survival in clinical transplantation seemed to be limited by 
differences in the methods used to detect antibody/immune 
complex-mediated immunosuppression (544).
Clonal deletion theory: Terasaki proposed this hypothesis which
states that the primary function of blood transfusion is to immunise 
patients and not to induce tolerance or enhancement or to serve as a 
donor selection mechanism (547).
According to this theory the transplant acts as a secondary 
stimulus to transfusion, and if the patient is then treated with 
immunosuppressive drugs in high dosage the proliferating reactive 
cells are killed or inactivated. Hence, the critical differences 
between a transfused and non-transfused patient is in the timing of 
the rejection in relation to maximal immunosuppression. To support 
his theory, Terasaki pointed out that multiple transfusions are more 
effective than a single transfusion and in experimental 
transplantation, blood transfusion not followed by immunosuppression 
has been found to be less effective (547). Woodruff in the early 
1960s suggested the possibility of promoting graft survival by clonal 
elimination (548). He tested this hypothesis experimentally by 
injecting mice intravenously with allogeneic spleen cells, treating 
them with whole-body irradiation or immunosuppressive drugs, and 
challenging them with a skin graft from a mouse of the strain that 
provided the spleen cells. Clonal elimination was not demonstrated 
in those experiments, but the use of a free skin graft as a challenge 
test of non-reactivity is different from experimental models of 
vascularised whole organ transplants (549). However, recent findings 
from studies of DST protocols are not in accord with this theory and 
support the view that transfusion induces inhibition of anti-donor 
immune responses rather than stimulation (550, 551). These findings 
suggest that alloreactive T cell blasts induced by allografting 
following DST may be eliminated, not simply by immunosuppressive 
therapy, but also by autoregulatory mechanisms, such as anti-receptor 
antibodies or suppressor cells. This view helps to explain instances 
in which DST alone, without immunosuppression, enhanced cardiac and 
renal allograft survival in rats (428, 552).
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In conclusion the explanation of the transfusion effect in 
renal transplantation is unclear. It seems likely that apart from 
the possible relevance of a selection factor, both non-specific and 
specific mechanisms are implicated. These involve suppressor cell 
activity with antibody or immune complex-mediated suppression leading 
to inactivation or decloning of proliferating reactive host cells and 
the induction of a state of unresponsiveness.
Blood Transfusion In the Cyclosporin Era
The European multi-centre study on the effect of Cyclosporin in 
renal graft survival did not provide evidence for a beneficial effect 
of pre-transplant blood transfusion (553). This was contrary to 
initial findings from the CTS report (425, 453) and results from 
Oxford where in two randomised studies, graft survival was 
significantly better in transfused Cyclosporin treated patients (87%) 
than in those non-transfused (58%) (554, 555). Results from UCLA
also supported this view (556). By 1986 the debate had developed as 
a large multi-centre study from Scandinavia (557) and other smaller 
single-centre studies reported the absence of the transfusion effect 
in Cyclosporin-treated transplant recipients (558, 559). At the 11th 
International Congress of the Transplantation Society in Helsinki, 
Opelz, reporting for the CTS, surprised the audience by showing that 
in his database too, the transfusion effect had disappeared (560). 
In the years 1982 and 1983, graft survival at one year was 60% in 
non-transfused and 80% in transfused Cyclosporin-treated recipients. 
Since then there has been a steady improvement in graft survival 
among non-transfused transplant recipients, so that by 1985 the 
benefit of transfusion was reduced to about a 5% difference in graft 
survival regardless of whether patients were treated with Cyclosporin 
or not (560). Thus by 1985, graft survival at one year in 
non-transfused Cyclosporin-treated recipients had improved from 60% 
to 80% and in non-transfused-azathioprine treated patients, from 50% 
to 70%. Similar results were observed in recipients of one 
HLA-haplotype-matched related transplants receiving DST (560). The 
explanation for these surprising results is not clear. A recent 
editorial in the Lancet suggested that more accurate diagnosis of 
rejection utilising renal biopsies and advances in its treatment
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could be a contributory factor to the improved results (561). At the 
beginning, the impact of these findings in changing existing blood 
transfusion protocols was rather slow and cautious as many units were 
achieving excellent results with one-year graft survival of 80-85% 
(561). At the last International Congress of the Transplantation 
Society in Melbourne, Opelz suggested that the minor beneficial 
effect of transfusion on graft survival does not justify a deliberate 
transfusion policy of potential transplant recipients (562).
The Effect of Blood Transfusion Outwith Transplantation
As interest in the blood transfusion effect in the field of 
clinical transplantation was fading in the last few years, an 
editorial assembled an impressive series of unexpected consequences 
of blood transfusion outwith transplantation (563). The list 
included a) remissions of rheumatoid arthritis by blood transfusions,
b) the effect of a husband's blood transfusion in cases of 
spontaneous abortion, c) enhancement of AIDS by an immunosuppressive 
factor in the blood, and d) the effect of blood transfusions in the 
prognosis of neoplasia. There are numerous reports suggesting that 
non-transfused cancer patients survived longer compared to patients 
who have received blood. The reports relate to carcinoma of the 
colon and rectum, breast, lung, kidney, uterine cervix, tissue 
sarcomas, and prostate (563). Experimental studies in rats have 
supported these clinical findings by showing that inoculated sarcoma 
had a faster rate of growth if the animals had been transfused 
previously with compatible allogeneic blood (564).
The possible implications of blood transfusion in areas other 
than transplantation was raised some years ago by Woodruff and van 
Rood (565). They suggested that since the transfusion effect seemed 
to be partly non-specific, transfusions might modify immune responses 
to a wide range of antigens of other than transplanted tissue. They 
also reviewed the literature on the effect of blood transfusion in 
relation to a) enhancing AIDS; 2) benefiting autoimmune disease; 
3) contributing to an increased incidence of lymphomas and skin 
cancer in transplant recipients and 4) facilitating the growth, 
spread or recurrence of tumours in other transfused patients. They
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concluded that evidence of the relationship between these phenomena 
was still inconclusive and encouraged the collection of more data 
(565).
More recently Singh et al revived interest in blood transfusion 
as a promoting factor of tumour growth by demonstrating a link 
between sarcoma and blood transfusion in rats (566). Another recent 
study from Newcastle described an association between recurrence of 
colorectal cancer and perioperative blood transfusion (567). These 
reports suggest that it is worth pursuing the transfusion effect 
outwith transplantation by further prospective studies.
96
EXPERIMENTAL DESIGN AND AIM OF THE STUDY
The experimental design of the study is shown schematically in 
Figure 1. Forty eight dialysis patients who had not received 
previous blood transfusion were randomly allocated to receive 5 or 10 
units of third party blood in the form of packed cells at two week 
intervals prior to admission to the transplant pool. The blood was 
matched for ABO and Rhesus blood groups but not for HLA antigens. 
Twelve dialysis patients and 12 healthy subjects who had not received 
previous blood transfusion were also studied as control groups. The 
characteristics of the 48 transfused patients and the 12 uraemic 
controls are shown in Table 1. In the group of the normal controls 
there were 7 males and 5 females with a mean age of 36 years (range, 
24-59 years).
The CMI of the transfused patients was measured by skin testing 
with DNCB and four recall antigens before the first blood transfusion 
and 14 days after the last blood transfusion. Haematology and 
biochemistry results were recorded at these times. In addition, 
prior to the first and 14 days after each transfusion patients were 
screened for: a) complement levels, b) cytotoxic antibodies, c)
titres of IgG secreting cells (plaque forming cells, PFC) in the 
peripheral blood, both spontaneously and after stimulation with PWM 
and SAC using a protein A assay, and d) PGE production in 
supernatants from both Con-A stimulated cultures and unstimulated 
ones of PBMC.
The uraemic control patients were skin tested with DNCB and the 
four recall antigens and these tests were repeated 3 months later, (a 
time interval equivalent to that of the transfused patients) . 
Haematology and biochemistry results were recorded and complement 
levels and cytotoxic antibodies were measured and assays of PFC, PGE 
production were performed on three or four occasions over the period 
of 3 months. The group of normal subjects was used as a control 
group for the measurement of the complement levels, PGE production, 
PFC titres* * The methods and
results from this randomised controlled study are described in the 
first 8 chapters. In chapter 9 I describe results from a large
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number of patients with regard to factors determining the response to 
the DNCB skin test and its value as a means of predicting renal 
allograft survival.
The data were stored in the current Glasgow University 
Mainframe Computer which is an ICL 2988, operating under the ICL VME 
system. All computations were done with the statistical computing 
packages Minitab (568) and SPSS-X (569). The tests of statistics 
which have been applied using these packages will be discussed in the 
respective chapters. Probability values were considered significant 
when p < 0.05.
The aim of this thesis was:
a) to assess the effect of blood transfusion in uraemic patients,
b) to see whether individuals with strong and weak reactions to
DNCB and recall antigens differ in their response to blood 
transfusion, and try to define the optimum number of 
transfusions for each group to achieve a beneficial effect,
c) to see whether blood transfusion induced changes in the immune
response could be monitored with simple skin tests
d) to define possible factors determining the response to DNCB and
assess the predictive value of this skin test regarding renal 
graft survival.
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T ra n f u s e d  P a t i e n t s
5 units
DNCB 0-3 (21
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DNCB >3
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II U ra e m i c  C o n tr o ls
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III Normal C o n tr o ls
© - No t ra n s f u s i o n
Figure 1. Experimental design of the hlood transfusion 
trial; (numbers in circles represent numbers of subjects 
allocated within each group).
TABLE 1. CHARACTERISTICS OF THE PATIENTS IN THE 
BLOOD TRANSFUSION TRIAL
Transfusion group Uraemic control group
(n?121
Sex:
Males 37 (77%) 8 (67%)
Females 11 (23%) 4 (33%)
Age:
Mean ± SD 41 ±  12 44 ± 15
Range 18 - 59 18 - 63
Original renal disease:
G1omerulonephr i t i s 14 (29%) 5 (42%)
Pyelonephritis 12 (25%) 0
Polycystic kidneys 6 (13%) 0
Hypertensive
nephrosclerosis 4 (8%) 3 (25%)
Diabetes 7 (15%) 2 (17%)
Alport's syndrome 1 (2%) 0
Analgesic nephropathy 1 (2%) 0
Hypoplastic kidneys 0 1 (8%)
Renal artery stenosis 0 1 (8%)
Unknown 3 (6%) 0
Type of dialysis:
Haemodialysis 36 (75%) 8 (67%)
CAPD 12 (25%) 4 (33%)
Parity (n-15):
0 2 3
1 1 1
2 1 0
3 5 0
4 1 0
5 1 0
CHAPTER 1. SKIN TESTING WITH DNCB
1.1 Introduction
The DNCB skin test is a simple and reproducible in vivo test of 
CMI. Several reports have been published with regards to the 
applications of the test both in experimental work (218-220,227,228, 
230,232,234,235) and in clinical trials (221-225,398-403, 
406-408,411). Previous studies from this unit have shown that only 
one third of long-term dialysis patients display the strong reaction 
to DNCB which is characteristic of that seen in normal controls 
(359,399-402,570). These strong responders, who are presumed to have 
intact CMI, are more likely to reject a renal allograft (399-402), 
respond better to vaccination against hepatitis B (359), and are less 
liable to develop infections (570). One of the main questions during 
these studies has been what factors determine the response to the 
DNCB test. It was found that sex, the type of kidney disease,
duration of dialysis and blood transfusion status may influence the
response to the test (399,402). However, the correlation was not
strong, and there was overlap between blood transfusion and the other 
three variables. Having described the association between blood 
transfusion, DNCB test and graft survival (399-402), the next 
questions addressed were, firstly, whether the transfusion-induced 
immunosuppression could be monitored by means of sequential skin 
tests, and secondly, whether the poor graft survival in the strong 
responders could be improved with more transfusions (571). This was 
the background against which the present randomised controlled study 
was initiated, as far as the DNCB test is concerned.
1.2 Patients and Methods
Patients
Table I showed the details of the sixty previously dialysis 
patients who had not received prior blood transfusion and who were 
tested with DNCB. Forty eight of these patients were subsequently 
given blood transfusions ('transfused') and the remaining 12
comprised the uraemic controls. In the transfused group there were 
37 males and 11 females with a mean age of 41 years (range 18-59 
years). All patients had recently been established on dialysis
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between one and three months prior to entering the study. Thirty six 
patients were on haemodialysis (4 hours thrice weekly) and 12 on 
CAPD. The control group^l2 uraemic patients was comparable to the 
'transfused' patients in terms of sex (8 males and 4 females), age 
(mean 44.3, range 18-63 years) and type of dialysis (haemodialysis 8 
and CAPD 4) . Although the original renal diseases were not fully 
comparable between the two groups, the difference was not 
statistically significant. After allocation by random numbers, 30 of 
the 60 patients were transfused with 5 and 18 with 10 units 
respectively of third party packed red cells at two week intervals. 
The remaining 12 patients acted as controls. The randomisation was 
done after the DNCB skin test was carried out in order to achieve 
comparable numbers of weak and strong reactors in the groups of 
patients receiving 5 or 10 units of blood, as shown in Figure 1.
Methods
The DNCB skin test was carried out as previously described 
(359,399,402,571) prior to the first and two weeks after the last 
transfusion in the transfused patients, and in the uraemic controls 
it was repeated after 3 months. The method is shown in Figure 1.1 
and was carried out as follows:
a) Primary sensitisation: The sensitising solution was prepared by 
disolving crystals of l-chloro-2,4-dinitrobenzene (DNCB, BDH 
Chemicals Limited) in acetone to give a 2% solution (20mg of DNCB per 
lml of acetone). This solution was stored in a glass bottle covered 
with foil at 4°C, and was discarded after 2-3 days if unused. Using 
a micropipette, 0.1ml of this solution, ie 2000ug of DNCB, was 
applied to a 2cm diameter area of the volar aspect of the dominant 
forearm (or the forearm with the vascular access in haemodialysis 
patients). The sensitised skin area was cleaned with a medi-swab and 
was encircled by the ring of a scissors handle. After the 
application the solution was allowed to dry and was covered with a 
dressing. Patients were asked to keep it dry for 24 hours.
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b) Challenge sensitisation: Fourteen days after the initial
sensitisation, patients were tested with five different 
concentrations of DNCB (2ug, 4ug, 8ug, 16ug and 32ug) which were 
dried onto 1cm diameter felt pads of aluminium test strips (Al-test, 
Astra Chemicals, Herts). These five concentrations were prepared by 
dissolving crystals of DNCB in acetone to give an initial 
concentration of 3.2mg/ml, which subsequently was serially diluted to 
give the 1.6mg/ml, 0.8mg/ml, 0.4mg/ml and 0.2mg/ml solutions; lOul of 
each of these dilutions were then added onto the corresponding pads 
of the patches, the lower concentration being dried to the bottom 
pad. The patches were applied with micropore to the volar area of 
the opposite forearm for 48 hours. After 48 hours the reaction was 
scored thus: 0 - no reaction or erythema only; 1 - erythema and
induration confined to the patch; 2 - erythema and induration
extending beyond the patch; 3 - as for 2 plus blistering. The DNCB 
score recorded was the sum of the scores for all five patches and 
therefore gave a range of 0 to 15. The cut off point between strong 
and weak responders was arbitarily derived from the lowest DNCB score 
recorded in a group of 15 healthy controls, which was 4. Hence, 
patients scoring 0-3 were classed as weak responders (Figure 1.2), 
and patients scoring 4-15 were classed as strong responders (Figure
1.3).
Statistical analysis
Comparison of the DNCB scores was carried out using the paired 
t test and the unpaired t test. When the numbers were small the 
significances were double checked with the non-parametric Wilcoxon's 
rank sum tests (the signed rank test, and the unsigned rank test or 
the Mann-Whitney-Wilcoxon test). Differences in the distribution of 
a variable in the groups were estimated using the chi-square test, 
with Yates' correction when one of the expected values was less than 
five.
1.3 Results
The results of the DNCB skin testing are shown in Table 1.1. 
Prior to blood transfusion 27 of the 48 patients were strong 
responders (56%), and the remaining 21 patients were weak responders
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(44%) . Among the latter group 10% (5 of 48) of the patients were 
anergic, ie DNCB score 0. The first test in the control group showed 
that 67% (8 of 12 patients) were strong and 33% (4 of 12) were weak 
responders respectively. On repeating the test the majority of both 
transfused and control patients showed higher DNCB scores (Figure
1.4). In the transfused patients the mean DNCB score increased from 
4.8 to 6.8 (p < 0.001), and in the controls from 5.8 to 6.9 (p < 
0.05); the latter difference failed to reach statistical significance 
using the signed rank test (Table 1.1). Overall, 6 of the 60 
patients (12%) changed from weak to strong responders and one vice 
versa. Anergic patients tended to remain anergic in both transfused 
and control groups (7 of 8 patients). Six weak responders became 
strong responders after blood transfusion, and one strong responder 
changed to a weak responder. In the controls such change was not 
observed because 3 of the 4 weak responders were anergic (Figure
1.4). As a result of these changes after blood transfusion the 
proportion of the strong and weak responders in the transfused 
patients changed to 67% (32 of 48) and 33% (16 of 48) respectively, 
which was not significantly different from the repeat tests in the 
controls (Table 1.1).
Table 1.2 and Figure 1.5 show the changes in the DNCB skin test 
scores in the weak and strong responders for both the transfused 
patients and the controls. The mean score of the weak responders in 
the transfused patients changed from 1.5 to 2.4 (NS), whereas in the 
controls it remained unchanged. By contrast, the mean score of the 
strong responders increased from 7.3 to 10.1 in the transfused 
patients (p < 0.001), and from 8.5 to 10.1 in the controls (paired t 
test, p < 0.025; signed rank test, NS).
Table 1.3 shows the results of the DNCB test in relation to the 
number of transfusions. Prior to the transfusion, of those who 
received 5 units of blood 57%, (17 of 30) and 43% (13 of 30)
respectively were strong and weak responders. The comparable figures 
for those who received 10 units of blood were 56% (10 of 18) and 44% 
(8 of 18). After blood transfusion the difference in the number of 
weak and strong responders between the two transfusion groups was not 
significant. Neither was there a significant difference between 
these two groups and the controls. Figure 1.6 shows the individual
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DNCB scores in patients receiving 5 and 10 units of blood and in the 
controls. Both transfusion groups showed an increase in the mean 
DNCB score, although the difference reached statistical significance 
only among patients receiving 5 transfusions.
Finally, from Table 1.4 and Figure 1.7 it is evident that
overall, only strong responders had significant changes in their 
response to DNCB on repeat testing, regardless of the amount of blood 
transfused (5 or 10 units) or whether or not they were given 
transfusion at all.
1.4 Conclus ions
1) Sequential skin testing with DNCB does not reflect changes
induced by blood transfusion.
2) Repeated immunisation with DNCB in previously non-transfused 
dialysis patients has as a result stronger anamnestic 
reactions, providing a primary strong response has been
elicited, regardless of the amount of transfusions (5 or 10 
units) or whether they were transfused at all.
3) Anergic patients tend to remain anergic, and patients with a
strong primary response have stronger responses on repeating 
the test when primary immunisation has taken place prior to any 
blood transfusion.
103
14 DAYS ODAYS
200032
Figure 1.1. Schematic representation of the DNCB skin 
test; numbers represent the sensitising solution (0 days) 
and the challenge doses (14 days) of DNCB.
Figure 1.2. Example of a weak DNCB responder; this 
patient!s reaction was only erythema to the top patch 
and nothing to the remaining four lower patches (DNCB 
score =0).
Figure 1.3. Example of a strong DNCB responder; 
this patient's reaction was blistering to all 5 
patches (DNCB score = 15).
TABLE 1.1. RESULTS OF THE DNCB SKIN TEST IN THE TRANSFUSED
PATIENTS AND IN THE URAEMIC CONTROLS
Transfused patients Uraemic controls 
(n-481 iXLrlZl
Pre-BT Post-BT At 0 At 3 months
Patients with score:
>3 (strong
responders) 27(56%) 32(67%) 8(67%) 8(67%)
0-3 (weak
responders) 21(44%) 16(33%) 4(33%) 4(33%)
0 (anergic) 5(10%) 5(10%) 3(25%) 3(25%)
DNCB score:
Mean + SD 4.8+3.6* 6.7±4.8* 5.8±5.0+ 6.9±5.5+
SEM 0.5 0.7 1.4 1.6
Median 4.0 7.0 5.5^ 6.5^
Change of score: 
From 0-3 to >3 
From > 3 to 0-3
6 of 21(29%) 
1 of 27(4%)
None
None
Paired t test: *t - 4.139, p < 0.001; +t - 2.493, p < 0.05. 
Signed rank test: ^NS
CONTROLS
n=12
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Figure 1.4. DNCB skin test scores in the 48 
transfused patients and in the 12 uraemic controls; 
BT = blood transfusion.
TABLE 1.2. RESULTS OF THE DNCB SKIN TEST IN THE WEAK AND STRONG
RESPONDERS
Transfused patients 
(n«48)
Pre-BT Post-BT
Uraemic control 
(n-12)
At 0 At 3 months
DNCB score of 
weak responders
Mean ± SD
SEM
Median
n°21
1. 5±1.2 
0.3 
1.0
2. 4±2.4 
0.5 
2.0
n°=4
0.5+1.0 
0.5 
0.0
0. 5±1.0 
0.5 
0.0
DNCB score of
strong responders n°27 n°8
Mean ± SD 7.3±2.8* 10.1±3.1* 8.5±3.7+ 10.1±3.4+
SEM 0.5 0.6 1.3 1.2
Median 6.0 11.0 8.0^ 8.0^
Paired t test: *t - 3.919, p < 0.001; +t - 2.876, p < 0.025. 
Signed rank test: ^NS
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Figure 1.5. DNCB skin test scores in the transfused 
weak and strong responders and in the uraemic controls.
TABLE 1.3. RESULTS OF THE DNCB SKIN TEST IN THE PATIENTS RECEIVING
5 AND 10 UNITS OF BLOOD AND IN THE URAEMIC CONTROLS
Transfused patients Uraemic controls
5 units (n»30) 10 units (n»=18) (n-12)
At 3
Pre-BT Post-BT Pre-BT Post-BT At 0 months
strong
responders 17(57%) 23(77%) 10(56%) 9(50%) 8(67%) 8(67%)
weak
responders 13(43%) 7(23%) 8(44%) 9(50%) 4(33%) 4(33%)
anergic 3(10%) 3(10%) 2(11%) 2(11%) 3(25%) 3(25%)
DNCB score:
Mean+SD 4.7+3.7* 7.0+4.5* 4.9±3.6+ 6.1±5.2+ 5.8±5.0$ 6.9±5.5$ 
SEM 0.7 0.8 0.9 1.2 1.4 1.6
Median 4.0** 7.5** 4.5++ 5.0++ 5.0t{ 6.5({
Change of score:
From 0-3
to >3 6 of 13 (46%) None None
From >3
to 0-3 None 1 of 0 (10%) None
Paired t test: *t — 4.330, p<0.001;"*"t «■ 1.451, NS; ^t “ 2493, p<0.05. 
Signed rank test: **p<0.04; "^NS; NS
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Figure 1.6. DNCB skin test scores in the patients 
receiving 5 and 10 units of blood and in the uraemic 
controls.
TABLE 1.4. RESULTS OF THE DNCB SKIN TEST IN THE WEAK AND STRONG
RESPONDERS RECEIVING 5 AND 10 UNITS OF BLOOD AND IN THE CONTROLS
Transfused patients 
5 units (n«30) 10 units (n=18)
Pre-BT Post-BT Pre-BT Post-BT
Uraemic controls
At 3 
At 0 months
DNCB score of
weak responders n°13
Mean+SD 1.5+1.2 3.0+2.9
SEM 0.3 0.8
Median 1.0 2.0
n°8
1.5+1.2 1.4+1.1
0.4 0.4
1.5 1.5
n°4
0.5+1.0 0.5±1.0
0.5 0.5
0.0 0.0
DNCB score of 
strong
responders n=-17 n—10 n-=8
Mean+SD 7.1+3.0* 10.1±2.8* 7.6±2.2+ 9.9±3.8+ 8.5±3.7{ 10.1±3.4*
SEM 0.7 0.7 0.7 1.2 1.3 1.2
Median 6.0** 9.0** 7.5++ 11.0++ 8.0** 8.0**
Paired t test: *t—3.987, p<0.005; ^t—1.744 NS; *t—2.876, p<0.025. 
Signed rank test: **p<0.01; ++p<0.01; **NS
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Figure 1.7. DNCB skin test scores in the weak and 
strong responders receiving 5 and 10 units of blood 
and in the uraemic controls (• = weak responders,
0 = strong responders).
CHAPTER 2. SKIN TESTING WITH RECALL ANTIGENS
2.1 Introduction
A possible advantage of the DNCB test over DTH skin tests using 
recall antigens is that it tests the response to a new antigen and 
does not therefore require or test for immunological memory (399) . 
However, many reports have shown that anergy to recall antigens may 
also have predictive value and may be associated with increased 
morbidity and mortality (298-302,404,405,417), and with improved 
graft survival (398,410). In a recent study it was suggested that 
the beneficial effect of blood transfusion on graft survival could be 
monitored by skin testing with a battery of several recall antigens 
(410) . This chapter describes the use of skin testing in the 
assessment of the transfusion effect.
2.2 Patients and Methods
Patients
In addition to the DNCB test, 23 of the 60 patients described 
in the previous chapter were also skin tested with four recall 
antigens. Seventeen of the patients were in the transfusion group 
and 6 were uraemic controls. Nine of the 17 patients received 5 
units of blood and the other 8 had 10 units. Among the transfused 
patients there were 14 males and 3 females with a mean age of 42 
years (range 25-59 years). The original diseases were 
glomerulonephritis (6), pyelonephritis (4), polycystic kidneys (3), 
hypertensive nephrosclerosis (1), diabetic nephropathy (2), and 
unknown (1). Fifteen patients were on haemodialysis and 2 patients 
were on CAPD. In the group of the uraemic controls there were 4 
males and 2 females with a mean age of 48 years (range 31-63 years). 
The original diseases were glomerulonephritis (1), hypertensive 
nephrosclerosis (2), diabetic nephropathy (2), and renal artery 
stenosis (1). Three patients were on haemodialysis and 3 patients 
were on CAPD.
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Methods
Patients were skin tested as described by Bradley et al (302) 
with 0.1ml of each of four recall antigens, namely, purified protein 
derivative (PPD) 100 units per ml (Evans Medical Limited, Liverpool), 
Candida albicans 0.5% (2003) M2646 (Bencard, Brentford, Middlesex), 
Streptokinase 10 units plus Streptodornase 2.5 units (Varidase, 
Lederle Laboratories, Hampshire), and mumps skin test antigen, USP 
(Eli Lilly and Co., Indianapolis, USA). The antigens were injected 
intradermaly several centimetres apart on the volar aspect of the 
forearm and the response was measured as the diameter of induration 
at 24 and 48 hours. Patients were defined as 'responders' if one or 
more of the antigens produced 5mm or more induration, and 
'non-responders' (anergic) if none of the antigens caused a reaction 
of 5mm or greater. To quantitate further the response to each 
antigen the following scoring system was used for each antigen: 0 - 
induration less than 5mm, 1 - induration 5-9mm, 2 - induration
10-19mm, 3 - induration more than 19mm. The score for the four
antigens, therefore, ranged from 0 to 12. The test was carried out 
at the same time as the DNCB test, ie prior to the first and two 
weeks after the last blood transfusion in the transfused patients, 
and twice in the uraemic controls with an interval of approximately 3 
months.
Statistical analysis
The comparison of the scores was done using both Students' t 
tests (paired and unpaired) , and the non-parametric rank sum tests 
(the signed rank test, and the rank test for unpaired samples or the 
Mann-Whitney-Wilcoxon test). The correlation between the DNCB and 
the recall antigen scores was done using linear regression analysis.
2.3 Results
The results of skin testing with the recall antigens are shown 
in Figure 2.1. In the 17 patients who were transfused, the mean 
score rose from 3.8 prior to blood transfusion to 5.0 after the last 
transfusion. Similarly, the 6 uraemic controls showed an increase in 
their mean score from 3.3 to 4.8. The statistical significance of 
these differences is shown in Table 2.1; the increase in skin test
105
score of the controls failed to achieve significance using the signed 
rank test possibly because of the small sample number. Overall, 
there was only one non-responder (anergic, total score 0) amongst the 
6 controls, and the remaining 5 controls together with all the 
transfusion group were responders (96%). The anergic patient 
remained anergic on repeat testing. Thus despite the increase in the 
mean score, by definition there was no change of non-responders to 
responders and vice versa, unlike the DNCB test.
Figure 2.2 shows the results of skin testing with recall 
antigens, with regards to the number of transfusions. Both groups of 
patients receiving 5 and 10 units of blood showed an increase in the 
mean skin test score from 3.6 to 5.0 and from 4.1 to 5.0 respectively 
as did the controls whose score increased from 3.3 to 4.8. The 
statistical analysis of these changes is shown in Table 2.2; only the 
increase in skin test score seen in patients receiving 5 transfusions 
was significant using both parametric and non-parametric tests.
Figures 2.3 and 2.4 represent the plots of the recall antigen 
scores against the DNCB scores, on the first and second occasions in 
the 23 patients in whom both tests were performed. On neither 
occasion was there a significant correlation. Furthermore, of the 
four patients who were anergic to DNCB only one was also anergic to
the recall antigens as well. This finding suggests that the DNCB 
test and the recall antigen test provide a measure of different 
aspects of the cell-mediated immune response and therefore define 
different subpopulations of responders and non-responders.
2.4 Conclusions
1) The response to skin testing with recall antigens is not
altered by blood transfusion in previously non-transfused
patients who have recently been established on dialysis.
2) The response to repeat skin testing with recall antigens tends 
to be increased in these patients, irrespective of whether they 
receive blood transfusion, or of the amount of blood they are 
given.
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3) There is no correlation between the response to the DNCB test
and the response to skin testing with recall antigens which 
suggests that the two tests define different sub-populations of 
responders and non-responders.
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TABLE 2.1. RESULTS OF THE SKIN TEST WITH RECALL ANTIGENS IN THE
TRANSFUSED PATIENTS AND IN THE URAEMIC CONTROLS
Recall antigen 
Mean + SD 
SEM
Median
Transfused patients 
(n=17)
Pre-BT Post-BT
Uraemic controls 
.(n=il 
At 0 At 3 months
score:
3.8+1.7* 
0.4 
4.0**
5.0+1.5* 
0.4 
5. 5**
3.3+2.6+ 4.8+2.7+
1.1
3.5h
1.1
5.0h
Paired t test: *t - 4.515, p < 0.001; +t - 3.503, p < 0.02. 
Signed rank test: **p < 0.01; "^NS.
TRANSFUSED 
n = 17
CONTROLS
n=6
RECALL
ANTIGENS
SCORE
1 2 -
RECALL
ANTIGENS
SCORE
- 1 2
10 - -1 0
-8
6 -
•••
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2 - - 2
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Figure 2.1. Scores of the skin test with recall 
antigens in the transfused patients and in the 
uraemic controls.
TABLE 2.2. RESULTS OF THE SKIN TEST WITH RECALL ANTIGENS IN THE
PATIENTS
RECEIVING 5 AND 10 UNITS OF BLOOD AND IN THE URAEMIC PATIENTS
Recall 
antigen 
score:
Transfused patients 
5 units 10 units
in=9) (n^81
Pre-BT Post-BT Pre-BT Post-BT
Uraemic controls 
(n-6).
At 3 
At 0 months
Mean+SD 3.6+1.7* 5.0+1.2* 4.1+1.7+ 5.0±1.9+ 3.3±2.6$ 4.8±2.7$
SEM
Median
0.6
4.0**
0.4
5.0**
0.6
4.0h
0.7
5.5n
1.1
3.5{{
1.1 
5.0{ {
Paired t test: *t - 3.833, p<0.01; +t — 2.497, p<0.05; 
*t - 3.503, p<0.02.
Signed rank test: **p < 0.05; "^NS; ^NS.
TRANSFUSED CONTROLS
n=6RECALLANTIGENS
SCORE
1 2 -
5 units  
n=9
10 units  
n=8
RECALL
ANTIGENS
SCORE
- 1 2
-1 0
8 - -8
6 - -6
4 - - 4
2 - -2
Pre— BT Post — BT Pre— BT Post — BT At 0  At 3m onths
Figure 2.2. Scores of the skin test with recall 
antigens in the patients receiving 5 and 10 units 
of blood and in the uraemic controls.
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Figure 2.4. Correlation between the DNCB scores and 
the recall antigen scores on the repeat tests.
CHAPTER 3. FACTORS DETERMINING THE RESPONSE TO SKIN TESTING WITH 
DNCB AND RECALL ANTIGENS
3.1 Introduction
Although it is generally accepted that the presence of uraemia 
depresses the immune response there is some experimental evidence 
which apparently contradicts this well established view 
(381-383,412). The controversy arises mainly from differences 
between experimental uraemic models (383) and between in vitro 
methods used to measure the immune response (341,348,369,374, 
377,383). It is possible that the endogenous depression of immune 
response which results from uraemia may have been overemphasised, and 
that exogenous factors such as blood transfusion, surgical 
operations, infections and administration of drugs may all contribute 
to the depressed immunity seen in uraemic patients (286,296,297, 
306-309,379,393,394,399,402,410,571). For this reason, the selected 
group of patients described in this thesis, who have never received a 
blood transfusion or renal allograft and who have recently been 
established on dialysis, constitutes a useful population in which to 
study the different factors which may determine the immune response.
3.2 Patients and Methods
All 48 patients in the transfusion group and the 12 uraemic 
controls (Table 1) were studied to see whether there was any 
association between a number of variables and the DTH skin test 
results. The variables examined were patient sex, age, original 
disease, the type of dialysis, parity, and standard haematology and 
biochemistry results. Blood samples were taken on the morning of the 
day during which the skin tests were carried out, either before the 
commencement of haemodialysis or prior to the first bag change in the 
CAPD patients. On the test day urine was collected for 24 hours to 
assess the residual urine volume. In order to see whether the 
response to the DNCB skin test was an HLA-associated phenomenon, the 
HLA-DR phenotypes and response to the skin test were studied in 57 of 
the 60 patients who had been tissue typed. Tissue typing was carried 
out in the regional Tissue Typing Laboratory using the standard 
NIH-Terasaki method (572).
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As the DTH skin test results sometimes changed on repeat 
testing (see Chapter 1 and 2), the association between the patient 
variables and the skin test results were examined for both first and 
repeat tests. However, as the DNCB score increased to a similar 
degree in both the transfused and control groups on repeat testing, 
the two groups have been considered together for the analysis of 
these variables. Furthermore, none of the variables which changed 
significantly after transfusion showed any correlation with the DTH 
skin test results as will be discussed in the results section.
Statistical analysis
The significance of differences between means was determined by 
a univariate analysis using the paired and unpaired t tests. 
Multivariate analysis (proportional hazards Cox analysis) was not 
applied because the numbers were small. However, since it is 
possible in a study with many variables for one of them to come up as 
signficant by chance, the strength of the statistical significance 
was checked by correction of the p value by multiplying it by the 
number of the variables studied (573) . Differences in the 
distribution of a variable in the groups were estimated using the 
chi-square test with Yates' correction; in the analysis of the 
association between HLA-DR antigens and the response to the DNCB test 
the p value was further corrected by multiplying it by the number of 
antigens studied. The correlation between the haematology and 
biochemistry results and the skin test scores was done using linear 
regression analysis.
3.3 Results
Table 3.1 shows that none of the patient details namely, sex, 
age, original disease, type of dialysis and parity showed a 
significant effect on the response to the DNCB test. Table 3.2 shows 
that of 19 haematology and biochemistry variables only 2 changed 
significantly after blood transfusion in the transfusion group, 
namely, haemoglobin and serum iron. The former increased from 8.3 +
1.2 g/dl to 10.9 + 1.6 g/dl (p<0.0000), and the latter from 1 2 + 4  
umol/1 to 20 + 4 umol/1 (p<0.0000). These two values after 
transfusion were also significantly higher compared to the values of
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the controls at 3 months (p<0.001, and p<0.0000 respectively). Serum 
creatinine and serum albumin also increased after transfusion, but 
the difference was not sufficient to remain significant after 
correction of the p value. By contrast, all the variables in the 
controls remained unchanged. Although in the transfused group there 
was a rise in haemoglobin and serum iron between the two tests which 
did not occur in the control group, the increase in the DTH skin test 
results did not differ between the two groups. Table 3.3 illustrates 
that none of the patient variables showed a significant correlation 
with the DNCB scores at the first test. Neither was there any 
correlation at the second test with regard to any variable and 
particularly with regard to haemoglobin and iron which increased 
significantly after blood transfusion. Serum chloride and serum 
calcium showed a weak correlation on the repeat test which was not 
significant after correction of the p value. Figures 3.1 and 3.2 
represent the plots of the serum chloride and calcium respectively 
against the DNCB scores, and show an absence of correlation. Also 
Table 3.4 shows that the haematology and biochemistry values did not 
differ significantly between the weak and strong DNCB responders on 
the occasion of both tests.
When skin testing was carried out with recall antigens, there 
was a weak correlation between serum bicarbonate and serum aluminium 
and the recall antigen scores at the first test, but this was lost 
after correction of the p value. None of the haematological or 
biochemical variables correlated significantly with the scores on 
repeating the test (Table 3.5). Figures 3.3 and 3.4 represent the 
plots of the serum bicarbonate and serum aluminium respectively 
against the recall antigen scores and there appears to be a 
significant correlation in these graphs. However, this is likely to 
be accidental, since it has been detected only at the first test and 
not on repeat testing, whereas both the first and second tests are 
thought to represent anamnestic reactions.
The question of whether the response to the DNCB skin test is a 
genetically controlled event was investigated by looking into the 
possible association between HLA-DR antigens and percentage of strong 
and weak responders. Figure 3.5 shows the distribution of the DR 
antigens in the 57 patients. The commonest specificities were DR3
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(42%), DR4 (40%) and DR2 (35%), and the least common were DR5 (7%), 
DR1 (14%) and DR7 (14%), while DRW6 was found in 25%. Undefined 
specificities and homozygotes were grouped together under blank 
(23%). From Figure 3.6 it can be seen that at the first test DRW6 
positive patients were significantly more likely to be strong 
responders compared to DRW6 negative patients (93% vs 47%, p<0.04; 
the p value was corrected for the number of DR antigens studied). 
This association exists even in this small selected group of patients 
and supports our finding in an earlier larger series (574,575). 
Finally, the DRW6 effect was not found on repeating the test (86% vs 
60%) , because of the increase in strong responders among the DRW6 
negative patients at that time (Figure 3.7).
3.4 Conclus ions
1) In a group of patients with chronic renal failure who were
recently started on dialysis and who had not received previous 
blood transfusion, the response to the DNCB test was not 
related to the sex, age, original renal disease, type of 
dialysis or parity of the patients.
2) A number of haematological and biochemical parameters do not
correlate with the response to DNCB and recall antigens, and 
this is the case even for haemoglobin and serum iron which 
change considerably after transfusion.
3) HLA-DRW6 positive patients are significantly more likely to be
strong DNCB responders, but on repeat immunisation this is not 
observed.
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TABLE 3.1. ASSOCIATION BETWEEN PATIENT DETAILS AND RESPONSE TO THE 
DNCB SKIN TEST (ALL PATIENTS n - 6O’)
First test Second test
Patient Weak Strong Weak Strong
details responders responders resoonders responders
Sex:
Males (n=45) 17(38%) 28(62%) 13(29%) 32(71%)
Females (n=15) 8(53%) 7(47%) 7(47%) 8(53%)
Age (mean + SD) 40.5+10.6 42.3±13.3 42.4+9.8 41.4±13.3
Original disease: 
Glomerulonephritis 
(n - 19) 10(53%) 9(47%) 10(53%) 9(47%)
Pyelonephritis 
(n - 12) 4(29%) 8(71%) 3 (25%) 9(75%)
Polycystic 
(n - 6) 1(17%) 5(83%) 1(17%) 5(83%)
Hypertension 
(n - 7) 1(14%) 6(86%) 1(14%) 6(86%)
Diabetes 
(n - 9) 6(67%) 3(23%) 2(22%) 7(78%)
Miscellaneous 
(n - 7) 3(43%) 4(57%) 3(43%) 4(57%)
Type of dialvsis: 
Haemodialysis 
(n - 44) 17(39%) 27(61%) 17(39%) 27(61%)
CAPD 
(n - 16) 8(50%) 8(50%) 3(19%) 13(81%)
Parity:
Nulliparous 
(n - 5) 3(60%) 2(40%) 3(60%) 2(40%)
Parous, 1-5 
(n - 10) 5(50%) 5(50%) 4(40%) 6(60%)
TABLE 3.2. HAEMATOLOGY AND BIOCHEMISTRY DATA IN THE TRANSFUSED
PATIENTS AND IN THE CONTROLS 
Transfusion erouo Controls
(n - 48) (n - 12)
Variable Pre-BT Post-BT At 0 At 3 months
Hb (g/dl) 
WBC (xlO /l)
8.3+1.2* 10.9±1.6*,** 8.2+1.0 9.0±1.4**
6.5+1.4 6.9+1.7 7.3+1.2 7.4+1.3
Na (mmol/1) 140+3 139j;3 139±2 140±3
K (mmol/1) 4.6+0.6 4.8+0.7 4.5+0.9 4.5+0.7
Cl (mmol/1) 102±4 101+3 100±5 100±4
CO2 (mmol/1) 23±2 23±3 23±3 23±3
Urea (umol/1) 21+5 
901+183{
22±5 
1001+203{
20±5 20±6
Creatinine (umol/1) 890+269 910+272
Aik phos (U/l) 96+33 91+33 105+48 101+60
Ca (mmol/1) 2. 3±0.2 2.4+0.2 2.3+0.2 2.4+0.2
PO^ (mmol/1) 1. 7±0.3 1.8+0.4 1. 6±0. 5 1.7±0.5
SGOT (U/l) 17+6 17+6 17±6 17±6
SGPT (U/l) 19±8 22±10 22±7 20±S
Albumin (g/1) 39+4$ 41±4$ 39+5 41±3
Globulin (g/1) 25+4 25+3 27+3 26+3
Iron (umol/1) 12±4+ 20±4+,++ 10±3 10±4++
PTH (ng/1) 1490+1310 1410+1360 1780+1660 1910+2000
Aluminium (umol/1) 1. 7±1.0 1.4+0.8 1.9+1.3 1.1+0.5
Urine volume (1) 1.0+0.4 0.8±0.4 0. 7±0.3 0.6±0.3
Paired t test: *t - 9.026, p<0.0000; - 2.522, pcor<0.25, NS
- 2.634, pcor<0■19» NS; +t - 9.473, p<0.0000
Unpaired t test:**t - 4.133, P c o r ^ ’^ ’ ++t “ 6.873, p<0.0000
TABLE 3.3. CORRELATION COEFFICIENT (r) BETWEEN HAEMATOLOGY AND 
BIOCHEMISTRY DATA AND THE DNCB SCORES (ALL PATIENTS n - 60)
DNCB scores
Variable First test Second test
r r
Hb (g/dl) 
WBC (xlOVl)
-0.056 0 .177
-0 .177 0 .096
Na (mmol/1) -0 .234 -0 .002
K (mmol/1) 0,.151 0 .095
Cl (mmol/1) 0,.008 0,.263*
CO2 (mmol/1) -0,.081 -0,.248
Urea (mmol/1) 0,.064 0,.089
Creatinine (umol/1) -0..046 0,.025
Aik phos (U/l) -0,.052 0,.025
Ca (mmol/1) -0..206 -0., 318+
PO^ (nmol/1) 0,,019 0..055
SGOT (U/l) 0..100 -0.,028
SGPT (U/l) 0.,058 -0.,057
Albumin (g/1) 0..000 -0..041
Globulin (g/1) 0.,081 -0.,052
Iron (umol/1) 0.,077 0.036
PTH (ng/1) 0.094 -0. 119
Aluminium (umol/1) 0.004 -0. 149
Urine volume (1) 0.070 0. 210
*t - 2.076, p < 0.05, pcor < 0.95, NS 
+t - 2.554, p < 0.02, pcor < 0.38, NS
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TABLE 3.4. ASSOCIATION BETWEEN HAEMATOLOGY AND BIOCHEMISTRY DATA 
AND RESPONSE TO THE DNCB SKIN TEST (ALL PATIENTS, n - 60>
Variable
Hb (g/dl)
WBC ( x l O V l )
Na (mmol/1)
K (mmol/1)
Cl (mmol/1) 
CC>2 (mmol/1) 
Urea (mmol/1)
Aik phos (U/l) 
Ca (mmol/1)
PO^ (mmol/1) 
SGOT (U/l)
SGPT (U/l)
Albumin (g/1) 
Globulin (g/1)
Iron (umol/1) 
PTH (ng/1)
Urine volume (1)
First test 
Weak Strong
responders responders
Second test
Weak
responders
Strong
responders
(n=25) (n=35) (n=20) (n=40)
8.4+1.2 8. 2+1.1 10.0+1.6 10.8+1.8
7.1+1.3 6.4+1.4 6.7+1.6 7.1+1.6
140+2 139+2 140+3 139±3
4.5+0.7 4.6+0.7 4.8+0.6 4. 7±0.7
102±4 102±4 100±4 101±3
23+2 23+3 23+3 23±3
21+5 21±5 21+5 21±5
891+220 904±189 984+254 982+203
106+32 92+38 93±27 93±45
2. 3+0.2 2. 3+0.2 2.5+0.2* 2.3+0.2*
1.7+0.3 1.7+0.4 1.8+0.4 1.7+0.4
17±7 18±5 17±6 17dt6
21+9 19±6 20±9 22±8
38±5 39±4 42±3 41±4
25+3 26±4 26±3 25±3
11+3 11+4 18+6 18±6
1627+1419 1492+1362 1972±1802 1279±1292
1.8+1.2 1.8+1.0 1.5+0.8 1.3+0.8
0.9+0.4 1.0+0.4 0.7+0.3 0.9+0.4
Unpaired t test: *t - 2.354, p < 0.02, Pcor <0.38, NS
TABLE 3.5. CORRELATION COEFFICIENT (r'i BETWEEN HAEMATOLOGY AND 
BIOCHEMISTRY DATA AND THE RECALL ANTIGEN SCORES 
(ALL PATIENTS, n - 20^
Recall antigen scores 
First test Second test
Variable r r
Hb (g/dl) 
WBC (xlO /l)
0.142 0.437
0.044 -0.178
Na (mmol/1) 0.245 0.051
K (mmol/1) -0.220 0.003
Cl (mmol/1) 0.150 -0.338
CO2 (mmol/1) 0.537* -0.265
Urea (mmol/1) -0.295 -0.257
Creatinine (umol/1) -0.288 -0.026
Aik phos (U/l) -0.145 -0.092
Ca (mmol/1) 0.203 -0.269
PO^ (mmol/1) -0.428 0.137
SGOT (U/l) 0.225 0.282
SGPT (U/l) 0.275 0.179
Albumin (g/1) 0.267 0.282
Globulin (g/1) 0.232 0.187
Iron (umol/1) -0.034 0.193
PTH (ng/1) -0.151 » 0.068
Aluminium (umol/1) -0.520 0.326
Urine volume (1) 0.153 0.241
*t - 2.700, p < 0.02, pcor < 0.38, NS 
+t - 2.582, p < 0.02, pcor < 0.38, NS
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CHAPTER 4. RENAL ALLOGRAFT SURVIVAL IN PATIENTS UNDERGOING 
TRANSPLANTATION
4.1 Introduction
The aim in the management of the transplant patient is to 
achieve optimal patient and graft survival while minimising the side 
effects of immunosuppression. In recent years elective blood 
transfusion has occupied a large part of this effort both in clinical 
practice and research. One of the objectives of this study was to 
see whether transfusion of 5 or 10 units of blood in dialysis 
patients with presumed impaired (weak DNCB responders) or intact CMI 
(strong DNCB responders) had any different effect on subsequent renal 
allograft survival. This chapter will describe details of the 
transplant outcome in weak and strong DNCB responders who received 5 
or 10 units of blood.
4.2 Patients and Methods
Thirty two of the 48 patients in the transfusion group were
transplanted with a cadaveric renal graft by the end of 1985. In all
cases this was their first transplant. There were 25 males and 7
females, and their mean age was 40 years (range, 20-59 years). The
first patient was transplanted at the beginning of May 1983 and the
last in mid-July 1985. Up to the end of 1983 azathioprine was used
and- -thereafter
as the main immunosuppressant (along with steroids) cyclosporin was 
introduced. This change in the immunosuppression protocol was not 
anticipated when this study was designed in August 1982, but it was 
thought that it would not be ethical to deprive the patients who 
entered the study from receiving cyclosporin because of its apparent 
superiority. Therefore, 11 of the 32 transplants received
azathioprine and prednisolone, 18 patients received cyclosporine and 
prednisolone, 2 patients were commenced on cyclosporine and
eventually were changed to azathioprine because of delayed graft
function, and one patient was treated with cyclophosphamide and
prednisolone because she developed persistent azathioprine-induced 
leucopenia. Azathioprine was given in an average dose of 2mg/kg/day 
aiming to keep the WBC count more than 4000/mm . The starting dose 
of cyclosporin in the first half of 1984 was 17.5mg/kg/day reducing
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to 15mg at one week, and to lOmg at 3 weeks; thereafter the dosage 
was adjusted to achieve optimal serum creatinine levels and trough 
whole blood cyclosporin levels ranging between 200-400ng/l. From 
mid-1984 a lower cyclosporin dose regimen was adopted starting with 
15mg/kg/day for one week reducing to lOmg for two weeks, with 
subsequent further reductions as before. The initial prednisolone 
dose in both patients receiving azathioprine and cyclosporine was 
20mg/day reducing to 15mg at 3 months, 12. 5mg at 6 months, and 20mg 
on alternate days at one year after transplantation. Rejection 
episodes were treated either by 500mg intravenous methylprednisolone 
pulses for two or three successive days or by increasing the oral 
prednisolone dose according to the Belfast regimen (436). The 
diagnosis of rejection was based on clinical grounds and ultrasound 
findings, and in most occasions was confirmed by biopsy. Selection 
of recipients was done on a best match basis giving priority to 
HLA-DR matching. Transplantation was carried out across a negative T 
cell crossmatch on both current and historical sera. The time of 
graft failure was defined either as the time of transplant 
nephrectomy or of recommencing dialysis. The end point of the 
follow-up was 31.5.86, giving a follow-up time of between 8 and 45 
months for the entire group.
Statistical analysis
The introduction of cyclosporin in this study made the 
interpretation of the transplantation results more complicated. The 
already small numbers of patients in the groups of weak and strong 
responders receiving 5 and 10 units of blood were inevitably affected 
by the two different immunosuppressive regimens. Therefore, 
actuarial graft survival was not considered in the statistical 
analysis. Graft survival has been expressed as the proportion of 
functioning grafts at the end of the study. Comparison of 
percentages was done using the chi-square test. Fisher's exact test 
was computed when there were fewer than 20 cases in a 2x2 table; 
Yates' corrected chi-square was computed for all other 2x2 tables. 
Comparison of the number of HLA mismatches and rejection episodes was 
carried out using the Mann-Whitney-Wilcoxon test.
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4.3 Results
Twenty two of the 32 transplants (69%) had a functioning renal 
graft at the conclusion of the study. Seven of the remaining 10 
patients lost their graft because of irreversible rejection, and the 
other three failures were non-immunological; of these three, two
patients died with functioning grafts (one from septicaemia and the 
other from a myocardial infarct) , and one transplant was an early 
technical failure due to renal artery thrombosis.
Figure 4.1 shows the graft survival in weak and strong DNCB 
responders receiving 5 or 10 units of blood; in the first part of the 
figure (a) patients have been allocated on the basis of their
response to DNCB at the first test, and in the second part of the 
figure (b) according to their DNCB status on repeating the test. The 
repeat test was carried out after the last elective transfusion. 
Although the graft survival in weak DNCB responders was better on 
both occasions compared to that of the strong responders the 
differences were not significant. Twelve of the 16 grafts in the 
weak responders were functioning by the end of the study (75%) , three 
of the remaining transplants underwent irreversible rejection, and 
one patient died with a functioning graft 14 months after the 
operation. In the strong responders 10 of the 16 grafts (63%) were
functioning at the end of the study, four grafts had rejected, one
patient with ongoing chronic rejection died with a functioning graft 
at 16 months, and there was one technical failure (Figure 4.1a). The 
rationale in analysing the graft survival of taking into account the 
DNCB status on repeating the test (Figure 4.1b) is justified by the 
fact that 6 of the weak responders who underwent transplantation were 
found to be strong responders on the repeat test. This implies that 
there is a proportion of uraemic patients who had delayed strong 
reaction at the first test, which has not been detected at the 
reading of the scores 48 hours after the challenge immunisation. The 
reaction of these patients became clearly strong in the anamnestic 
response on repeating the test. Two of the 6 weak responders who had 
changed to strong responders rejected their grafts. This slightly 
increased the difference in graft survival between weak and strong 
responders (80% vs 64%), although it was still not significant. This 
is an interesting point which may affect analyses of larger numbers
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of transplants, and will be discussed later in Chapter 9. With 
regard to the number of transfusions (5 or 10 units) and the graft 
survival in the weak and strong responders the numbers are too small 
to draw out any firm conclusion; nevertheless, the difference did not 
appear to be significant (Figure 4.1).
Table 4.1 shows that the number of patients treated with 
azathioprine or cyclosporine was comparable in the weak and strong 
responders (31% and 63% vs 38% and 50% respectively). The
proportion of well matched grafts was also not significantly 
different, and the mean number of mismatches per patient were 
identical in the two groups. In contrast, there was a significant 
difference in the number of patients presenting with rejection 
episodes between weak and strong DNCB responders (p < 0.025). Eleven 
of the 16 weak responders had no rejection episodes (69%),4 patients 
had one episode (25%), and one patient had three rejections (6%). In 
the 16 strong responders 5 patients had no rejection episodes (31%), 
5 patients had one episode (31%), 2 patients had 2 episodes (13%), 
and 4 patients had three episodes (25%). Hence, in the former group 
there was a total of 7 rejections among 5 patients, and in the latter 
group 21 rejections among 11 patients which gives a mean number of 
rejection episodes per patient 0.44 in the weak responders compared 
to 1.31 in the strong responders (p < 0.025). There was not any 
significant difference in the timing of the first rejection episode 
between the two groups. Four of the 5 weak responders (80%) had 
their first episode within the first week from the operation compared 
to 7 of the 11 strong responders (64%).
In Table 4.2 is shown the same information as in the previous 
Table taking into account the DNCB status on the repeat test. The 
change in the six patients from weak to strong responders did not 
upset the comparability of the two groups in terms of 
immunosuppression and tissue matching. However, the difference in 
the prevalance of rejection episodes in the two groups did not reach 
statistical significance because of the smaller numbers in the weak 
responder group which was reduced from 16 to 10 patients.
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4.4 Conclusions
The small number of transplants in the weak and strong DNCB 
responder group were further affected by the two different 
immunosuppressive regimens. Thus, the results in this chapter can 
only suggest trends and do not justify firm conclusions. Weak DNCB 
responders appeared to have better graft survival and less rejection 
episodes compared to strong DNCB responders, and whether the 
patients received 5 or 10 units of blood did not seem to associate 
significantly with the transplant outcome. These points will be 
further discussed in Chapter 9 of this thesis based on the findings 
from a retrospective analysis of a larger number of transplants.
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Figure 4.1. Graft survival in weak and strong DNCB 
responders receiving 5 or 10 units of blood; 
a = DNCB score at first test, b = DNCB score on 
repeating the test.
TABLE 4.1. TRANSPLANTATION DATA OF WEAK AND STRONG DNCB RESPONDERS
AT THE FIRST TEST
Immunosuppression:
Weak Responders Strong responders
n-16 n-16
Azathioprine 5 (31%) 6 (38%)
Cyclosporin 10 (63%) 8 (50%)
Combination 1 (6%) 2 (12%)
Number of patients with
HLA mismatches: A B DR A B DR
0 4(25%)
1 4(25%)
2 8(50%)
5(31%)
7(44%)
4(25%)
8(50%)
7(44%)
1(6%)
2(12%)
8(50%)
6(38%)
3(19%)
12(75%)
1(6%)
6(38%)
8(50%)
2(12%)
Mean mismatches/ 
patient 1.3 0.9 0.6 1.3 0.9 0.6
Number of patients with 
relection episodes:*
0
1
2
3
11(69%)
4(25%)
0
1(6%)
5(31%)
5(31%)
2(13%)
4(25%)
Total number of rejections 
Mean rejections/patient:
7
0.44**
21
1.31**
Duration of praft function 
Mean + SD (months) 17.4+9.5 15.6+11.2
TABLE 4.2. TRANSPLANTATION DATA OF WEAK AND STRONG DNCB RESPONDERS
ON THE REPEAT TEST
Weak responders 
n=10
Strong responders 
n»22
Immunosuppression
Azathioprine
Cyclosporine
Combination
Number of patients with 
HLA mismatches:
4 (40%)
5 (50%) 
1 (10%)
7 (32%) 
13 (59%) 
2 (9%)
B DR B DR
3(30%) 4(40%) 5(50%) 3(14%) 4(18%) 9(41%)
3(30%) 4(40%) 4(40%) 9(41%) 15(68%) 11(50%)
4(40%) 2(20%) 1(10%) 10(45%) 3(14%) 2(9%)
Mean mismatches/ 
patient: 1.1
Number of patients with 
rejection episodes:*
0.8
Total number of rejections 
Mean rejections per patient:
0.6
8(80%)
1(10%)
0
1(10%)
4
0.40**
Duration of praft function
Mean + SD (months): 19.4 + 10.1
1.3 1.0 0.7
8(36.5%)
8(36.5%)
2(9%)
4(18%)
24 
1.10**
15.2 + 10.2
*x2 - 6.158, DF - 3, NS; **t - 1.696, NS
CHAPTER 5. DEVELOPMENT OP PANEL REACTIVE ANTIBODIES FOLLOWING 
TRANSFUSION AND TRANSPLANTATION
5.1 Introduction
The main concern with regards to a deliberate transfusion 
policy prior to renal transplantation is the risk of producing 
sensitisation against the HLA antigens of future kidney donors 
(420,440,443,456,465,479,491-496,509-513). In addition to blood 
transfusion, sensitisation may also result from a previous failed 
transplant or from a previous pregnancy (456,465,479,491,492). There 
is a considerable variation in titre, specificity and persistence of 
cytotoxic HLA antibodies in patients awaiting transplantation, and 
this fact may to some extent be due to individual differences in the 
patient's immune response (457,493,494). The aim of this chapter is 
to see whether weak or strong DNCB responders differ in the 
development of lymphocytotoxic antibodies ie panel reactive 
antibodies (PRA) after elective blood transfusion, and to define the 
optimum number of transfusions in order to achieve a beneficial 
effect on graft survival, while keeping the risk of sensitisation to 
a minimum.
5.2 Patients and Methods 
Patients
All 48 patients in the transfusion group and the 12 uraemic 
controls (Table 1) were followed up to determine the development of 
PRA (Figure 5.1). Sera from the patients in the transfusion group 
were harvested prior to the first and 2 weeks after each transfusion, 
and from the controls at monthly intervals. Thereafter all patients 
were followed up every month for a mean period of 18.5 months (range 
8-36 months) after the last elective blood transfusion. Thirty two 
of the 48 patients underwent transplantation (see Chapter 4); the 
remaining 16 patients were not transplanted during the study. The 
mean follow up in the former group was 16.6 months (range 8-36 
months) and in the latter group was 22.3 months (range 8-28 months); 
during this period 9 of the 16 patients who were not transplanted 
were given packed cells when transfusion was indicated on clinical 
grounds (range 1-18 units).
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Methods
Sera were screened for PRA using the standard Terasaki-NIH 
microcytotoxicity test (572) using a long incubation time (576). 
Purified T lymphocytes prepared by rosetting with neuraminidase were 
recovered from a selected panel of 30 healthy volunteers covering the 
range of HLA-A, B and C specificities. In summary, lul of T 
lymphocytes was added to lul of antiserum in Greiner microtest 
plates, and incubated for 60 minutes. Using a multiple needle 
dispenser 5ul of rabbit complement was added and plates were 
incubated for a further 120 minutes. Both incubations were carried 
out at room temperature (22°C) . Then, 3ul of 5% eosin, and a few 
minutes later 8ul of formaldehyde were added. All sera were judged 
to be positive when more than 20% of the target cells were killed. 
Positive and negative controls were included in each test. The 
results were not known until the end of the study, so exclusions with 
regards to sensitisation status of the patients were not made. This 
reflects our policy in clinical practice, since patients awaiting 
transplantation after they have completed the elective 5 units of 
packed cells, receive further packed cells regardless of the level of 
PRA should they require transfusion on clinical grounds.
Statistical analysis
Comparisons of differences of sensitisation rates between 
groups were done using the chi-square test with Yates' correction. 
Differences of means of PRA were not analysed statistically because 
the numbers of sensitised patients within subgroups were small. 
Therefore, findings in this chapter should be viewed as indicative of 
trends rather than leading to firm concluding remarks.
5.3 Results
None of the 12 controls developed PRA. In contrast, the rate 
of sensitisation after 5 and 10 units of blood is shown in Table 5.1. 
Six of the 30 patients receiving 5 units (20%) , and 7 of the 18 
patients receiving 10 units of blood (39%) had PRA in their latest 
sera. Looking at the entire range of sera, the peak sensitisation 
rates were 27% amd 44% respectively. The incidence of sensitisation 
was higher among the strong DNCB responders compared to the weak
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responders, but the numbers were too small to reach statistical 
significance (Table 5.1). However, the importance of the individual 
patient's immune response, as measured by the DNCB test, in response 
to blood-transfusion induced PRA is better demonstrated in Table 5.2, 
which shows the rate of senisitisation prior to the first and after 
each transfusion in the weak and strong DNCB responders. Strong DNCB 
responders developed cytotoxic antibodies earlier compared to weak 
responders. After the third unit of blood none of the 21 weak DNCB 
responders had PRA compared to 22% of the strong responders. This 
difference just failed to reach statistical significance with Yates' 
correction. After the fifth transfusion, however, the numbers of 
sensitised patients in the two groups become more comparable. Figure
5.2 shows in logarithmic scale the level of PRA in weak and strong 
DNCB responders receiving 5 units of blood. After the third 
transfusion none of the 13 weak responders had PRA compared to an 
overall mean of 4% of the 17 strong DNCB responders. After the fifth 
transfusion, however, both weak and strong responders had identical 
mean PRA at 10%. Figure 5.3 shows the 8 patients who initially had 
no antibodies and in whom these developed in the course of the 5 
transfusions. None of the 6 sensitised patients of both strong and 
weak DNCB responders had broad reactivity after 4 transfusions (all 
had less than 35%) , and it was only after the fifth unit of blood 
that patients tended to become more broadly reactive against the 
panel (32-76%). It is also interesting that the 2 sensitised weak 
DNCB responders had negligible reactivity prior to the fifth 
transfusion, but after that they responded in a comparable way to the 
strong DNCB responders. The same pattern of response was found in 
the patients receiving 10 transfusions (Figure 5.4). Again, after 
the fifth transfusion the level of PRA in the 2 groups was almost 
identical, ranging from 10% after the fifth transfusion to 16% after 
the tenth unit of blood. During the first 4 transfusions the level 
of PRA was zero in the weak DNCB responders compared to 8-9% in the 
strong responders. In Figure 5.5, which shows the patients 
sensitised in the course of 10 transfusions, it can be seen that, 
with the exception of one patient, the reactivity prior to the fifth 
unit is low and becomes stronger thereafter. The exception was a 
woman with a history of five pregnancies and with a positive (20%)
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background reactivity. This patient developed broad sensitisation 
(more than 80% PRA) after the second transfusion and remained highly 
sensitised thereafter. The fact that females are of higher risk to 
becoming sensitised because of previous immunisation from pregnancies 
(Table 1), is shown in Table 5.3. Although the differences were not 
significant, a larger proportion of women became sensitised, 
particularly after 10 units of blood, and they tended to retain the 
antibodies for longer compared to men, judging from the peak and the 
latest PRA figures in the 2 groups. Table 5.4 shows the development 
of cytotoxic antibodies before and after each elective transfusion 
and the follow-up thereafter in the patients who had not received an 
allograft by the end of the study. Of the patients who became 
sensitised during the elective transfusions and did not require 
further blood on clinical grounds (numbers 1, 3 and 7 in Table 5.4), 
all 3 eventually lost their antibodies within a year from the last 
elective transfusion. Patients requiring an occasional further 
transfusion (numbers 2, 4, 8, 9 and 10) had fluctuating PRA titres, 
the blood always having a booster effect on their reactivity, but 
which again was eventually lost or declined. In contrast, 2 patients 
(numbers 5 and 6) who required a further 18 and 13 units of blood 
respectively after the elective transfusions, developed broadly 
reactive antibodies, including those with the more common anti-HLA 
specificities, namely, HLA-B8, HLA-B12 and HLA-A2. Table 5.5
summarises the data of the patients who underwent transplantation and 
classifies them according to the development of peak and 
pre-transplant PRA and also peak titres after the transplant. 
Patients transplanted with zero PRA in the complete series of 
pretransplant samples, and with zero (group 1) or very low
post-transplant titres (range 4-19%) (group 2), all had successful 
outcome (mean graft survival 19 months, range 8-31 months). In the 
third group, 5 patients had a transplant across positive (range 
13-61%), but declining PRA titres (range 0-26%), and the
post-transplant response was also low (range 0-26%); all 5 patients 
had a successful outcome (mean graft survival 12 months, range 8-16 
months). By contrast all 5 patients transplanted with zero
pretransplant PRA, but with high post-transplant titres (range 
56-87%) lost their grafts within 5-14 months (group 4). Finally, all
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3 patients with high (range 32-100%), non-declining pretransplant
titres (range 65-96%), and with equally high post-transplant titres
(range 52-100%) also lost their grafts within a month (group 5).
5.4 Conclusions
1) Strong DNCB responders develop cytotoxic antibodies earlier 
after blood transfusion in comparison with weak DNCB 
responders, but after 5 units of blood both rate and level of 
PRA are comparable in the two groups.
2) The risk of broad sensitisation of patients receiving 3 or 4 
units of blood is negligible, but may increase with more 
transfusions.
3) Elective pretransplant transfusion of packed cells should be 
limited to 3 or 4 units, and thereafter patients should receive 
less immunogenic blood products such as frozen or filtered red 
cells should they require transfusion on clinical grounds.
4) Women are at higher risk of developing antibodies, and those 
with preformed PRA should be given less immunogenic transfusion 
protocols.
5) Negative or declining PRA titres in the pretransplant sera 
predict high graft survival, while high titres after 
transplantation are commonly associated with graft failure.
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TABLE 5.1. SENSITISATION RATES AFTER 5 AND 10 UNITS 
OF ELECTIVE BLOOD TRANSFUSION
Latest PRA:
All patients
Weak DNCB responders
Strong DNCB responders
Number of 
sensitised patients
5 units
6 of 30 (20%) 
2 of 13 (15%) 
4 of 17 (24%)
10 units
7 of 18 (39%) 
2 of 8 (25%) 
5 of 10 (50%)
Peak PRA:
All patients 8 of 30 (27%) 8 of 18 (44%)
Weak DNCB responders 2 of 13 (15%) 3 of 8 (38%)
Strong DNCB responders 6 of 17 (35%) 5 of 10 (50%)
TABLE 5.2. SENSITISATION RATE IN WEAK AND STRONG DNCB RESPONDERS
AFTER BLOOD TRANSFUSION
Number of sensitised patients
Number of
transfusion 0 1 2 3 4 5  6 7 8 9  10
Weak DNCB
responders 0/21 0/21 1/21 0/21* 1/21 3/21 2/8 1/8 2/8 3/8 2/8
5% - 5% 14% 25% 13% 25% 38% 25%
Strong DNCB
responders 1/27 4/27 5/27 6/27* 5/27 5/27 1/10 2/10 2/10 5/10 5/10
4% 15% 19% 22% 19% 19% 10% 20% 20% 50% 50%
*x2 - 5.353, p < 0.025, Yates1 x2 - 3.495, NS
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Figure 5.2. Mean + SEM percent PRA titres in 
the weak (0) and strong DNCB responders (•) 
receiving 5 units of packed cells.
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TABLE 5.3. SENSITISATION RATES AFTER 5 AND 10 TRANSFUSIONS
IN MALES AND FEMALES
Latest PRA: 
Males 
Females
Peak PRA:
Number of 
sensitised patients
5 units 
(n-30)
4 of 23 (17%) 
2 of 7 (29%)
10 units
(nr-lS)
4 of 14 (29%) 
3 of 4 (75%)
Males
Females
6 of 23 (26%) 
2 of 7 (29%)
5 of 14 (36%) 
3 of 4 (75%)
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TABLE 5.5. SUMMARY OF PATIENTS UNDERGOING TRANSPLANTATION
Graft HLA
Patients %PRA Failure Mismatches CYA AZ
(n-32) Peak Pre-Tx Post-Tx n A.B DR H U
Group 1
(n-14) 0 0 0 0 2.1 0.5 7 6
Group 2
(n-5) 0 0 9±5 0 2.4 0.8 3 1
Group 3
(n-5) 30+19 5+10 5+10 0 1.6 0.6
Group 4
(n-5) 0 0 70+11 5 2.4 0.6
Group 5
(n-3) 78+39 82+16 72+25 3 2.3 1.3
CYA/AZ
n
1
1
0
1*
CYA - cyclosporine, Az - azathioprine, 
*Azathioprine/cyclophosphamide
CHAPTER 6. THE EFFECT OF PRE-TRANSPLANT TRANSFUSION ON IgG-SECRETING 
CELLS
6.1 Introduction
Previous studies have shown that blood transfusion may alter 
lymphocyte reactivity of uraemic patients due to an increase in 
non-specific suppressor activity mediated by either suppressor T 
cells or monocytes (393,394,531-535,537). Activation of B cells by 
polyclonal B cell activators is regulated by suppressor T cells. One 
means of assessing the role of suppressor cells at the cellular level 
is to examine the production of immunoglobulin by peripheral blood 
lymphocytes in response to two polyclonal B cell activators that 
differ in their dependence on regulation by suppressor cells. 
Pokeweed mitogen (PWM) induced immunoglobulin synthesis is influenced 
by T suppressor cells (249,250), whereas the response to 
Staphylococcus Aureus, Cowan I (SAC) is only partially T cell 
dependent; the proliferation of B cells in response to SAC is not 
dependent on T cells, while the differentiation into immunoglobulin 
secreting cells is T cell dependent (577). The aim of this chapter 
is to describe the effect of third party blood transfusion on 
IgG-secreting cells both spontaneously and after stimulation with PWM 
and SAC, using a reverse haemolytic protein A plaque forming cell 
(PFC) assay.
6.2 Patients and Methods 
Patients
Twenty six of the 48 patients in the transfusion group were 
studied of whom 20 were males (77%) and 6 females (23%) with a mean 
age of 39.2 years (range 20-59 years). Their original renal diseases 
were glomerulonephritis 9 (35%), pyelonephritis 7 (27%), polycystic 
kidneys 3 (11%), hypertensive nephrosclerosis 3 (11%), diabetes 2 
(8%), and of unknown origin 2 (8%). Twenty patients were on
haemodialysis (77%) and the remaining 6 patients were on CAPD (23%). 
With regard to their clinical characteristics, these 26 patients were 
representative of the entire group of 48 transfused patients (Table 
1). The breakdown of the 26 patients according to their response to 
the DNCB skin test and the number of transfusions they received is
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shown in Figure 6.1. Ten patients were weak DNCB responders and 16 
were strong responders. Fourteen patients (6 weak and 8 strong 
responders) received 5 units of blood, and the other 12 patients (4 
weak and 8 strong responders) had 10 transfusions. Twelve 
non-transfused uraemic controls (Table 1) and 12 healthy subjects 
were also studied. In the group of healthy controls there were 7 
males and 5 females with a mean age of 36 years (range, 24-59 years).
Methods
The 26 transfused patients were studied prior to and at 14-day 
intervals after each transfusion. The two control groups were also 
studied sequentially on 3 to 4 occasions over a period of three 
months. Peripheral blood mononuclear cells (PBMC) were prepared from 
heparinised blood by separation on Ficoll Hypaque (Nyegaard, 
Birmingham, UK) , and were cryopreserved in liquid nitrogen. All PBMC 
samples from each subject were assayed in one experiment to avoid 
test to test variation. Initial studies had shown that cells could 
be cryopreserved without loss of plaque forming cell activity.
The PFC assay: The principle of the assay is schematically shown in
Figure 6.2. Sheep red blood cells (SRBC) coated with staphylococcal 
protein A which had been mixed with anti-Ig antisera, PBMC, and 
complement are incubated in a Petri dish containing agar. 
Immunoglobulin released by plasma cells from within the population of 
PBMC combines with the antisera forming complexes which in turn are 
bound on the surface of the SRBC through the Fc portion of the 
antisera. Complement activation causes a zone of lysis of SRBC 
surrounding a central plasma cell which is visible to the naked eye 
as a plaque on the agar layer.
The PFC assay was performed as described by Gronowicz et al 
(578) and modified by Bird and Britton (579). SRBC (Flow 
Laboratories, UK) were washed six times in normal saline and then 
coated with protein A (Pharmacia, Uppsala, Sweden). The coating was 
carried out by incubating one volume of SRBC with one volume of 
protein A (0.5mg/ml) and ten volumes (2.5 x 10M) of chromic chloride 
(Analar, BDH Chemicals, Poole, England) for 45 minutes at 37°C with 
continuous rotation. After incubation the protein-A coated SRBC were 
washed three times with Hank's balanced salt solution (HBSS, Gibco,
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Paisley, Scotland) and were used for up to 5 days after preparation. 
The spontaneous PFC assay was performed by adding the reagents listed 
below to 750ul of agar, which was supplemented with 2mg/ml of 
DEAE-dextran (Pharmacia, Uppsala, Sweden) and 1% polyethelene glycol 
6000 (PEG 6000, Sigma, St Louis, USA) and was kept in 46°C water 
bath:
a) 25ul protein-A-coated SRBC
b) lOOul of PBMC suspension
c) 25ul (1:30) rabbit antisera specific for heavy chains of human 
IgG (Dako Immunoglobulins, Copenhagen, Denmark)
d) 25ul (1:4) of SRBC absorbed guinea pig complement (Sera-Lab 
England) diluted in HBSS.
After mixing in a vortex mixer, three 200ul drops were pipetted into 
a plastic 90mm Petri dish (Sterilin, Teddington, England) and a 24mm 
x 32mm coverslip immediately placed on top of each drop. The plates 
were then incubated for 8 hours at 37°C in 5% CO2 in air in a 
humified incubator. Potential PFC were identified by the naked eye 
as holes in the agar (Figure 6.3), and the presence of a lymphoid 
cell at the centre of the haemolytic spots was confirmed by 
microscopy (Figure 6.4). The plaques were counted and the results 
were expressed as the mean PFC count (of triplicate determinations 
per million plated cells). To perform the PFC assay on lymphocyte 
cultures stimulated with PWM and SAC, 0.5 x 10^ PBMC in one ml of 
medium (RPMI 1640 supplemented with 10% foetal calf serum, 
penicillin/streptomycin and L-glutamine) were cultured for six days 
in 12x75cm plastic tubes (Sterilin, Teddington, England) in the 
presence of optimal dilutions of PWM (1:100, Gibco, Paisley, 
Scotland) or SAC (1:1000) which was prepared following the procedure 
described by Forsgren et al (580). At the end of the culture period, 
the cells were washed twice in ice-cold HBSS, and then counted in a 
haemocytometer. Their viability was assessed and they were then 
assayed for IgG-secreting cells using the PFC assay as described 
above.
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Statistical analysis
There was a large intersubject variation in the IgG-PFC counts 
and in order to show this, mean, standard deviation, standard error 
of mean, range and median values have been estimated. Because of 
this variation, graphic representation of data was carried out using 
a semi-logarithmic scale. The distribution of PFC counts was not 
normal and there was a substantial departure from linearity in the 
examination of the scattergrams, so the results have been analysed 
using non-parametric tests. Since the direction of the results could 
not be predicted, two-tailed significance values (p values) have been 
applied. Comparison of mean values between unpaired populations was 
done using the Mann-Whitney-Wilcoxon test which although based on 
ranks utilises most of the quantitative information inherent in the 
data. Comparison of mean values in paired samples was carried out 
using the Wilcoxon matched-pairs signed rank test which utilises both 
direction and magnitude in the ranking of differences. The 
correlation between variables was done using two non-parametric 
counterparts of the Pearson correlation coefficients, namely, the 
Spearman and the Kendall correlation coefficients. Also, these two 
tests were used in multiple regression analysis in the examination of 
inter-relations between more than two variables. Comparison of 
values between groups was also done using one-way analysis of 
variance. Although this is a parametric test, it is an extremely 
useful one, since the F ratio reflects significance of differences 
both between and within the groups, the latter expressing the degree 
of individual variation and functioning as a sort of 'standard error 
of the variance'.
6.3 Results
Table 6.1 and 6.2 show the IgG-PFC counts in the 2 control 
groups and in the transfusion group prior to and after each 
transfusion respectively. Judging from the range and standard 
deviations it is clear that there was a large intersubject variation 
in both spontaneous IgG-PFC counts and those after stimulation with 
SAC and PWM. This was more pronounced in the transfusion group 
particularly after the fifth unit of blood. As a result, the 
standard error after the tenth unit of blood was approximately
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twofold compared to that prior to transfusion. Another point of 
caution comes from the comparison between mean and median values, the 
former being higher on all occasions. This suggests that the 
distribution of the values is positively skewed and mean counts are 
drawn in the direction of the extreme values.
6.3.1 Comparison of IgG production between controls and transfused 
patients
From Table 6.1 it is apparent that the IgG-PFC counts in the 2 
control groups remained unchanged over a period of 3 months. In 
contrast, there were significant changes in the transfusion group 
with regard both to the spontaneous counts and those after PWM 
stimulation. Before describing the statistical details of these 
changes, it is worth looking at the comparison of IgG-PFC counts 
between healthy subjects and non-transfused uraemic patients (Figure 
6.5). The difference between the two groups in the spontaneous and 
SAC-induced IgG-PFC counts was highly significant (mean + SEM, 1426 + 
340 vs 300 +157, p < 0.0001, and 15480 + 1480 vs 3743 + 1220, p <
0.0000, respectively), whereas the difference in the PWM-induced
counts was not significant (mean + SEM, 28707 + 2862 vs 26066 +
5184). The latter finding suggests that B cell function in 
non-transfused uraemic patients is comparable to that of normal
subjects. Thus, the defect in Ig secretion which was detected in the 
spontaneous and SAC-driven systems may be due to altered activity of 
other mediators involved in B cell activation which can be defined by 
these systems.
Figure 6.6 shows the comparison of IgG-PFC counts between the
transfusion group prior to and after the 5th and 10th unit of blood
and the uraemic controls at 0 and 3 months. The difference between 
the 2 groups in the spontaneous IgG-PFC assay at the start of the 
study (Figure 6.6a) is significant (mean + SEM, 214 + 24 vs 385 + 46, 
p < 0.02) but this is presumed to be a chance finding arising from 
patient selection. However the difference after the 5th and 10th 
transfusion was highly significant and was due to an increase in the 
spontaneous IgG-PFC after transfusion (after 5 BT: mean + SEM, 215 + 
25 vs 460 + 44, p < 0.0002, after 10 BT: 215 + 25 vs 655 + 140, p <
0.008). Despite this increase, Tables 6.1 and 6.2 show that the
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IgG-PFC counts in the transfused group after the 5th or 10th unit of 
blood, were still significantly lower than those of the normal 
controls at 3 months (after 5BT: mean + SEM, 460 + 44 vs 1579 + 383, 
p<0.001, after 10 BT: 655 + 140 vs 1579 + 383, p<0.006). The
difference in the IgG-PFC counts after stimulation with SAC between 
the transfused and non-transfused uraemic groups (Figure 6.6b) was 
not significant both prior to and after the 5th or 10th transfusion 
(mean + SEM, 2935 + 1*14 vs 4551 + 1032, 2916 + 1286 vs 3721 + 709, 
and 2916 + 1286 vs 4973 + 1789, respectively). The difference in 
SAC-IgG-PFC between uraemic and normal controls at 3 months was 
highly significant (mean + SEM, 2916 + 1286 vs 15642 + 1545, p<0.001) 
as was the difference between transfused patients after the 5th or 
10th unit of blood and the normal controls (3721 + 709 vs 15642 + 
1545, p<0.0002, 4973 + 1789 vs 15642 + 1545, p<0.0008). The
difference between the uraemic control and transfused groups in the 
IgG-PFC counts after stimulation with PWM (Figure 6.6c) was not 
significant prior to transfusion (mean + SEM, 30968 + 5851 vs 21145 + 
4517), but became significant after the 5th unit of blood due to a 
decrease in the IgG-PFC counts in the transfused group (mean + SEM, 
32080 + 5669 vs 13433 + 2796, p < 0.002). However, after the 10th 
unit of blood the counts had risen again so that the difference had 
disappeared (mean + SEM, 32080 + 5669 vs 21156 + 9361). In the 
PWM-driven system IgG production in the transfused group after the 
5th unit of blood was significantly depressed in comparison with the 
normal controls at 3 months (mean + SEM, 13433 + 2796 vs 28176 + 
2933, p<0.004). In contrast, the difference between uraemic and 
normal controls at 3 months was not significant (mean + SEM, 32080 + 
5669 vs 28176 + 2923) . The difference in the mean PWM-IgG-PFC counts 
between the transfused group after the 10th unit of blood and the 
normal controls at 3 months did not reach statistical significance 
(mean + SEM, 21156 + 9361 vs 28176 + 2923).
6.3.2 IgG production in the transfusion group
Despite the large intersubject variation in the IgG-PFC counts 
the kinetics of their appearance following transfusion was fairly 
reproducible resulting in significant changes. This is shown in 
Figure 6.7 which is the graphic version of Table 6.2. In the
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spontaneous assay the mean IgG-PFC counts showed an overall 
progressive increase after each transfusion; the differences between 
background counts and those after the 1st, 2nd, 3rd, 5th, 8th, 9th 
and 10th unit of blood were significant (Figure 6.7a). Although the 
mean values progressively increased up to the 10th transfusion, this 
did not lead to greater statistical significance, firstly, because 
the numbers of patients decreased from 26 to 12 after the 5th 
transfusion, and secondly, because the difference in the median 
values was less pronounced (Table 6.2). Within the patients 
receiving 10 units of blood there were three with much higher values, 
and as a result of this the mean counts were drawn in that direction. 
In the SAC-driven system there was a mild degree of suppression of 
the mean IgG-PFC counts by the 5th transfusion and thereafter the 
mean counts were increased by the 10th unit of blood, but the 
difference compared to the background counts was not significant at 
any time (Figure 6.7b and Table 6.2). In contrast, after stimulation 
with PWM there was a progressive suppression of mean IgG-PFC counts 
which became significant after the second transfusion and was greater 
after the 5th unit of blood. However, further transfusion in the 12 
patients receiving 10 units of blood had an enhancing effect on the 
mean IgG-PFC counts and the difference between post-6th to post-10th 
BT IgG-PFC counts compared to the background ones was not significant 
(Figure 6.7c and Table 6.2). This finding raises the question as to 
whether this rise in IgG-PFC counts after the 6th BT is a genuine 
result which may reflect feedback or contrasuppressor activity after 
the 6th transfusion. To examine this I looked into the individual 
changes in the PFC counts. Figures 6.8, 6.9, and 6.10 show the
individual spontaneous, SAC-, and PWM-induced IgG-PFC counts 
respectively, before and after 5 or 10 units of blood. To coincide 
with the 0.05 level of statistical significance, changes were defined 
as significant when they fell outwith the range of the mean change 
plus 2 standard deviations of the 12 uraemic controls over a period 
of 3 months (Table 6.3). Thus, Table 6.4 shows the proportional 
changes in PFC counts after 5 and 10 units of blood in the transfused 
patients. Figure 6.11 illustrates these changes, and Figure 6.12 
shows the proportion of patients with unchanged, enhanced or 
suppressed IgG production.
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In the spontaneous system 12 of the 26 patients (46%) had a 
significant increase in the IgG-PFC counts after the 5th transfusion 
(mean + SEM, 112 + 26%, range, 31% to 339%), in 2 patients (8%) the 
counts were depressed, and in the remaining 12 patients (46%) there 
was no significant change (Figure 6.11a and Figure 6.12). In the 12 
patients who received 10 units of blood the proportion of patients 
with increased (7/12), unchanged (4/14) and depressed counts (1/12) 
after the 5th transfusion remained similar after the 10th 
transfusion (8/12, 3/12, and 1/12 respectively) (Figure 6.11a);
however, the overall mean + SEM change in these 12 patients increased 
from 65 + 30% (range, -68% to 339%) to 120 + 55% (range, -59% to 
621) . Although this difference was not statistically significant 
(Figure 6.8), it suggests that further transfusion in these patients 
had a further enhancing effect on spontaneous IgG production mainly 
from the patients who had already responded with an increase after 5 
units of blood.
In the SAC-driven system the IgG-PFC counts remained unchanged 
in most of the patients (19/26, 73%), in 2 patients there was a
significant increase (8%), and in the remaining 5 patients (19%) IgG 
production was significantly depressed after 5 units of blood (mean + 
SEM, 53 + 4%, range 44% to 65%) (Figure 6.11b and 6.12). Further 5 
units of blood had again an enhancing effect in IgG production in 
those patients who had already responded with an increase after 5 
transfusions (patients no. 9, 14 and 20) (Figure 6.11). None of
these changes after stimulation with SAC was significant.
In contrast, after stimulation with PWM 18 of the 26 patients 
(69%) had a significant suppression of IgG production after 5 units 
of blood (mean + SEM, 54 + 4%, range 22% to 80%), in 3 patients there 
was no change (12%), and in the remaining 5 patients (19%) there was 
a significant increase (mean + SEM, 131 + 51%, range, 41% to 332%) 
(Figure 6.11c and 6.12). In the 12 patients receiving a further 5 
units of blood the proportion of patients with increased (3/12), 
unchanged (1/12) and suppressed counts (8/12) was identical after the 
10th transfusion. However, in the 3 patients with increased counts, 
(number 9, 14 and 20) there was a further enhancement in IgG
production (from 332% to 721%, from 84% to 233% and from 98% to 161%, 
respectively) and in the those with suppression of counts there was
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further suppression from a mean + SEM, 52 + 6% (range, 22% to 80%) to 
67 + 6% (range, 32% to 87%) (Figure 6.11c). Although these
differences were not signficant (Figure 6.10), the very large 
enhancement in IgG production in the 3 patients outbalanced the 
suppression observed in 8 of the 12 patients receiving 10 
transfusions. Consequently, the difference in IgG-PFC counts after 
10 units of blood compared to background values was not significant 
(Figure 6.10). Therefore, the progressive increase in IgG production 
after the 5th transfusion in the PWM-driven system described earlier 
in Figure 6.7c was due to the very high increase induced in 3 
patients (No. 9, 14 and 20), rather than to an overall feedback or 
contrasuppressor activity. Interestingly, these 3 patients had a 
very marked increase in IgG production after transfusion both 
spontaneously and after sitmulation with SAC and PWM.
6.3.3 The effect of blood transfusion on IgG production in weak and 
strong DNCB responders.
The 26 patients in the transfusion group were divided according 
to their response to DNCB, as it was shown in Figure 6.1, in order to 
see whether weak and strong DNCB responders differ in IgG production 
following transfusion. Table 6.5 shows the mean IgG-PFC counts in 
the 12 uraemic controls divided into the 4 weak and 8 strong DNCB 
responders. There were no differences between the weak and strong 
responders over the period of 3 months. Tables 6.6, 6.7 and 6.8 show 
the mean spontaneous, SAC- and PWM-induced IgG-PFC counts 
respectively following transfusion in the 10 weak and 16 strong DNCB 
responders before and after each unit of blood. Statistical analysis 
of these Tables is shown in Figures 6.13, 6.14 and 6.15 respectively.
The difference in mean spontaneous IgG production between weak 
and strong DNCB responders was not significant following 1-5 units of 
blood (Figure 13a,b). However, from the 6th transfusion onwards in 
the patients receiving 10 units the weak DNCB responders had 
significantly higher mean IgG-PFC counts compared with the strong 
responders (Figure 6.13c). This difference was due to the fact that 
all 4 weak DNCB responders (No. 3, 4, 9 and 20) had a significant 
increase in spontaneous IgG production by the 10th transfusion 
compared to 4 of the 8 strong DNCB responders (Figure 6.8 and 6.11a).
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Although the numbers are small, this finding suggests that after 
intensive exposure to alloantigens at least a proportion of patients, 
who have been classed as weak responders by the DNCB test, will 
respond with a high rate of IgG production. A similar finding in 
this group of patients with regards to production of cytotoxic 
antibodies following transfusion was described in the previous 
chapter.
After stimulation with SAC the difference between weak and 
strong DNCB responders in mean IgG-PFC counts following transfusion 
showed a similar pattern to that of the spontaneous counts (Figure 
6.14). However, the statistical significance with respect to the 
difference between the 2 groups after the 6th-10th unit of blood was 
weak, and again was due to the very high IgG response in 2 of the 4 
weak DNCB responders (No 9 and 20) (Figure 6.9 and 6.11b).
In the PWM-driven system the difference in the mean IgG-PFC 
counts between the 10 weak and 16 strong DNCB responders became 
significant after the 2nd, 3rd, 4th and 5th unit of blood (p<0.03, 
0.03, 0.02 and 0.05 respectively) (Figure 6.15a). This difference 
was due to suppression of IgG production in the strong DNCB 
responders in whom the mean IgG-PFC after the 2nd, 3rd, 4th and 5th 
unit of blood were significantly lower compared to the background 
counts (p<0.02, on all occasions). In contrast, the decrease in the 
mean IgG-PFC counts in the weak DNCB responders did not reach 
statistical significance (Figure 6.15a). The difference between weak 
and strong responders was partly due to an increase in IgG production 
among the 4 weak responders who received 10 blood transfusions 
(Figure 6.15c). In this particular group by the 5th transfusion, 
weak DNCB responders had unchanged mean IgG-PFC compared to 
background counts, whereas by then strong DNCB responders had a 
significant suppression (p<0.04); after the 7th transfusion there was 
an increase in the mean IgG production in the former group, which in 
combination with the further suppression observed in the strong DNCB 
responders resulted in the significant difference between the 2 
groups after the 10th unit of blood (p<0.03). However, in the other 
split group of the 14 patients receiving 5 units of blood (Figure 
6.15b) weak DNCB responders had a significant suppression in mean 
IgG-PFC counts soon after the 2nd unit of blood (p<0.03), which
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remained so until after the 5th transfusion; strong DNCB responders 
in this group had also a progressive suppression which did not reach 
statistical significance compared to pre-transfusion counts, and the 
difference in mean IgG production between the 2 groups was not 
significant at any time.
Furthermore, the level of the individual PWM-IgG-PFC counts 
between weak and strong DNCB responders prior to and after the 5th 
transfusion was indistinguishable (Figure 6.10). Also, the 
difference in the proportion of patients in the 2 groups with 
increased, unchanged or suppressed IgG production did not appear to 
be significant (Figure 6.11c). After the 5th unit of blood in the 10 
weak DNCB responders, 2 patients had enhanced (20%), one patient 
unchanged (10%) and the remaining 7 patients (70%) suppressed IgG-PFC 
counts (mean + SEM, 52+7% ); in the 16 strong DNCB responders 3
patients had increased (19%) , 2 patients unchanged (13%) and the
remaining 11 patients (69%) suppressed IgG-PFC counts (mean + SEM, 
55+4%). Interestingly however, after the 10th transfusion there 
appeared to be a further enhancement or suppression of IgG production 
in both weak and strong DNCB responders who already had increased or 
suppressed IgG-PFC counts respectively by the 5th transfusion. In 
the former patients (No. 9 and 20) IgG production increased from 332% 
and 98% after the 5th unit to 721% and 161% after the 10th unit 
respectively, and in the latter patient (No. 14) from 84% to 233% 
(Figure 6.11c). In the patients whose IgG-PFC counts showed
suppression, in the weak DNCB responders (No. 3 and 4) IgG-PFC counts 
were further suppressed from 70% and 54% after the 5th transfusion to 
87% and 61% after the 10th unit of blood respectively. In the 6
strong DNCB responders (No. 5, 6, 8, 10, 17 and 18) the mean + SEM
suppression after the 5th transfusion was further suppressed from 
49+7% to 65+8% after the 10th unit of blood. Although these
individual differences are not statistically significant, they may be 
of biological significance in the sense of individual variation in 
the BT-induced immunosuppression and the amount of blood required to 
achieve this suppression. Yet, in all of these, the DNCB skin test 
did not prove to be a satisfactory means of predicting the
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spontaneous, SAC- and PWM- induced IgG response following third party 
transfusion. It provided, however, a very useful measurement in 
assessing the complexity of these responses.
6.3.4 Inter-relations between IgG-PFC counts following transfusion, 
cytotoxic antibodies, rejection episodes and transplant outcome.
So far, it has become evident that there is a different pattern 
of spontaneous and PWM- induced IgG production following transfusion. 
It has been shown that spontaneous IgG-PFC counts increased 
significantly in about half of the patients after 5 units of blood 
and this increase became more pronounced with a further 5 
transfusions. On the other hand, more than two thirds of the 
patients showed a significant suppression of IgG production in the 
PWM-driven system, whereas in a similar proportion of patients after 
stimulation with SAC there was no significant change. It was also 
shown that few patients had a high rate of IgG production both 
spontaneously and after stimulation with SAC or PWM following blood 
transfusion. This raised the question whether the kinetics of 
IgG-PFC counts in response to blood transfusion in the spontaneous, 
PWM-, SAC- driven system correlated with each other. In other words 
did the patients we studied respond with enhancement, suppression or 
no change in IgG production in all three systems? And if so, how 
does this response correlate with other variables of clinical 
importance, such as, cytotoxic antibodies, rejection and transplant 
outcome?
Table 6.9 shows that the correlation between spontaneous and 
PWM-IgG-PFC counts was not significant at any time, namely, neither 
before nor after each of the 1-10 transfusions. In contrast IgG 
production in the PWM- and SAC-driven system showed a good 
correlation, and this was also the case plotting SAC-induced against 
spontaneous counts. Figure 6.16 illustrates the absence of any 
linearity between spontaneous and PWM-IgG-PFC prior to and after the 
fifth transfusion, whereas after the tenth unit of blood the 
correlation was linear because of a simultaneous increase of counts 
in 2 patients (No 9, 20) against both axes; this correlation was
significant using the parametric Pearson test r=0.737, p<0.006), but 
the non-parametric Spearman test failed to reach significance because
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of the small numbers. Although PWM and SAC, as polyclonal B cell 
activators, differ in their dependence on T cells, IgG production in 
these two systems showed a positive correlation before and more 
convincingly, after transfusion (Figure 6.17). There was also a 
positive correlation between spontaneous and SAC- induced IgG 
production following blood transfusion which again was more 
pronounced after the tenth transfusion (Figure 6.18). This finding 
suggests that there is a disassociation between spontaneous and PWM- 
induced IgG production, which tends to disappear after more than 5 
units of blood and this seemed to be due to a clearer distinction 
between patients with enhanced, suppressed or unchanged PFC counts 
following that amount of transfusion.
Fifteen of the 26 patients studied in this chapter underwent 
transplantation following blood transfusion (Table 6.10). Nine of 
the 15 patients had received 5 units and the remaining 6 patients 10 
units of blood. The mean waiting time from the last elective 
transfusion to transplantation was 4.9 months (range, 1-15 months). 
Two patients were treated with azathioprine and prednisolone, one 
patient had azathioprine followed by cyclosporin and the remaining 13 
patients received cyclosporin and prednisolone. Nine patients did 
not have any rejection episodes while of the other 6 patients, 4 had 
one episode, one had 2 episodes and the final patient had 3 episodes. 
Thirteen of the 15 patients had a functioning graft at the end of the 
study, one patient's kidney underwent irreversible rejection at 7 
months, and one patient died with a functioning graft 16 months after 
transplantation.
Tables 6.11 and 6.12 show the relation between rejection 
episodes, IgG-PFC counts and cytotoxic antibodies after the fifth and 
tenth transfusion respectively, using both parametric and 
non-parametric correlation coefficients judged from the appearance of 
linearity in the scattergrams. The correlation between spontaneous
SAC- and PWM-IgG-PFC counts has already been discussed (Table 6.9), 
and it is obvious that using Pearson's correlation coefficients in 
Table 6.11 the statistical significance is stronger compared to that 
of Spearman's in Table 6.9. IgG production in the PWM- and SAC- 
driven system does not correlate with either PRA or rejection 
episodes. Spontaneous IgG-PFC counts after the fifth unit of blood
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correlated with PRA at that time (Pearson's r—0.497, p<0.01), but 
this was not the case after the tenth transfusion (Table 6.12); 
however, the significance of the correlation after 5 units of blood 
was based only on three positive values of PRA (Figure 6.19a) and 
application of the non-parametric Spearman test showed that the 
correlation with this test was not significant on either occasion. 
Similar limitations applied in correlating spontaneous IgG-PFC counts 
with the rejection episodes which proved to be not significant after 
five units of blood and showed a weak correlation after the tenth 
transfusion (p<0.05). This again was not significant using 
non-parametric tests (Figure 6.19b). The correlation between 
rejection episodes and PRA was not significant (Figure 6.19c). 
Finally, the transplant outcome has not been included in this 
multiple regression analysis, because there was only one patient with 
irreversible rejection.
6.3.5 Summary of results
Polyclonal B cell activation studies, which were carried out to 
assess the response to elective transfusion, in previously 
non-transfused uraemic patients, showed a large intersubject 
variation. Despite this, uraemic patients prior to transfusion had 
significantly lower spontaneous and SAC- induced counts of IgG 
secreting cells compared to normal controls, whereas the difference 
in PWM- induced IgG-PFC counts was not significant. After blood 
transfusion, IgG production in the PWM-driven system was suppressed 
in more than two thirds of the patients compared to that in normal 
controls and non-transfused uraemic controls. On the other hand, 
spontaneous IgG-PFC showed a significant increase in response to 
transfusion, whereas SAC-IgG-PFC remained overall unchanged. Within 
the main groups there were subgroups with enhanced, unchanged or 
suppressed IgG production, both spontaneously and after stimulation 
with SAC or PWM. The DNCB skin test did not separate patients with a 
high or low rate of IgG production in response to transfusion. 
Although not conclusive, there was some indication that blood 
transfusion-induced immunosuppression may be more easily produced in 
strong DNCB responder whereas weak responders were capable of very 
high IgG production, particularly after more than 5 units of blood.
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Whatever effect blood transfusion had in the individual patients 
(enhancement, suppression or unresponsiveness) it was demonstrable by 
the fifth transfusion. A further 5 units of blood did not have a 
significant effect in the same direction, ie enhancement or 
suppression, and the overall proportion of patients with these 
responses did not change. There was a clear disassociation between 
spontaneous and PWM- induced IgG production before and after one to 5 
units of blood and the former showed a weak correlation with PRA and 
rejection episodes. However because of the small numbers, a 
correlation between PRA and rejection episodes was not established.
6.4. Conclus ions
1) Spontaneous and SAC- induced IgG production in previously 
non-transfused uraemic patients was significantly lower 
compared with normal subjects. In contrast, the counts of IgG 
secreting cells after stimulation with PWM was normal.
2) Blood transfusion had a suppressive effect on IgG production in 
the PWM-, but not in the SAC- driven system, resulting in 
significantly lower IgG-PFC counts compared to those of uraemic 
and normal controls.
3) Spontaneous IgG production following transfusion was increased 
and there was some evidence, though inconclusive, that this may 
correlate with the development of cytotoxic antibodies and 
subsequent rejection episodes.
4) Subgroups of patients with a high or low response of IgG 
production, both spontaneously and after stimulation with SAC 
and PWM were observed, but the DNCB skin test failed to 
identify these patients.
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5) The blood transfusion-induced suppression of IgG-PFC counts 
detected in the PWM- driven system appeared to be at least 
equally induced in weak and strong DNCB responders. Some of 
the former patients were capable of responding with a very high 
rate of IgG production, particularly after more than 5 
transfusions.
6) More than 5 units of packed cells had a further, though 
non-significant enhancing or suppressive effect in spontaneous, 
SAC- and PWM-induced IgG production, but the overall proportion 
of patients with this varying response did not change.
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I. Transfused
5 units
DNCB 0-3
10 units
5 units
DNCB
10 units
II. Uraemic controls
DNCB 0-3
DNCB > 3
o
©
No transfusion
IIIo Normal controls
©
No transfusion
Figure 6.1. Breakdown of the subjects according to 
their response to the DNCB skin test and the number of 
blood transfusions; 0-3 = weak responders, y 3 = strong 
responders.
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Figure 6.2. Schematic representation of the reverse 
haemolytic protein-A plaque assay.
Figure 6.3. Macroscopic appearance of haemolytic 
plaques in a Petri dish.
Figure 6.4. Microscopic appearance of a haemolytic 
plaque with a central lymphoid cell and the zone of 
SRBC lysis surrounding it.
TABLE 6.1. SPONTANEOUS. SAC-. AND PWM-INDUCED 
IgG-PFC COUNTS IN THE TWO CONTROL GROUPS
IgG-PFC counts/I0— cells
Praemic controls Normal controls
(n^l2) (n^l2)
At 0 At 3 months At 0 At 3 months
Spontaneous:
Mean ±  SD 214±82 215±87 1426+1178 1579±1326
SEM 24 25 340 383
Median 208 194 943 963
Range 84-353 95-386 416-3654 462-4532
SAC stimulation:
Mean ± SD 
SEM
Median
Range
2935±4897
1414
1370
1120-18432
2916+4454
1286
1421
956-19958
15480+5128
1480
13540
11892-28705
15642+5353
1545
13190
10942-27200
PWM stimulation:
Mean ±  SD 
SEM
Median
Range
30968±20269
5851
25254
9750-72500
32080±19638
5669
24909
12410-67502
28707±9913
2862
28767
11498-43504
28176+10125
2923
27126
13673-45370
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Figure 6.5. Comparison of IgG-PFC counts (mean + SEM) 
between normal controls and previously non-transfused 
uraemic patients (pre-transfusion counts of the patients 
in the transfusion group and counts at 0 of the uraemic 
controls); open bars = control, shaded bars = uraemic 
patients.
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Figure 6.6. Comparison of IgG-PFC counts (mean -  SEM) 
between the transfusion group prior to and after the 
5th or 10th unit of blood and the uraemic controls at 
0 and at 3 months; a = spontaneous, b = SAC stimulation, 
c = PWM stimulation; open bars = control, shaded bars = 
transfusion group.
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Figure 6.7. IgG-PFC counts (mean + SEM) in the 
transfused patients prior to and after each of 
5-10 units of blood; a = spontaneous, b = SAC 
stimulation, c = PWM stimulation; p values against 
background counts.
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Figure 6.8. Spontaneous IgG-PFC counts in the transfusion 
group before and after the 5th or 10th unit of blood;
0 =  patients receiving 5BT, Q  = patients receiving 10BT; 
open symbols = weak DNCB responders, shaded symbols = strong 
DNCB responders; numbers inside symbols correspond to numbers 
of patients in Table 6.4.
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Figure 6.9. IgG-PFC counts after stimulation with SAC 
in the transfusion group before and after the 5th or 10th 
unit of blood; Q =  patients receiving 5BT> Q  = patients 
receiving 10BT; open symbols = weak DNCB responders, shaded 
symbols = strong DNCB responders; numbers inside symbols 
correspond to numbers of patients in Table 6.4.
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Figure 6.10. IgG-PFC counts after PWM stimulation in the 
transfusion group before and after the 5th or 10th unit of 
blood; Q  = patients receiving 5BT,| |= patients receiving 
10BT; open symbols = weak DNCB responders, shaded symbols = 
strong DNCB responders; numbers inside symbols correspond to 
numbers of patients in Table 6.4.
TABLE 6.3. PERCENT CHANGE OF IgG PFC COUNTS IN THE
12 URAEMIC CONTROLS OVER A PERIOD OF 3 MONTHS
% change of IgG-PFC
Controls Spontaneous SAC PWM
1. SW -24 -8 -2
2. MS +3 -5 +3
3. MMcG +0.5 +33 +4
4. JB -4 +13 +6
5. CMcD -2 +16 +7
6. AK +11 +4 +7
7. WY +20 +34 +7
8. JH +17 -12 +8
9. WB +16 -1 +9
10. DH +13 -3 +15
11. CB -15 +5 +17
12. JMcI -10 -15 +27
Mean ± SD +2 ±  14 +5 ±  16 +9 ± 8
TABLE 6.4. PERCENT CHANGE OF IgG-PFC COUNTS FROM BACKGROUND VALUES 
AFTER 5 OR 10 UNITS OF BLOOD IN THE TRANSFUSED PATIENTS
% Change of IgG-PFC 
Spontaneous SAC PWM
Post Post Post Post Post Post
Patients 5BT 10BT 5BT 10BT 5BT 10BT
1. JB +15 -9 -38
2. TS +13 -44 -80
3. SW +339 +135 -57 -78 -70 -87
4. MM +102 +621 -24 -3 -54 -61
5. WH +92 +49 +13 -2 -45 -76
6. AK +4 -26 +5 +7 -58 -87
7. KM +45 -65 -71
8. JP +83 +272 -4 -7 -22 -32
9. JMcG +88 +286 +151 +288 +332 +721
10. JD -11 -5 -8 -3 -41 -61
11. WY -13 +11 -0.3
12. PM +169 -6 +41
13. TC +6 +17 -61
14. JL +127 +93 +33 +87 +84 +233
15. LA +34 -46 +100
16. JH +7 +14 -53
17. BJ -68 -59 -2 -5 -70 -68
18. MS -10 -21 -8 -3 -56 -63
19. WG +197 -5 -53
20. CS +4 +37 +42 +62 +98 +161
21. RF +22 +7 +3
22. PF +31 +58 +15 +13 +2 +20
23. RH -70 -55 -67
24. RB +38 +5 -62
25. JG -10 -3 -40
26. LMcL -23 -19 -30
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Figure 6.11. Percent change of IgG-PFC counts after 3 or 
10 units of blood in the transfusion group; area between 
lines represent the mean + 2SD range of change in the 
uraemi c c ontrols; o  = patients receiving 5 BT, □  = patients 
receiving 10 BT, open symbols = weak DNCB responders, 
shaded symbols = strong DNCB responders.
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Figure 6.12. Proportion of patients with unchanged, 
enhanced or suppressed IgG production following 5 units 
of transfusion both spontaneously and after stimulation 
with SAC and PWM.
TABLE 6.5 IgG-PFC COUNTS IN THE WEAK AND STRONG
DNCB RESPONDERS OF THE URAEMIC CONTROLS
Spontaneous 
SAC-st imulation
IgG-PFC (mean + SD cotint s/10** cells)
Weak responders (n=4  ^ Strong responders (n=8)
At 0 At 3 month At 0 At 3 month
224±41 229+59 209±99 208+101
1801+596 2061+519 3501+6035 3343+5516
PWM-
stimulation 34130+21432 36332+23111 29414+20982 29954+19015
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Figure 6.13° Spontaneous IgG-PFC counts (mean + SEM) in the weak 
(open bars) and strong DNCB responders (shaded bars) before and 
after each transfusion; a = all 26 transfused patients (weak 
responders = 10, strong responders = 16); b = patients receiving 
5 units (weak responders = 6, strong responders =8); c = patients 
receiving 10 units (weak responders = 4, strong responders = 8)0
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Figure 6.14U IgG-PFC counts (mean + SEM) after stimulation with 
SAC in the weak (open bars) and strong DNCB responders (shaded 
bars) before and after each transfusion; a = all 26 transfused 
Patients (weak responders = 10, strong responders = 16); b = 
Patients receiving 5 units (weak responders = 6, strong responders 
=8); c = patients receiving 10 units (weak responders = 4, strong 
responders = 8).
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Figure 6.15. IgG-PFC counts (mean + SEM) after stimulation with 
PWM in the weak (open bars) and strong DNCB responders (shaded 
bars) before and after each transfusion; a = all 26 transfused 
Patients (weak responders = 10, strong responders = 16); b =
Patients receiving 5 units (weak responders = 6, strong responders = 
®)» c = patients receiving 10 units (weak responders = 4, strong 
rasponders = 8).
TABLE 6.9. SPEARMAN CORRELATION COEFFICIENTS AND TWO-TAILED
SIGNIFICANCE BETWEEN IgG-PFC COUNTS BEFORE AND AFTER 
EACH BLOOD TRANSFUSION
Number PWM- Spontaneous PWM- SAC- SAC- Spontaneous
o f IgG- IgG- IgG- IgG- IgG - IgG-
tra n s fu s io n PFC vs PFC PFC vs PFC PFC vs PFC
0 (n=26) -0 .241 0.497 0.046
NS 0.010 NS
1 (n=26) 0.060 0.442 0.569
NS 0.024 0.002
2 (n=26) -0 .105 0.485 0.474
NS 0.012 0.015
3 (n=26) -0 .049 0.561 0.488
NS 0.003 0.011
4 (n=25) 0.241 0.540 0.523
NS 0.004 0.006
5 (n=26) -0 .025 0.566 0.350
NS 0.003 NS
6 (n=12) -0 .02 8 0.539 0.594
NS NS 0.042
7 (n -1 2 ) 0.315 0.469 0.713
NS NS 0.009
8 (n=12) 0.392 0.546 0.762
NS NS 0.004
9 (n=12) 0.539 0.462 0.769
NS NS 0.003
10(n=12) 0.476 0.559 0.525
NS NS NS
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Figure 6.16. Correlation between spontaneous and PWM- 
induced IgG-PFC counts in the transfusion group; a = before 
transfusion, b = after the 5th transfusion, and c = after 
the 10th transfusion.
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Figure 6.17. Correlation between PWM- and SAC- induced
IgG-PFC counts in the transfusion group; a = before transfusion,
b = after the 5th transfusion, and c = after the 10th transfusion.
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Figure 6.18. Correlation between spontaneous and SAC- 
induced IgG-PFC counts in the transfusion group; a = before 
transfusion, b = after the 5th transfusion, and c = after 
the 10th transfusion.
TARLE 6 .1 0 . PATIENTS UNDERGOING TRANSPLANTATION WITH POLYCLONAL 
B CELL ACTIVATION STUDIES FOLLOWING BLOOD TRANSFUSION
Months
P a tie n ts *  Number o f la s t  BT- Immuno- R e jec tio n  Transp lant
n=15 transfusions I * suppression episodes outcome
2. TS 5 1 Azathi opri ne 0 Functi oni ng
3. SW 10 3 Azathi opri ne 0 Functi oni ng
5. WH 10 3 Cyclospori n 0 Functioning
9. JMcG 10 8 Cyclospori n 3 Functioni ng
10. JD 10 9 Cyclosporin 1 Functioning
11. WY 5 15 Cyclosporin 1 Functioni ng
12. PM 5 8 Cyclosporin 0 Functioning
13. TC 5 4 Cyclosporin 1 Di ed
Functioni ng
18. MS 10 3 Cyclospori n 0 Functi oni ng
19. WG 5 1 Cyclospori n 1 Rejecti on
20. CS 10 1 Cyclosporin 0 Functioning
21. RF 5 2 Cyclosp/AzatH 2 Functi oni ng
23. RH 5 1 Cyclosporin 0 Functioning
24. RR 5 10 Cyclosporin 0 Functioni ng
25. JG 5 4 Cyclosporin 0 Functioning
*Numbers of patients presented to correspond numbers of patients in Table 
6.4 and Figures
TABLE 6.11. INTERRELATIONS BETWEEN REJECTION EPISODES. 
IgG-PFC COUNTS AND CYTOTOXIC ANTIBODIES (PRAl AFTER THE
5TH TRANSFUSION
Variables 
SAC IgG-PFC
Spontaneous
IgG-PFC
%PRA
Relection 
episodes
Pearson correlation coefficients and 2-talled 
significance
PWM- SAC- Spontaneous
IgG-PFC IgG-PFC IgG-PFC %PRA
0.784
n-26
p=0 . 0 0 0
0.188 0.384
n-26 n-26
NS NS
-0.209 0.092 0.497*
n-26 n-26 n-26
NS NS p-0.01
0.047 0.300 0.012 0.287
n-9 n—9 n—9 n—9
NS NS NS NS
*Spearman r-0.314, NS; Kendall r-0.262, NS
TABLE 6.12. INTERRELATIONS BETWEEN REJECTION EPISODES. 
IgG-PFC COUNTS AND CYTOTOXIC ANTIBODIES PRA AFTER THE
10TH TRANSFUSION
Variables 
SAC IgG-PFC
Spontaneous
IgG-PFC
%PRA
Relection 
episodes
Spearman: * r- 
Kendall: * r-
Pearson correlation coefficients and 2-tailed 
significance
PWM SAC Spontaneous
IgG-PFC IgG-PFC IgG-PFC %PRA
0.953
n- 1 2
p-0 . 0 0 0
0.737 0.624
n- 1 2  n- 1 2
p—0.006 p—0.03
-0.031 -0.127 -0.158
n- 1 2  n- 1 2  n- 1 2
NS NS NS
0.810* 0.746 0.801** 0.272
n- 6  n— 6 n— 6 n— 6
p-0.05 NS p-0.05 NS
0.338, NS, **r-0.676, NS
0.258, NS, **r-0.603, NS
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CHAPTER 7. EFFECT OF BLOOD TRANSFUSION ON IN VITRO PROSTAGLANDIN E 
RELEASE IN UNSTIMULATED AND Con-A STIMULATED PERIPHERAL BLOOD 
MONONUCLEAR CELL CULTURE SUPERNATANTS
7.1 Introduction
The concept that prostaglandins of the E series (PGE) mediate 
inflammatory responses and function as regulators of immune responses 
has been widely established (79-83,85-106). Prostaglandins have 
been shown to directly inhibit the lymphocyte blastogenic responses 
to both antigenic and mitogenic stimulation (97) , as well as to alter 
lymphocyte responsiveness indirectly through an effect on other 
mediators. It has been reported that they inhibit the production of 
interleukin 2 and down-regulate the expression of Class II MHC 
antigens by antigen presenting cells thereby indirectly inhibiting T 
cell activation and proliferation (103,581-585). However, the role 
of PGE on B cell proliferation and differentiation has not been 
clearly defined. There is now convincing evidence to suggest that 
there are species differences with regards to PGE participation in B 
cell activation (Reviewed in 101). For example in both the rat and 
mouse, antibody responses, as measured by haemolytic plaque 
formation, are inhibited by PGE (101), whereas in rabbits and humans, 
PGE stimulates IgG and to a lesser extent IgM production (101). 
Reports on the effect of PGE on human primary and secondary antibody 
responses to vaccination give conflicting results (101). Most of the 
studies which have attempted to define the immunoregulatory role of 
PGE have been carried out in experimental models or healthy humans. 
PGE-mediated immunoregulation is abnormal in certain diseases 
(85,92,94,101,102) but little is known about it in the uraemic state. 
The complexity of such potential regulatory mechanisms in uraemia may 
be further influenced by exogenous events, such as blood transfusion. 
In a preliminary report from this study it was suggested that blood 
transfusion may induce changes in PGE secretion which differed in 
weak and strong DNCB responders (586).
This chapter aims to examine to what extent blood transfusion 
may interfere with PGE synthesis and host cellular and humoral 
responses in previously non-transfused uraemic patients.
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Patients and Methods
Patients
In all 48 patients from the transfusion group (Table 1) with 
the exception of one female, PGE concentrations were carried out in 
PBMC culture supernatants before and after each of the 5 or 10 blood 
transfusions. Hence, among the 47 transfused patients described in 
this chapter, there were 37 males and 10 females and their mean age 
was 41 years (range 18-59 years). The woman who was not studied in 
this chapter was treated by haemodialysis and her original renal 
disease was hypertensive nephrosclerosis. She was a strong DNCB 
responder and she had been allocated to receive 1 0  units of blood. 
Therefore, the overall characteristics of the original transfusion 
group (Table 1) were only slightly affected and the random allocation 
of the patients with regards to their response to the DNCB skin test 
and the number of transfusions they received was altered by one 
accordingly (Figure 7.1). In addition to the 47 patients in the 
transfusion group the 1 2  uraemic controls and the 1 2  healthy subjects 
were also studied.
Methods
Specimen collection and handling: Blood samples were taken in a
preservative free heparin bottle before and 14 days after each 
transfusion in the transfusion group and on 3 - 4 occasions in the 
controls over a period of three months. The mononuclear cells were 
separated on a Ficoll-Hypaque gradient and 4 x 10^ cells were 
cultured in 2ml of medium 199, which contained glutamine, 
penicillin-streptomycin and 10% pooled plasma (Gibco-Bioccult, 
Paisley, Scotland) without and with lOug/ml of concanavalin A (con A, 
Sigma Chemicals Co., St Louis, USA) for 48 hours at 37°C in 5% CC^. 
After 48 hours the culture supernatants were harvested and were 
stored at -20°C. Supernatants from each subject collected serially 
in this way were tested in the same experiment along with specimens 
from one uraemic and healthy control to avoid test to test variation. 
In a few patients blood samples were not taken on every occasion 
after blood transfusion and in a few others there was insufficient 
cells to carry out the cultures. Thus, different numbers of the 48
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patients appeared prior to and following transfusion. To compensate 
for this, statistical analysis was carried out using both matched, 
paired and unpaired tests.
PGE Radioimmunoassay
Principles of the method: The PGE radioimmunoassay (Clinical Assays
Travenol - Genentech, Diagnostics, Cambridge, Mass., USA) offers a 
sensitive method of measuring PGE content in serum, plasma, culture 
supernatants and tissues by measuring the competitive binding of 
tritium-labelled PG and unlabelled PG antibody to PG. The principle 
of the assay is based on the competitive binding principles of 
radioimmunoassays as developed by Yalow and Berson (587), and the 
technique described here is a modification of procedures published by 
Levine et al (588) and Gutierre-Cernosek et al (589). Alkaline 
treatment of extracted samples converts PGE to prostaglandin B (PGB). 
The known-radioactive PGB from sample extracts or PGB standards 
compete with a constant amount of tritium-labelled PGB^ ([ H ] 
PGB^)tracer for binding sides on the PGB^ antibody which is held at a 
limiting concentration. The amount of [ H] PGB^ which will bind the 
antibody is inversely proportional to the amount of non-radioactive 
PG in the assay tube. A standard curve is prepared from 6 standards 
ranging from 8.2 to 2000pg/tube and the PG concentrations of the 
samples are interpolated from the standard curve. Separation of 
antibody bound PGB from free PGB is achieved by precipitating the 
anti-PG/PG complex with the second antibody. After centrifugation 
the pellets are resuspended and the bound radioactivity is measured 
in a liquid scintillation counter.
Test procedure: The reagents supplied with the kit were.
1) Tritium PGB^ tracer,
2) Rapid anti-PGB^ serum,
3) Tris buffer concentrate,
4) Normal rabbit serum,
5) Goat anti-rabbit serum,
6 ) PGB-^  standard calibrated at 40ng/ml,
7) Gelatine 250A.
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Preparation of the standards: Five standards were prepared from
reconstituted PGB^ standard at 40ng/ml. Into 5 polypropylene tubes 
(12 x 75mm) marked 1/3, 1/9, 1/27, 1/81, 1/243, 0.6ml of gel tris 
buffered was pipetted using a 1 .0 ml semi-automatic adjustable 
pipette. The reconstituted PGB^ standard was called the 1/1 
standard, 0.3ml of which was added to the 1/3 tube and mixed 
thoroughly. Subsequently 0.3ml of the 1/3 tube was added in the tube 
marked 1/9 and after thorough mixing serial dilution was repeated in 
the same fashion to the last tube. Thus the standard PGB^ 
concentrations in the 1/1, 1/3, 1/9, 1/27, 1/81, and 1/243 tubes were 
2000, 667, 222, 74, 25, and 8.2pg/0.05ml respectively.
Preparation of the samples: In order to convert PGE into PGB 50ul of
the samples were diluted with 950ul gel tris buffer in calibrated 
tubes with screw caps and lOOul of IN sodium hydroxide was added. 
The caps were screwed tightly and after being well mixed the tubes 
were placed in a boiling bath for five minutes. The samples were 
left to cool in room temperature and the pH was adjusted to 7.4 using 
IN acetic acid.
Assay procedure: The assay procedure included the preparation of the
standard curve from which the unknown PGE content in the sample was 
determined.
1) All reagents reached room temperatures and were mixed 
before use.
2) The polypropylene tubes were labelled in duplicate as 
follows:
Tube no. Contents of tubes PGB^ added
(pg/0.05ml)
Tl, T2 Total counts (tracer) -
1 , 2 Non-specific binding (NSB) -
3, 4 PGBX blank (BQ) 0
5, 6 PGB^ standard, 1/243 8 . 2
7, 8 PGB^ standard, 1/81 25
9, 1 0 PGB^ standard, 1/27 74
1 1 , 1 2 PGB^ standard, 1/9 2 2 2
13, 14 PGB^ standard, 1/3 667
15, 16 PGB^ standard, 1 / 1 2 0 0 0
17, 18 Patient sample extract unknown
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3) Gel tris buffer was added in the following volumes, 
1.1ml to tubes 1 and 2, 1.0ml to tubes 3 and 4, and 
standard tubes 3-16, and 0 .6 ml to sample extract tubes 
17 to end.
4) 50ul of each PGB^ standard and 400ul of each patients 
sample extract were added into the appropriate tube in 
duplicate.
3
5) 50ul of reconstituted [ H] PGB-^  tracer was added to 
all tubes and the tubes Tl, T2 were capped.
6 ) 50ul of rabbit anti-PGB^ serum was added to all the 
tubes except Tl, T2 and NSB and was mixed thoroughly 
on a vortex mixer.
7) Tubes were incubated for 60 minutes in a 37°C incubator 
from the time the antiserum was added.
8 ) lOOul of reconstituted normal rabbit serum was added to 
all tubes except Tl, T2, followed by addition of lOOul 
of goat anti-rabbit serum to all tubes except Tl, T2 
with thorough mixing on a vortex mixer.
9) Tubes were covered and incubated for at least 18 to 20 
hours at 2-8°C.
10) All tubes but Tl, T2 were centrifuged in a refrigerated 
centrifuge at 2-8°C for 30 minutes at a relative 
centrifugal force of 1600 g.
11) Each tube was decanted except Tl, T2 into a waste 
beaker and the rim of each tube was vigorously tapped 
on to absorbent paper to remove any residual 
supernatant.
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12) lOOul of 0.1N sodium hydroxide was added to all tubes 
including Tl, T2 and they were vortexed to mix and 
dissolve the precipitate.
13) The solution of all tubes was decanted into 
correspondingly numbered scintillation vials ensuring 
maximum transfer and the tubes were discarded.
14) 10ml of scintillation fluid was added to all vials and 
after vortexing, all vials were counted in a beta 
scintillation counter for at least 5 minutes.
The results were calculated from the standard curve. Counts 
per minute (CPM) for each tube were recorded and the percent bound 
(Bn) for each standard was calculated from the formula:
CPM - NSB
Bn= -----------  x 100
Be
where NSB = non-specific binding (average CPM in vials 1,2), and Be — 
corrected maximum binding, calculated from the average CPM in the 
blank vials 3,4 minus the NSB, that is, Be - BO - NSB. The percent 
bound for the PGB^ standards (vertical axis) were plotted against the 
PGB^ concentration (horizontal axis) on 4-cycle semi-logarithmic 
graph paper and the best fitting curve was drawn. Table 7.1 and 
Figure 7.2 show typical data and a typical standard curve 
respectively. The percent bound corresponding to each control and 
patient sample extract were calculated from the same formula and were 
located on the vertical axis. The point at which a horizontal line 
intersected the standard curve was read as the PGB^ concentration in 
pg/tube from the horizontal axis. Correction of the PGB^ 
concentration for each extracted sample to the amount present in the 
original sample was carried out by multiplying with a correction 
factor, namely 60, which was calculated based on the original amount 
of the sample used in the extraction procedure, an extraction 
efficiency factor, and a dilution factor for the fraction of extract 
used as inhibitor in the assay. The final PGE concentration in the 
original sample was expressed in ng/ml/4xl0^ cells.
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Statistical analysis
There was a large intersubject variation in the individual PGE 
concentrations and examination of histograms showed that the 
distribution of values was not normal. Therefore, comparison of mean 
values between and within groups was done using the Mann-Whitney 
test. For paired matched data the Wilcoxon rank test was applied. 
Correlation between sets of individual parameters was carried out 
using Pearson (parametric) and Spearman (non-parametric) correlation 
coefficients depending on the appearance in the scattergrams.
7.3 Results
7.3.1 Effect of blood transfusion on in vitro PGE synthesis
Results of mean + SD, SEM, median and range of PGE release in 
supernatants before and after each unit of blood in the transfusion 
group, and in the two control groups over a period of three months 
are shown in Table 7.2. In vitro synthesis of PGE in unstimulated 
and Con-A stimulated culture supernatants from PBMC showed a large 
intersubject variation both in the transfusion group and in the two 
control groups. The distribution of the values was positively 
skewed, but despite the wide range the SEM was not high due to the 
large number of patients who were included in this study. The 
statistical analysis of Table 7.2 is shown in Figure 7.3.
PGE synthesis both in unstimulated and stimulated cultures in 
the two control groups did not change significantly over the period 
of three months. In contrast, there were highly significant changes 
induced by blood transfusion in the transfusion group. PGE synthesis 
was significantly higher in Con-A stimulated culture supernatants 
after the 3rd, 4th, 5th and 10th unit of blood compared to background 
values (mean + SEM, 19 + 3 vs 46 + 6 , p<0.0002; 19 + 3 vs 37 + 6 , 
p<0.006; 19 + 3 vs 36 + 5, p<0.007 and 19 + 3 vs 30 + 6 , P<0.04 
respectively). This increase in PGE release peaked after the third 
blood transfusion and remained elevated until after the 6 th unit of 
blood. Thereafter PGE synthesis fell to background levels but rose 
again after the 10th unit of blood. In vitro PGE synthesis following 
the 3rd transfusion was significantly higher compared to that of the 
uraemic controls at 3 months (mean + SEM, 46 + 6 vs 1 9 + 5 ,  p<0.04). 
An unexpected finding from the analysis of these results was that in
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unstimulated culture supernatants PGE concentrations after the 3rd 
unit of blood showed a significant increase compared to background 
values (mean + SEM, 18 + 3 vs 38 + 6 , p<0.007). This could be due to 
mitogenic activity in the culture medium (ie pooled plasma) which was 
maximal after the 3rd transfusion.
Figure 7.A shows the individual PGE concentrations of Con-A 
stimulated cultures in the transfused patients prior to and after the 
3rd, 5th and 10th unit of blood and in the 2 control groups. PGE 
values were widely scattered and covered the full scale of measurable 
concentrations using the estimated standard curves. Most of the 
values in the transfused patients before transfusion were under 
20ng/ml (25 of 39, 64%), which was the average concentration in the
uraemic controls over the period of 3 months. After the 3rd, 5th and 
1 0 th unit of blood the respective figures in the transfused patients 
were 24% ( 8 of 34), 43% (16 of 37) and 31% (4 of 13). This indicates 
that an increase in PGE synthesis after transfusion occurred in most 
of the patients. This is illustrated in Figure 7.5 which shows the 
individual changes in PGE synthesis in stimulated cultures after the 
3rd, 5th and 10th unit of blood in the transfused patients and in the 
two control groups. Twenty one of the 26 patients had increased PGE 
synthesis after the 3rd unit of blood (81%), while the remaining 5 
patients (19%) had unchanged or decreased synthesis. The overall 
increase was highly significant (Wilcoxon paired rank test: mean +
SEM, 15 + 3 vs 48 + 7, p<0.0004). After the 5th and 10th unit of
blood 72% (23 of 32 patients) and 77% (10 of 13 patients)
respectively had increased PGE concentrations and the remaining 
patients had decreased values. The overall increase after the 5th 
transfusion was also highly significant (mean + SEM, 17 + 2 vs 38 + 
6 , p<0.007), but after the 10th unit of blood the significance was
weak (mean + SEM, 12 + 3 vs 30 + 8 , p<0.04). In contrast, in the
two control groups the changes were not significant.
7.3.2 Effect of blood transfusion on in vitro PGE synthesis in weak 
and strong DNCB responders
Results of PGE concentrations in unstimulated and Con-A 
stimulated culture supernatants in the weak and strong DNCB 
responders before and after transfusion are shown in Table 7.3 and
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Figure 7.6. At the start of the study the difference between weak 
and strong DNCB responders in PGE concentrations was not significant 
in either unstimulated or stimulated cultures. Also, the difference 
between the two groups was not significant at any time after each 
transfusion. However, strong DNCB responders showed a significant 
increase of PGE synthesis in the stimulated cultures following the 
3rd, 4th and 5th transfusion compared to their own background values 
(p<0.001, p<0.03, p<0.009 respectively), whereas weak DNCB responders 
did not. After the 3rd unit of blood the former group had 
significantly higher PGE release in the unstimulated cultures as well 
(p<0.01). Figure 7.7 shows the individual changes of PGE 
concentrations in stimulated cultures in the weak and strong DNCB 
responders after the 3rd and 5th transfusion. It is obvious that in 
strong responders the increase in PGE synthesis was highly 
significant on both occasions (p<0.006 and p<0.009), while weak 
responders showed an increase of weak significance only after the 
third unit of blood (p<0.03).
With regard to the number of transfusions, the difference of 
PGE values in patients receiving 5 or 10 units was not significant 
(Table 7.4 and Figure 7.8), and this was also the case when the 
patients were divided into weak and strong DNCB responders. (Table 
7.5).
7.3.3 Correlation between PGE synthesis. IgG production, cytotoxic 
antibodies and transplant outcome.
The polyclonal B cell activation studies which were described 
in the previous chapter showed that there was a significant increase 
in spontaneous IgG-PFC counts after transfusion while in the PWM 
driven system IgG production was suppressed. These studies were 
carried out on aliquots of blood samples with the PBMC of which the 
in vitro PGE concentrations in cultures stimulated with Con-A were 
also measured. Table 7.6 shows the Spearman correlation coefficients 
between these PGE concentrations before and after each blood 
transfusion and the respective spontaneous, SAC- and PWM- induced 
IgG- PFC counts. There was no correlation between in vitro PGE 
synthesis and IgG production spontaneously or after stimulation with 
PWM at any time prior to or after transfusion. In contrast in the
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SAC- driven system there was a strong positive correlation before 
transfusion (Spearman r-0.504, p<0.017, Pearson r-0.556, p<0.007) 
(Figure 7.9) which disappeared after transfusion. These findings 
suggest that, firstly, PWM- induced IgG production is not sensitive 
to an immunoregulatory role of PGE in B cell activation, and 
secondly, SAC- induced IgG production appears to be PGE- sensitive in 
the non-transfused uraemic patients but this effect disappears after 
transfusion.
Plotting of PGE concentrations against cytotoxic antibodies 
after 5 and 10 units of blood (described in Chapter 5) did not show 
any correlation.
Twenty six of the 47 patients studied in this Chapter were 
subsequently transplanted and had PGE radioimmunoassays performed 
before and after the last elective blood transfusion (5 or 10 units). 
Nineteen grafts were functioning at the end of the study, 4 had 
irreversibly rejected, 2 patients had died with functioning grafts 
and in one case the transplant was a technical failure. Of the 19 
successful transplants, 12 were treated with Cyclosporin (63%), 6 had 
Azathioprine (32%) and one had a combination of the two regimens 
(5%). Of the 4 patients who rejected their grafts, 3 received 
Azathioprine and one Cyclosporin. Although the number of patients 
with graft rejection was small and the difference in immnosuppressive 
treatment was in favour of the graft acceptors, an interesting 
difference emerged from comparison of PGE synthesis in the 2 groups 
(Figure 7.10). Rejectors had higher PGE concentrations in Con-A 
stimulated culture supernatants compared to those of acceptors before 
pre-transplant transfusion (mean + SEM, 45 + 10 vs 17 + 5, p<0.05). 
After the last elective transfusion (5th or 10th unit) the increase 
of PGE synthesis was highly significant in the latter group (mean + 
SEM, 17 + 5 vs 46 + 9, p<0.005), but in the former 4 patients the 
change was not significant (mean + SEM, 45 + 4 vs 48 + 26). This 
observation, although inconclusive, suggests that differences in PGE 
kinetics before and after transfusion exist in pre-transplant 
patients and may play a role in the mechanisms involved in graft 
rejection.
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7.4 Conclus ions
1) In vitro PGE synthesis in Con-A stimulated PBMC culture 
supernatants in previously non-transfused uraemic patients was 
comparable to that of healthy subjects.
2) Blood transfusion in these patients induced a significant 
increase of PGE synthesis which was more pronounced after the 
3rd, 5th and 10th units of blood transfused.
3) The difference in PGE concentrations in stimulated cultures 
between weak and strong DNCB responders before any transfusion 
was not significant, but the latter group showed a more 
vigorous PGE synthesis in response to subsequent blood 
transfusion compared to that of the weak DNCB responders.
4) Transfusion of a further five units of blood did not have any 
significant effect in PGE concentrations in comparison with the 
initial five units, the maximum effect of which was observed 
after the 3rd transfusion in patients receiving both 5 and 10 
units.
5) PGE concentrations did not correlate with IgG production in the 
peripheral blood either spontaneously or after stimulation with 
PWM before and after one to ten transfusions.
6 ) In contrast, IgG production in the SAC-driven system showed a 
good correlation with PGE synthesis before transfusion which 
disappeared after the first unit of blood.
7) In vitro PGE release in stimulated PBMC cultures was not 
associated with the development of cytotoxic antibodies 
following transfusion.
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8 ) Patients who were successfully transplanted showed a 
significant increase of PGE concentrations in stimulated 
cultures after the last elective pre-transplant transfusion. 
In contrast, in a small number of patients with irreversible 
graft rejection such an increase was not observed.
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I, Transfused Patients
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5 units
DNCB 0-3
10 units
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DNCB 0-3
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DNCB>
III. Normal controls
©    No transfusion
Figure 7.1. Breakdown of the subjects according to their 
response to the DNCB skin test and the number of blood 
transfusions; 0-3 = weak responders, y 3 = strong responders.
TABLE 7.1 RECORDING OF TYPICAL DATA IN A PGE RADIOIMMUNOASSAY
Tube no. Contents of tubes
T1 Total counts (tracer)
T2 Total counts (tracer)
CP bound 
11353 
11680
% bound 
(avera&el
Non-specific binding (NSB) 
Non-specific binding (NSB)
320
337
PGB1 blank (Bo), Opg/tube 
PGB1 blank (Bo), Opg/tube
5064
5371
PGB1 standard, 8.2pg/tube 
PGB1 standard, 8.2pg/tube
5227
4719
96%
PGB1 standard, 25pg/tube 
PGB1 standard, 25pg/tube
4508
4944
90%
9
10
PGB1 standard, 74pg/tube 
PGB1 standard, 74pg/tube
3998
3839
73%
11
12
PGB1 standard, 222pg/tube 
PGB1 standard, 222pg/tube
2752
2912
51%
13
14
PGB1 standard, 667pg/tube 
PGB1 standard, 667pg/tube
1566
1465
24%
15
16
PGB1 standard, 2000pg/tube 
PGB1 standard, 2000pg/tube
1091
977
12%
17
18
Patient sample (AM) 
Patient sample (AM)
1575
1612
26%
% Bound
1 0 0
80
60
40
20
0
667748.2 25 222 2000
PGE concentration (Pg/tube)
Figure 7.2. Typical standard curve in a PGE 
radioimmunoassay from the data in Table 7.1.
TABLE 7.2. PROSTAGLANDIN E CONCENTRATIONS IN UNSTIMULATED AND
CDfTT”STIMULATED PBMC CULTURE SUPERNATANTS IN THE 
TRANSFUSION GROUP BEFORE AND AFTER EACH OF 1-10 UNITS OF 
PACKED CELLOND IN THE~7R0~£0NTR0L GROUPS
PGE concentrations (n g /m l)
No. BT 0 1 2 3 4 5 6 7 8 9 10
Unstimulated. n=36 n=30 n=32 n=31 n=31 n=36 n=ll n=12 n=12 n=10 n=12
Mean + SD 18+16 22+23 19+17 38±31 25+28 23±24 25±17 13±7 13±13 15+18 13±8
SEM 3 4 3 6 5 4 5 2 4 6 2
Median 11 11 16 29 16 13 22 13 9 10 14
Range 1-71 1-78 0-65 0-110 2-120 2-120 7-59 2-25 3-48 3-62 3-31
Stimulated: n=39 n=30 n=32 n=34 n=33 n=37 n=13 n=13 n=12 n=10 n=13
Mean +SD 19+19 30+31 25+21 46+35 37±32 36+33 38+31 21±19 23+20 19+17 30+21
SEM 3 6 4 6 6 5  9 5 6 5 6
Median 14 16 17 35 26 24 31 13 13 14 28
Range 1-102 0-120 1-74 0-120 2-120 3-120 10-120 7-79 5-66 5-62 4-66
Uraemic controls Normal controls
At 0 At 3 months At_0 At 3 months
Unstimulated: n=12 n=10 n=10 n=ll
Mean + SD 23+24 17+17 17+13 16+31
SEM 10 5 4 9
Median 9 12 11 6
Range 2-111 3-60 6-43 2-107
Stimulated n=12 n=ll n=12 n=12
Mean +SD 20±21 19+15 27±24 26±33
SEM 6 5 7 10
Median 12 14 21 9
Range 2-78 5-52 4-81 1-107
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Figure 7.4. PGE concentrations released in PBMC culture 
supernatants stimulated with Con A in previously non-transfused 
dialysis patients before and after 3,5 and 10 units of packed 
cells, and in the uraemic and normal controls at 0 and 3 months; 
square areas represent mean + SEM; statistics are the same as 
in Figure 7.3.
PGE 
ng/ml 
120
100
80
60
40
20
0
p< 0.0004 p <0.007 p <0.04 NS
n=26 n=32
BT 0 3 0 5
n=11 
Uraemic
NS
n=12
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Controls
Figure 7.5. PGE concentrations released in Con A stimulated 
PBMC culture supernatants in the transfusion group before 
and after 3,5 and 10 units of packed cells, and in the 
uraemic and normal controls at 0 and 3 months.
TABLE 7 .3 .  PROSTAGLANDIN E CONCENTRATIONS IN UNSTIMULATED AND CON-A 
~1>TIMUTATED~PBMC CULTURE' SUPtR NATANT 5 ~TFTTHE~REAK“ ARD~STRI5NG~DNCB~ 
RESPONDERS IN THE TRANSFUSiON GROUP BEFORE'AND'AFTER EACH OF 1-10
UNITS*OF'PACKED CELLS
Mean ±  SEM PGE concentrations (n g /m l)
No BT 0 1 2 3 4 5 6 7 8 9 10
DNCB 0-3- n=15 n=12 n=13 n=12 n=14 n=15 n=6 n=5 n=6 n=6 n=4
Unstimul ated 21+4 21+8 15+3 34+8 32+10 16+3 31+8 13+2 18+7 10+2 18±5
n=17 n=12 n=13 n=14 n=14 n=15 n=7 n=6 n=6 n=6 n=5
Stimul ated 23+6 25+7 25+6 41±9 46+11 26±5 30±7 26±11 30+10 13±2 29+9
DNCB >3: n=21 n=18 n=19 n=19 n=17 n=21 n=5 n=7 n=6 n=4 n=8
Unstimul ated 16+3 23+5 22+4 40+7 19+4 28+7 18+5 13+3 8±2 22+14 11±2
n=22 n=18 n=19 n=20 n=19 n=22 n=6 n=7 n=6 n=4 n=8
Stimulated 16±3 33+8 25±5 50±8 30+5 43+8 47 + 17 17+4 16+.4 29±13 31+8
PGE
ng/ml
60
40
20
0
0.01
60
40
20
0
003
BT 0 1  2 3 4 5 6 7 8 9  10
Figure 7.6. Mean + SEM concentrations in unstimulated (a) 
and Con A stimulated (b) PBMC culture supernatants in the 
transfusion group before and after each of 1-10 units of 
packed cells; open circles = weak DNCB responders, closed 
circles = strong DNCB responders; number of patients tested 
on each occasion shown in Table 7.3.
PGE
ng/ml
P <0.03 
120 „ p .
100
80
20
n=10 n=16
Weak Strong
DNCB responders
NS
n=13
Weak
p <0.009
n=19
Strong
DNCB responders
Figure 7.7. PGE concentrations in PBMC culture 
supernatants stimulated with Con A in the weak and strong 
DNCB responders before and after the 3rd transfusion (a), 
and before and after the 5th transfusion (b).
TABLE 7.4. PROSTAGLANDIN E CONCENTRATIONS IN UNSTIMULATED AND 
C0N-A STIMULATED PBMC CULTURE SUPERNATANTS IN PATIENTS 
RECEIVING 5 OR 10 UNITS OF PACKED CELLS
Mean ±. SEM PGE concentrations (ng/ml)
No. BT: J ? I 2 3 4  5 6 7 8  9 10
5 B T : n=23 n=19 n=2Q n=20 n=23 n=25
Unstimulated 21±4 26±6 22±4 41+8 19±3 26±6
n=25 n=19 n=20 n=23 n=24 n=25
Stimulated 19±3 33±7 28±5 50±8 31±5 42±7
10 BT n=13 n=ll n=12 n=Jl n=8 n=ll n=ll n=12 n=12 n=10 n=12
Unstimulated 12±3 15+5 14±3 32+7 41±3 16+3 25±5 13±2 13±4 15±6 13+2
n=14 n=ll n=12 n=ll n=9 n=12 n=13 n=13 n=12 n=10 n=13
Stimulated 18+7 24+9 20+6 37±9 52±16 21+6 38±9 21+5 23+6 19+5 30+6
PGE
ng/ml
80
0 1  2 3 4 5 6 7 8 9  10
No. of blood transfusions
Figure 7.8. Mean + SEM PGE concentrations in Con A 
stimulated PBMC culture supernatants before and after each 
transfusion in patients receiving 5 and 10 units of packed 
cells; number of patients tested on each occasion are shown 
in Table 7.4.
TABLE 7.5. PROSTAGLANDIN E CONCENTRATIONS IN UNSTIMULATEO AND CON-A 
S T I H U O T F D  PBMC CULTURE"SUPERNATANTS"IN THE WEAK AND STRONG DNCB'RESPONDERS
RECEIVING 5 OR 10 UNITS OF PACKED CELLS
Mean ±  SEM PGE concentrations (ng/ml)
1 2 3 4 5 6 7 8 9 10
DNCB 0-3 :
5 BT n^lO _n=9 n=8 HfZ n=10 n=10
Unstimul ated 25+6 26+10 15+1 32+13 18+5 15+4
n = ll n=9 n=8 n=9 n=10 n=10
Stimulated 21+4 28+10 25+7 41+14 29+7 29+7
10BT n=5 n=3 n=5 n=5 n=4 n=5 n=6 n=5 n=6 n=6 n=4
Unstimulated 12+3 5+1 18+7 37+9 65+29 17+4 31+8 13+2 18+7 10+2 18+5
n=6 n=3 n=5 n=5 n=4 n=5 n=7 n=6 n=6 n=6 n=5
Stimul ated 27+15 16+4 25+13 41+10 88±26 18+4 30+7 26+11 30+1C1 13±2 29+10
DNCB >3:nr- n=13 n=10 n=12 n=13 n=13 n=15
Unstimul ated 18+4 26+7 27+6 45±10 20+5 32+9
n=14 n=10 n=12 n=14 n=14 n=15
Stimulated 18+4 38±11 31±7 56±9 32+7 51_±11
10JT n=8 n=8 n=7 n=6 n=4 n=6 n=5 n=7 n=6 n=4 n=8
Unstimul ated 13+5 18+7 12±2 28+10 18±6 16+5 18+5 13+3 8+2 22+14 11+2
n=8 n=8 n=7 n=6 n=5 n=7 n=6 n=7 n=6 n=4 n=8
Stimul ated 12±5 27±12 16 ±5 35±15 23±6 24±10 47±17 17*4 16 ±5 29*13 31 *8
TABLE 7.6. CORRELATION BETWEEN SPONTANEOUS SAC-AND PWM-INDUCED
IeG-PFC COUNTS IN THE PERIPHERAL BLOOD AND PGE CONCENTRATIONS IN 
PBMC CULTURE SUPERNATANTS STIMULATED WITH CON-A BEFORE AND AFTER
1-10 UNITS OF BLOOD
Spearman correlation coefficients
Spontaneous SAC- PWM
Variable IsG-PFC IeG-PFC IrG-PI
Before BT (n-22) -0.234 0.504 0.385
NS p<0.017 NS
After 1BT (n=20) 0.357 0.253 0.233
NS NS NS
After 2 BT (n»19) -0.185 -0.058 0.112
NS NS NS
After 3 BT (n-21) -0.121 0.147 0.109
NS NS NS
After 4 BT (n-19) -0.226 0.081 0.033
NS NS NS
After 5 BT (n-21) 0.082 -0.287 -0.329
NS NS NS
After 6 BT (n-9) 0.200 0.000 0.050
NS NS NS
After 7 BT (n-10) 0.207 0.000 0.499
NS NS NS
After 8 BT (n-10) 0.236 0.018 0.406
NS NS NS
After 9 BT (n-8) 0.119 -0.381 0.000
NS NS NS
After 10 BT (n-11) 0.100 -0.082 0.100
NS NS NS
x103 SAC- 
20 L IgG-PFC o
10 -
5 - 
■
1 . 
0.5 -
O
o
8°6
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°  8  O
n=22
Pearson r=0.556, p <0.007 
Spearman r=0.504, p <0.017
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Figure 7.9. Correlation between PGE concentrations in PBMC 
culture supernatants stimulated with Con A and SAC-induced 
IgG-PFC counts in the peripheral blood; plotted values 
represent those prior to any blood transfusion in 22 of the 
48 patients in the transfusion group.
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Figure 7.10. PGE concentrations in Con A stimulated PBMC 
culture supernatants before and after 5 or 10 units of 
packed cells in patients who subsequently had a transplant 
and accepted or rejected the graft.
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Figure 8.1. Serum complement levels in the transfusion 
group before and after each blood transfusion (BT), and in 
the uraemic and normal controls at 0 and at 3 months; 
a = C^, b = C^, c = factor B and d = C1 inhibitor.
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TABLE 8.3. ASSOCIATION BETWEEN THE DNCB SKIN TEST AND COMPLEMENT
Spearman correlation coefficients
Variable C3 C4 B Factor Cl Inhibitor
DNCB 
1st test
-0.221
n-25
NS
0.107
n-25
NS
0.007
n-25
NS
0.263
n-25
NS
Before BT
-0.050
n-37
NS
0.203
n-37
NS
-0.011
n-37
NS
0.126
n-37
NS
After 5BT
0.031
n-12
NS
0.308
n-12
NS
0.082
n-12
NS
0.313
n-12
NS
After 10BT
DNCB
repeat test
-0.006
n-37
NS
0.161
n-37
NS
0.067
n-37
NS
0.180
n-37
NS
After 5BT
0.219
n-12
NS
0.125
n-12
NS
-0.125
n-12
NS
0.318
n-12
NS
After 10BT
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Figure 8.2. Correlation between spontaneous IgG-PFC and SAC- 
induced IgG-PFC counts with serum C^ Inhibitor levels.
CHAPTER 8. THE EFFECT OF BLOOD TRANSFUSION ON SERUM COMPLEMENT 
LEVELS
8.1 Introduction
Ac t ivation of the complement system leading to 
hypocomplementaemia and complement mediated tissue injury may occur 
in certain types of glomerulonephritis such as post-streptococcal and 
mesangiocapillary glomerulonephritis (reviewed in 590). In chronic 
renal failure, chemotaxis, opsonisation, phagocytosis and 
bacteriolysis, in all of which complement has a role, are impaired 
(314,323,328,329,331-337). Thus abnormalities of the complement 
system may exist in chronic renal failure yet only a few reports have 
been published and these contain conflicting results (331-337). As 
blood transfusion is associated with suppression of the immune 
response and altered lymphocyte reactivity (393,394,531-535,537), and 
complement has an immunoregulatory role in antibody induction and in 
the generation and maintenance of memory B cells (reviewed in 107), 
it seemed worth looking at complement levels before and after planned 
blood transfusion in renal failure. Thus in this chapter the 
association between complement levels and IgG production occurring 
spontaneously and after stimulation with SAC and PWM is described 
both in weak and strong DNCB responders and before and after blood 
transfusion.
Patients and Methods 
Patients
In 40 of the 48 transfused patients (Table 1) a complement 
profile was carried out prior to and following blood transfusion. 
Among these 40 patients there were 31 males and 9 females and their 
mean age was 40.4 years (range 18-59 years). The original renal 
diseases were glomerulonephritis 14 (35%), chronic pyelonephritis 10 
(25%), polycystic kidneys 4 (10%), hypertension 3 (7.5%), diabetes 5 
(12.5%), Alport's syndrome 1 (2.25%) and of unknown origin 3 (7.5%). 
Thirty one of these patients were on haemodialysis and the remaining 
9 patients were on CAPD. As a result of the randomisation at the 
begining of the study these 40 patients were allocated according to 
their response to the DNCB test and the number of transfusions as
150
follows. Of the 19 weak DNCB responders, 13 patients received 5 
units of packed cells and 6 patients had 10 units; the remaining 21 
patients were strong DNCB responders of whom 11 patients received 5 
units of blood and the remaining 10 patients had 10 units. In 
addition to the patients in the transfusion group the 12 uraemic and 
the 12 normal controls were also studied.
Methods
Serum samples in the transfusion group were harvested before 
and 14 days after each transfusion from the same blood specimens 
taken to perform the other tests described in previous chapters. 
There was not sufficient sera to carry out complement profiles on all 
occasions, so the number of patients differs prior to and following 
each transfusion. To compensate for this, statistical analysis was 
done using both matched paired and unpaired tests. The two control 
groups were tested 3 to 4 times over a period of 3 months.
Estimation of C3, C4, factor B and Cl inhibitor serum levels
were carried out using the single radial immunodiffusion technique 
(107) which is the standard method used in this hospital. Functional 
tests of complement activation were not done because sera has to be
stored at -70°C and not at -20°C, as was the case in this study.
Statistical Analysis
The individual variation in complement levels was not large and 
the standard error was relatively small and consistent. However, the 
distribution of the values was not normal, so comparison of mean 
complement levels between and within groups was done using the 
Mann-Whitney test for unpaired samples and the matched paired 
Wilcoxon test for paired samples. Regression analysis was done using 
both Pearson (parametric) and Spearman (non-parametric) correlation 
coefficients depending on the appearance in the scattergrams.
8.3 Results
Table 8.1 shows the mean serum complement levels in the 
transfusion group prior to and after each transfusion, and in the 
two control groups over a period of three months. The statistical 
analysis is shown in Figure 8.1.
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The difference in mean C3 levels following each blood 
transfusion in comparison with the background mean value was not 
significant at any time except following the ninth unit of blood 
(Figure 8.1a). This significance was a weak one and very likely to 
be accidental since it is not consistent with the overall pattern. 
The difference in C3 levels in the two control groups was not 
significant over a period of three months. Also, C3 concentrations 
prior to and after the fifth or tenth unit of blood were not 
significant in comparison with both uraemic and normal controls at 0 
and at 3 months, respectively.
Comparison between C4 levels prior to and following each 
transfusion showed no significant difference and this was the case 
also when mean values were compared between the transfusion group 
before and after the fifth or tenth transfusion and those of the 
uraemic controls at 0 and at 3 months. However, mean C4 
concentrations of patients both in the transfusion group and in the 
uraemic controls appeared to be consistently higher compared to those 
of the normal controls. Mean C4 levels in the transfusion group 
after the fifth and tenth unit of blood were significantly higher 
compared to levels in normal controls at 3 months (mean + SEM, 478+30 
v 327+30, p<0.01, and 526+57 v 327+30, p<0.03 respectively). Also 
the difference in C4 concentration between uraemic and normal 
controls at 3 months was significant (mean + SEM, 476+26 v 327+30,
p<0.008).
A similar finding was observed in Cl inhibitor concentrations. 
Blood transfusion did not induce any changes in serum levels but mean 
values in both transfused and uraemic controls were consistently 
higher compared to those of the normal controls. Levels after the 
fifth or tenth transfusion were significantly higher than those of 
normal controls at 3 months (mean + SEM, 283+9 v 215+12, p<0.001 and 
281+12 v 215+12, p<0.004 respectively). Also the Cl inhibitor
concentration was significantly higher in the uraemic controls than 
in the normal controls at 0 and at 3 months (mean + SEM, 324+41 v 
253+17, p<0.009 and 319+22 v 215+12, p<0.003 respectively) (Figure 
8.Id). This finding shows that uraemic patients regardless of blood 
transfusion status tend to have higher C4 and Cl inhibitor serum 
levels than healthy subjects.
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There were no differences in factor B levels between the 
transfusion group, the uraemic controls and the normal controls in 
any combination of comparisons (Figure 8.1c).
Table 8.2 shows the serum complement levels in the transfusion
group divided into weak and strong DNCB responders. Blood
transfusion did not have any effect on C3, C4 factor B and Cl 
inhibitor concentrations in either group. The difference in mean C3 
levels between weak and strong DNCB responders prior to and after the 
second and fourth transfusion was significant (p<0.02, p<0.008 and 
p<0.02 respectively), but this was an inconsistent finding since the 
difference in C3 levels between normal controls, who by definition 
are strong DNCB responders, and the overall group of uraemic patients 
was not significant (Figure 8.1a). To further check this, 
regression analysis of DNCB scores at the first and on the repeat 
test against the concentration of complement components was performed 
and did not show any correlation before and after the fifth or tenth 
transfusion (Table 8.3).
In order to see whether there was any association between
complement components and IgG production, the individual serum C3, 
C4, factor B and Cl inhibitor levels before and after each
transfusion were plotted against the respective spontaneous, SAC- and 
PWM- induced IgG- PFC counts. There was no correlation between serum 
C3 concentrations and IgG production in any system and this was the 
case also with regard to C4 and factor B levels. There was a weak 
correlation between serum Cl inhibitor concentration after the fifth 
t r a n s f u s i o n  an d  the r e s p e c t i v e  s p o n t a n e o u s  a n d  
SAC-IgG-PFC counts (Figure 8.2). The significance of this 
correlation, although interesting in theory, is rather uncertain and 
inconsistent, since it was not confirmed by the non-parametric 
Spearman test and was not observed on any occasion other than after 
the fifth transfusion.
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8.4 Conclus ions
1) Transfusion of 1-10 units of blood does not induce any 
measurable changes in C3, C4, factor B and Cl inhibitor levels 
in previously non-transfused uraemic patients.
2) C3 and factor B concentrations in uraemic patients are 
comparable to those of normal controls, whereas C4 and Cl 
inhibitor levels are significantly higher.
3) There is no difference in C3, C4, factor B and Cl inhibitor
levels between weak and strong DNCB responders and blood 
transfusion has no effect on complement component 
concentrations in either group.
4) There is no correlation between serum C3, C4, factor B and Cl 
inhibitor levels and IgG production both spontaneously and 
after SAC or PWM stimulation before or after transfusion.
5) It should be emphasised that the above statements are made with 
regard to measureable serum complement levels and do not 
exclude possible activation of the complement cascade or its 
components in cellular interactions in response to blood 
transfusion.
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CHAPTER 9. THE RESPONSE TO THE DNCB SKIN TESTING IN URAEMIC PATIENTS
AND ITS PREDICTIVE VALUE IN RENAL TRANSPLANTATION
9.1 Introduction
We have shown in previous studies that strong DNCB responders 
are more likely to reject a renal allograft (399-402,571). This 
association between the DNCB response and graft survival was found 
irrespective of whether the patient had received previous blood 
transfusion or the type of blood product given frozen red cells, 
whole blood or packed cells. These results were obtained from the 
analysis of data during a period when deliberate blood transfusion 
prior to transplantation was not being practised. Since 1979, all 
patients have been deliberately given a minimum of 5 units of packed 
cells prior to the transplant. With the adoption of this deliberate 
transfusion policy, we observed that the DNCB skin test had lost its 
predictive value because the improvement in graft survival had 
occurred almost entirely among the strong DNCB responders (571). We 
looked into factors determining the response to the DNCB and found 
that sex, polycystic kidney disease, duration of dialysis and blood 
transfusion might influence the response to the test (402). As there 
is an overlap between the effect of blood transfusion and the other 
three factors, we needed to clarify the precise effect of transfusion 
on the DNCB response. This was done by setting up the randomised 
control study which has been discussed in the previous chapters. 
This study confirmed that a strong response to DNCB is more likely in 
previously non-transfused uraemic patients than in those already 
transfused and is maintained after transfusion. This suggests that 
primary immunisation to DNCB is a crucial event and blood transfusion 
may interfere with the response to it.
The aim of this chapter is to analyse retrospectively our 
experience with DNCB skin testing from that point of view and try to 
explain the apparent discrepancies in our previous studies.
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Patients and Methods
Patients
From 1975 to 1984 the DNCB skin test was carried out in 535 
patients. There were 321 males (60%) and 214 females (40%) with a 
mean age of 38.7 years (range, 10-69 years). The original renal 
diseases were glomerulonephritis 194 (36%), pyelonephritis 133 (25%), 
polycystic kidneys 54 (10%), hypertension 39 (7%), diabetes 24 (5%), 
Alport's syndrome 13 (2%), analgesic nephropathy 8 (1.5%),
hypoplastic kidneys 8 (1.5%), SLE 6 (1%), nephronophthisis 5 (1%), 
amyloidosis 4 (1%), Henoch Schonlein purpura 4 (1%), renal artery 
stenosis 3 (.5%), interstitial nephritis 3 (.5%), tuberculosis 3 
(.5%), renal vascular disease 3 (.5%), Wegener's granulomatosis 2 
(.5%), 7 patients (1.5%) had miscellaneous diseases and in 22 (4%) 
the disease was of unknown origin. Forty one of these patients were 
in end-stage renal failure and tested prior to commencement of 
dialysis, 464 patients were tested while on dialysis (372 on 
haemodialysis and 92 on CAPD) in 4 different hospitals in Glasgow, 
and the remaining 30 patients were tested after transplantation while 
receiving immunosuppression.
The DNCB skin tests were carried out as described in Chapter 1 
by three doctors over a period of 10 years. Twenty percent of the 
patients (105 of 535) were sensitised by Dr A Diamandopoulos during 
1975 - 1978, 55% (296 of 535) by Dr M A Watson during 1978 - 1981 and 
the remaining 25% (134 of 535) by the author during 1981 - 1984. 
From 1975 - 1981 the timing of sensitisation to DNCB was random, but 
from 1981 onwards was within 3 to 6 months from commencement of 
dialysis. Follow-up tests were performed after variable intervals of 
3, 6, 12, 24 or more months from each other. Prior to May 1979 there 
was no deliberate blood transfusion policy and patients were given 
whole blood, fresh concentrated red cells or frozen red cells, as 
required for symptomatic anaemia. From May 1979 onwards, all 
patients were deliberately transfused with 5 units of fresh 
concentrated red cells, one unit at two week intervals, before their 
names were added to the transplant waiting list. After the elective 
blood transfusion more blood (whole blood or packed cells) was given
156
to patients if clinically indicated. In addition to this, patients 
on the transplantation list from one of the 3 hospitals, received one 
unit of elective transfusion every 6 months after the last elective 
transfusion.
Three hundred and forty four of the 505 patients who had the 
DNCB skin test prior to or after commencement of dialysis were 
subsequently transplanted. Two hundred and eighty four of these 
patients were immunosuppressed with azathioprine and prednisolone, 57 
received cyclosporin A and prednisolone and the remaining 3 had a 
combination of the two regimens. From 1975 to May 1979 a high 
initial dose of prednisolone was used and thereafter a low 
prednisolone regimen was adopted. Cyclosporin A was introduced at 
the beginning of 1984. The immunosuppression protocols have been 
described in previous studies (390,399,447,571) and in Chapter 4. 
The diagnosis of rejection episodes was based on clinical grounds, 
combined with the use of ultrasound and biopsy, and they were treated 
either by iv methylprednisolone pulses or by a 10 day course of high 
dose oral prednisolone. Selection of recipients was done on a best 
match basis and transplantation was carried out only when the T cell 
crossmatch was negative using both current and historical sera. HLA 
matching, and the crossmatch and PRA techniques have been described 
in Chapter 5. The time of graft failure was defined as the time of 
transplant nephrectomy or recommencing dialysis. For the estimation 
of patient survival, patients were considered at risk from the date 
of transplantation to 6 months after graft failure. The follow-up of 
these patients was extended to the end of 1985.
Statistical Analysis
Data regarding the following variables were recorded and stored 
in the computer. Sex, age, original renal disease, nephrectomy prior 
to transplantation, the hospital where patients were treated, ABO and 
rhesus blood group, parity, type of dialysis, duration of dialysis, 
number and type of blood transfusion, the DNCB scores on each 
occasion, the time interval and number of blood transfusions between 
tests and transplantation, HLA-DR phenotypes, transplant outcome,
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type and number of transplant, HLA mismatches, type of 
immunosuppression, onset of graft function, number of rejection 
episodes, timing of first rejection episode, and PRA at the time of 
the DNCB test, and prior to and after transplantation. Statistical 
analysis in this chapter was carried out using both univariate and 
multivariate analysis. Crosstabulation of distribution of two or 
more categorical variables was computed using the chi-square test. 
Fisher's exact test was applied when there were fewer than 20 cases 
in a 2 x 2 table and Yates' correction was computed for all other 2 x 
2 tables. In the analysis of possible association between HLA DR 
antigens and response to DNCB, p values were corrected multiplying 
them by the number of DR antigens included in the analysis. 
Comparison of mean values between groups was carried out using one 
way analysis of variance, the Mann-Whitney and the Wilcoxon tests. 
Regression analysis was done using the Pearson and Spearman tests. 
Multiple regression analysis was carried out to check correlation and 
possible overlapping effect between variables. Stepwise discriminant 
analysis was also used to see which were the most significant 
variables in the model, and multiple regression was repeated 
controlling for these variables in order to confirm and exclude the 
overlapping effect. Graft survival was estimated using life table 
analysis and comparisons between subgroups was done using a statistic 
D, which was calculated from the survival scores using the algorithm 
of Lee and Desu (569) . D is distributed as chi-square with g-1 
degress of freedom, where g - the number of groups under the null 
hypothesis that the subgroups are samples from the same survival 
distribution. The larger the D statistic, the more likely that the 
subgroups come from different survival distributions.
Results
9.3.1 Response to DNCB in the pre-dialvsis. dialysis and transplant 
patients
Results of the DNCB scores in the pre-dialysis, dialysis and 
transplant patients are shown in Figure 9.1. The scores of a 
historical group of 15 normal controls were also included in this
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figure to illustrate the cut off point between weak and strong DNCB 
responders. The difference in the mean score between pre-dialysis 
and dialysis patients was not significant (3.5+4.0 v 3.2+3.5), but 
transplant patients, as expected, had significantly lower reponse 
compared to both groups (1.0+1.7 v 3.5 +4.0, p<0.005, and 1.0+1.7 v 
3.2+3.5, p<0.001 respectively). The proportion of strong responders 
was also significantly lower among the transplant patients (3 of 30, 
10%) compared to that of pre-dialysis and dialysis patients (16 of 
41, 39%, p<0.01 and 160 of 464, 34%, p<0.01 respectively) (Figure 
9.2). Two thirds of the transplant patients were anergic (20 of 30, 
67%) compared to approximately one third of the two other groups (17 
of 41, 41% and 148 of 464, 32%).
All 30 transplants were sensitised to DNCB under 
immunosuppression with azathioprine and prednisolone within the first 
year from the operation. The idea of doing this was to test the 
effectiveness of the pharmacological immunosuppression in relation to 
graft survival. This idea was eventually abandoned because of the 
small proportion of strong responders among transplants. Of the 3 
strong responders, however, all had functioning grafts at the end of 
the study after 11, 11 and 10 years from the time of the test, and so 
did 23 of the 27 weak responders (85%) with an average of a 10 year 
graft survival. Of the remaining 4 transplants in the latter group, 
2 died with a a functioning graft after 6 months and 3 years from 
left ventricular failure and empyema of the gall bladder 
respectively, one rejected the graft after 5 years and one transplant 
was a technical failure. Judging from these findings, it is unlikely 
that the DNCB test would have been of any predictive importance in 
this group of patients. Therefore, these patients will not be
further discussed in the following sections.
The analysis which will be described from here on is based on 
the pre-dialysis and dialysis patients. These two groups were 
comparable in terms of sex, age and original renal disease. Fifty 
two percent of the latter patients were tested within three months 
from commencement of dialysis, 80% within one year and 11% (50 of 
464) after 3 or more years of dialysis (Table 9.1).
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9.3.2 Factors determining the response to DNCB in end-stape renal 
failure.
Among the 505 patients (41 predialysis and 464 dialysis 
patients) who were considered for analysis in this section, there 
were 329 weak DNCB responders (65%) , and the remaining 176 were 
strong responders (35%). The results of the DNCB scores of these 
patients are shown in Table 9.2 and Figure 9.3 illustrates the 
cummulative percentages. Thirty three percent of the patients (165 
of 505) were anergic to DNCB and only 5% (34 of 505) had a score >10. 
Their mean DNCB score was significantly lower compared to that of the 
historical group of normal controls (3.2 + 3.6 v 9.1 + 2.6, p<0.001). 
The CMI, therefore, in these patients as assessed by the DNCB skin
test was profoundly depressed. To examine what factors might be
associated with the response to DNCB, we looked into the possible 
association with the following variables, firstly, in a univariate 
fashion analysis.
Sex: Among the 505 patients there were 303 males (60%) and 202
females (40%). The males appeared to have significantly more strong 
responders compared to females (118 of 303, 39% v 58 of 202, 28%, 
p<0.01) (Figure 9.4).
Age: The mean age in the weak and strong responders was 38.4 + 13.4 
years (range, 10-69 years) and 40.2 + 12.5 years (range, 12-67 
years), respectively. The difference between the two groups is not 
significant. Also, the prevalence of strong responders in the 
different age groups was not significantly different (Figure 9.5).
Original renal disease: Figure 9.6 shows that the frequency of
strong responders patients with polycystic kidneys, although 
statistically not significant, was the highest among the various 
other diseases.
Nephrectomy: Twenty two of the 505 patients had had bilateral
nephrectomy prior to the test. Only two of them were strong 
responders (9%) , while in the remaining 483 non-nephrectomised 
patients there were 174 (36%), p<0.02 (Figure 9.7).
Hospital: The hospital where patients had been treated at the time
of testing was not a significant factor (Figure 9.8).
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ABO and rhesus blood groups: In 444 of the 505 patients information
with regard to ABO and rhesus blood groups was available. The 
incidence of strong responders was not significantly different in the 
four ABO blood groups nor in the rhesus positive or negative patients 
(Figure 9.9).
Parity: Data on parity was available in 186 of the 202 females
(92%). In 75 of them there was no history of pregnancy, miscarriage, 
stillbirth or termination and in the remaining 103 there was such a 
history. The difference in strong responders among nulliparous and 
parous women was not significant (Figure 9.10).
Type of dialysis: Of the 464 dialysis patients 372 were treated with
haemodialysis and the remaining 92 with CAPD. The difference in the 
response to DNCB between the two groups was not significant (Figure 
9.11).
Duration of dialysis: The mean duration of dialysis prior to the
test in the weak DNCB responders was 12.2 + 19.5 months (range, 1-168 
months), while that of the strong responders was 5.9 + 11.7 months 
(range, 1-94 months). The difference between the two groups is 
highly significant (p<0.0002). Figure 9.12 shows that the proportion 
of strong responders progressively decreased from 48% (53 of 111) 
among patients sensitised within a month from commencement of 
dialysis to 12% (6 of 49) in those sensitised after two years of 
dialysis (x2 - 23.400, DF - 5, p<0.0003).
Blood transfusion: The variable with the strongest association,
among all significant variables, with the response to DNCB was the 
number of blood transfusions prior to the test. The mean number of 
transfusions in the 329 weak responders was 5.5 + 8.4 units (range,
0-92 units), while that of the 176 strong responders was 1.9 + 3.4 
units (range, 0-24 units), p<0.0000. Figure 9.13 shows the 
progressive decline in strong response to DNCB with the number of 
transfusions prior to the test. Among the 171 patients who were 
sensitised to DNCB prior to any transfusion there were 97 strong 
responders (57%). In patients sensitised after one unit of blood 
there were 55% strong responders (12 of 22), but after two
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transfusions there was a marked fall to 28% (21 of 74) and this
decline progressed to only 6% (1 of 16) in the patients sensitised 
after more than 20 units of blood (x^ - 68.467, DF - 7, p<0.0000). 
Interval between last transfusion and test: Among the 334 patients
who were sensitised to DNCB after one or more units of blood the time 
interval between the last transfusion and the test was known in 292 
patients (87%). The difference between the 212 weak responders whose 
mean interval was 16.4 + 40.8 weeks (range, 1-468 weeks), and that of 
the 80 strong responders whose interval was 17.8 + 38.9 weeks (range,
1-240 weeks) was not significant. Also, the proportion of strong 
responders was not significantly different among patients sensitised 
after variable time from the last transfusion (Figure 9.14).
Panel reactive antibodies (PRA): Information on PRA prior to the
test was available in 351 patients. Two hundred and twenty two of 
them were weak responders and the remaining 129 were strong 
responders. The difference between the two groups in PRA in both 
current and historical sera was not significant. Weak responders in 
current sera had a mean + standard deviation of 4.2 + 15% PRA (range, 
0-91%) and strong responders had 4.2 + 16% (range, 0-95%). In 
historical sera the respective values for weak and strong responders 
were 6.2 + 18.6% (range, 0-100%) and 4.9 + 17.4% (range, 0-95%). 
Figure 9.15 shows that the proportion of strong responders was not 
significantly different in the split groups of patients with 0, 1-20, 
21-80 and 81-100% PRA prior to the test. These findings could be 
explained on the basis of observations from Chapters 5 and 6, where 
weak DNCB responders were capable in eliciting comparable antibody 
production to that of strong responders when given more than 3 units 
of blood. Thus, pre-existence of PRA in multi-transfused patients 
does not seem to preclude, interfere or predict subsequent response 
to DNCB.
Period when the test had been performed: It has already been
mentioned that the 505 patients were tested over a period of 10 years 
by 3 different investigators. There were differences in the timing 
of the test with regard to blood transfusion and commencement of 
dialysis between the three periods. In the early period patients
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were sensitised to DNCB irrespective of their transfusion status and 
the duration of dialysis. After 1981, however, we attempted to 
sensitise patients soon after commencement of dialysis and there was 
a deliberate policy to sensitise more patients prior to any blood 
transfusion and see what happened with the follow-up testing. Figure 
9.16 shows that there were progressively more strong responders 
during the three periods (25%, 32% and 45% respectively, - 10.826, 
DF - 2, p<0.005). This raised the question of reproducibility of the 
test and possible research bias or subjective error, but multivariate 
analysis, as will be discussed later, showed that this was not the 
case.
HLA-DR phenotypes: Table 9.3 shows the frequency of HLA-DR antigens 
in 362 of the 505 patients (72%) in whom tissue typing had been 
carried out. Table 9.4 shows the frequency of weak and strong DNCB 
responders in relation to their HLA-DR phenotypes. There were more 
strong responders among DRW6 positive patients (52%) but the 
difference was not significant after correction of the p value for 
the number of antigens.
So far, with regard to factors which might be associated with 
the response to DNCB, 5 variables were found by univariate analysis 
to be significant. These were sex, nephrectomy, duration of 
dialysis, blood transfusion and the period during which patients were 
sensitised to DNCB. There is overlap between these variables, and 
this is clearly demonstrated in Table 9.5, which shows the 
correlation coefficients between these variables. All four variables 
which correlated with the response to DNCB showed a strong 
correlation with blood transfusion as well (bottom line in Table 
9.5). These correlations were confirmed with the Spearman rank 
coefficients. Thus, patients sensitised in the earlier period had 
received more blood, were on dialysis for longer and included more 
nephrectomised patients among them. The same conclusion applies vice 
versa for the duration of dialysis and nephrectomised patients. With 
regard to sex, females had received more blood (p<0.002), but there 
was no correlation between sex and the other three variables, namely,
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time period, duration of dialysis and nephrectomy. Therefore, it 
seemed logical to see what happens when the overlapping effect of 
blood transfusion is taken into consideration.
The partial correlation procedure in the SPSSX statistical 
package computes correlation coefficients controlling for one or more 
other variables. Using this procedure, correlation between the DNCB 
scores and the other four significant variables, while controlling 
for the variable blood transfusion, gave the results shown in Table 
9.6. The variables, nephrectomy and time period were not significant 
any more and sex showed only a weak correlation (p<0.05). The 
duration of dialyis, however, showed a strong inverse correlation 
with the DNCB scores (p<0.007).
Stratification of patients in non-transfused and transfused prior to 
the test.: To double check these results, cross-tabulation of
categorical variables and frequencies of continuous variables were 
carried out after patients had been stratified into those who were 
sensitised to DNCB prior to any transfusion and those sensitised 
after one or more transfusions. Figure 9.17 shows the proportion of 
weak and strong responders according to their sex in the 171 and 334 
patients who were sensitised to DNCB prior to any and after one or 
more units of blood respectively. The difference was not significant 
in either group. From the number of males and females in this figure 
it is apparent that there were more females in the transfused group 
compared to males (150/202, 74% v 184 of 303, 61%, x^ - 9.909,
p<0.005). Also, females in the transfused group had received more 
units of blood compared to males (mean + SD, 7.0 + 7.7 v 5.9 + 8.4, 
p<0.05). From these findings it appears that there is a 
contradiction with the findings from the partial correlation 
analysis, where sex was found to be weakly significant after 
excluding the transfusion effect. This is due to the fact that in 
the latter analysis, the response to DNCB was used as a continuous 
variable (ie, DNCB scores, 0-15), while here this variable has been 
transformed to a dichotomous variable (ie, weak or strong 
responders). This contradiction implies that the significance of sex 
in the response to DNCB, if any, could be due not only to the fact
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that females were more likely to have been transfused prior to
sensitisation, but also they were likely to have received more blood
as well. With regard to the nephrectomised patients, all 22 of them
had been transfused prior to the test and had received more
transfusions (mean + SD, 12.0 + 12.6 v 6.1 + 7.6, p<0.03) compared to
non-nephrectomised patients. Figure 9.18 shows the proportion of
weak and strong responders in the 334 transfused patients in relation
to nephrectomy. The difference in strong responders between patients
who had and had not had nephrectomy is not significant (10% v 24%).
The proportion of strong responders during the three time periods in
the 171 non-transfused patients was not significantly different (68%,
54% and 56% respectively) (Figure 9.19). However, in the transfused
o
patients the difference was significant (13% v 24% v 34%, x - 8.155, 
DF - 2, p<0.02) due to a difference in the number of transfusions 
prior to the test. Patients in the first period had received a mean 
+ SD of 8.8 + 13.0 units of blood compared to 5.6 + 6.3 and 6.8 + 6.6 
in the second and third period (p< 0.008 and p<0.012 respectively).
Table 9.7 shows the statistics for the duration of dialysis and
the number of blood transfusion in the subgroups of the
S
non-transfused and traij^fused weak and strong DNCB responders. 
Patients sensitised to DNCB after one or more units of blood had been 
on dialysis for longer compared to those who were sensitised prior to 
any transfusion (mean + SD, 12.8 + 19.8 v 3.9 + 7.5, p<0.0000). The 
difference in the duration of dialysis between weak and strong 
responders in the non-transfused patients, however, was not 
significant (4.1 + 7.2 v 3.7 + 7.8). It should be said, though, that 
the range of dialysis duration in 90% of these patients (129 of 144) 
was 1-6 months. Thus one can hardly comment on the significance of 
the duration of dialysis from findings in this particular subgroup. 
In contrast, in the 319 transfused patients weak responders had been 
on dialysis for longer compared to strong responders (mean + SD, 14.2 
+ 21.0 v 8.3 + 14.4, p<0.02) and had also received significantly more 
units of blood (7.1 + 9.0 v 4.3 + 3.8, p<0.002). Hence, as the 
duration of dialysis is closely related to the number of transfusions 
(r-0.237, p<0.000, Table 9.5) and since it failed to come up as a
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significant variable in the stepwise discriminant analysis which will 
be described further, I would tend to attribute the significance of 
this variable described here to the amount of blood rather than to 
the duration of dialysis per se.
Association between HLA DRW6 and response to DNCB: All the other
variables, but one, which were not significantly associated with the 
response to DNCB in the original analysis, were also not significant 
after the stratification for blood transfusion status. The exception 
was found in the HLA-DR phenotypes, in that the presence of the 
HLA-DRW6 was significantly associated with a stronger response to 
DNCB. Table 9.8 shows the proportion of strong responders in 
patients sensitised prior to any and after one or more units of blood 
according to their HLA-DR phenotypes and Figure 9.20 shows this 
information graphically. HLA-DRW6 positive patients were 
significantly more likely to be strong responders (17 of 19, 90%) 
when sensitised prior to any blood transfusion compared to HLA-DRW6 
negative patients (58 of 150, 50%), pcor<0.01. In patients tested
after transfusion, however, the DRW6 effect was not found, as strong 
responders in this group did not significantly differ among DRW6 
positive and negative patients (6 of 25, 24% v 59 of 203, 29%). 
Stepwise discriminant analysis: The stepwise discriminant analysis
is a statistical technique that defines the set of variables which 
maximises discriminating power in the model of the analysis, or in 
other words defines the variables that best discriminate between, or 
separate groups. Using this technique to define the variables that 
best correlate with the response to DNCB from the 505 cases which 
were processed, only 73 cases with no missing values in any of the 
discriminating variables were used in this analysis. Two variables, 
namely, sex and the number of transfusions prior to the test came up 
as significant factors when the tolerance level was set at p<0.05. 
After five steps of selection, none of the remaining variables passed 
the tolerance criterion, including the DRW6, apparently because of 
the small numbers in this model of analysis.
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9.3.3 Follow-up DNCB skin testing
Table 9.9 summarises the results of mean DNCB scores in the 
entire group of 505 patients and the breakdown groups during 
follow-up skin testing. Seventy five percent (380 of 505) of the 
patients had a second test performed, 51% (259 of 505) were followed 
up with a further third test and only 7% (35 of 505) had a fourth 
test done. The mean DNCB score in the entire population increased 
significantly from 3.2+3.6 to 3.9+4.4, 4.1+4.9 and 5.5+6.1 on the 
second, third and fourth test (p<0.0001, p<0.0001, p<0.02
respectively) (Figure 9.21). This increase reflected an increase of 
similar significance in the subgroup of patients who were sensitised 
to DNCB prior to any blood transfusion whose score increase from 
4.8+3.8 to 6.1+4.3, 6.7+4.9 and 7.1+6.4 after the second, third and 
fourth test respectively. In contrast, in patients who were 
sensitised to DNCB after transfusion, the mean score did not show any 
significant change. However in the breakdown groups of weak and 
strong responders an interesting pattern emerged with regard to 
timing of sensitisation to DNCB. Figure 9.22 shows that strong 
responders in the groups of patients sensitised both before and after 
transfusion had a significant increase in their mean DNCB scores. In 
the former group the score increased from 7.4+2.9 to 8.7+3.3, 
10.0+3.3 and 12.3+3.6, and in the latter group from 7.2+2.9 to 
7.8+3.5, 8.7+3.2 and 8.2+5.7 after the second, third and fourth tests 
respectively. In contrast, weak responders showed an opposing 
change. Patients sensitised prior to transfusion had a significant 
increase in the mean score from 1.4+1.2 to 2.6+2.8 and 2.7+3.2 after 
the second and third test as opposed to those sensitised after 
transfusion who showed a significant decrease from 0.9+1.1 to 0.6+1.3 
and 0.6+1.9 at the respective times.
These findings imply that strong responders tend to retain and 
even give stronger response on subsequent tests regardless of blood 
transfusion status at the time of sensitisation to DNCB. Contrary to 
that, transfusion status seems to be crucial at sensitisation for 
weak responders, in the sense that those who were sensitised prior to 
any blood are likely to increase their response in follow-up tests
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and at least a proportion of them change to strong responders. This 
view is demonstrated in Figures 9.23 - 9.26, which show cummulative 
percentages of weak and strong responders on the first, second and 
third test with respect to blood transfusion status at sensitisation 
to DNCB. From Figure 9.23 is apparent that 33% (21 of 63) of the 
weak responders sensitised prior to transfusion changed to strong 
responders on the second test, and a further 30% (13 of 44) changed 
on the third test. In contrast there was only a 6% (5 of 82) and 4% 
(2 of 53) change from strong to weak responders after the second and 
third test respectively in those who were sensitised before 
transfusion (Figure 9.24). Using the McNemar chi-square test, which 
fits best for before and after treatment changes, these differences 
between changes from weak to strong responders and vice versa, ie, 
33% v 6% and 30% v 4%, were both significant at p<0.004. Figure 9.25 
shows that the proportional change from weak to strong responders was 
negligible in patients sensitised after one or more units of blood (3 
of 172, 0.2% on the second test, and a further 3 of 123, 0.2% on the 
third test) . Also the change from strong to weak responders in this 
group of patients was not significant (7 of 63, 11% after the second 
test and one of 39, 3% after the third test) (Figure 9.26). Within 
strong responders of patients sensitised prior to and after 
transfusion, the proportion of patients with higher scores increased 
markedly. In the former group at the first test, 19 of the 97 strong 
responders (20%) had a score of more than 9 compared to 29 of 53 at 
the second test (55%) (x2-19.437, p<0.0001) (Figure 9.2it).
Similarly, in the strong responders who were sensitised after
transfusion there was an increase from 19% (15 of 79) to 38% (15 of 
39), (x 2-5.213, p<0.02).
Table 9.10 shows the time intervals between serial tests in the 
entire population and the various groups and subgroups. Although the 
difference in months between the second and third tests was
significant between patients sensitised prior to and after
transfusion (11.1+12.3 v 16.5+15.0, p<0.003), this was not the case
for the interval between the first and second test and between the
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third and fourth test. Therefore, one could not explain the pattern 
of response to DNCB observed in Figure 9.21 on the basis of shorter 
or longer intervals between the tests in the two groups.
Table 9.11 shows the number of transfusions given between the 
tests. Patients sensitised prior to any transfusion had less blood 
in the period between the first and second test compared to those 
sensitised after transfusion (3.7+4.9 v 6.7+11.6, p<0.004), but
thereafter both groups received a comparable number of transfusions. 
Furthermore although strong responders in the latter group received 
significantly more blood compared to strong responders in the former 
group (6.1+8.1 v 3.6+5.1, p<0.02), both groups displayed a comparably 
significant increase in their mean DNCB score on the second test 
(Figure 9.22.). In contrast, weak responders who were sensitised 
after transfusion, although they did not receive significantly more 
blood between tests compared to weak responders sensitised before 
transfusion, showed a further descrease in their mean scores on the 
second and third test as opposed to their comparison group which 
showed a significant increase.
From these results, it is obvious that the DNCB test after the 
primary response, when carried out serially gives an anamnestic 
reaction, which to a certain extent depends on the blood transfusion 
status at the time of sensitisation. Subsequent transfusions did not 
seem to interfere with secondary responses to DNCB in strong 
responders, while in weak responders they may have a further 
suppressive role.
9.3.4 The predictive value of the DNCB skin test in renal 
transplantation.
Three hundred and forty four of the 505 predialysis and 
dialysis patients whose CMI was assessed using the DNCB test 
underwent transplantation in the years between 1975-1985. These 
transplants represented 64% (344 of 535) of the total number of 
transplants carried out successively during this period. Patients 
treated with azathioprine represented 75% of the consecutive 
transplants from 1975-1984 (284 of 334), but the 57 transplants
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treated with cyclosporin accounted for only 36% of the total 
transplants receiving cyclosporine between 1984-85 (57 of 157
transplants). Overall, there were 213 males (62%) and 131 females 
(38%) and their mean age was 37.6 years (range, 14-65 years). Eighty 
six percent (295 of 334) of the patients were treated with 
haemodialysis and the remaining 14% (49 of 334) with CAPD prior to
transplantation. The overall duration of dialysis prior to the
operation was 25.4 + 25.0 months (range, 1-177 months). Ninety three
percent of the patients received cadaveric grafts (320 of 334), and 
the remaining 7% (24 of 334) received grafts from live related
donors. Three hundred and thirteen were first transplants (91%), 25 
second (7%) and 6 third transplants (2%). There were only 17 
patients (5%) who did not receive any blood prior to transplantation 
in the early period, 120 patients had 1-5 units (40%), 112 patients
had 6-10 units (28%) and the remaining 95 patients (27%) were 
multitransfused (range 11-101 units of blood). Sixty seven percent 
of the total amount of blood given prior to transplantation was whole 
blood or packed cells and the remaining 33% was frozen or filtered 
cells. The mean interval between the last transfusion and the 
operation was 7.4 months (range, 1-144 months). Sixty six percent of 
the patients were transplanted within six months from the last 
transfusion, 20% within a year and the remaining 14% after more than 
a year had elapsed. At the end of the study, irrespective of 
follow-up length, 184 patients had a functioning graft (54%), 128 had 
rejected irreversibly (37%), 22 died with functioning grafts (6%), 5 
transplants were technical failures (1.5%), 4 died later on dialysis 
after they had rejected the graft (1.5%) and one patient died on 
dialysis after his kidney was lost due to technical failure.
Among all the transplants there were 227 weak DNCB responders 
(66%) and the remaining 117 were strong responders (34%). These 
percentages were similar in the breakdown groups of patients treated 
with azathioprine and cyclosporin (66%, 34%, 65%, and 35%
respectively). Table 9.12 summarises the characteristics of weak and 
strong responders in the patients treated with azathioprine. There 
were more females among the weak DNCB responders, and patients in
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this group had been on dialysis for longer and had received more 
transfusions prior to transplantation compared to strong responders. 
The difference, however in age, type and number of transplant and in 
HLA-A,-B and DR mismatches between the two groups was not 
significant.
In the life table analysis of graft survival all graft losses 
were considered as failures. Only the three patients who had 
combined immunosuppression with azathioprine and cyclosporine were 
excluded from the analysis in the breakdown groups by 
immunosuppressive regimen. As there was a considerable change from 
weak to strong DNCB responders from the first to last test, 
particularly in patients sensitised to DNCB prior to any blood 
transfusion, life table analysis of patient and graft survival in 
weak and strong DNCB responders was carried out using both the first 
and the last test prior to transplantation. In patients who only had 
one DNCB test, the results were used both in the analyses of the 
first test and those involving the last test. Figure 9.27 gives the 
overall actuarial patient and graft survival in the 344 transplants. 
Patient survival was 91%, 90%, 89%, 87% and 87% from one to five
years respectively after transplantation. In the breakdown groups of 
transplants treated with azathioprine patient survival was almost 
identical to that of the entire population at these times (90%, 89%, 
88% and 86%) and in the cyclosporin group with shorter follow-up, 
patient survival at 12 and 18 months was 96%. The overall graft 
survival, including all losses, was 52%, 40%, 30%, 22% and 16% from 
one to five years after transplantation respectively. Graft survival 
in patients treated with azathioprine was 58%, 47%, 35%, 26% and 20% 
at these times while in patients treated with cyclosporin it was 79% 
at 6 months and 65% at one year. However it should be said that due 
to the small number of patients and the short follow-up time the 
standard error of the cummulative survival at one year in the 
cyclosporin group was 7% as opposed to that of the azathioprine group 
which was one percent. Neither the first nor the last DNCB test had
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any predictive value with regards to patient survival in the weak and 
strong responders which in both groups was identical to that of the 
entire population.
Figure 9.28 shows the actuarial graft survival in the 189 weak 
and 95 strong responders, as classed by the first DNCB test in the 
group treated with azathioprine and prednisolone. Graft survival in 
the weak responders was 62%, 50%, 38%, 29% and 23% from one to five 
years after transplantation respectively which was significantly 
better compared to 49%, 41%, 29%, 21% and 14% in the strong
responders at these times (p<0.02). The difference in graft survival 
between the two groups was of greater significance when the last DNCB 
test was used to form the breakdown groups (Figure 9.29). On this 
occasion, weak responders had 64%, 52%, 41%, 32% and 25% graft
survival from one to five years respectively as opposed to 48%, 38%, 
26%, 17% and 10% in the strong responders (p<0.0003).
Table 9.13 summarises graft survival data in the weak and
strong responders treated with cyclosporin using both the first and
the last DNCB test. The difference between the two groups was not 
significant at any time during the nine months of follow-up. Thus, 
from this small group of transplants which as stated represents only 
36% of the overall cyclosporin treated transplants, it appears that 
the DNCB test has no predictive value in the cyclosporin era.
From the description of the characteristics of weak and strong 
DNCB responders in Table 9.12, it is apparent that weak DNCB 
responders received more blood transfusion prior to transplantation 
compared to strong responders. Is the predictive value of the DNCB 
test, therefore, in the azathioprine group affected by the amount of 
transfusion? Table 9.14 gives the cumulative graft survival in weak 
and strong responders of that group, stratifying the patients 
according to the number of transfusions they received prior to
transplantation. Using the first DNCB test, all breakdown groups of
weak responders, namely, without any blood transfusion, 1-5 units, 
6-10 and more than 10 units of blood, had better graft survival 
compared to that of the respective breakdown groups of strong 
responders. The difference in graft survival between the two
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breakdown groups receiving 1-5 units just failed to reach statistical 
significance. However, using the last DNCB test, the difference in 
graft survival between weak and strong responders was more pronounced 
in all subgroups and was highly significant in those receiving 1-5 
units of blood (Figure 9.30). As the difference in HLA matching was 
comparable in the two subgroups, it is reasonable to assume that the 
predictive value of the DNCB test with regard to graft survival in 
patients treated with azathioprine is genuine. From table 9.15, by 
contrast, one can see that in patients treated with cyclosporin the 
DNCB test does not have any value in predicting a difference in graft 
survival between weak and strong responders receiving 5, 6-10 or more 
than 10 units of blood prior to transplantation.
Table 9.16 compares the graft survival rates between the 17 
patients who were transplanted without any transfusion and those 
receiving 1-5, 6-10 and more than 10 units of blood, regardless of 
their response to DNCB. Graft survival was 19% and 21% better 
respectively at one year in patients receiving 1-5 and 6-10 units of 
blood, compared to patients without transfusion. This difference at 
one year was significant (p<0.02), but the difference between the 
overall curves of cumulative graft survival was not significant. In 
the cyclosporin group, all patients had been transfused and 
comparison of graft survival rates was made between breakdown groups 
of patients receiving 1-5, 6-10 and more than 10 units of blood
(Table 9.16). During the short follow-up the number of transfusions 
did not appear to affect graft survival at 3, 6 and 9 months in the 
cyclosporin group.
It is beyond the scope of this thesis to look at all factors 
that might be associated with renal allograft survival. Taking into 
account that the transplants studied in this section represent 64% of 
all consecutive transplants which were carried out between 1975 and 
1985, I attempted to look at some of these factors. In a univariate 
fashion analysis the variables that showed a significant correlation 
with the transplant outcome are shown in Table 9.17. The most 
significant variables, when all transplants were considered, were the 
type of immunosuppression, (the cyclosporin group had better graft
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survival, p-0.0001), the number of rejection episodes (p-0.0001) and 
the development of cytotoxic antibodies after transplantation 
(p-0.0001). Other significant variables were the number of HLA DR 
mismatches (p-0.008), the response to the last DNCB test (weak 
responders had better graft survival, p-0.025), and the donor source 
(live related donors were associated with better graft survival than 
cadaveric ones (p-0.03). In the azathioprine group, in addition to 
these variables, two more came up as significant, namely the time of 
the first rejection episode and the hospital where patients were 
treated prior to transplantation. The earlier the first rejection 
episode occurred the worse was the outcome (p=0.01), and patients 
treated in Stobhill Hospital and the Royal Infirmary appeared to 
have slightly better graft survival (p-0.03). However, the 
definition of the hospital variable is rather loose, as there was a 
considerable interchange of patients from one hospital to the other. 
Interestingly, in the small group of patients treated with 
cyclosporin the only variables which showed significant correlation 
with the transplant outcome were the number of HLA DR mismatches and 
the development of PRA after transplantation (p-0.005 and p-0.001 
respectively). Finally, the variables that came up as significant in 
Table 9.17 were analysed in a stepwise discriminant analysis, using 
only 101 of the 334 transplants because the remaining 233 had at 
least one missing discriminating variable. The set of variables 
which was separated as having, by order of significance, the most 
discriminating power with regard to transplant outcome were the 
development of cytotoxic antibodies after transplantation, the last 
DNCB test and the type of immunosuppressive regimen 
(chi-square-27.803, DF-3, p<0.00001).
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9.4 Conclusions
1) In a large population sample of predialysis and dialysis 
patients, regardless of any stratification for any parameter, 
CMI as assessed by the DNCB test was profoundly suppressed. 
Two-thirds of the patients had a weak response to DNCB and half 
of them were anergic. The remaining one-third of patients had 
a strong response comparable to that of normal subjects.
2) Among transplant patients with functioning grafts who had the 
DNCB test while under immunosuppression, two-thirds were 
anergic to DNCB, and only one in ten of those patients was a 
strong responder. The DNCB test did not appear to have any 
predictive value with regard to graft survival when carried out 
under immunosuppression.
3) In a univariate fashion analysis the factors which showed a 
significiant association with the response to DNCB were sex, 
nephrectomy prior to transplantation, time period when patients 
were tested, duration of dialysis and number of blood 
transfusions prior to the test. Blood transfusion proved to be 
the most significant variable in a multivariate analysis which 
excluded the interdependence and the overlapping effect between 
these variables.
Also, when patients were stratified in terms of whether they 
had been transfused or not at the time of sensitisation to DNCB 
the significance of the other variables was lost.
4) In a group of patients who were tested prior to any 
transfusion, the proportion of strong responders was two-fold 
higher compared to that of the overall unstratified population. 
There was a progressive decline in strong responders as 
patients received more blood.
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5) DRW6 positive patients were more likely to be strong responders 
when tested prior to any blood transfusion. However, in 
patients sensitised after one or more transfusions, the DRW6 
effect was not observed.
6) A number of factors did not show any association with the 
response to DNCB, namely, age, original renal disease, hospital 
of dialysis treatment, ABO and rhesus blood groups, parity, 
type of dialysis (CAPD or haemodialysis), interval between last 
blood transfusion and test and pre-existence of panel reactive 
antibodies prior to the test.
7) Follow-up DNCB skin testing showed that blood transfusion at 
the time of sensitisation to DNCB was of crucial importance for 
secondary responses to DNCB. Patients eliciting a strong 
primary response retained and gave even stronger responses on 
subsequent tests regardless of blood transfusion status at the 
time of sensitisation to DNCB. Contrary to that, weak 
responders who were sensitised after transfusion showed a 
further depression in their secondary responses, while weak 
responders sensitised prior to any transfusion were more likely 
to increase these secondary responses. As a result of this, 
approximately one-third of the latter patients changed to 
strong responders in follow-up tests.
8) The predictive value of the DNCB test with regard to graft 
survival in patients treated with azathioprine and 
prednisolone, was best expressed when the last test prior to 
transplantation was used. Weak DNCB responders had 
signficantly better graft survival compared to strong 
responders over a five year follow-up. This effect on graft 
survival was independent of the blood transfusion effect and 
was most clearly seen in patients receiving 1-5 units of blood.
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9) In transplant recipients treated with cyclosporin, the DNCB 
test did not have any predictive value.
10) In this series of transplants (which are 64% of all consecutive 
transplants in the Unit over that period), the set of factors 
which correlated significantly with the transplant outcome in a 
stepwise discriminant analysis were the development of panel 
reactive antibodies after transplantation, the last DNCB skin 
test and the immunosuppressive regimen. Patients treated with 
cyclosporin had better graft survival and interestingly most of 
the factors that were found to correlate significantly with the 
transplant outcome in patients treated with azathioprine did 
not correlate in the cyclosporin group.
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Figure 9.1. DNCB scores at the first test in predialysis, 
dialysis and transplant patients compared to normal controls; 
0 = one patient, • = 10 patients.
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Figure 9.2. Percent of weak (open bars) and 
strong DNCB responders (shaded bars) in predialysis, 
dialysis and transplant patients; areas under dotted 
lines represent anergic patients (DNCB score = 0).
TABLE 9.1. CHARACTERISTICS OP PRE-DIALYSIS AND DIALYSIS PATIENTS
Sex:
Pre-dialvsls
0=41
Male 24 (59%)
Female 17 (41%)
Age (Mean ± SD) 39 ± 13
Original disease:
Glomerulonephritis 8 (20%)
Pyelonephritis 12 (29%)
Polycystic 6 (15%)
Miscellaneous 10 (24%)
Unknown 5 (12%)
Duration of dialysis:
3 months 0
6 months 0
1 year 0
2 years 0
>3 years 0
Dialysis
n»464
279 (60%) 
185 (40%)
41 ±  12
172 (37%) 
111 (24%) 
46 (10%) 
119 (26%) 
16 (3%)
241 (52%) 
81 (18%) 
47 (10%) 
45 (19%) 
50 (11%)
TABLE 9.2. RESULTS OF DNCB SCORES IN 505 PATIENTS 
VITH END-STAGE RENAL FAILURE
DNCB No. of Cumulative
score oatients i i
0 165 32.7 32.7
1 46 9.1 41.9
2 61 12.1 54.0
3 57 11.3 65.3
4 29 5.7 71.0
5 22 4.4 75.4
6 35 6.9 82.1
7 23 4.6 86.7
8 18 3.6 90.3
9 15 3.0 93.3
10 7 1.4 94.6
11 7 1.4 96.0
12 7 1.4 97.4
13 5 1.0 98.4
14 3 0.6 99.0
15 5 1.0 100.0
cum %
patients
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Figure 9.3* Cumulative percentages of DNCB scores 
in the 505 predialysis and dialysis patients.
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Figure 9.4. Weak (open bars) and strong DNCB 
responders (shaded bars) in males and females; 
numbers on top of the bars represent number of 
patients.
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Figure 9.5. Percent of strong DNCB responders 
in different age groups in 505 predialysis and 
dialysis patients.
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Figure 9.6. Percent of strong DNCB responders 
in the 505 patients in relation to their 
original renal diseases.
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Figure 9.7. Weak (open bars) and strong DNCB 
responders (shaded bars) in the 505 patients 
without and with nephrectomy of their own 
kidneys prior to the test.
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Figure 9.8. Percent of weak (open bars) and strong 
DNCB responders (shaded bars) in the 505 patients 
who were treated in four different hospitals in 
Glasgow.
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Figure 9.9. Percent of strong DNCB responders in 
444 patients in relation to their blood group and 
rhesus.
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Figure 9.10. Percent of weak (open bars) and strong 
responders (shaded bars) in 186 dialysis women in 
relation to parity.
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Figure 9.11. Percent of weak (open bars) and 
strong DNCB responders (shaded bars) in 372 
haemodialysis and 92 CAPD patients.
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Figure 9.12. Percent of strong DNCB responders in 
464 patients in relation to duration of dialysis prior 
to the test.
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Figure 9.13. Percent of strong DNCB responders in 
505 patients in relation to blood transfusions they 
received prior to the test.
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Figure 9.14. Percent of strong DNCB responders in 
292 patients in relation to interval between last 
blood transfusion and sensitisation to DNCB.
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Figure 9.15. Percent of strong DNCB responders in 
351 patients in relation to their PRA at the time of 
the test; open bars = current PRA, shaded bars = 
historical PRA.
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Figure 9.16. Percent of weak (open bars) and 
strong DNCB responders (shaded bars) in 505 patients 
in relation to the period they were tested.
TABLE 9.3. FREQUENCY OF HLA-DR ANTIGENS IN 362 DIALYSIS PATIENTS
HLA DR 
+ve
HLA DR 
-ve
DR5 DR6 DR7DR1
51
14%
311
86%
DR2
113
31%
249
69%
DR3
111
31%
251
69%
DR4
144
40%
218
60%
30
9%
332
91%
44
12%
318
88%
99
27%
263
73%
Blank
131
36%
231
64%
TABLE 9 .4 . FREQUENCY OF WEAK AND STRONG DNCB RESPONDERS IN
DNCB 0-3
HLA-DR 
+ve
HLA-DR 
-ve
DNCB > 3 :
HLA-DR 
+ve
HLA-DR
RELATION TO THEIR HLA-DR ANTIGENS IN 
362 DIALYSIS PATIENTS
DR1 DR2 DR3 DR4 DR5 DR6 DR7 Blank
33/51 65/113 67/111 94/144 20/30 21/44 60/99 84/131
65% 58% 60% 65% 67% 48% 61% 64%
189/311 157/249 155/251 128/218 202/332 201/318 162/263 138/231
61% 63% 62% 59% 61% 63% 62% 60%
18/51 48/113 44/111 50/144 10/30 23/44* 39/99 47/131
35% 42% 40% 35% 33% 52% 39% 36%
122/311 92/249 96/251 90/218 130/332 117/318*101/263 93/321
39% 37% 38% 41% 39% 37% 38% 40%
*x^ - 3.905, pCO.05, P c o r ^ * ^
TABLE 9 .5 . CORRELATION COEFICIENTS AND TWO-TAILED 
SIGNIFICANCE BETWEEN THE DNCB TEST. BLOOD TRANSFUSION. 
SEX. NEPHRECTOMY. DURATION OF DIALYSIS AND PERIOD WHEN 
THE TEST WAS PERFORMED
Pearson co rre la tio n  c o e ffic ie n ts  
(n-460^
Time Duration
Variab le period of d ia lys is  Nephrectomy Sex
Duration -0.182
of d ia lys is  p -0 .000
Nephrectomy -0.261 0.190
p=0.000 p—0.000
Sex 0.000 0.024 0.066
NS NS NS
DNCB 0.160 -0.190 -0.096 -0 .132
score p -0 .001 p-0.000 p -0 .04 p—0.004
Blood -0.268 0.237 0.119 0.143
transfusion p—0.000 p-0.000 p -0 .01  p—0.002
DNCB
score
-0.316
p—0.000
TABLE 9.6 CORRELATION COEFFICIENTS BETWEEN THE DNCB TEST 
AND SEX. NEPHRECTOMY. DURATION OF DIALYSIS AND TIME PERIOD 
CONTROLLING FOR THE VARIABLE BLOOD TRANSFUSION
V ariab le
DNCB
scores
Pearson co rre la tio n  c o e ffic ie n ts  
(n=460^
Time Duration
period of d ia lys is  Nephrectomy
0.083 -0.125 -0.062
NS p -0 .007 NS
Sex
-0.093  
p -0 .05
%patients
100
80 ‘
60
40
20
0
NS
70
49
27
25
n=119 n=52
Male Female
Non-transfused
NS
136
48
n=184
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119
31
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n=150
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Figure 9.17. Percent of weak (open bars) and strong 
DNCB responders (shaded bars) in 171 patients 
sensitised to DNCB prior to any blood transfusion and 
334 patients sensitised after one or more units of 
blood.
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Figure 9.18. Percent of weak (open bars) and 
strong DNCB responders (shaded bars) in 334 
with and without nephrectomy who were transfused 
prior to the test.
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Figure 9.19. Percent of strong DNCB responders in the 
171 and 334 patients who were sensitised to DNCB prior 
to any and after one or more transfusions respectively 
in relation to the period they were tested.
TABLE 9 .7 . DURATION OF DIALYSIS AND BLOOD TRANSFUSIONS 
PRIOR TO THE DNCB SKIN TEST
For e n tire  population (n=464^:
Sensitised o r io r to BT (^=145)
DNCB 0-3 (n=60)
DNCB >3 (n-85)
Sensitised a f te r BT fn-319}
DNCB 0-3 (n-243) 
DNCB >3 (n-76)
Mean a. SD
Months of 
d ia lys is
10.5±17.5
Number o f 
transfusions
4.3+7.3
3. 9±7.5 *  
4.1±7.2+ 
3.7±7.8+
0.0 
0.0 
0.0
12.8+19.8* 
14.2+21.0{ 
8.3±14.4{
6.4+8.1  
7.1+9.0++ 
4.3+3.8++
*p<0.0000 ; +NS ; {p<0.02; ++p<0.002
TABLE 9 .8 . ASSOCIATION BETWEEN HLA-DR ANTIGENS AND 
STRONG DNCB RESPONDERS IN 362 DIALYSIS PATIENTS
Sensitised n r io r  
to  BT (n=134,>:
DR1 DR2 DR3 DR4 DR5 DR6 DR7 Blanl
HLA-DR +ve 9/18 22/40 25/48 29/54 3/10 17 /19* 23/39 21/39
50% 55% 52% 54% 30% 90% 59% 54%
HLA-DR -ve 66/116 53/94 50/86 46/80 72/124 58/115* 52/95 54/95
Sensitised a f te r  
BT <'n«228'):
57% 56% 58% 58% 58% 50% 55% 57%
HLA-DR +ve 9/33 26/73 19/63 21/90 7/20 6/25 16/60 26/92
27% 36% 30% 23% 35% 24% 27% 28%
HLA-DR -ve 56/195 39/155 46/165 44/138 58/208 59/203 49/168 39/136
29% 25% 28% 32% 28% 29% 29% 29%
°/o
strong responders
100
*x =10.084
p < 0.01*cor x80
22
20
48 10n= 18
17*
23
21
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40
20
26
19
21 6
16 26
0 n- 33
DR1
73
DR2
63 90 20 25 60 92
DR3 DR4 DR5 DR6 DR7 Blank
Figure 9.20. Percent of strong DNCB responders in 
relation to their HLA-DR antigens in 134 patients 
sensitised prior to any blood transfusion (a), and 
in 228 patients sensitised after one or more units 
of blood (b).
TABLE 9.9. DNCB SCORES AT FOLLOW-UP
SKIN TESTING IN THE 505 PATIENTS
DNCB scores (mean ± SD^
1st tes t 2nd te s t 3rd te s t 4th te s t
For e n tire  oonulation:
n-505 
3 .2±3.6
n=*380 
3 .9±4.4 *
n=259 
4 . 1±4.9 *
n=35 
5 .5±6.1{
Sensitised n r io r  to  BT
n-171 
4. 8±3.8
n-145 
6 .1±4.3 *
n=97 
6 .7±4.9 *
n=17
7.1±6.4{
DNCB 0-3
n-74
1.4±1.2
n-63 
2 .6±2.8*
n=44 
2 .7±3.2$
n-10
3.4±5.3
DNCB >3
n=97 
7.4+2.9
n-82 
8 .7±3.3*
n—53 
10.0+3.3*
n°7 
12 .3+3 .6#
Sensitised a f te r  BT
n-334 
2 .4±3.2
n«235 
2 .5±3.9
n-162 
2 .6±4.1
n-18 
4. 1±5.5
DNCB 0-3
n-255 
0.9+1.1
n-172 
0 .6+ 1 .3 *
n—123 
0 .6+ 1 .9 *
n-12 
2.1+4.3
DNCB >3
n-79 
7.2+2.9
n-63
7 .8±3. 5+
n-39
8 .7±3.2 *
n—6 
8.2+5.7
p values against respective 1st te s t: *p<0.0001; +p<0.006;
$p<0.008; {p<0.02; #p<0.03
DNCB 
14 .score
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10
8
0
0.02
*
0.0001
0.0001
* 0.02
0.0001
0.0001
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Figure 9.21. Mean + SEM DNCB scores in the 505 
patients (O  ), and in the breakdown groups of 
patients sensitised to DNCB before any transfusion 
(0) and after one or more units of blood (•); 
p values against respective 1st test; number of 
patients tested on each occasion are shown in 
Table 9.9.
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0.0001
0.04
0.0001
0.006
0 .0080.0001
0.00010.0001
0.00010.0001
1st test 2nd test 3rd test 4th test
Figure 9.22. Mean + SEM DNCB scores in the weak 
(circles) and strong responders (squares); open 
symbols = patients sensitised to DNCB prior to any 
transfusion, closed symbols = patients sensitised 
after one or more units of blood; p values against 
respective 1st test (*), and between groups; number 
of patients tested on each occasion are shown in 
Table 9.9.
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Figure 9.23. Cumulative percent of DNCB scores in 
74 weak responders who were sensitised to DNCB 
prior to any transfusion indicating those who 
changed to strong responders on serial testing; 
numbers on top of the bars represent number of 
patients with the respective DNCB score.
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Figure 9.24. Cumulative percent of DNCB scores in 97 
strong responders who were sensitised to DNCB prior to
any transfusion indicating those who changed to weak 
responders on serial testing; numbers on top of the 
bars represent number of patients with the respective 
DNCB score.
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Figure 9.25. Cumulative percent of DNCB scores in 
255 weak responders who were sensitised to DNCB after 
one or more units of blood indicating those who 
changed to strong responders on serial testing; 
numbers on top of bars represent number of patients 
with the respective DNCB score.
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Figure 9.26. Cumulative percent of DNCB scores in 
79 strong responders who were sensitised to DNCB 
after one or more units of blood indicating those 
who changed to weak responders on serial testing; 
numbers on top of the bars represent number of patients 
with the respective DNCB score.
TABLE 9.10 TIME INTERVALS BETWEEN FOLLOW-UP DNCB SKIN TESTS
Months between tests  (mean ±. SD3
lst-2nd 2nd-3rd 3rd-4th
n-380 n-259 n-35
For e n tire  population: 1 2 .7±12.4 1 4 .5±14.3 2 5 .1±21.3
Sensitised o rio r to BT
n-145 
1 1 .2±12.9
n-97
11.1±12.3*
n=18
22.1±25.3
DNCB 0-3
n-63 
1 2 .1±14.9
n-44 
12.8+14.8+
n-11 
1 7 .8±20.7
DNCB >3
n=82 
10.4±11.1
n—53 
9 .7±9.8}
n-7
28.7±31.8
Sensitised a fte r  BT n-235 n-162 n—17
1 3 .6±12.0 16 .5±15.0 * 2 8 .4±16.1
DNCB 0-3
Ti-172
13.9+11.9
n-123 
16.9+15.7+
p-12
30.3±16.1
DNCB >3
n-63
12.9±12.6
*p<0.003 ;
n-39
15.1±12.9{
+p<0.05 ; {p<0.004
n-5
23.6+16.8
TABLE 9.11. BLOOD TRANSFUSIONS GIVEN DURING 
TIME INTERVALS BETWEEN FOLLOW-PP DNCB SKIN TESTS
No o f transfusions (mean ±  SD)
lst-2nd  
n-380
For e n tire  population: 5 .5±9.7
n-145
Sensitised o r lo r  to  BT
DNCB 0-3
DNCB >3
Sensitised a f te r  BT
DNCB 0-3
DNCB >3
n-63 
3. 9±4.7'
n-82 
3.6+5.I 1
n-235
BdL 11 ^ 
6.8+12.6
n-63
6 .1+8 .1{
2nd-3rd
n-259 
5.5+9.6
n-97 
4.8±7.4
n—44 
5. 5±7 .0
n-53 
4 .2±7.8
n—162 
5.9+10.7
n-123
5.9±10.7
n-39
5.6+11.0
3rd -4th
n-35 
9.1±12.8
n-18
7.0+12.2
n-11 
8 .7±15.5
n-7 
4. 3±3.5
n-17
11.3+13.4
3=12 
8. 7±9.2
n-5
16. 5jfcl9.3
*p<0.004 ; +NS ; {p<0.02
TABLE 9.12 CHARACTERISTICS OF WEAK AND STRONG DNCB
RESPONDERS UNDERGOING TRANSPLANTATION UNDER AZATHIOPRINE AND PREDNISOLONE
Weak responders 
(n»189^
Strong responders p
(n=95^ value
Sex:
Male
Female
106 (56%) 
83 (44%)
69 (73%) 
26 (27%) 0.007
Age (mean ±. SD> 38 .9±13.6 39.7±12.3 NS
Duration of 
d ia ly s is  (months) 28.4+28.2 15.9+12.6 0.0001
No o f BT (mean + SD) 11.7+13.1 7.1+8.7 0.0001
Tvne o f Tx: 
Cadaveric 
Live
175 (93%) 
14 ( 7%)
87 (92%) 
8 ( 8%) NS
No o f Tx: 
1st 
2nd 
3rd
170 (90%) 
14 ( 7%) 
5 ( 3%)
90 (95%) 
5 ( 5%) 
0 NS
HLA-A mismatches:
0 59 (31%) 36 (38%)
1 91 (48%) 39 (40%)
2 39 (21%) 20 (21%) NS
HLA-B mismatches:
0 65 (34%) 34 (36%)
1 94 (50%) 49 (51%)
2 30 (16%) 12 (13%) NS
HLA-DR mismatches:
0 62 (50%) 38 (48%)
1 53 (43%) 31 (39%)
2 8 (17%) 10 (13%) NS
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Figure 9.27. Actuarial patient and graft survival (GS) 
in the 344 transplants; A  = patient survival,□= GS, 
all patients (n=344), 0 = GS, patients treated with 
azathioprine (n=284), • = GS, patients treated with 
cyclosporin (n=57); all graft losses included, 3 
patients with combined immunosuppressive regimen were 
excluded from GS analysis.
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Figure 9.28, Actuarial graft survival in the 284 
transplants treated with azathioprine; comparison between 
189 weak (0) and 95 strong DNCB responders (□), as 
classed by the first DNCB test.
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Figure 9.29. Actuarial graft survival in the 
284 transplants treated with azathioprine; comparison 
between 179 weak (0) and 105 strong DNCB responders 
(□), as classed by the last DNCB test.
TABLE 9.13 CUMULATIVE GRAFT SURVIVAL IN WEAK AND STRONG 
DNCB RESPONDERS IN THE 57 TRANSPLANTS TREATED WITH CYCLOSPORIN
F irs t  DNCB te s t :
Weak responders (n=*37) 
Strong responders (n=20)
Cumulative % g ra ft su rv iva l (±SE) 
3 months 6 months 9 months 
89+5 84+6 65+8
85+8 70+10 65+11
Last DNCB te s t :
Weak responders (n-33) 88+6 82±7 67±8
Strong responders (n-24) 87+7 75+9 63+10
TABLE 9.14 CUMULATIVE GRAFT SURVIVAL IN WEAK AND STRONG
DNCB RESPONDERS IN THE 284 TRANSPLANTS TREATED WITH 
AZATHIOPRINE IN RELATION TO THE NUMBER OF TRANSFUSIONS 
PRIOR TO TRANSPLANTATION
Cumulative % g ra ft  su rv iva l (±SE)
F irs t  DNCB te s t
Weak resoonders: 1 vear 2 vears 3 vears 4 vears 5 vears
0 BT (n -8 ) 50+18 38+17 38+17 25+15 .
1-5 BT (n -5 2 )* 63+7 58+7 46+7 38+7 27+6
6-10 BT (n-63) 67+6 49+6 37±6 25+6 21+5
>10 BT (n=65) 58±6 46+6 34+6 26+6 25+5
Strong responders:
0 BT (n -9 ) 33+16 33±16 33±16 33±16 33+16
1-5 BT (n -4 5 )* 53±7 42±7 24±6 20±6 23+5
6-10 BT (n-28) 50±9 43±9 32±9 18±7 7±5
>10 BT (n-13) 46+14 38+14 38+14 23+12 15+10
Last DNCB tes t 
Weak responders:
0 BT (n -8 ) 50+18 38±17 38±17 25±15 -
1-5 BT (n-45)+ 73±7 71+7 58+7 49±8 36±7
6-10 BT (n-61) 67±6 49+6 38+6 26+6 21±5
>10 BT (n-65) 56+6 44+6 33+6 27+6 25+5
Strong responders:
0 BT (n -9 ) 33±16 33±16 33±16 33±16 33±16
1-5 BT (n -5 2 )+ 46±7 33±7 17±5 13±5 8jA
6-10 BT (n-30) 50±9 43±9 30±8 17±7 7±5
>10 BT (n-14) 57+13 50+13 43+13 21+11 14+9
*D -3 .358, p<0.06; +D-17.343, p<0.00001
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Figure 9.30. Actuarial graft survival in 97 transplants 
treated with azathioprine who had received 1-5 units 
of blood prior to transplantation; comparison between 
weak (0) and strong DNCB responders (Q), as classed 
by the first (open symbols) and the last DNCB test 
(closed symbols).
TABLE 9.15 CUMULATIVE GRAFT SURVIVAL IN WEAK AND STRONG DNCB
RESPONDERS IN THE 57 TRANSPLANTS TREATED WITH CYCLOSPORIN IN RELATION TO 
NUMBER OF TRANSFUSIONS PRIOR TO TRANSPLANTATION
Cumulative % graft survival (± SE~)
First DNCB test 
ffeak responders:
1-5 BT (n=13) 
6-10 BT (n-14) 
>10 BT (n-10)
3 months
92±7
93±7
80+13
6 months
92±7
79±11
80+13
9 months
69±13
64±13
60+16
Strong responders:
1-5 BT (n-7) 
6-10 BT (n-7) 
>10 BT (n-6)
86+13
86+13
83±15
71+17
57+19
83±15
57+19
57+19
83±15
Last DNCB test 
Weak responders:
1-5 BT (n-8) 
1-6 BT (n-14) 
>10 BT (n-11)
88±12
93±7
82+12
88+12
79+11
82+12
75±15
64±13
64+15
Strong responders:
1-5 BT (n-12) 
6-10 BT (n-7) 
>10 BT (n-5)
92±8
86+13
80+18
83±11
57±19
80+18
58+14
57±19
80±18
TABLE 9.16 CUMULATIVE GRAFT SURVIVAL IN THE 284 TRANSPLANTS TREATED WITH
AZATHIOPRINE AND IN THE 57 TRANSPLANTS TREATED WITH CYCLOSPORIN 
IN RELATION TO NUMBER OF BLOOD TRANSFUSIONS PRIOR TO TRANSPLANTATION
Azathioprlne
Group
Cumultative % graft survival (±SE)
No. of BT: 1 year 2 vears 3 years 4 vears 5 vears
0 (n-17) 
1-5 (n-97) 
6-10 (n-91) 
>10 (n-79
41+12
60+5
62±5
56+6
35±12
51±5
47±5
45+6
35±12
36+10
35±5
35+5
29±11
30+5
23±4
26+5
18±9
21+4
16±4
23+5
Cvclosoorin
Group
No. of BT: 3 months 6 months 9 months
1-5 (n-20) 
6-10 (n-21) 
>10 (n-16)
90±7
90±6
81+10
85±8
71±10
81±10
65ill
62+11
69±12
TABLE 9.17 CORRELATION COEFFICIENTS OF THE VARIABLES WHICH SHOWED A 
SIGNIFICANT ASSOCIATION WITH THE TRANSPLANT OUTCOME
Spearman correlation coefficients
Variable Transplant outcome
Azathioprlne 
All transplants group
Last DNCB 0.121 0.141
n-344 n-284
test p-0.025 p-0.02
HLA DR 0.165 0.125
mismatches n-261 n-204
p=0.008 p=0.01
Cadaver/Live -0.118 -0.168
transplant n-334 n-284
p-0.03 p—0.004
No. of rejection 0.343 0.322
episodes n-217 n-195
p-0.0001 p-0.0001
%PRA post 0.510 0.518
transplant n-305 n-251
(peak^ p-0.0001 p-0.0001
Azathioprlne/ -0.204
Cvclosporlne n-344
p-0.0001
Hospital NS -0.126
n-284
p-0.03
Time of 1st -0.203
rejection NS n-156
episode p-0.01
Cvclosporlne
group
NS
0.370 
n-57 
p—0.005
NS
NS
0.437 
n—51
p-0.001
NS
NS
DISCUSSION
In order to clarify the effect of blood transfusion in uraemic 
patients we set up the prospective controlled study which has been 
discussed in the first eight chapters of this thesis. Although a 
controlled study is the classical research design, restricting the 
observations to two groups has an inherent limitation which is to 
overlook the complexity and variability of the phenomena under 
investigation. The questions we have posed and aimed to provide an 
answer to were: a) whether individuals with a strong or weak reaction 
to DNCB differ in their response to blood transfusion and try to 
define the optimum number of transfusions for each group to achieve a 
beneficial effect; b) to see whether blood transfusion-induced 
changes in CMI responses could be monitored with simple skin tests, 
and c) to define possible factors determining the response to DNCB 
and assess the predictive value of this skin test in graft survival.
The research design necessary to provide experimental answers 
to the above questions would require comparison of more than two 
groups with more subjects in each group. Luckily more patients were 
available and were used in Chapter 9 to retrospectively analyse 
results of DNCB skin testing from a viewpoint suggested by the 
prospective study. This methodology proved useful and shed light on 
discrepancies reported in previous studies from our centre.
In the following four sections I shall discuss these points and 
try to put forward an answer to the questions we have raised, based 
on analysis of the results obtained from both the prospective and 
retrospective data.
The effect of blood transfusion on skin testing in uraemia
The first point which deserves attention is the finding of a 
higher proportion of strong DNCB responders in the group of dialysis 
patients who had not received prior transfusion. Among the 60 
patients were 58% strong and 42% weak reactors (Table 1.1). Thirteen 
percent had no reaction on first testing and they are included among 
the weak reactors. These figures are strikingly different from our 
previous studies where strong DNCB responders were found to account 
for between 21% and 31% of patients (399-402,571). Retrospective 
analysis of DNCB testing in 505 patients, which has been described in
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Chapter 9, showed that there were 35% strong responders, and the 
remaining 65% were weak responders, 33% being anergic (Table 9.2). 
This difference in the proportion of strong responders between 
patients described in Chapters 1 and 9 is attributed to the effect of 
blood transfusion, as there was an impressive decline in strong DNCB 
responders in Chapter 9 with the increasing number of patients 
transfused prior to the test (Figure 9.13). Among the 171 patients 
who were sensitised to DNCB prior to any transfusion, the proportion 
of strong responders (57%) was identical to that described in Chapter 
1 (58%). With two previous transfusions there were fewer strong 
responders at 28% and the number fell to only 6% in the patients 
sensitised after more than 20 units of blood (Figure 9.13). From 
these findings it is evident that uraemia and blood transfusion had a 
synergistic effect in suppressing CMI response in these patients.
In our historic group of normal controls all 15 individuals had
a strong DNCB response (score more than 3) as measured by our 
semiquantitative method, none of them being anergic, ie score 0 
(Figure 9.1). Catalona and Chretien studied 143 healthy controls and 
found that 3.5% had impaired reactivity to DNCB, 2.8% of them being 
anergic (293). Rolley et al found 65 of 66 normal individuals with a 
positive response to DNCB (398) . Only 24 of his 154 dialysis 
patients (16%) responded to DNCB and there were no significant 
differences between patient groups classified by their DNCB response 
with regards to various parameters including the number of known 
blood transfusions (398).
These results regarding DNCB response in normal individuals are 
in accord with our results but there Is a discrepancy in the
proportion of strong responders in dialysis patients and the results 
of the transfusion effect between Roley and ourselves. This
discrepancy is an example of the numerous conflicting reports which 
have been produced in the study of immune responses in uraemia. 
Although there is general agreement that suppression of DTH is a 
manifestation of the uraemic syndrome, the proportion of 
non-responder patients varied widely from 28-87% using recall 
antigens (356, 406) and from 49-84% using the DNCB skin test (398, 
406). These variations are due to differences in the protocols of 
sensitisation or other factors that might interfere with expression
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of CMI by skin testing, such as malnutrition (286, 306, 307), 
infections (296, 297), surgery (379), immunosuppressive agents (286, 
308, 309) and blood transfusion (393, 394, 410).
With regards to blood transfusion, Valderrabano et al noticed 
an increase in non-responders to recall antigens from 46% to 63% 
within three years of introducing a policy of deliberate blood 
transfusion in their unit (410) . Russ et al using a protocol based 
on our earlier studies, confirmed our results by showing that the 
reactivity to DNCB of previously transfused patients was lower than 
those who had not been previously transfused (408) . In order to 
circumvent the influence of the uraemia-induced immunodepression, 
Gerbase-DeLima et al studied the DNCB response in multi-transfused 
non-uraemic patients with a sickle cell disease and thalassaemia and 
found 50% and 60% responders respectively compared to over 90% of 
normal individuals (591).
These results provide evidence suggesting that the primary 
response to skin testing using DNCB and recall antigens in uraemic 
patients is affected by blood transfusion. Most of the reports which 
have been reviewed in the introduction regarding immune responses in 
uraemia have not taken into account this point. So, it seems 
probable that the effect of uraemia in inducing immunosuppression 
might have been overemphasised.
This issue becomes more evident when one reviews the results we 
obtained from the sequential skin testing. Patients who were 
immunised with DNCB and recall antigens prior to any transfusion 
gave stronger anamnestic reactions on repeating the test regardless 
of the amount of blood they had received or whether they were 
transfused at all (Figure 1.4, 1.6, 2.1, 2.2 and Table 9.9, Figure 
9.22, 9.23). Only anergic patients tended to remain anergic and
there is some evidence from Chapter 9 that weak responders who were 
sensitised to DNCB after one or more units of blood might have 
further depression of their reaction on repeating the test (Figure 
9.22).
Indeed, both the individual DNCB reactivity and the proportion 
of strong responders was increased on repeating the test in patients 
who were sensitised to DNCB prior to blood transfusion (Tables 1.1, 
9.9, and Figures 9.23, 9.26). These findings suggest that primary
180
immunisation to DNCB is a crucial event and blood transfusion may 
interfere with the response to it by exerting a suppressive effect on 
the afferent arm of the immune response.
An early study in 1962 on the immune response in uraemic 
rabbits is reminiscent of the importance of the timing of the primary 
sensitisation (343). Gowland et al found that severely uraemic 
rabbits failed to clear bovine albumin following primary 
sensitisation, but clearance was very effective when rabbits were 
sensitised before uraemia was established. Furthermore, an abnormal 
antibody response to bovine serum albumin occurred only when rabbits 
were immunised with the antigen while uraemic. Those animals which 
were immunised prior to the establishment of uraemia showed normal 
antibody responses when subsequently challenged with the antigen 
while uraemic.
Similar results to ours were obtained by Russ et al who 
skin-tested with DNCB 25 dialysis patients before and after a three 
month period in which three transfusions were given and found an 
increase in DNCB score (408). Increased reactivity to DNCB with 
transfusion has been also reported in rhesus monkeys (592).
Support for these stronger anamnestic reactions following 
rechallenge with DNCB has also been provided from in vitro studies 
of contact sensitisation in man with DNCB (253, 270, 601, 602).
Miller and Levis reported that the in vivo primary response to DNCB 
correlated with the in vitro blastogenesis using DNCB to stimulate 
leukocyte cultures from DNCB-sensitised healthy subjects (253). DNCB 
rechallenge boosted the in vitro response and DNCB-induced 
blastogenesis which tended to remain elevated for longer than has 
been observed following primary sensitisation with DNCB (601). This 
increased blastogenic activity on rechallenge with DNCB was 
associated with significant lymphokine activity suggesting an 
amplifying mechanism of CMI involving recruitment of previously 
uncommitted lymphocytes (602). This was confirmed in uraemic patients 
by Hamilton et al in our centre who showed that leukocyte migration 
inhibition by a DNCB/RBC conjugate started to decline three months 
after the primary sensitisation to DNCB, but it was fully restored 
when patients were repatched (270).
181
Giacchino et al, in contrast, reported that three strong DNCB 
responders changed to weak when transfused but the number of patients 
was very small and it is not stated whether these patients had been 
transfused prior to the primary sensitisation to DNCB (593).
It appears from these observations that sequential skin testing 
does not reflect changes induced by blood transfusion, as we found 
stronger anamnestic reactions also in uraemic controls who were not 
transfused at all (Figures 1.4, 2.1). This is an important point 
because sequential skin testing has been applied in several clinical 
conditions as a means of testing restoration of CMI. It has been 
alleged that a few months of treatment by CAPD restores the response 
to DNCB to normal as opposed to the effect of haemodialysis (387). 
Our results suggest that CMI is comparable as measured by DNCB 
testing in these two groups and does not improve in CAPD patients 
when the blood transfusion effect has been taken into account (594). 
Follow-up skin testing gave anamnestic reactions which were 
comparable in the two groups when patients were stratified according 
to whether they had been transfused or not at the time of 
sensitisation to DNCB. It would be interesting to apply a similar 
approach in pulmonary and miliary tuberculosis (595, 596), in
surgical patients (300) and following drug therapy with levamisole 
(300,597), cimetidine (598,599), NSAIDs (86,92,97,599) and zinc 
(600). Restoration of CMI as measured by skin tests using DNCB and 
recall antigens has been described in all these conditions. 
Interestingly, Diamanopoulos in his PhD thesis described restoration 
of the response to DNCB and PPD in two of seven dialysis patients 
using levamisole in our centre (597) . Both these patients were 
sensitised before they commenced haemodialysis and prior to any blood 
transfusion.
Therefore, interpretation of DTH tests should be careful when 
the design of the experiment does not exclude factors which might 
influence the development of a specific immunological memory and 
subsequent secondary responses.
Many investigators have used more than one test to define CMI 
defects in uraemia and these have been reviewed in the introduction. 
Kunori et al used different antigens to study the in vitro lymphocyte 
reactivity in uraemic patients and observed different low responders
182
with each mitogen (373). cTApice et al used different functional 
assays to investigate suppressor activity in uraemic patients and 
found discordant results, supporting previous suggestions that 
different assays measure different suppressor cell populations (392). 
In our patients, there was no correlation between the response to the 
DNCB test and the response to skin testing with four recall antigens, 
which suggests that the two tests define different subpopulations of 
responders and non-responders (Figure 2.3, 2.4). Diamanopoulos,
however, in his thesis found a correlation between the DNCB and PPD 
test in 11 dialysis patients (597). These discrepancies most likely 
are due to differences in patient selection.
Factors determining the response to DTH in uraemia
DTH has been traditionally thought to reflect in vivo CMI 
responses which involve primarily two cell types, T helper cells and 
antigen presenting cells (APC). Numerous studies have described 
impaired DTH to skin test preparations in both non-dialysed (348, 
356,366,397), and dialysed uraemic patients (334,349,348,356,366, 
387,398-411) and in uraemic animals (412). However, this well 
established view has been challenged by considerable experimental 
evidence which suggests that uraemic lymphocytes are not 
intrinsically defective, but a suppressive host milieu or other 
exogenous factors such as blood transfusion, surgery, malnutrition, 
infections and drugs may all contribute to alterations in their 
reactivity both in man (286,296,297,306-309,379,393,394,399,402,410, 
571) and animals (382-393,412,415).
In this thesis it has been shown that more than half of the 
uraemic patients who had never received a blood transfusion or renal 
allograft and who had recently been established on dialysis were 
capable of eliciting a normal DTH response to DNCB (Chapter 1). This 
finding partly supports the view that the endogenous 
immunosuppression due to uraemiSl may have been over emphasised.
In an earlier study we looked into factors determining the 
response to DNCB and found that sex, polycystic kidney disease, 
duration of dialysis and transfusion might influence the response to
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the test (402). This, however, was not confirmed in the prospective 
study where age, sex, original disease, type of dialysis and parity 
of the patients did not relate to the response to DNCB (Table 3.1).
The number of patients in the prospective study is small, but a 
detailed analysis of factors determining the response to DNCB in 505 
patients has clarified the controversy (Chapter 9.3.2). In a 
univariate fashion analysis the factors which showed a significant 
association with the response to DNCB were sex, nephrectomy prior to 
transplantation, time period when patients were tested, duration of 
dialysis and number of blood transfusions prior to the test. In a 
multivariate analysis, however, which excluded the interdependence 
and the overlapping effect of blood transfusion between these 
variables, the only significant variable proved to be blood 
transfusion (Table 9.5, 9.6, 9.7). The importance of the other 
variables was lost when patients were stratified in terms of whether 
they had been transfused or not at the time of sensitisation to DNCB 
(Figures 9.17-9.19).
Roley et al, also did not find any correlation between DNCB 
response and various parameters including age, sex, race, original 
disease, duration of dialysis, ABO and rhesus blood types, previous 
nephrectomy or splenectomy and cytotoxic antibodies (398). This is in 
agreement with our results, but they did not find that blood 
transfusion is a significant variable either. Maxwell et al also did 
not show any association between DNCB response and transfusion in 
diabetic uraemic patients (403). Rolley et al has classified his 
patients into responders and non-responders according to negative, 
positive, and early or irritant response (398). Maxwell et al 
designated his patients as being either positive or negative 
according to the induration present in an area where a challenge dose 
of 50 and lOOug was applied 14 days after the 2000ug sensitising dose 
(403). These protocols are different from our semiquantitative 
method where we use smaller challenging doses (399-402,571,574,575). 
This may account for the fact that these authors did not describe the 
transfusion effect on DNCB testing. Russ et al who adopted our own 
method of sensitisation reported results similar to ours (408). 
Valderrabano et al using seven recall antigens (Multitest) described 
an increase in the number with anergy from 46% in 1982 to 63% in 1985
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after the introduction of a policy of deliberate transfusion in 209 
patients awaiting transplantation and anergy was more frequent in 
patients who had received more transfusions (410). In contrast, 
Stoffner et al, utilising the Multitest in 253 patients, did not 
detect any association between DTH response and pre-transplant blood 
transfusions (414).
It can be recalled from the introduction that a number of 
metabolites were thought to be responsible for the inhibitory effect 
of uraemic sera on lymphocyte reactivity, namely methylguanidine, 
quanidinosuccinic acid, cAMP, corticosteroids, antileukocyte and 
lymphocytotoxic antibodies, and decreased levels of thymosin and 
vitamin coenzyme (317). Apart from certain physicochemical 
parameters, such as increased osmolality due to sucrose and urea, pH 
and increased sodium, potassium and calcium concentrations in human 
lymphocyte cultures inhibited PHA stimulation (603). The results 
from this thesis do not support any association between a number of 
haematological and biochemical parameters and the in vivo response to 
DNCB and recall antigen both prior to and after the transfusion of 5 
or 10 units of blood (Tables 3.3-3.5). A couple of weak correlations 
which were observed were restricted, as the statistical significance 
was established at the 0.05 level and the number of computations is 
large enough to justify one in twenty parameters to come up as 
significant by chance. Another reason which limits the importance of 
these correlations is the restriction of the range of the studied 
variables within that seen in end-stage uraemia. Roley et al also 
did not find any association between DNCB response and peripheral 
WBC, serum urea and albumin levels (398), and the same conclusion was 
reached by Diamanopoulos (597).
Malnutrition has been implicated as a cause of depression of 
DTH (286, 306, 307), but it is unlikely that this was a major issue 
in our dialysis population. In a large population of 505 patients it 
is expected that nutritional deficiency would be equally distributed 
between weak and strong DNCB responders. CMI in geriatric patients 
as tested by a battery of tests including skin tests with DNCB and 
four recall antigens was found to be impaired (304). We did not find 
an association between age and the response to DNCB, but the number 
of patients exceeding the age of 65 was small (Figure 9.5).
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Surgery has also been claimed to be associated with impaired 
DTH response in non-uraemic man (298-300, 302) and rats (379), but 
not in mice (412) . Our results suggest that patients who had 
undergone nephrectomy and were not tested immediately after surgery 
proved to have depressed DNCB response because they had received 
blood transfusions prior to the test (Figures 9.7, 9.18). Among
transplant patients with functioning grafts, who had the DNCB test 
while under immunosuppression two-thirds were anergic (score 0) and 
only one in ten had a strong response (Figure 9.1, 9.2). This
confirms that immunosuppressive agents interfere with DTH responses 
(286, 308, 309).
An interesting finding was the association between HLA-DRW6 and 
the response to DNCB skin test. DRW6 positive patients were 
significantly more likely to be strong responders when tested prior 
to any blood transfusion as compared to DRW6 negative patients. This 
finding was confirmed both in the prospective study (Figure 3.6) and 
in the retrospective analysis with a larger number of patients (Table 
9.8, Figure 9.20). In patients sensitised to DNCB after one or more 
transfusions, however the DRW6 effect was not found (Table 9.8, 
Figure 9.20). This evidence supports the concept that HLA-DRW6 is a 
marker of strong CMI, although this strong response can be modified 
by blood transfusion.
In 1941 Chase, on the basis of different degrees of contact 
sensitivity within groups of guinea pigs, showed by breeding 
experiments that the immune response of guinea pigs to DNCB skin 
sensitisation was influenced by hereditary factors (180). Since then 
it has been established that genetically controlled variations in 
immune response can be mediated by the immune response (Ir) genes 
(111, 114-117, 121-129). The evidence that DTH reactions are under 
the control of the Ir genes was provided by experiments using inbred 
strains of non-responder and responder animals which differed only at 
the I region of the MHC. These animals were tested for their immune 
responses to synthetic polypeptides either by quantitating an 
anti-hapten response using the antigens as carriers or by direct 
measurement of DTH to the antigens. As DTH reactions are T 
cell-dependent phenomena, it was suggested that the Ir gene control 
is linked to MHC and is expressed at T cell level (115, 128, 604).
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The association between HLA-DRW6 and a strong response to DNCB in our 
patients is in accordance with this principle, as DR antigens are the 
human counterpart of murine la molecules, the Ir region in mice (604, 
605) .
A number of reports from Leiden have described HLA-DRW6 
pre-transplant patients as high responders to certain renal allograft 
antigens (606, 607). Baldwin et al showed that DRW6 was a high-Ir 
gene for the production of antibodies against a non-HLA antigen 
present on renal endothelium and peripheral blood monocytes (606) and 
Hendriks et al reported that DRW6 positive individuals produce more 
anti-DR antibodies than DRW6 negative ones (607). These antibodies 
were mainly directed against antibodies present on B cells or 
monocytes and were associated with irreversible renal graft 
rejection; HLA-DR matching significantly improved graft survival only 
in DRW6-positive recipients (607). The DRW6 effect on graft survival 
was confirmed by several reports from other centres (408-412), but 
was not supported by Kerman et al (613). Opelz, analysing the CTS 
data, was also unable to demonstrate a significant DRW6 effect (614). 
However, because HLA-DRW6 is a heterogeneous and difficult to define 
antigen, he analysed separately the 9th Workshop-typed transplants
and a strong DRW6 effect was apparent (614).
The Leiden group later examined the DRW6 donor effect on graft 
survival and reported that DRW6 in the donor has a beneficial effect 
on graft survival regardless of the match and the presence or absence 
of DRW6 in the recipient (615-617). They suggested that the presence 
of DRW6 or another class II determinant in linkage disequilibrium 
with DRW6 activated a suppressor cell circuit which inhibits 
allograft rejection. However, they were unable to propose a good
mechanistic explanation for either the recipient or donor DRW6
phenomenon, as supporting proof provided by experimental and in vitro 
systems has been rather poor (reviewed in 604, 617). Lehner showed
that HLA-DRW6 positive T cells in vitro have a higher affinity for 
some streptococcal antigens than DRW6 negative T cells (618). 
Sercarz et al described epitopes on artificial molecules which 
induced suppressor T cells in mice with particular H-2 haplotypes
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(619), and suppressor T cell-dependent low responsiveness to 
microbial antigen has been associated with the DQW1 determinant (604, 
620) .
These studies clearly indicate the existence of human Ir genes, 
the HLA-D and HLA-DR molecules, which are similar to la antigens in 
mice, and can function as restriction elements determining reactivity 
to simple and complex antigens. HLA-DRW6 could be such an Ir gene 
regulating the interplay between the cellular components involved in 
the DTH reaction. From *fable 9.8, however, it is evidence that the 
DRW6 positive strong responders represent only 23% (17 of 75) of the 
total number of strong responders among our group of patients who 
were sensitised to DNCB prior to any transfusion. Previous reports 
of family studies in humans suggested that the control of T cell 
proliferative responses to synthetic polypeptides appeared to be a 
polymorphic one, unlikely to be mediated by a single dominant Ir gene 
(604). The control of such a complex event as DTH may be mediated by 
an Ir trait coded for by gene(s) in high linkage disequilibrium with 
DRW6.
This influence of DRW6 on the DNCB response could not be 
demonstrated in the patients sensitised to DNCB after blood 
transfusion (Table 9.8). This, together with the overall lowered 
incidence of strong responders in the transfused group, implies that 
transfusion suppresses the induction of responsiveness to DNCB by 
interfering with the function of HLA-DR antigens as restriction 
elements in cellular interactions in the DTH reaction. We have 
recently reported that IgG-PFC responses induced by polyclonal 
activators were significantly suppressed in the PWM-driven system 
after 5 units of third-party blood in pretransplant patients (624), 
and the degree of suppression in both DRW6 positive and DRW6 negative 
patients was equal (575). This is in agreement with the results from 
Donnelly et al who found no difference in the degree of 
transfusion-induced plasma suppressive activity between DRW6 positive 
and DRW6 negative patients (546, 612). Thus, it appears that
HLA-DRW6 is a marker of strong CMI response, although this strong 
response can be modified by blood transfusion.
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The predictive value of the DNCB test in graft survival
In 1977 Rolley et al tested the CMI of 154 dialysis patients 
using the DNCB skin test and showed a correlation between the 
reaction to DNCB and the outcome of transplantation (398). He found 
a striking 78% graft survival at two years in non-responders to DNCB 
compared to 29% in responders. This result was supported by a series 
of studies from our unit (399-402, 571). Watson et al showed that 
graft survival at six months was 71% and 15% in the weak and strong 
DNCB reactors respectively (399), and this difference was 
reproducible in the follow-up reports (400-402). In these early 
studies it was noted that weak DNCB reactors required more blood 
transfusions to maintain their haemoglobin level and it seemed likely 
that the weak DNCB reactors had greater bone marrow depression than 
strong reactors which could not only reduce the number and function 
of lymphocytes but also reduce red cell production (399). This 
theory could have offered an explanation for the depressed CMI 
respond and the greater need for blood transfusion in the weak DNCB 
responders, but conclusive evidence to support this view was lacking. 
On the contrary, there was evidence to suggest that lymphopenia did 
not appear to correlate with suppressed DTH responses (366). 
Therefore the predictive value of the DNCB test in renal 
transplantation was partly linked to the blood transfusions effect 
(399) , but later this effect was shown to be independent of the 
influence of the DNCB response, as the six month graft survival was 
better in all groups of weak reactors compared to strong reactors 
receiving no blood, frozen cells or whole blood/packed cells (402).
These first reports were based on data analysis from a period 
when patients were transfused only for reasons of clinical need, but 
from June 1979 a policy of deliberate transfusion prior to transplant 
was introduced. All patients received 5 units of concentrated red 
cells before being considered for transplantation. Another important 
change after 1981 was a deliberate policy to sensitise to DNCB more 
patients prior to any blood transfusion and see what happened with 
the follow-up skin testing, whereas in the early period the timing of 
the DNCB test was carried out irrespective of their transfusion 
status. In 1983 we compared the results of graft survival from 
transplants between 1975-79 and June 1979-81 and we found that the 6
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month survival of weak DNCB reactors was comparable at 73% and 71% , 
whereas the survival in strong reactors improved from 36% to 61% 
(571). Thus DNCB testing appeared to have lost its predictive value 
for transplant outcome, because, with the adoption of deliberate 
pre-transplant transfusion the improvement in graft outcome was 
observed to occur almost entirely in the strong DNCB responder who 
appeared to require more transfusion than did weak reactors to 
improve graft survival (571).
Other workers had suggested that increasing amounts of blood 
improved graft survival (425, 426, 440, 443, 456, 457), but this was 
not so in some centres (446, 448, 459, 460). Briggs from our centre 
reported in 1978 that the beneficial effect of transfusion was no 
greater in patients transfused more than 5 units compared to those 
given less than 5 units (447). In 1983, we observed that graft 
survival in strong DNCB responders improved from 20% in those without 
any blood prior to transplantation to 38% in those receiving 1-5 
units, and to 72% in those receiving more than 5 units (571). In the 
prospective study described in Chapter 4 the number of transplants 
was too small to justify firm conclusions, although it appeared that 
strong DNCB responders had more rejection episodes and the number of 
transfusion (5 or 10 units) did not seem to associate significantly 
with the transplant outcome (Tables 4.1, 4.2).
It has already been discussed that an important observation 
from follow-up DNCB skin testing was that patients eliciting a strong 
primary response retained and gave even stronger responses in 
subsequent tests regardless of blood transfusion status at the time 
of sensitisation to DNCB. Also, weak responders who were sensitised 
prior to any transfusion were more likely to show increased secondary 
responses, and as a result of this approximately one third of the 
latter patients changed to strong responders in follow-up tests. 
This is the most likely explanation for loss of the predictive value 
of the DNCB test we described in 1983 (571). When we analysed graft 
survival in patients treated with azathioprine and prednisolone, 
using both first and last DNCB test prior to transplantation, the 
predictive value of the test was best expressed with the last test 
(Figure 9.28, 9.29). A similar conclusion was reached by Russ et al 
(408). They showed that patients whose DNCB reactivity increased
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when tested before and after a three month period in which three 
transfusions were given, had worse graft survival compared to those 
whose score did not change enough to cross the division between weak 
and strong reactors. It is interesting that many of our patients, 
particularly those tested prior to transfusion, experienced greater 
reactivity at 72-96 hours compared with the 48 hour reading which was 
used to classify them as weak or strong responders. This may reflect 
the immunosuppressive effect of uraemia and suggest that some of the 
patients who were not anergic and classed as weak responders at the 
first test, may be better labelled by a later than 48 hour reading or 
a second test. It appears that the discrepancy with regard to 
predictability of the DNCB test was not related to the amount of 
blood given to strong responders, but to the fact that one third of 
patients changed reactivity as a result of the policy to sensitise 
them to DNCB prior to blood transfusion (Figures 9.23, 9.26). This 
view is also supported by the finding that the weak DNCB responders 
had better graft survival compared to strong responders over a five 
year follow-up, and this effect was independent of the amount of 
transfusion and was most clearly shown in patients receiving 1-5 
units of blood (Table 9.14, Figure 9.30).
Apart from Roley et al (398) and our own centre, several 
reports have confirmed the predictive value of DTH tests in graft 
survival in patients treated with azathioprine and steroids (403, 
408-410). Others, however, did not show this ability to predict 
outcome. Light et al (406) and Harris et al (411) did not find any 
correlation between response to DNCB and transplant outcome. Both 
authors used different sensitisation protocols from ours, which 
included a smaller primary sensitisation dose and larger challenge 
dose on repatching. As a result of that, Light et al in 37 
unselected dialysis patients had a higher proportion of strong 
responders (51%) compared to ours (35%) and the extensive use of 
antilymphocyte globulin in the strong DNCB responder^ may explain the 
discrepancy (406). The proportion of responders in.Portsmouth study 
was no different from ours, but in addition to the different 
sensitisation protocol they scored their patients in a different way 
which was based on a control group consisting of 6 normal volunteers
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and 4 surgical patients (411). It is likely, therefore, that we may 
have defined a different subpopulation of responders and 
non-responders.
In transplant recipients treated with CyA we found that the 
DNCB test did not have any predictive value (Table (9.13). This is 
not surprising as CyA proved to be a powerful immunosuppressive agent 
with specific action on many T cell dependent functions both in 
experimental and clinical studies. CyA has been shown to inhibit the 
generation of cytotoxic T cells in humans, the GVHD, chronic 
inflammatory reactions, the humoral response to T cell dependent 
antigens, and DTH reactions (622-625). The latter two activities are 
mediated by T helper cells through inhibition of lymphokine 
production such as IL-2 and T cell differentiation factor (622, 623). 
With regard to DTH reactions, which primarily involve T helper cells 
and APC, CyA has also been shown to inhibit production of IL-1, 
colony stimulating factor, INF-^ and possibly other inflammatory 
lymphokines regulating the interaction between T helper cells and APC 
(622-625). Rabbit dendritic cells have been shown to be sensitive to 
CyA, although it is not clear whether the effect is a direct one on 
the dendritic cells or via a secondary effect of presentation of CyA 
to T cells by the dendritic cells (626). In clinical practice, 
Kerman et al showed that CyA improved allograft survival in strong 
responders designated as such by a battery of non-specific assays, 
including DTH skin testing (627) . It can also be recalled that Light 
et al failed to describe any predictive value of the DNCB test in 
patients receiving another powerful immunosuppressive compound, ALG 
(406). It appears, therefore, that in the CyA era the DNCB test has 
no clinical application. However, in recent randomised studies, Wood 
et al tried to convert patients from CyA to azathioprine and 19% of 
the patients experience rejection leading in some to the need to 
restart CyA (554, 555, 628). It would be interesting to know whether 
these patients were strong responders.
Blood transfusion-induced immunosuppression in uraemia
Previous studies, which have been reviewed in the introduction, 
have shown that blood transfusion induces both non-specific 
immunosuppression mediated by suppressor cell activity or blocking
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antibodies/complexes and specific unresponsiveness mediated by 
anti-idiotypic antibodies (391,393,394,458,495,516,531-546). The 
most favoured hypothesis is that transfusion alters the lymphocyte 
reactivity of uraemic patients due to an increase in non-specific 
suppressor activity via T suppressor cells or monocytes 
(391,393,394,531,534). As T suppressor cells regulate immunoglobulin 
(Ig) production (248-250,577,579), one means of assessing their role 
at the cellular level is to examine the production of Ig by PBMC in 
response to polyclonal B cell activators which differ in their 
dependence on suppressor cells. PWM-induced Ig synthesis is 
influenced by suppressor cells, whereas the response to SAC is not 
regulated by Con A-induced suppressor T cells (249,577).
In Chapter 6 we described the effect of third-party blood 
transfusion on IgG secreting cells both spontaneously and after 
stimulation with PWM and SAC using a PFC assay, and the results are 
summarised in section 6.3.5.
The first important point is that uraemic patients prior to 
transfusion had significantly lower spontaneous and SAG-IgG-PFC 
counts compared to normal controls, but the difference in PWM-IgG-PFC 
counts was not significant (Figure 6.5). This finding suggests that 
B cell function in non-transfused uraemic patients is comparable to 
normal and the defect in IgG secretion which was detected in the 
spontaneous and SAC-driven systems may be due to altered reactivity 
of other mediators involved In B cell activation. This observation 
was confirmed when we extended the in vitro analysis of B cell 
function to a larger number of patients (629a),
We showed that EBV-induced stimulation of B cells, which occurs 
in the absence of T cells (250,579), had normal PFC responses, 
indicating that uraemic B cells retain a normal potential to secrete 
Ig. This is in agreement with some previous studies which reported 
that primary and secondary antibody responses in uraemia are normal 
(reviewed in 317). The low proliferative responses to PHA in our 
patients confirmed previous reports of depression of T-cell dependent 
activity in uraemia (335,373,380,384,385,388,397). This finding 
indicates a defect in the T cell proliferation process. PFC 
responses to the T cell dependent activator, PWM, were normal in the
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non-transfused uraemic patients, suggesting that T helper activity 
was intact. Unlike PWM, SAC interacts with B cells directly without 
stimulation of T cells and the resulting proliferation is T cell 
independent, but full differentiation of B cells depend on T cell 
help (248,577). This supports the concept that responses to SAC may 
require pre-activated T helper cells and the abnormal SAC-IgG-PFC 
responses in uraemia might be due to impaired pre-activation of T 
helper cells. The role of T suppressor cells in the uraemia-induced 
defect in T cell proliferation is rather unlikely, as SAC is little 
influenced by increased suppressor T cell activity, whereas responses 
to PWM should be profoundly affected (249) . This view is in 
agreement with that of d'Apice et al who failed to support the 
possibility that suppressor cells are involved in the 
immunodeficiency of uraemia (392). On the other hand, Langhoff et al 
were able to show that addition of exogenous IL-2 normalised the 
impaired responses to PHA and Con A of uraemic lymphocytes (629). 
This finding suggests that IL-2 plays a central role in the impaired 
responses in uraemia. A very recent study from the same centre 
showed that accessory cell function and IL-1 activity was normal in 
uraemia whereas the defect in T cell proliferation was primarily 
linked to decreased IL-2 production (630). In another recent study 
the presence of an abnormally high proportion of pre-activated T 
cells, as measured by elevated concentrations of soluble IL-2 
receptors, was held responsible for the impaired T-cell dependent 
response to hepatitis B vaccination of haemodialysis patients (631).
To conclude the discussion with regards to uraemia induced 
suppression, it seems from our results in uraemic patients prior to 
any transfusion, that the defect must lie within the T cell 
proliferation process. Other studies are in agreement with this 
view, and IL-2 activity seems to be primarily involved in this 
defect.
After blood transfusion in our patients, IgG production in the 
PWM-driven system was progressively suppressed (Figure 6.7). This 
suppression was significant after the second unit of blood and peaked 
after the fifth unit. In contrast, SAC-IgG-PFC counts remained 
basically unchanged during the transfusion course. The 
interpretation of these results is based on the differing effects of
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PWM and SAC. As full differentiation of B cells to Ig production in 
response to SAC is dependent on helper T cells (248,577), and 
SAC-IgG-PFC counts were not affected by transfusion , it is assumed 
that blood transfusion does not affect helper T or B cell function. 
In contrast as PWM-induced B cell differentiation is influenced by 
suppressor T cells (249), it would be likely that the decreased 
PWM-IgG production after transfusion is due to activation of 
suppressor T cells.
This finding confirms results from other studies where T 
suppressor cells were involved in the transfusion effect. Smith et 
al described an increase in Con A induced suppressor cell activity in 
previously non-transfused uraemic patients after a transfusion with 
two units of packed red cells (393,394). This suppressor activity 
was not related to the number of suppressor T cells nor to the 
development of cytotoxic antibodies, and returned to normal by 20 
weeks from transfusion. Lenhard et al, utilising MLC and Con A 
suppressor assays in previously non-transfused patients, showed that 
blood transfusion induced at least two different cell mediated 
immunoregulatory mechanisms (534). In the early post-transfusion 
period, non-specific immunosuppression was probably mediated by the 
action of monocytes, whereas in a later phase, increasing suppressor 
T-cell activity was demonstrable. Both effects seemed to be 
dependent on the number of transfusions and the time interval between 
them (632). In a more recent study in rats, Lenhard et al showed 
that multiple DST depressed subsequent antibody responses to the 
blood donor and this was transferable by suppressor T cells carrying 
the MRC 0X8 marker (633) . Klatzmann et al also studied the 
suppressive effect of blood transfusion in selected previously
non-transfused uraemic patients. They found a sustained decrease in
MLR after the second or third transfusion (634), and this is in
agreement with our results. The induction of suppression appeared to
be primarily non-specific, because the response to cells from the 
specific blood donor, as well as to third party stimulating cells, 
was generally inhibited (634). However, the existence of two 
different types of suppression was suggested, one of which was 
alloantigen non-specific and radiosensitive, whereas the second was
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radioresistant and specific, through soluble mediators, for cells 
sharing at least one HLA-DR antigen with the blood donor who had been 
used for transfusion (634,635).
From these studies it is evident that suppressor T cells may be 
primarily involved in the blood transfusion effect, and our findings 
provide evidence that inhibition of Ig production resulting from 
transfusion is possibly mediated by suppressor T cell activity.
With regard to spontaneous IgG-PFC counts, there was an overall 
progressive increase after each transfusion (Figure 6.7), which was 
due to a significant increase in IgG production in 46% of the 
transfused patients (Figure 6.12). The reason for this is not clear, 
and it is likely that this increase in resting B cell activity 
reflects a specific or non-specific response to antigens present on 
the transfused cells. Regression analysis showed that there was no 
correlation between spontaneous IgG-PFC counts and cytotoxic 
antibodies developing after 5 or 10 units of blood (Tables 6.11, 
6 .12) .
Within the main group of transfused patients there were 
subgroups with a high or low rate of IgG production both 
spontaneously and after stimulation with SAC or PWM (Table 6.4, 
Figure 6.11), but the DNCB skin test failed to identify them (Figure 
6.11). Again this confirms a point which has been raised earlier, 
that different tests define different subpopulations of responders 
and non-responders (373) . The same conclusion was reached in 
multitransfused non-uraemic patients, where no correlation was found 
between the response to DNCB and the response to PHA, cytotoxic 
antibodies and the MLC inhibitory effect (591). With regard to the 
degree of the transfusion-induced suppression of IgG production in 
the PWM-driven system, there was no difference between weak and 
strong DNCB responders. This finding provides an answer to one of 
the questions we posed when this experiment was planned. Thus, it 
appears that strong DNCB responders are equally immunosuppressed 
after transfusion compared to weak responders. Furthermore, whatever 
effect blood transfusion had on the individual weak or strong DNCB 
responders, ie enhancement, suppression or unresponsiveness, it was 
demonstrable by the fifth transfusion. Also further 5 units of blood
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did not change significantly their overall reactivity, suggesting 
that strong DNCB responders do not seem to require more transfusions, 
as we had thought in an earlier study (571) .
The prostaglandins (PGs) have been enjoying massive attention 
from the research community, particularly with regard to their role 
as regulators of immune responses. Although numerous studies have 
established the immunosuppressive effect of PGs under in vitro 
conditions (reviewed in 81,83, 5,86,92,94,101), most of the studies 
have been carried out in experimental models or healthy humans. 
PGE-mediated immunoregulation is abnormal in certain diseases (85, 
92, 94, 101, 102) and very little is known about the complexity of 
such mechanisms in the uraemic state.
In 1976 Webb and Osheroff reported that following intravenous 
injection of sheep erythrocytes in mice there was a 20 to 80 fold 
increase in PGF2a in the spleen (636). This elevation of splenic 
GF2a level was blocked by indomethacin, and this inhibition enhanced 
DNA synthesis induced in MLR only in whole spleen cell cultures and
not in cultures purified from adherent cells.
This was the first indication that PG-mediated alterations in 
immune response could be induced by infusion of blood products. At 
the same time there were few conflicting reports which linked graft 
survival with PGE1 in the rat, mouse and dog model (99,637,638). 
When the transfusion effect on graft survival was well established in 
the early 1980's, we thought it would be interesting to include 
measurement of PGE activity in our prospective blood transfusion 
protocol.
In a preliminary report which was published in 1985, we 
observed that transfusion induced an increase in PGE release, which 
was mainly due to the increase observed in weak DNCB responders 
(586) . Strong DNCB responders produced concentrations of PGE 
comparable to those of weak DNCB responders only after transfusion of 
8-10 units of blood. This finding fitted the hypothesis we had 
expressed then, that strong DNCB responders might require more blood 
to elicit a beneficial effect on graft survival (571).
The final results from this experiment have been described in
Chapter 7, and only partly confirm the results from the preliminary 
study. The first point of interest was that the in vitro PGE
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synthesis in Con A stimulated PBHC culture supernatants in previously 
non-transfused uraemic patients was comparable to that of the 
healthy controls (Table 7.2 and Figure 7.3). Lenhard et al also did 
not find any difference in pre-transfusion PGE2 and PGF2a release in 
25 dialysis patients compared to normal controls (639) . This 
suggests that the uraemia induced immunosuppression is mediated by 
mechanism(s) which might not involve PGE activity. Evidence to 
support this view comes from experimentally induced uraemia in rats. 
Alevy and Slavin found that adherent spleen cells from uraemic 
animals display a more potent suppressor activity than do control 
adherent cells (382). The suppression mediated by uraemic adherent 
spleen cells was not inhibited by indomethacin, as opposed to that of 
controls, and furthermore the uraemic adherent suppressor cells did 
not have la antigens, whereas control adherent cells had (382). 
Similar results indicating the presence of more than one suppressor 
mechanism in rats have been reported by Mattingly et al (640) and 
Folch and Waksman (641). In human PBMC, Rice et al described three 
suppressor cell systems, only one of which is dependent on PG 
synthesis (642). In patients with sarcoidosis there is evidence
suggesting that there may be at least two adherent cell subsets 
inducing suppression only one of which is mediated by PG (643,644).
In uraemic patients, Langhoff and Ladefoged demonstrated that 
their lymphocytes had a 3 to 4-fold increase in sensitivity to
methylprednisolone compared to normal controls which caused 50% 
suppression of T cell proliferation in response to PHA and Con A 
(645). This inhibitory effect is thought to be mediated through 
inhibition of IL-2 release (629), and the difference in the 
inhibitory effect of steroids on IL-2 production between uraemic
patients and controls suggests differing interactions at a cellular
level. Smith et al, however, showed that the addition of 
flurbiprofen to the Con A enhancement cultures of dialysed and normal 
subjects caused a significant decrease in suppressor cell activity 
indicating that the suppression seen both in dialysed and normal 
controls is mediated by PGE (393).
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From these studies it is evident that there may be more than 
one mechanism regulating responses of immunocompetent cells, and 
which mechanism prevails might depend on specific in vitro conditions 
or a disease state.
Blood transfusion in our uraemic patients induced a significant 
increase of PGE synthesis which was more pronounced after the 3rd 
unit of blood (Figures 7.3, 7.5). The presence, however, of the
increased PGE release was not associated with the PWM-IgG-PFC
suppression which was observed following transfusion of one to ten 
units of blood (Table 7.6). In vitro studies using human cells have
not clearly defined a role for PGE in the regulation of B cell
responsiveness. Goodwin et al reported that PGE2 had minimal 
inhibitory effect on PWM-induced DNA synthesis in cultures of 
unseparated human lymphocytes, whereas significant inhibition of PHA 
and Con A induced H-thymidine incorporation was noted (646). Stobo 
et al showed heterogeneity in the response of human PBMC to PGE, as 
high density cells were very sensitive to PGE-mediated suppression 
whereas the proliferative response of low-density cells was enhanced 
by PGE (100). Thompson et al provided further evidence of a function 
dichotomy in PGE sensitivity of B cell subsets in response to PWM or 
staphylococcus aureus (SA)-stimulated cultures (647). PGE suppressed 
SA-induced B cell proliferation but not PWM-stimulated B cell DNA 
synthesis, because PGE did not inhibit the production of BCGF 
activity from PWM-stimulated T cells. This suggests that the 
secretion of some, but not all, regulatory lymphokines produced by 
activated T cells may be inhibited by PGE, as for example happens 
with the secretion of IL-2 (581-585).
These varied effects of PGE were described in normal human PBMC 
and indicated the complexity of regulatory interactions between 
macrophages, T cells and B cells. With regard to uraemic patients 
Lenhard et al, like us, found that transfusion of three units of 
blood Induced a dose dependent increase of PGE concentrations in 
LPS-stimulated PBMC which inhibited MLR responses (639). They 
attributed the transfusion induced suppression to activation of a 
short lived T suppressor cell by PGE.
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Fisher et al reported that PGE at high concentrations in normal 
humans may activate a short lived radiosensitive T suppressor cell 
which displayed the same characteristics as Con A-activated T 
suppressor cells (648). On the other hand, the existence of a
PG-producing suppressor cell in healthy subjects has been identified 
in a population of glass adherent mononuclear cells which suppressed 
T-cell mitogenic activity (646).
It can be recalled that Klatzmann et al, when studying the 
beneficial effect of transfusion in uraemic patients, suggested the 
existence of two types of suppression, one which was non-specific and 
radiosensitive and the other specific and radioresistant (634,635). 
van Rood and Lenhard et al also tried to implicate a two-step process 
(an early non-specific and a later specific) in order to reconcile 
differing findings with regard to the transfusion effect (458,534, 
632).
Our results support this possibility as we did not observe any 
correlation between PGE concentrations, which are known to exert some 
suppressive activity, and transfusion induced suppression of IgG 
production in the PWM-driven system. Roy et al in a Con A
enhancement assay also were unable to associate suppressive activity 
induced by 1-5 units of blood with PGE2 release In culture 
supernatants (649). These findings are in agreement with failure of 
flurbiprofen to produce significant decrease in suppressor activity 
to Con A enhancement cultures of lymphocytes from transfused patients 
in the study of Smith et al (393).
The difference in PGE concentrations between weak and strong 
DNCB responders prior to and after 1-10 transfusions was not 
significant in our patients (Table 7.3, Figures 7.6, 7.7).
Furthermore, transfusion of a further five units of blood did not 
have any significant effect in PGE concentrations compared to the 
initial five units in the whole group of patients (Table 7.4, Figure 
7.8) nor in the weak and strong DNCB groups individually (Table 7.5). 
These findings are not in accord with the results in our preliminary 
report (586), apparently because of the difference in the number of 
patients and the large intersubject variation in PGE concentrations 
before and after transfusion (Figure 7.4). These results imply that 
PGE concentrations did not interfere with the expression of DTH
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responses to DNCB in our patients. Furthermore, to the extent that 
the transfusion effect is mediated by PGE concentrations, strong DNCB 
responders do not appear to acquire stronger suppressive activity 
compared to weak DNCB responders following transfusion regardless of 
the amount of blood. In other words, using PGE concentrations as a 
measure of transfusion-induced suppression, it appears that strong 
DNCB responders do not require more blood to achieve suppression 
comparable to that of weak DNCB responders. This again does not 
confirm the hypothesis we proposed in 1983 (571).
As mentioned before, in the mid 1970's there were conflicting 
reports in experimental animal models which had associated graft 
survival with PGE (99, 637, 638). More recent reports suggest that 
PGE enhances graft survival. Strom and Carpenter reported that
treatment of rats with a PGE1 derivative with a prolonged half-life 
resulted in a near complete protection of renal grafts from 
immunologic damage, despite withholding immunosuppressive therapy 
until day 4 following transplantation (650). Campbell et al 
implanted a pump in a canine model and continuously delivered PGE1 
into the renal transplant artery (651). Although allograft failure 
was not prevented, there were striking differences in the histology 
between treated and untreated transplants. PGE1 perfusion resulted 
in the appearances of large numbers of polymorphonuclear leukocytes, 
but few lymphocytes, whereas in the control allografts, the picture 
was typical of lymphocyte-mediated acute rejection.
In our study, patients who were subsequently transplanted and 
had a successful outcome showed a significant increase in PGE levels 
after the last elective transfusion, whereas in a small number of 
patients who rejected their graft, such an increase was not observed 
(Figure 7.10). Roy et al, who also was unable to directly associate 
the suppressive activity after transfusion with PGE2, found 84% graft 
survival at one year in those whose suppressive Con A ratio was more 
than 5 after transfusion, compared to 56% among those with a Con A 
ratio less than 5 (649). These results, although inconclusive,
suggest that PGE might be an important m ediator in 
transfusion-induced immunoregulatory events.
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The effect of blood transfusion on serum complement levels 
after transfusion was described in Chapter 8. There was no 
measurable effect in the entire group of patients, nor in the weak 
and strong DNCB groups individually. Complement has an 
immunoregulatory role in antibody induction and generation of memory 
B cells (reviewed in 107), but we did not find any correlation 
between complement levels and IgG production either spontaneously or 
after SAC or PWM stimulation before or after transfusion.
The last point to be discussed in this thesis is the 
development of cytotoxic antibodies following transfusion, which has 
been described in Chapter 5. We were aiming to define the optimum 
number of transfusions in weak and strong DNCB responders required to 
achieve a beneficial effect on graft survival, while keeping the risk 
of sensitisation to a minimum. The risk of broad sensitisation was 
negligible after 3 or 4 units of blood but was increased with more 
transfusions particularly in women. This is in agreement with 
previous studies (491-496, 509-513). The sensitisation rate was not 
significantly different between weak and strong DNCB responder 
patients (Table 5.1), but the latter patients developed cytotoxic 
antibodies earlier after transfusion. After 5 units of blood both 
the rate and level of PRA were comparable in the two groups (Table 
5.2, Figures 5.2-5.5). Gerbase-DeLima et al also did not find any 
association between DNCB and cytotoxic antibodies in multitransfused 
non-uraemic anaemic patients (591). Early development of PRA before 
the 5th transfusion has been associated with worse graft survival 
compared to those sensitised beyond the fifth transfusion and it was 
thought that the former patients represent a group of high responders 
(493) . In our study the DNCB test detected this group of high 
responders.
The beneficial effect of transfusion in our study seemed to 
have occurred after the first three transfusions, since PWM-IgG 
suppression and PGE release were significantly increased by then. As 
there were no differences in suppressor activity between weak and 
strong DNCB responders after the 3rd unit of blood, and the risk of 
sensitisation increased with further transfusion in both groups, we 
established a policy of giving three units of blood to our 
pre-transplant patients after obtaining these results.
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This study was based on the hypothesis that strong DNCB 
responders might require more blood in order to achieve a beneficial 
graft survival. The results did not confirm this hypothesis, but 
shed light on discrepancies, provided useful observations on the 
application and interpretation of DTH skin tests, and further 
established the presence of uraemia and transfusion induced 
suppression in these dialysis patients. Fisher (652) has claimed
that ' the null hypothesis is never proved or established, but is
possibly disproved in the course of experimentation. Every 
experiment may be said to exist only in order to give the facts a 
chance of disproving the null hypothesis'.
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